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ABSTRACT
The ubiquitous and oncogenic human herpes-virus Epstem-Barr virus (EB V) establishes 
a latent infection and promotes the long-term survival of the infected host cell by 
targeting the molecular machinery that controls cell fate decisions, including apoptosis, 
proliferation and differentiation These host-virus interactions are likely to play a 
crucial role in the development of EBV-associated malignancies such, as Burkitt’s 
lymphoma, Hodgkin’s disease, nasopharyngeal carcinoma and tumours in lmmuno- 
suppressed individuals It has previously been shown m our laboratory that two EBV 
latent proteins, latent membrane protein 1 (LMP1) and EBV nuclear antigen 2 
(EBNA2), which are major effectors of cellular phenotypic change, can independently 
regulate expression of the cellular bfl-1 gene Bfl-1 is an anti-apoptotic protein of the 
Bcl-2 family, whose preferential expression m hematopoietic and endothelial cells is 
controlled by inflammatory stimuli In this study, it is reported that LMP1 and EBNA2 
regulate bfl-1 activity through interactions with components of the NF-kB and Notch 
signalling pathways respectively NF-kB composed of p65 sub-units trans-activated the 
bfl-1 promoter m the EBV-negative cell line DG75, and an NF-icB-like binding site at 
position -52 to -43 relative to the transcription start site was essential for this effect An 
RBP-Jk/CBF1 mutant blocked EBNA2-mediated trans-activation of bfl-1 in DG75 
cells, indicating an important role for this DNA-binding protein in bfl-1 trans-activation 
by EBNA2 Although RBP-Jk/CBFI is  also essential for signalling by the cellular 
equivalent of EBNA2, mtra-cellular Notch (NotchIC), this protein was not found to 
trans-activate the bfl-1 promoter Both EBNA2 and LMP1 are expressed in EBV- 
mfected cell lines, and EBNA2 is responsible for induction of LMP1 Blocking of 
either EBNA2- or LMP1-mediated signalling in EBV-mfected cell lines did not 
dramatically affect the level o f bfl-1 promoter activity However, when both EBNA2 
and LMP1 signalling were blocked simultaneously, a significant decrease m the level of 
bfl-1 activity was observed These data indicate a role for both EBNA2 and LMP1 in 
the regulation of the promoter for the bfl-1 gene m the context of the EBV-infected cell 
These findings are relevant to our understanding of EBV persistence in the infected 
host, and its role in malignant disease
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CHAPTER 1
An Introduction to Epstein-Barr Virus Biology
1.1 The discoveiy of Epstein-Barr virus (EBV)
Cancer is one o f the most common diseases known to man, with more than 10 million 
people diagnosed with the disease every year throughout the world (World Health 
Organisation, 2004). The disease is complex and can have both genetic and 
environmental causes. Viruses have also been found to be involved in the development 
of some cancers. It is estimated that virus infections account for approximately 15 % of 
the worldwide cancer incidence (zur Hausen, 1991), demonstrating the urgent need to 
identify the exact role for viruses in cancer. Viruses may contribute to the development 
of human tumours by different mechanisms, indirectly by inducing immuno­
suppression or by modifying the host cell genome without persistence o f viral DNA, or 
directly by expressing oncoproteins or by altering the expression o f host cell proteins. 
The oncogenic viruses that are implicated in human disease are diverse and vary greatly 
in the complexity o f  their genomes, their target tissues and their requirements for 
additional co-factors during tumourigenesis. Some members o f the human herpes 
viruses, most notably Epstein-Barr virus (EBV), have been linked to a number o f 
cancers o f both lymphoid and epithelial origin.
The discovery o f EBV was a direct result o f the association o f the virus with Burkitt’s 
lymphoma (BL). Denis Burkitt demonstrated in 1958 that the distribution of the 
endemic form o f a tumour that mainly arises at the jaw o f children was dependent on 
geographical and climatic factors (Burkitt, 1958). This led to speculations that a 
biological agent might be involved in the aetiology o f the disease (Burkitt, 1962). After 
meeting Epstein in the early 1960s, Burkitt provided him with several lymphoma 
biopsies. However, Epstein failed to identify the pathogen associated with the tumours 
from fresh biopsies, and only after tumour cells were successfully grown in culture were 
Epstein, Achong and Barr able to identify replicating virus particles by electron 
microscopy in cell lines derived from African Burkitt’s lymphoma (Epstein et a l., 
1964). The association o f EBV with BL was subsequently proven through the use o f 
serological techniques to detect viral genes expressed in tumours. Although it was the 
association with BL that led to the discovery o f the virus, EBV is found to be 
widespread in all human populations, with a prevalence o f over 90 % in adults. Primary 
infection usually occurs during early childhood and is generally asymptomatic. 
However, primary infection that is delayed until adolescence or early adulthood may 
cause a self-limiting lymphoproliferative disease, infectious mononucleosis (IM).
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Infection results in the establishment o f a life-long carrier state characterised by the 
persistence o f antibodies to several viral gene products and the secretion o f infectious 
virus in saliva (IARC Monographs, 1997).
1.2 Classification of EBV
Humans are the exclusive natural host for EBV, which is classed as a herpes virus based 
on its structural properties. Taxonomists have renamed EBV as human herpes virus 4 
(HHV4), but EBV is still its commonly used name (IARC Monographs, 1997). Herpes 
viruses are biologically classified into three subfamilies: alpha, beta and gamma, with 
EBV belonging to the gamma-herpes virus subfamily and the genus Lymphocryptovirus. 
The gamma-herpes viruses are classified on the basis o f their biological properties 
rather than their genomic organization (Kieff, 1996). Viruses of this subfamily are 
characterised by their tropism for lymphoid cells and their capacity to induce cell 
proliferation in vivo and cell immortalisation in vitro. It is precisely these biological 
properties, particularly the involvement o f the gamma-herpes viruses in cell 
proliferation, and thus cancer, which has generated most o f the interest and study o f this 
virus subfamily.
1.3 Structure of EBV
Like other herpes viruses, EBV consists o f a toroid protein core that is wrapped with 
double-stranded DNA (Figure 1.1). The DNA wrapped protein core is contained 
within an icosahedral nucleocapsid with 162 capsomeres approximately 100 nm in 
diameter. The major EBV capsid proteins are 28, 47 and 160 kDa in size. A protein 
tegument surrounds the nucleocapsid and is enclosed by an outer envelope with external 
glycoprotein spikes. The most abundant EBV proteins within the envelope and 
tegument are the glycoproteins gp350/220 and gpl52 respectively (Dolynuik et a l., 
1976; Epstein and Achong, 1973).
3
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Figure 1.1: A  Schem atic representation o f the herpes virus structure. EBV consists o f  a toroid 
protein core (illustrated in black) that is wrapped with double-stranded DNA (DS DN A, green). The 
D N A  wrapped protein core is contained within a nuclecapsid (red). A  protein tegument surrounds the 
nucleocapsid and is enclosed by an outer envelope with external glycoprotein spikes
1.4 EBV genome
The EBV genome is a linear, double-stranded 172 kbp DNA molecule with a 60 % 
guanine/cytosine composition (KiefF, 1996). The EBV genome includes 85 known 
genes that occupy most o f the viral DNA (Wensing and Farrell, 2000). As with many 
viruses, however, complicated differential splicing o f RNA transcripts means the 
number o f proteins transcribed may far exceed the number o f genes. The DNA o f the 
B95.8 strain o f EBV has been cloned as a set o f overlapping EcoBl and BamHI 
restriction endonuclease fragments (Arrand et al., 1981), which was an important 
prerequisite that enabled EBV to be the first herpes virus for which the complete DNA 
sequence was obtained (Baer et al., 1984). As a consequence o f Arrand’s findings, 
regions o f the EBV genome have become known by their position on the BamHI 
restriction endonuclease map (Figure 1.2B). Open reading frames (ORFs) are named 
using a four-digit number and acronym, for example BKRF1 refers to the first rightward 
ORF o f the BamHI K region o f the genome. Features o f the EBV genome (Figure 
1.2A), which are also found in other gamma-herpes viruses, include randomly reiterated 
3 kb internal direct repeats (IR1) that separate the genome into short (US) and long
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(UL) unique domains (Hayward et al., 1980). Interspersed within the UL regions are 
short repeated sequences (IR2-IR4). At each end o f the DNA molecule are 4-12 copies 
o f a 500 bp terminal repeat (TR) (Kintner and Sugden, 1979). The TRs at each end of 
the linear genome join together to form a closed circular episome in the nucleus o f 
latently infected cells.
Figure 1.2: Features o f the EBV genom e. (A) The linear EBV genome comprises a short unique region 
(U l)  separated from a long unique region (U2-U5) by a large repeating element, the internal repeat, IR1. 
The long unique region is interspersed with several minor internal repeat elements IR2-IR4. In latently 
infected cells, the genome fuses at the terminal repeats (TR) to form a circular episome. H** denotes the 
heterogeneity in this region due to the variable number o f  TRs in different virus isolates and in different 
clones o f  EBV-infected cells. (B) The BamHL restriction map o f the B 95.8 genome. Fragments are 
named according to size, with the Bam Hl A fragment being the largest.
Two subtypes o f EBV are known to infect humans, originally referred to as A and B 
and now called types 1 and 2 (Kieff, 1996). Type 1 and type 2 EBV appear to be 
identical over the bulk o f the EBV genome, but show allelic polymorphism (with 50-80 
% sequence homology depending on the locus) in a subset o f latent genes, namely the 
Epstein-Barr virus nuclear antigen (EBNA)-LP, EBNA2, EBNA3A, EBNA3B and 
EBNA3C (Sample et a l., 1990). Type 1 EBV is predominant in many Western 
countries, whereas both types are widespread in equatorial Africa, New Guinea and 
perhaps certain other regions (Young et a l., 1987). Studies suggest that type 1 isolates 
are more potent than type 2 in achieving B cell transformation in vitro. In addition to
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this broad distinction between EBV types 1 and 2, there is also minor heterogeneity 
within each virus type, which is most easily detected as a variation in the size o f the 
EBNA proteins (Murray and Young, 2001). These differences have been used to trace 
virus transmission within families and from transplant donors to recipients. The balance 
o f evidence to date suggests that most healthy individuals are infected with only one 
virus type, although a small number o f healthy virus carriers do harbour multiple, 
perhaps sequentially acquired EBV strains (Brooks et al., 2000). By contrast, most 
immunologically compromised patients are infected with multiple EBV strains (Murray 
and Young, 2001).
1.5 EBV infection in vivo
It is widely accepted that EBV infects more than 90 %  o f the world’s adult population 
and the virus is transmitted from host to host via saliva (Thompson and Kurzrock, 
2004). Primary infections occurring during early childhood are normally silent or 
asymptomatic. However, infection that is delayed until late adolescence or early 
adulthood is associated with the debilitating non-malignant lymphoproliferative 
syndrome infectious mononucleosis (IM), which is also known as glandular fever 
(IARC Monographs, 1997). IM is characterised by a variety o f symptoms, including 
fever, malaise, lymphadenopathy (marked swelling o f peripheral lymphoid tissues) and 
the presence o f atypical dividing lymphocytes in the peripheral blood (Eliopoulos and 
Young, 2001). Incoming virus establishes a primary focus o f lytic replication in the 
stratified squamous epithelium o f the oropharynx (Murray and Young, 2002; Sixbey et 
al., 1984). Lytic replication describes the full cycle o f virus infection, leading to the 
production o f new infectious virus progeny, and eventually lysis o f the infected cell. 
Oropharyngeal infection is followed by a latent infection (type HI) o f B cells as they 
traffic in close proximity to the infected epithelial cells (Figure 1.3 A), resulting in B cell 
proliferation and viral spread throughout the B cell compartment. Many o f the 
proliferating cells are removed by the emerging latent-antigen-specific primary T cell 
responses, but some escape by down-regulating antigen expression and establishing a 
stable reservoir o f resting EBV-positive memory B cells, in which viral antigen 
expression is mostly suppressed (Young and Rickinson, 2004).
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1.6 EBV persistence in vivo
After initial infection, EBV persists in the host for life, in a circulating subset o f resting 
memory B cells. These cells carry the virus in a latent form, and there is a low level 
continuous or intermittent production o f infectious virus into saliva (Yao et al., 1985). 
Several lines o f evidence support a role for the B lymphocyte as the site o f EBV 
persistence in vivo (Murray and Young, 2001). Firstly, therapy aimed at eliminating 
virus replication using long-term acyclovir treatment eliminates virus excretion from the 
oropharynx, but does not affect the level o f latent infection in B cells (Emberg and 
Andersson, 1986). As soon as the treatment is halted, virus can be detected in the 
oropharyngael secretions at pre-treatment levels (Yao et al., 1989). In addition, studies 
o f EBV strains in donor-recipient pairs, before and after bone marrow transplantation, 
have shown that the recipient’s strain disappeared from the oropharynx and was 
replaced by the donor’s strain, indicating that the bone marrow B cells harbour EBV 
(Gratama et al., 1990). Furthermore, patients with X-linked aggamaglobulinaemia, who 
are deficient in mature B cells, are found to be free o f EBV infection, suggesting they 
are not able to maintain a persistent infection (Young, 1999).
EBV is thought to exist in the peripheral blood within the IgD' memory B cell pool, 
with EBV gene expression limited to latent membrane protein 2A (LMP2A) and 
possibly EBNA1 (Babcock et al., 1998). The exact route o f entry to the memory B cell 
pool is still a matter o f much debate. In vitro, both naïve and memory B lymphocytes 
seem equally susceptible to EBV infection (Young and Rickinson, 2004). One view is 
that the naïve B cell compartment is the main target o f new EBV infections in vivo. 
Viral transformation drives naïve B lymphocytes into memory by mimicking the 
physiological process o f antigen-driven memory B cell development in lymphoid tissue, 
involving somatic immunogloblin (Ig) gene hypermutation during transit through a 
germinal centre (Babcock et al., 1998, Babcock et al., 2000). However, this view is 
difficult to reconcile with the finding that EB V-infected cells in the tonsils from patients 
with IM localise to extra-follicular areas and not germinal centres. Although some o f 
the infected cells display a naïve phenotype, the expanding clones preferentially involve 
cells with a mutated phenotype that are typical o f antigen selected memory cells (Kurth 
et al., 2000). An alternative view, therefore, envisages infection o f pre-existing 
memory cells as a direct route to memory. This is consistent with the finding o f EBV-
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infected B cells in tonsils but does not explain the apparent disappearance o f the naive B 
cell population (Young and Rickinson, 2004).
The reservoir o f EBV-infected memory B cells is stably maintained and becomes 
subject to the same physiological controls governing memory B cell migration and 
differentiation as a whole (Laichalk et a l., 2002). Such a strategy brings with it the 
possibility o f antigen-driven recruitment o f infected cells into germinal centres, 
entailing the activation o f their latency programmes, leading to progeny that either re­
enter the circulating memory pool or differentiate to become plasma cells that might 
migrate to mucosal sites in the oropharynx (Young and Rickinson, 2004). 
Differentiated plasma cells that migrate to the oropharynx undergo lytic cycle 
replication, providing a source o f low-level shedding o f infectious virus into the 
oropharynx, where the virus can spread to other individuals via saliva. Lytic replication 
in the oropharynx might also initiate new growth-transforming latency type III 
infections o f naive and/or memory B cells; these new infections might possibly 
replenish the B cell reservoir, but are more likely to be efficiently removed by the 
memory T cell response (Young and Rickinson, 2004). The interactions between EBV 
and host cells are summarised in Figure 1.3.
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F igu rel.3 : Putative in vivo interactions between Epstein-Barr virus and host cells. (A) Primary 
infection. Incoming virus establishes a primary focus o f  lytic replication in the orophaiynx (possibly in 
the mucosal epithelium), after which the virus spreads throughout the lymphoid tissues as a latent (type 
III latency) growth-transforming infection o f  B cells. Many o f  these proliferating cells are removed by 
the emerging latent-antigen-specific primary-T-cell response, but some escape by down-regulating 
antigen expression and establishing a stable reservoir o f  resting EBV-positive memory B cells, in which  
viral antigen expression is mostly suppressed (latency type 0). Different views on the sequence o f  events 
are shown. (B) Persistent infection. The reservoir o f  EBV-infected memory B cells becomes subject to 
the physiological controls governing memory B cell migration and differentiation as a whole. 
Occasionally, these EBV-infected cells might be recruited into germinal-centre reactions, entailing the 
activation o f  different latency programmes, after which they might either re-enter the reservoir as memory 
cells or commit to plasma-cell differentiation, possibly m oving to mucosal sites in the oropharynx and, in 
the process, activating the viral lytic cycle (adapted from Young and Rickinson, 2004).
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Long-term EBV co-exists with most human hosts without overt serious consequences. 
However, in a small percentage o f individuals, the virus may be implicated in the 
development o f malignancy. Experimental and clinical evidence have linked EBV to 
various tumours o f lymphoid origin: Burkitt’s lymphoma (BL), Hodgkins’ disease 
(HD), lymphomas in immuno-compromised individuals and certain T cell lymphomas. 
In addition the virus has been linked to epithelial cell malignancies, including 
nasopharyngeal carcinoma (NPC) and gastric carcinomas. EBV-associated 
malignancies are outlined in Table 1.1 (adapted from Thompson and Kurzrock, 2004).
Table 1.1: EBV-associated malignancies 
Disease Subtype % EBV Description
positivity
1.7 EBV-associated malignancies
Burkitt’s lymphoma Endemic 
(BL) Nonendemic
> 9 5 %  An aggressive lymphoma 
15-30%  occurring endemically in 
equatorial Africa and Papua New  
Guinea and non-endemically 
sporadically throughout the 
Western world. Both disorders are 
characterised by deregulation o f  c-  
myc expression, resulting from 
translocation o f  the c-myc gene to a 
location close to the enhancers o f  
the antibody genes.
Hodgkin’s disease M ixed cellularity 
(HD)
70 %
lymphocyte depleted > 95 %
nodular sclerosing 10-40 %
lymphocyte predominant < 5 %
HD is characterised by an 
expansion o f Reed-Stemberg cells, 
which are postulated to be o f  B cell 
lineage.
Non-Hodgkin’s Nasal T/NK > 9 0 %
lymphoma Angioimmunoblastic unknown
lymphadenopathy
A non-B cell non-Hodgkin’s 
lymphoma occurring in T cells and 
natural killer (NK) cells.
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Post-transplant 
lymphoproliferative 
disorders (PTLD)
> 9 0 %  B lymphomas occurring in T-cell
immuno-compromised individuals 
follow ing transplantatioa
AIDS-associated IP-CNS
lymphoma other
>  95 % B lymphomas that occur in the
30-50 % immunoblastic primary central
nervous system (IP-CNS) o f  T-cell 
immuno-compromised AIDS 
patients.
Leiomyosarcomas in 
i mmuno-suppressed 
individuals
frequent Smooth muscle tumours in 
immuno-compromised patients.
Nasopharyngeal 
carcinoma (NPC)
anaplastic > 9 5 %  An undifferentiated carcinoma o f
the nasopharynx in the Chinese 
provence o f  Canton, Hong Kong, 
Taiwan and some parts o f Alaska 
and Greenland.
Gastric carcinoma Lymphoepithelioma-like > 90 %
Adenocarcinoma 5-25 %
Carcinomas o f the stomach 
resembling NPC.
Breast carcinoma Medullary carcinoma 
Adenocarcinoma
0-51% Carcinomas o f  the breast
1.8 EBV latent genes and transformation
EBV preferentially infects B lymphocytes and possesses the unique ability to transform 
resting B cells into permanent, latently infected lymphoblastoid cell lines (LCLs) in 
vitro (Young and Rickinson, 2004). This system has provided an invaluable tool for 
studying the transforming potential o f the virus. Infection o f other cells, mainly 
epithelial cells, is less efficient and not as extensively studied. B-cell transformation by 
EBV, resulting in the establishment o f LCLs, therefore remains the dominant in vitro 
model o f infection (Young and Rickinson, 2004).
11
In EBV-transformed LCLs, every cell carries multiple extra-chromosomal copies o f the 
viral episome and constitutively expresses a limited set o f viral gene products, the so- 
called latent products, which comprise six EBV nuclear antigens (EBNAs 1, 2, 3 A, 3B, 
3C and EBNA-LP) and three latent membrane proteins (LMPs 1, 2A and 2B) (Kieff and 
Rickinson, 2001). A diagram showing the location and transcription o f the EBV latent 
genes on the double-stranded viral DNA episome is shown in Figure 1.4.
12
OriP
K>:, I
A
a G e1 -©3ZR c b T  d
C W W W W W W Y H  F Q U P o I m I l  W / k  B G D\|/XVH
*
N,hot
B
in w w w w w w
— i—
EBNALP EBNA2 L BNA3A EBNA3B E.BNA3C EBNA1
TR
LMP1
F igu rel.4: EB V  latent genes. (A) A schematic representation showing the location and transcription o f  
the EBV latent genes on the double-stranded viral D N A  episome. The origin o f  replication (OriP) is 
shown in orange. The large green solid arrows represent exons encoding each o f the latent proteins, and 
the arrows indicate the direction in which the genes encoding these proteins are transcribed. The latent 
proteins include six nuclear antigens (EBNAs 1, 2, 3A, 3B, 3C and EBNA-LP) and the three latent 
membranes (LMPs 1, 2A and 2B). EBN A-LP  is transcribed from a variable number o f  repetitive exons. 
LM P2A  and LM P2B  are composed o f  multiple exons, which are located on either site o f  the terminal 
repeat (TR) region, which is formed during the circularisation o f  the linear DNA to produce the viral 
episome. The blue arrows at the top represent the highly transcribed non-polyadenylated RNAs E B E R 1  
and EBE R 2; their transcription is a consistent feature o f  latent EBV infection. The long outer green arrow 
represents EBV transcription during a form o f latency known as type III latency, in which all the EBNAs 
are transcribed from either the Cp or Wp promoter; the different EBNAs are encoded by individual 
mRNAs that are generated by differential splicing o f  the same long primary transcript The inner, shorter 
red arrow represents the EBN A1  transcript, which originates from the Qp promoter during latency type I 
and latency type II. Transcripts from the Bam Hl A region can be detected during latent infection but no 
protein arising from this region has been definitively identified. The locations o f  the BARFO and BARF1 
coding regions are shown here. (B) Locations o f the open reading frames for the EBV latent proteins on  
the BamHl restriction endonuclease map o f  the prototype B95-8 genom e (adapted from Young and 
Rickinson, 2004).
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Transcripts from the BamHL A region o f the viral genome (BART transcripts) are also 
detected in LCLs. In addition to the latent proteins and BARTs, LCLs display abundant 
expression o f the small, non-polyadenylated (and therefore non-coding) RNAs, EBER1 
and EBER2. The function o f these transcripts is not clear but they are consistently 
expressed in all forms of latent EBV infection (Young and Rickinson, 2004) and have 
served as excellent targets to detect EBV in tumours (Murray and Young, 2001). This 
pattern o f latent EBV gene expression, which appears to be activated only in B-cell 
infections, is referred to as type III latency, and is a characteristic o f most lymphomas in 
immuno-compromised individuals (Murray and Young, 2001). At least 2 other forms 
o f EBV latency are observed. In latency type I, which is a characteristic o f BL, only 
EBNA1, the EBERs and the BARTs are regularly detected. In latency type II, which is 
observed in EBV-associated HD and NPC, the EBERs, EBNA1 are expressed together 
with LMP1 and LMP2. The types o f EBV latency are summarised in Table 1.2.
Table 1.2: EBV latency pattern and associated malignancies
Latency
type
Viral genes 
expressed
Associated malignancies References
Type I EBNA1
EBERs
BARTs
Burkitt’s lymphoma Sbih-Lammali et al., 1996. 
Rowe et a l., 1987.
Type 11 EBNA1
EBERs
LMP1
LMP2
BARTs
Hodgkin’s disease 
Nasopharyngeal carcinoma 
Peripheral T/NK lymphoma
Liebowitz and Kieff, 1993.
Type III All EBNAs
EBERS
LMP1
LMP2
BARTs
AIDS-associated lymphomas 
PTLD
Liebowitz and Kieff, 1993. 
Niedobitek et a/., 1997.
Other EBERs
EBNA1
EBNA2
Smooth muscle tumours Lee et al., 1995
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In vitro studies using LCLs have provided insight into the sequence o f events occurring 
during EBV infection o f B lymphocytes. EBV infection begins with the attachment o f 
the major viral envelope glycoprotein gp350/220 to the CD21 (also known as CR2) 
receptor on the surface o f B cells (Nemerow et a l., 1987; Tanner et al., 1987). CD21 is 
a member o f the Ig super-family and functions as the receptor for the C3d component o f 
complement. The EBV envelope glycoproteins gp350 and gp220 are translated from 
abundant late replication cycle EBV mRNAs, which are transcribed from the same 
gene. The mRNA for gp350 is not spliced, whereas the mRNA for gp220 is spliced in 
frame. CD21 is the only known B-lymphocyte protein that binds gp350/220 (Kieff,
1996). The penetration o f B cells by EBV also involves the viral glycoproteins gp25 
and gp42/38 in a complex with gp85. This complex mediates an interaction between 
EBV and the major histocompatability complex (MHC) class II molecules, which serve 
as a co-receptor for virus entry into B cells (Knox and Young, 1995).
Post-attachment events are complex. CD21 becomes cross-linked, which triggers an 
initial activating signal that is thought to prepare the cell for EBV infection. EBV 
binding to CD21 immediately activates the tyrosine kinase lyk and mobilises calcium 
(Cheung and Dosch, 1991; Gordon et a l., 1986). This is followed by an increase in 
mRNA synthesis, blast transformation, homotypic cell adhesion, surface CD23 
expression and interleukin (IL)-6 production. The viral genome is then uncoated and 
delivered to the nucleus where it immediately circularises (Thompson and Kurzrock, 
2004). Circularisation o f the viral genome and transcription from the W promoter begin 
a cascade o f events leading to expression o f all latent genes. EBV does not encode an 
RNA polymerase, and uses host cell RNA polymerase II for transcription o f viral RNAs 
(Kieff, 1996). The EBV nuclear antigen leader protein (EBNA-LP) and EBNA2 are the 
first proteins to be detected upon EBV infection (Thompson and Kurzrock, 2004). At 
24 - 48 hours post-infection, a promoter shift occurs where the C promoter (Cp) is used 
instead o f the initial Wp promoter. Activation o f the Cp promoter leads to a higher 
level o f transcription o f  the EBNA mRNAs. Many transcripts now pass the 
polyladenylation site downstream o f EBNA2 and extend to EBNAs 1, 3A, 3B and 3C 
(Kieff, 1996). The different EBNAs are encoded by individual mRNAs generated by 
differential splicing o f the same long “rightward” primary transcript expressed from one 
of two promoters (Cp or Wp) located close together in the Banitil C and W regions o f 
the genome (Murray and Young, 2001) (Figure 1.5). The processing o f the transcripts 
is then determined by their polyadenylation sites (Kieff, 1996).
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Figure 1.5: A  sim plified outline o f the splicing o f the EBV nuclear antigen coding m RNAs. All the
EBNAs are transcribed from either the Cp or Wp promoter; the different EBNAs are encoded by 
individual mRNAs generated by differential splicing o f  the same long primary transcript
By 32 hours post-infection, all EBNAs and latent membrane proteins (LMPs) are 
expressed. The LMP transcripts are expressed from separate promoters in the BamHl N 
region of the EBV genome, with the leftward LMP1 and rightward LMP2B mRNAs 
apparently controlled by the same bi-directional promoter (Murray and Young, 2001). 
EBER expression lags behind by approximately 24 hours and does not reach substantial 
levels until approximately 70 hours post-infection. The EBV genome is extensively 
transcribed during latent infection and only a highly restricted complexity o f RNA is 
processed into cytoplasmic polyadenylated polyribosomal mRNA. Polyadenylation 
may determine splicing and thereby regulate expression o f 6 EBNAs from the same 
promoter (Kieff, 1996). However, cis or trans factors may also play a role in splice 
choice, although none have been identified. It is possible that the EBERs or EBNA 
(particularly LP) act as these factors (Kieff, 1996).
EBV-infected LCLs show high levels o f expression o f the B cell activation markers 
CD23, CD30, CD39 and CD70, and o f the cell adhesion molecules lymphocyte- 
function-associated antigen 1 (LFA1; also known as CD1 la/18), LFA3 (also known as 
CD58) and intercellular cell adhesion molecule 1 (ICAM1; also known as CD54) (Kieff 
and Rickinson, 2001; Rowe et a l., 1987). These markers are usually absent or
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expressed at low levels on resting B cells, but are transiently induced to high levels 
when these cells are activated into short term growth by antigenic or mitogenic 
stimulation, indicating that EBV-induced immortalisation can be elicited through the 
constitutive activation o f the same cellular pathways that drive physiological B cell 
proliferation (Young and Rickinson, 2004). The ability o f EBNA2, EBNA3C and 
LMP1 to induce LCL-like phenotypic changes when expressed individually in human B 
cell lines indicates that these viral proteins are key effectors o f the immortalisation 
process (Wang et al., 1990). The role o f EBV latent genes in the in vitro transformation 
o f B cells has been confirmed more recently by the generation o f recombinant forms o f 
EBV that lack individual latent genes. Studies using such viruses have confirmed the 
absolute requirement for EBNA2 and LMP1 in the transformation process, and have 
also highlighted a crucial role for EBNA1, EBNA-LP, EBNA3A and EBNA3C (Kieff 
and Rickinson, 2001).
Epithelial cells generally do not express CD21, suggesting that EBV enters these tissues 
by other, as yet unidentified, cellular receptors. Various human epithelial cells can be 
infected in vitro either by direct contact with high-titre virus supernatant or by co­
cultivation with EBV-producing B cells, such as Akata (Imai et al., 1998). This 
suggests an in vivo model o f EBV infection whereby epithelial tissues might be infected 
by virtue of their close proximity to (i) infectious virus present in saliva or (ii) lyrically 
infected B cells resident near or within epithelial tissues, for example adjacent to the 
sub-epithelial sinus in tonsil or within nasopharyngeal mucosa (Murray and Young, 
2001).
1.9 Structure and functions of the EBV latent genes
The transformation o f B cells by EBV involves the co-ordinated action o f several latent 
gene products. EBV uses its viral proteins, the actions o f which mimic several growth 
factors, transcription factors and apoptotic factors, to usurp control o f cellular pathways 
that regulate diverse homeostatic cellular functions, allowing both cellular 
transformation and the establishment o f a latent infection in the memory B cell 
compartment. The structural and functional properties o f the EBV latent genes are 
addressed below.
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1.9.1 Epstein-Barr virus nuclear antigen 1 (EBNA1)
EBNA1 is a 73 kDa sequence-specific DNA-binding protein which is expressed in all 
EBV-associated tumours and EBV-proliferating cells in healthy EBV carriers. The 
protein consists o f a short amino terminal, a 20-40 kDa glycine-alanine repetitive 
sequence flanked by arginine rich regions, and a highly charged acidic carboxy terminal 
sequence (Hennessy and Kieff, 1983). The glycine-alanine repeat is thought to act as an 
inhibitor o f MHC class I-restricted presentation, and appears to function in inhibiting 
antigen processing via the ubiquitin-proteasome pathway (Levitskaya et a l., 1995). 
Failure to present EBNA1-derived peptides results in ineffective CD8+ T cell responses 
to EBNA1 when expressed in target cells. A nuclear localisation sequence, DNA 
binding domain and a dimerisation domain have also been mapped on the EBNA1 
protein (Figure 1.6).
Figure 1.6: Functional dom ains o f Epstein-Barr virus nuclear antigen 1. EBNA1 is a multifunctional 
73 kDa protein o f  641 amino acids. The protein consists o f  a short amino terminal, a 20-40 kDa glycine- 
alanine repetitive sequence (GlyAla) that varies in length between viral strains. The glycine-alanine 
sequence is flanked with arginine rich regions (GlyArg). A nuclear localisation sequence (NLS), DNA  
binding domain and a protein dimerisation domain have also been mapped on the highly charged acid 
carboxy terminus o f  the EBNA2 protein (adapted from Avolio-Hunter and Frappier, 1998).
EBNA1 plays a number o f important roles during latent EBV infection of human host 
cells. Importantly, EBNA1 activates replication o f the viral genome once every cellular 
S phase (Adams, 1987; Yates and Guan, 1991). This is important because EBV DNA 
rarely integrates into the host cell genome and is usually carried as circular DNA
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episomes in latently infected cells (Humme et al., 2003). Therefore, EBV requires a 
mechanism for replicating viral DNA before mitosis and distributing episomes into 
progeny cells during cell division. EBNA1 fulfils these tasks by both initiating virus 
replication and by segregating the viral episomes during cell division to ensure the EBV 
genome is stably maintained (Kieff and Rickinson, 2001). EBNA1 is known to 
associate with cellular metaphase chromosomes through chromosome binding-domains 
within its N-terminus, an association that is required for both the partitioning of oriP 
plasmids and for their replication (Sears et a l , 2004). Furthermore, EBNA1 activates 
transcription o f other EBV latent gene products.
All of these functions require direct binding of EBNA1 in a sequence specific manner to 
oriP, the origin o f viral replication, which is composed o f two distinct EBNA1 binding 
elements (Ambinder et a l., 1990; Jones et al., 1989; Rawlins et a l ,  1985). These two 
binding elements contain various copies o f the EBNA1 recognition sequence 
T AGG AT AGC AT AT GCT ACCC AG AT CC AG (Kieff, 1996). One o f these two 
regions, the dyad symmetry (DS) element, which contains four EBNA1 binding sites, is 
the site o f initiation o f episomal replication (Wysokenski and Yates, 1989). The other 
region, the family o f repeats (FR) consists o f 20 EBNA1 binding sites and functions as 
an EBNA1-dependent replication enhancer (Wysokenski and Yates, 1989). It has been 
established that EBNA1 binds to DNA as a dimer and that dimérisation is essential for 
DNA binding (Chen et al., 1993; Jones et a l ,  1989; Shah and Ambinder, 1992). Upon 
binding o f EBNA1 to the plasmid origin o f replication, EBV uses host enzymes to 
mediate all remaining steps in replication (Thompson and Kurzrock, 2004).
As well as supporting DNA replication, EBNA1 binding to FR trans-activates the Cp 
promoter, located about 3 kb away on the EBV genome, and other heterologous 
promoters with copies o f the FR upstream (Middleton and Sugden, 1994; Reisman and 
Sugden, 1986; Sugden and Warren, 1989), resulting in the trans-activation of other EBV 
latent genes. EBNA1 binding sites are also present at +10 to +34 nucleotides just 
downstream o f  the Qp promoter (Sample et al., 1992). It is thought that promoter Qp 
operates in response to many transcription factors to ensure and maintain EBNA1 levels 
but is subject to feedback regulation by excess EBNA1 (Nonkwelo et a l ,  1997).
In addition to its involvement in DNA replication and trans-activation, the presence o f 
EBNA1 has been suggested to also contribute a selective advantage to tumour cells.
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Evidence for this is based on a transgenic mouse system where EBNA1 expression 
resulted in the development o f B cell lymphomas (Wilson et a l , 1996). In addition, 
there is some evidence that EBNA1 may mediate some effects on immunoglobulin 
enhancer elements, which in turn regulate c-myc expression o f the translocated c-myc 
locus in BL cells (Magrath et al., 1993; Shiramizu et a l , 1991). The recent isolation o f 
EBV-negative Akata clones that show reduced tumourigenicity in nude mice, provides 
further evidence that EBNA1 may be involved in tumourigenicity, since the only viral 
protein known to be transcribed in the EBV-positive parental cell line is EBNA1 
(Shimizu e/ al 1994).
1.9.2 Epstein-Barr virus nuclear antigen 2 (EBNA2)
EBNA2 (together with EBNA-LP) is the first latent protein detected after EBV 
infection (Kieff, 1996). EBNA2 is a transcriptional trans-activator that is essential for 
EBV driven immortalisation. The inability o f one EBV strain, P3HR1, which carries a 
deletion of the gene that encodes EBNA2 and the last two exons of EBNA-LP, to 
transform B cells in vitro was the first indication o f the crucial role o f EBNA2 in the 
transformation process (Kieff and Rickinson, 2001). Restoration o f the EBNA2 gene in 
P3HR1 has unequivocally confirmed the importance of EBNA2 in B cell transformation 
and has allowed the functionally relevant domains o f EBNA2 to be identified 
(Hammerschmidt and Sugden, 1989; Cohen et a l , 1989). Additionally, EBNA2 is 
essential for the maintenance o f the transformed state. Using an LCL conditional for 
functional EBNA2 expression in the presence o f estrogen, it was shown that cells 
deprived of functional EBNA2 entered a quiescent non-proliferative state or die by 
apoptosis (Kempkes et a l , 1995b).
The EBNA2 gene encodes an 83 kDa protein that localizes in large nuclear granules and 
is associated with nucleoplasmic chromatin and nuclear matrix fractions (Petti et a l, 
1990). EBNA2 differs extensively between typel and type 2 EBV isolates (Aitken et 
a l, 1994) and is responsible for the biological difference that enables the typel strains 
to transform B lymphocytes more efficiently than type 2 (Rickinson et a l , 1987). The 
EBNA2 proteins identified in type 1 and type 2 EBV are called EBNA2A and 2B 
respectively, and only share about 50 %  sequence homology (Adldinger et a l , 1985). 
Characteristic structures o f the EBNA2 protein (Figure 1.7) are. (i) a negatively charged
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region at the amino-terminus, thought to play a role in homo-dimerization, (ii) a 
polyproline region consisting o f 10-40 consecutive prolines depending on the virus 
strain, (iii) a diversity region in the middle o f the protein where the homology between 
EBNA2A and 2B is very low, (iv) a domain responsible for the interaction with the 
DNA binding protein RBP-Jk/CBF1, ( v )  an arginine-glycine rich stretch o f around 18 
amino acids, (vi) a negatively charged region, which harbors a trans-activation domain, 
and (vii) a nuclear localization signal at the carboxy-terminus (Zimber-Strobl and Strobl 
2001).
Pro RBP-Jk
diversity ■  ■ 1
NLS
Dim ArgGly TAD
487 aa
Figure 1.7: Structural dom ains o f E pstein-Barr virus nuclear antigen 2. EBNA2 consists o f a 
negatively charged region at the amino-terminus, which is likely to play a role in homo-dimerization 
(Dim), a polyproline region (Pro) consisting o f  10-40 consecutive prolines depending on the virus strain, 
a diversity region, a domain responsible for interaction with RBP-Jk/CBFl (RBP-Jk), an arginine-glycine 
rich stretch (ArgGly) and a negatively charged region carboxy terminus, which harbors a trans-activation 
domain (TAD) and nuclear localization signal (NLS) (adapted from Zimber-Strobl and Strobl, 2001).
EBNA2 functions as a specific trans-activator of both viral genes and a number of 
cellular genes that in turn are involved in the immortalisation process. EBNA2 activates 
the transcription o f all other viral proteins expressed in LCLs by trans-activating (i) the 
BamHl C promoter Cp (Woisetschlaeger et al., 1990; Sung et a l 1991), from which 
transcription o f all EBNA genes is controlled and (ii) the promoters o f the latent 
membrane proteins LMP1 and LMP2 (Abbot et al., 1990; Fahraeus et al., 1990; Wang 
et al., 1990; Zimber-Strobl et al., 1991; Laux et al, 1994a). In addition, EBNA2 
activates the transcription o f cellular genes including CD21, the B lymphocyte 
differentiation marker (Cordier et a l , 1990), CD23, the B cell activation marker (Wang 
et a l, 1987; Wang et a l , 1990; Wang, et a l, 1991), the FGR tyrosine kinase (Knutson, 
1990; Patel et al, 1990), BATF which induces expression o f a B cell specific 
transcription factor o f the same name (Johansen et a l, 2003), the key proliferative
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transcription factor Myc (Jayachandra et al., 1999; Kaiser et al., 1999) as well as the 
chemokine receptor BLR2/EBH (Burgstahler et al., 1995).
1.9.2.1 EBNA2 interacts with the DNA binding protein RBP-Jk/CBF1
EBNA2 does not bind DNA directly but interacts with a sequence-specific DNA- 
binding protein, jK-recombinant-binding protein (RBP-Jk, also known as CBF1), and 
this is responsible for directing EBNA2 to promoters that contain RBP-Jk/CBF1 
binding sites (Grossman et al., 1994). The cognate DNA sequence element to which 
RBP-Jk/CBF1 binds is 5’-GTGGGAA-3’ and this sequence was first described in the 
EBNA2 responsive element (ERE) o f the LMP2A promoter (Zimber-Strobl et al.,
1993). Binding sites for RBP-Jk/CBF1 have subsequently been identified in other 
known EREs o f promoters activated by EBNA2 including the Cp, LMP1 and CD23 
promoters (Ling et al., 1993; Laux et al., 1994; Ling et al., 1994). RBP-Jk/CBF1 is 
ubiquitously expressed and highly conserved during evolution. In Drosophila, this 
protein is known as suppressor o f hairless (SuH) and is involved in signal transduction 
from the Notch receptor, a pathway that is important in cell fate determination 
(Artavanis-Tsakonaseia/., 1999).
Transient transfection assays using Gal4-CBF1 constructs revealed that RBP-Jk/CBFI 
functions as a transcriptional repressor. RBP-Jk/CBFI mediates repression (i) through 
direct contacts with the basal transcriptional machinery (BTM) (Olave et al., 1998), 
disturbing the TFIIA-TFIID interaction, which is essential for the initiation o f  
transcription and (ii) as a result o f histone deacetylation, which leads to chromatin 
remodelling and a loss o f transcription factor access to the nucleosome-associated 
promoter sequences. The RBP-Jk/CBFI repressor complex (Figure 1.8) includes the 
proteins SMRT/NcoR, HDAC1, HDAC2, SAP30, CIR and SKIP (Kao et al., 1998; 
Zhou et al., 2000a; Zhou et al., 2000b; Zhou and Hayward, 2001; Hsieh et al., 1999). 
In the co-repressor complex, SKIP binds to the carboxy terminal RID-2 domain of 
SMRT and along with SMRT is important for nuclear entry o f RBP-Jk/CBFI (Zhou and 
Hayward, 2001). SKIP also interacts with Sin3A (Zhou et a\., 2000a) and this, along 
with the fact that SAP30 is part o f the Sin3 complex, implies that Sin3 is also present in 
the complex.
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Figure 1.8: EBNA2-m ediated prom oter activation. (A) EBNA2 functions as a transcriptional activator 
by interacting with the DNA-binding JK-recombination-binding protein (RBP-Jk/CBF1) and relieving 
transcriptional repression that is mediated by a large multi-protein complex consisting o f SMRT, SIN3A. 
histone deacetylase 1 (HDAC1) and HDAC2. SKIP (Ski interacting protein) is another RBP-Jk- 
interacting protein that also interacts with the SMRT-HDAC co-repressor complex. EBNA2 abolishes 
RBP-JK-mediated repression by competing with the SMRT-HDAC co-repressor for binding to both RBP- 
Jk and SKIP. (B) The acidic domain o f  EBNA2 then recruits the basal transcription machinery (TFIIB, 
TFIIH and p300, not shown) to activate transcription. EBNA-LP cooperates with EBNA2 in RBP-Jk- 
mediated transcriptional activation by interacting with the acidic activation domain o f  EBNA2. The 
EBNA3 family o f  proteins modulate EBNA2-mediated RBP-Jk activation by interacting with RBP-Jk and 
competing for binding and activation by EBNA2 (adapted from Young and Rickinson, 2004).
EBNA2 trans-activates promoters by (i) binding to the repression domain o f RBP- 
Jk/CBF1 to relieve repression and (ii) by bringing a strong transcriptional activation 
domain to the promoter (Hsieh and Hayward, 1995). These properties were 
demonstrated in studies where an EBNA2 mutant capable o f binding to RBP-Jk/CBF1, 
but lacking the trans-activation domain, was able to relieve repression by displacing the 
RBP-Jk/CBFI co-repressor complex. Transcriptional up-regulation depended on the 
presence o f the EBNA2 trans-activation domain, which recruits co-activator proteins 
(Hsieh and Hayward, 1995; Wang et a l., 2000). During EBNA2 displacement o f the 
RBP-Jk/CBFI co-repressor complex, adjacent domains make contact with RBP-
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Jk/CBF1 and SKIP to displace SMRT (Figure 1.8). Direct competition for binding to 
SKIP has been demonstrated for SMRT and EBNA2 (Zhou et al., 2000a). Conserved 
region 5 (CR5) of EBNA2 binds SKIP and conserved region 6 (CR6) binds to RBP- 
Jk/CBF1. The locations o f CR5 and CR6 on the EBNA2 protein may be seen in Figure
1.9 below. A mutation within CR6 that abolishes EBNA2 binding to RBP-Jk/CBFI 
(WW323SR) completely abolishes EBNA2-mediated trans-activation (Ling and 
Hayward, 1995; Ling et al., 1993), and when incorporated into the virus, this mutation 
results in a non-immortalising EBV (Yalamanchili et al., 1994). Mutations within CR5, 
such as the II307 mutant, which are impaired for SKIP interaction are equally impaired 
for the trans-activating function o f EBNA2 (Zhou et al., 2000a). Introduction o f 
deletions that span CR5 into the EBV genome led to a mutant virus that either failed to 
immortalise B cells in vitro or resulted in B cell colonies that grew less than the wild 
type virus-immortalised controls (Harada et al., 1998). Taken together, these data 
indicate that EBNA2 requires contact with both SKIP and RBP-Jk/CBFI for effective 
activation of promoters containing RBP-Jk/CBFI binding sites.
Figure 1.9: The locations o f the SKIP and R BP-Jk/C B F I  interaction regions on the EBNA2 protein.
A schematic representation o f  the EBNA2 protein illustrating the relative locations o f  characterized 
functional domains and the position o f the WW323SR mutation. The amino acid numbers are indicated. 
CR5, CR6 and a nuclear localization signal (NLS) are also indicated.
1.9.2.2 Co-Activating Proteins Interact with EBNA2
EBNA2 interacts with other proteins to facilitate trans-activation of EBNA2-responsive 
genes. The acidic domain o f EBNA2 interacts with factors o f the basal transcription 
machinery to assemble the pre-initiation complex. These factors include TFIIH, TATA
24
box binding protein (TBP), associated binding factor TAF40, TFIIB, and the co­
activator plOO that interacts with TFIIE (Tong et al., 1995a; Tong et al., 1995b; Tong et 
al., 1995c). The trans-activation domain also interacts with the histone 
acetyltransferases (HATs) p300/CBP and PCAF (Wang et a l., 2000). HATs facilitate 
chromatin opening, which is necessary for initiation o f transcription. The viral protein 
EBNA-LP also acts as a co-activator o f EBNA2 (Nitsche et a l., 1997; Harada et al., 
1997). Outside the activation domain, EBNA2 interacts with the chromatin remodelling 
complex hSWl-SNF, which converts the chromatin structure to facilitate transcription 
(Wu et al., 2000a). Another protein DP103, the dead box protein, which is complexed to 
the survival neuron protein SMN, also binds to EBNA2 and these can cooperatively 
trans-activate the LMP1 promoter (Voss et al., 2001).
1.9.2.3 EBNA2-responsive elements (EREs)
The promoter elements responsible for EBNA2-mediated trans-activation have been 
mapped for the viral Cp, LMP1 and LMP2 promoters (Woisetschlaeger et al., 1990; 
Sung et al., 1991; Fahraeus et al., 1990; Wang et al., 1990; Zimber-Strobl et al., 1991; 
Laux et al., 1994a) and for the promoter o f the cellular gene CD23 (Wang et al., 1991). 
These EBNA2-responsive elements (EREs) are all relatively large, are orientation 
independent and confer EBNA2-responsiveness to heterologous promoters. 
Furthermore, they all contain at least one RBP-Jk/CBFI binding site (Zimber-Strobl and 
Strobl, 2001). Although the interaction between EBNA2 and RBP-Jk/CBFI is 
necessary for induction o f gene expression, additional factors bind within the enhancer 
elements to confer EBNA2-responsiveness (Meitinger et al., 1994). In the LMP1 
promoter, binding o f PU.l/Spi-B, which is also thought to interact with EBNA2, is 
absolutely necessary for EBNA2-mediated trans-activation (Johannsen et al., 1995; 
Laux et a l 1994b; Sjoblom et al., 1995). It has also been shown that a POU domain 
protein is involved in the EBNA2-mediated trans-activation of LMP1 (Sjoblom et al.,
1995). In the LMP2A promoter, beside RBP-Jk/CBFI two further proteins bind within 
the EBNA2-responsive region and contribute to EBNA2-mediated trans-activation. 
These proteins, however, have not been identified to date (Hoefelmayr et al., 1999). In 
the Cp promoter, binding o f the hnRNP protein AUF1 appears to cooperate with RBP- 
Jk/CBFI in EBNA2-responsiveness (Fuentes-Panana et al., 2000).
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1.9.2.4 Viral and cellular proteins counter-regulate EBNA2 activity
EBNA2 mediated trans-activation through RBP-Jk/CBFI can be disrupted by a number 
o f viral and cellular proteins. The EBV nuclear antigens EBNA3A, EBNA3B and 
EBNA3C compete with EBNA2 for binding to RBP-Jk/CBF1 (Johannsen et al.y 1996; 
Robertson et al., 1995; Le Roux et a l ,  1994). The RBP-Jk/CBF1-EBNA3C complex 
does not bind to DNA and so transcriptional activation is blocked by loss o f access to 
RBP-Jk/CBFI and loss o f  RBP-Jk/CBFI promoter targeting. The positive regulation o f 
EBNA2 by EBNA-LP binding and the balancing negative regulation by the EBNA3 
family places EBNA2 activity largely under viral control and the level o f the RBP- 
Jk/CBF1 complex (Hayward, 2004). One o f the Epstein-Barr Virus BamUl A rightward 
transcripts (BARTs) contains an open reading frame designated RPM Sl. This encodes a 
nuclear protein RPMS (Smith et a l., 2000), which interacts with RBP-Jk/CBFI and the 
RBP-Jk/CBF1-associated co-repressor CIR, to stabilize the RBP-Jk/CBF1 co-repressor 
complex, thereby negatively regulating the trans-activational effect o f EBNA2 (Zhang 
et a l., 2001). Furthermore, a cellular LIM protein, KyoT2, has also been identified, 
which dislocates RBP-Jk/CBF1 from DNA by competing with EBNA2 for binding to 
RBP-Jk/CBF1 (Taniguchi e ta l., 1998).
1.9.2.5 RBP-Jk/CBFI links EBNA2 to the cellular Notch signalling pathway
RBP-Jk/CBF1 also plays an important role in the Notch signalling pathway, which 
regulates cell fate decisions in many different organisms from worm to humans 
(Artavanis-Tsakonas et a l 1999). The Notch signalling pathway was originally 
discovered through genetic studies in the fruit fly Drosophila melanogaster, and the 
name derives from the effect o f some Notch alleles to create notched wings (Hansson et 
al., 2004). Cloning o f the Notch gene (Wharton et a l., 1985; Kidd et al., 1986) showed 
that it encodes a single trans-membrane receptor (Figure 1.10). The amino-terminus 
contains a signal peptide followed by multiple epidermal growth factor (EGF)-like 
repeats, which function as a ligand binding domain, and cystine-rich Lin 12/Notch 
repeats. The intracellular part contains the RAM domain and ankyrin repeats which are 
both important for RBP-Jk/CBFI interaction. Also, in the intracellular region lie three 
nuclear localization signals (NLS), and a C terminal PEST (proline-, glutamate, serine-, 
threonine-rich) region, which regulates protein stability (Weinmaster, 1997). A possible
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trans-activation domain has also been identified at the carboxy-terminus (Kurooka et 
al., 1998; Dumont et a l, 2000). Four Notch genes have been isolated and identified in 
vertebrates (Notch 1, Notch2, Notch3 and Notch4) and the structures o f the proteins 
encoded by these genes are strikingly similar to Drosophila Notch (Artavanis-Tsakonas 
et al., 1995; Greenwald, 1994; Lardelli et al., 1995; Uyttendaele et al., 1996). Like 
Drosophila Notch, the Notchl and Notch2 proteins contain 36 tandemly arranged EGF- 
like repeats, while Notch3 and Notch4 have 34 and 29 repeats respectively 
(Weinmaster, 1997).
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Figure 1.10: Structure o f the Notch receptor. The N-terminal o f  the Notch protein contains a signal 
peptide followed by multiple epidermal growth factor (EGF)-like repeats, that function as a ligand 
binding domain, and cysteine rich L inl2/Notch repeats (LN). These regions comprise the extracellular 
domain o f  the Notch protein (N ^ ). The intracellular part (N10) harbours the RAM domain and a series o f  
ankyrin repeats, which both interact with RBP-Jk/C BF1, 3 nuclear localisation signals (NLS), and a C- 
terminal PEST region. The arrows (SI to S3) indicate the sites o f  proteolytical cleavage during protein 
maturation and following binding o f  ligand (adapted from Zimber-Strobl and Strobl, 2001).
Notch receptors are activated by interaction with membrane bound ligands. The ligands 
that bind and activate Notch receptor belong to the DSL family, defined by the 
invertebrate ligands Delta, Serrate and LAG-2 (Henderson et al., 1994; Mello et al., 
1994; Tax et al., 1994). Vertebrate genes encoding both Delta-like (Delta 1 and Delta 
2) and Serrate-like (Jagged 1 and Jagged 2) subtypes have been isolated from humans, 
rats, mice, chickens and frogs (Weinmaster, 1997). The basic picture emerging from 
many different studies has the extracellular domain o f the ligands, expressed on the 
surface o f one cell, interacting with the extracellular domain o f the Notch receptor on an 
adjacent cell.
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Data from several groups have led to a model o f Notch activation involving proteolytic 
cleavages at three sites (SI to S3) (Baron, 2003). The location o f these sites on the 
Notch protein is indicated in Figure 1.10. After its synthesis in the endoplasmic 
reticulum (ER), the 300 kDa Notch receptor is transported through the secretory 
pathway to the trans-Golgi network, where it is constitutively cleaved by a furin-like 
convertase at SI, generating an N-terminal fragment o f 180 kDa that contains the Notch 
extracellular subunit (NotchEC) and a C-terminal fragment o f about 120 kDa containing 
a short extracellular part, the trans-membrane domain and the intracellular part 
(NotchIC). The two fragments are reassembled in the Golgi apparatus to a hetero­
dimer, which can then be expressed on the cell surface (Blaumueller et al., 1997, Logeat 
et a l., 1998). Proteolytic processing o f the 300-kDa precursor is an essential step in the 
formation o f the biologically active receptor, as only the cleaved fragments are present 
at the cell surface (Logeat et a l., 1998). Ligand-receptor interactions between cells in 
physical contact, result in two further cleavages. At first the disintegrin-metalloprotease 
tumour necrosis factor a-converting enzyme (TACE) catalyses the cleavage at S2, 
which removes most o f the extracellular part (Mumm et a l., 2000; Brou et al., 2000). 
S2-processed Notch acts as a substrate for a third proteolytic cleavage at S3 (Schroeter 
et al., 1998), which releases the intracellular region o f the Notch receptor (NotchIC). 
S3 cleavage is mediated by the y-secretase complex, an enzyme complex that 
constitutively cleaves certain trans-membrane domains with short extracellular stubs 
(De Strooper et al., 1999). A functional y-secretase complex is composed o f four 
proteins: presenilin, nicastrin, Pen-2 and Aph-I (Edbauer et al., 2003), and presenilin is 
thought to contain the protease activity (Selkoe and Kopan, 2003). As a result o f S3 
cleavage, NotchIC is translocated to the nucleus, where it interacts via the RAM domain 
and ankyrin repeats with RBP-Jk/CBF1 (Jarriault et al., 1995). In the absence o f a 
Notch signal, RBP-Jk/CBF1 can repress transcription through recruitment o f the 
HDAC-containing co-repressor complex. However, similarly to EBNA2, binding o f 
NotchIC displaces the repressor complex, resulting in the activation of transcription. 
Several target genes have been described, which are induced through the interaction o f 
NotchIC with RBP-Jk/CBF, for example the hairy enhancer o f split complex [E(spl)] 
related genes Hesl and Hes5, H eyl, Hey2 and HeyL (Jarriault et al., 1995; Nishimura 
et a l ,  1998; Maier and Gessler, 2000), ERBB-2 (Chen et a l ,  1997), NF-kB2 (Oswald et 
a l,  1998) and hairy-related transcription factor (HRT) (Nakagawa et a l ,  2000). Figure
1.11 summarises the activation o f NotchIC as a direct result o f ligand binding.
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Figure 1.11: The Notch signalling pathway. (1) Ligand (Delta 1, Delta 2, Senate 1, Senate 2) on a 
neighbouring cell binds to the Notch receptor. (2) The ligand-receptor interaction results in a series o f  
cleavages o f  the Notch receptor: At first the disintegrin-metalloprotease tumour necrosis factor a- 
converting enzyme (TACE) catalyses cleavage at S2, which removes most o f  the extracellular part o f  the 
Notch protein. S2-processed Notch acts as a substrate for a proteolytic cleavage at S3, which releases the 
intracellular region o f  the Notch receptor (NotchIC). S3 cleavage is mediated by the y-secretase complex. 
(3) As a result o f  S3 cleavage, NotchIC is translocated to the nucleus, where it interacts via the RAM  
domain and ankyrin repeats with RBP-Jk/CBFI. (5) Binding o f  NotchIC to RBP-Jic/CBFl displaces the 
co-repressor complex, allowing transcriptional activation o f Notch responsive genes. (6) Expression o f  
Notch responsive genes determines the fate o f  the cell.
1.9.2.6 EBNA2 and Notch-IC overlap in their functions and in their target genes
Both EBNA2 and NotchIC trans-activate genes by interacting with RBP-Jk/CBFI. 
Although there is no obvious sequence homology between these two proteins, they 
interact with similar regions o f RBP-Jk/CBFI and replace repressor proteins with their 
trans-activation domains. Furthermore, there are parallels between EBNA2 and 
NotchIC in the ways in which transcriptional activation through RBP-Jk/CBFI is 
modified. As was the case for EBNA2, co-activating proteins interact with NotchIC.
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These co-activating proteins include the HATs PCAF, GCN5 (Kurooka and Honjo,
2000) and p300/CBP (Oswald et al., 2001; Wallberg et al., 2002), which play a key role 
in chromatin opening and initiation o f transcription. In addition, full transcriptional 
activation by NotchIC requires the human homologue o f Drosophila Mastermind, 
MAML1, which binds to the ankyrin repeat domain o f Notch and also recruits 
p300/CBP (Wu et al., 2000b; Kitagawa et al., 2001; Fryer et al., 2002). As for EBNA2, 
NotchIC activity is also regulated in part by loss o f RBP-Jk/CBF1 binding. The LIM 
protein KyoT2 was identified in a yeast two-hybrid screen as an RBP-Jk/CBF1- 
interacting protein and shown to prevent DNA binding by RBP-Jk/CBF1 (Taniguchi et 
al., 1998). MINT/SHARP antagonizes NotchIC binding to RBP-Jk/CBF1 (Oswald et 
al., 2002; Kuroda et al., 2003). Overall, however, NotchIC function may be regulated 
less at the point o f the RBP-Jk/CBF1 complex and more through processes such as 
differential expression o f Notch ligands, receptor recycling and protein turnover 
(Tanigaki et al., 2003; Nickoloff et al., 2003).
Since both EBNA2 and Notch-IC proteins share a common mechanism for regulating 
target gene expression, it not surprising that they also overlap in the range o f functional 
activities and in the genes that they regulate. This is reflected in the ability o f both 
proteins to activate (i) the same RBP-Jk/CBF1-regulated genes in reporter assays 
(Hofelmayr et al., 1999), (ii) EBV latency promoters (with the exception o f LMP1) 
(Strobl et al., 2000) and (iii) effect expression o f the same cellular genes. Examples o f 
the latter are up-regulation o f BATF (Johansen et al., 2003) and CD21 (Strobl et al.,
2000) and down-regulation o f the Ig enhancer (Strobl et al., 2000; Morimura et al.,
2001). It has also been demonstrated that EBNA2 can activate the NotchlC-responsive 
Hesl promoter. Most likely by induction o f H esl, EBNA2 has the ability to suppress 
differentiation o f the myogenic cell line C2C12, similar to activated Notch (Sakai et al., 
1998; Kuroda et al., 1999). Additionally EBNA2 and Notch-IC have been shown to 
protect cells from apoptosis by binding to the cellular Nur77 (TR3/NGF1B) 
transcription factor that is a member o f the nuclear hormone receptor super-family (Jehn 
et al., 1999; Lee et al., 2002). The set o f promoters, which is regulated by EBNA2 and 
NotchIC, is overlapping but not identical. Only EBNA2, but not NotchIC, can induce 
LMP1, CD23 and c-myc expression and maintains proliferation o f immortalized B cells 
(reviewed in Zimber-Strobl and Strobl, 2001). In order to understand the extent to 
which EBNA2 is a functional equivalent to Notch, it will be important in the future to
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identify further target genes o f both these proteins and compare their roles in cell fate 
decisions, such as cell proliferation and differentiation.
EBNA2 immortalises B lymphocytes in culture to generate continually proliferating 
LCLs, demonstrating that EBNA2 stimulates B cell survival and growth proliferation in 
the setting o f EBV infection. Since EBNA2 associates with the RBP-Jk/CBF1 
repression complex in order to relieve repression and subsequently trans-activate target 
genes, EBNA2 can be regarded as a functional homologue of the activated Notch 
receptor (Hsieh et al., 1996). It has not been clear how to integrate these facts with 
work demonstrating that a dominant function o f Notch 1IC in hematapoiesis is to induce 
common lymphoid progenitors to adopt a T cell fate at the expense o f B cell 
development (Izon et al., 2002; Han et a i ,  2002; Radtke et al., 2002). Although the 
role o f Notch in the B cell compartment remains incompletely understood, recent 
findings allow speculation on the ways in which the EBNA2 usurping o f Notch function 
may sustain a lifelong EBV infection in the host (Hayward, 2004). Firstly, there is 
evidence that Notch signalling increases the formation o f hematopoietic stem cells. 
Jagged 1 is expressed on bone marrow stroma and on stromal cell lines and co-culture of 
murine marrow precursors with Jagged 1 increased the formation of precursor cell 
populations (Vamum-Finney et al., 1998;Varnum-Finney et al., 2003). Osteoblastic 
cells also express Jagged 1 and increased exposure to osteoblasts augments primitive 
haematopoietic cell growth in a Notch-dependent manner (Calvi et al., 2003). EBNA2- 
induced B lymphocyte proliferation may therefore be recapitulating a precursor stem 
cell response. This proliferation is thought to be important in expanding the infected 
cell population after primary EBV infection to permit establishment o f a life-long 
latency in the memory B cell compartment (Hayward, 2004).
1.9.3 The Epstein-Barr virus nuclear antigen 3 family (EBNA3A, EBNA3B and 
EBNA3C)
The EBNA3 family members are encoded by alternatively spliced transcripts initiated at 
the Cp promoter (Kieff, 1996). Conserved sequences are confined to the N-terminal 
third o f the EBNA3 proteins (Rowe, 1999). Studies with EBV recombinants have 
shown that EBNA3A and EBNA3C are essential for B cell transformation in vitro, 
whereas EBNA3B is dispensable (Roberston, 1997). EBNA3C can induce the up-
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regulation o f both cellular (CD21) and viral (LMP1) gene expression (Allday and 
Farrell, 1994), and repress the Cp promoter (Radkov et al., 1997). EBNA3C may also 
interact with the retinoblastoma protein, pRb, to promote transformation (Parker et al.,
1996). Although not essential for transformation, EBNA3B has been shown to induce 
expression o f vimentin and CD40 (Silins and Sculley, 1994). The EBNA3 family o f  
proteins act as transcriptional regulators by associating with the RBP-Jk/CBF1 
transcription factor and disrupting its binding to the cognate Jk sequence and to 
EBNA2. This results in repression o f EBNA2-mediated trans-activation (Robertson,
1997). Thus, EBNA2 and the EBNA3 proteins work together to precisely control RBP- 
Jk/CBF1 activity, thereby regulating the expression o f cellular and viral promoters 
containing RBP-Jk/CBF1 binding sites. More recently, EBNA3C has been shown to 
interact with the human histone deacetylase 1 (HDAC1), which in turn contributes to 
the transcriptional repression o f Cp by RBP-Jk/CBFI (Radkov et al., 1999).
1.9.4 Epstein-Barr virus nuclear antigen leader protein (EBNA-LP)
EBNA-LP, also known as EBNA5, is one o f the first viral proteins produced during 
EBV infection o f B lymphocytes (Kieff, 1996). EBNA-LP is encoded by the first ORF 
(leader sequence) o f the extensively spliced primary transcript, originating from either 
the Wp or Cp promoter, and encodes a protein o f variable size (20 -130 kDa) depending 
on the number o f BamYR W repeats contained by a particular EBV isolate. EBNA-LP, 
although apparently not essential for transformation, greatly enhances the efficiency o f  
the process (Hammerschmidt and Sugden, 1989; Mannick et al., 1991). EBNA-LP 
interacts with EBNA2 and is required for the efficient outgrowth o f virus transformed B 
cells in vitro (Mannick et al., 1991; Sinclair et al., 1994). Expression o f EBNA-LP 
together with EBNA2 in resting B lymphocytes results in the activation of cyclin D2, 
which is necessary to drive cells into the G1 phase o f the cell cycle (Sinclair et al.,
1994). EBNA-LP can also cooperate with EBNA2 to up-regulate expression o f the 
major EBV effector protein o f B cell transformation, LMP1 (Nitsche et al., 1997). 
Furthermore, EBNA-LP can bind and inactivate the cellular p53 and pRb protein 
tumour suppressor gene products (Szekely et al., 1993), also resulting in progression 
into the cell cycle.
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1.9.5 Latent membrane protein 1 (LMP1)
The frequent detection o f LMP1 in many EBV-associated malignancies led to the 
suggestion that this protein contributes to tumourigenesis. Several studies have shown 
that LMP1 possesses oncogenic properties. The expression o f  LMP1 leads to 
transformation o f rodent fibroblast cell lines and renders them tumourigenic in nude 
mice (Wang et al., 1985). In BL-derived cell lines, LMP1 induces many o f the 
phenotypic changes observed in EBV infection, including the up-regulation o f B cell 
activation markers and cell adhesion molecules (Kieff and Rickinson, 2001). LMP1 can 
also suppress cell death induced by a variety o f stimuli through the up-regulation o f 
anti-apoptotic proteins, such as Bcl-2, Mcl-1, Bfl-1, A20 and c-IAPs (Henderson et a l., 
1991; Fries et al., 1996; Wang et al., 1996; D ’Souza et al., 2000; Laherty et al., 1992, 
Hong et al., 2000). In addition, LMP1 expression blocks the normal process o f 
differentiation in epithelial cells, reminiscent of the undifferentiated phenotype 
frequently observed in NPC (Dawson et al., 1990). Furthermore, LMP1 expression in 
carcinoma cell lines promotes IL-8 production (Eliopoulos et al., 1999b) and up- 
regulation o f matrix metalloproteinases (MMPs) (Yoshizaki et al., 1998), suggesting 
that in addition to is transforming potential, LMP1 may influence angiogenesis and 
metastasis in EBV-associated tumours. In keeping with these in vitro findings, targeted 
expression o f LMP1 in the skin or B cell compartment o f transgenic mice leads to the 
induction o f hyper-proliferation and lymphomagenesis, respectively (Kulwichit et al., 
1998; Wilson al., 1990).
LMP1 is a 63 kDa integral membrane phosphoprotein belonging to the tumour necrosis 
factor receptor (TNFR)/CD40 super-family and functions as a constitutively active 
receptor (Gires et al., 1997), which mimics the cellular growth signal that normally 
results from the binding o f CD40 ligand (Thompson and Kurzrock, 2004). The LMP1 
protein can be divided into three domains (Figure 1.12). Firstly, an amino-terminal 
cytoplasmic tail (amino acids 1-23), which tethers LMP1 to the plasma membrane and 
orientates the protein. Secondly, a trans-membrane region, consisting o f six 
hydrophobic trans-membrane loops, which are involved in self-aggregation and 
oligomerisation (amino acids 24-186). Third, a long carboxy-terminal cytoplasmic 
region (amino acids 187-386), which possesses most o f the signalling activity o f the 
molecule (Young and Rickinson, 2004). LMP1 signals mainly from the intracellular 
compartments (Lam and Sugden, 2003). Both oligomerisation and localisation within
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glycosphingolipid-rich membrane rafts are essential for the initiation o f signalling 
(Clausse et a l., 1997; Eliopoulos and Young, 2001; Higuchi et al., 2001) resulting in the 
activation of several signalling pathways in a ligand-independent manner.
At least four signalling pathways have been implicated in the function o f LMP1, namely 
nuclear factor kB (NF-kB), c-Jun NH2 terminal kinase (JNK), p3 8/mitogen activated 
protein kinase (p38/MAPK) and janus kinase/signal transducers and activators of 
transcription (JAK/STAT) (Murray and Young, 2001). NF-kB is a key transcription 
factor involved in regulation o f  cell growth and apoptosis. NF-kB controls the 
expression of numerous cytokines, including lymphotoxin, which is an autocrine growth 
factor for EBV-transformed cells (Thompson and Kurzrock, 2004). p38/MAPK is also 
a central signalling pathway that regulates the activation o f the transcription factor 
ATF2 (Eliopoulos et a l., 1999b). LMP1 induces activation o f another member o f the 
MAPK family, namely JNK, resulting in the activation o f the pleiotropic transcription 
factor AP-1 (Eliopoulos et al., 1999a). The JAK/STAT pathway is activated by a 
number o f growth factors and cytokines that regulate transcription and control diverse 
cellular functions, such as proliferation, apoptosis and cell surface marker expression. 
LMP1 binds JAK3 leading activation o f the transcription factor STAT1 (Gires et al., 
1999). Taken together, the activating cascades associated with LMP1 lead to enhanced 
expression o f B cell surface adhesion molecules (LFA1, CD54 and CD58), B cell 
activation markers (CD23, CD39, CD40, CD44 and MHC class II), and morphological 
changes such as cellular clumping (Thompson and Kurzrock, 2004). As LMP1 
activates transcription factors that are key modulators o f cell growth, they might also be 
relevant to the role o f EBV in some cancers.
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Figure 1.12: Structure of LM P1. The EBV LMP1 is an integral membrane protein o f 63 kDa and can 
be subdivided into three domains. Firstly, an amino-terminal cytoplasmic tail, which tethers LMP1 to the 
plasma membrane and orientates the protein. Secondly, a trans-membrane region, consisting o f six  
hydrophobic trans-membrane loops, which are involved in se lf aggregation and oligomerisation. Third, a 
long carboxy'terminal cytoplasmic region, which possesses most o f  the signalling activity o f  the 
molecule. Two distinct functional domains referred to as C-terminal activation regions 1 and 2 (CTAR1 
and CTAR2) have been identified on the basis o f  their ability to activate the NF-kB signalling pathway 
(Huen et a l., 1995) (adapted from Young and Rickinson, 2004).
It is the cytoplasmic C-terminus o f LMP1 that is responsible for the transduction of 
signalling cascades that result in primary B cell transformation and phenotypic changes. 
Within the C-terminus o f LMP1 there are at least two major activating domains (Figures
1.12 and 1.13), C-terminal activating region 1 (CTAR1) and CTAR2. CTAR1 (also 
known as transformation effector site 1, TES1) is located proximal to the membrane 
(amino acids 186-231), binds TNFR-associated factors (TRAFs) (Devergne etal., 1996; 
Huen et al., 1995), and is essential for EBV-mediated B-cell immortalisation (Izumi et 
al., 1997; Kaye et al., 1995; Kaye et al., 1999). CTAR2/TES2, which is located near 
the C-terminus (amino acids 351-386), supports the long-term growth o f immortalised 
B cells (Izumi and Kieff, 1997) and recruits the TNFR-associated death domain
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(TRADD) protein and receptor-interacting protein (RIP) (Eliopoulos et a l., 1999a; Huen 
et a l 1995; Izumi e/ a l 1999). The molecular interactions and signalling pathways 
engaged by LMP1 are summarised in Figure 1.13). The activities o f CTAR1 and 
CTAR2 affect diverse signalling cascades and provide the basis for the molecular 
explanation o f the transforming properties o f LMP1.
LMPl
Figure 1.13: Schem atic representation o f the m olecular interactions and signalling pathways 
engaged by L M P l. The C-terminus o f  LM Pl contains at least two activating regions, referred to as C- 
terminus activation regions 1 and 2 (CTAR1 and CTAR2). CTAR1, which is essential for EBV-mediated 
B cell immortalisation, binds TRAF1, TRAF2, TRAF3 and TRAF5 and activates the NF-kB  and p38 
signalling pathways. CTAR2 supports the long-term growth o f  immortalised B cells and recruits 
TRADD to activated downstream signals, such as NF-kB, JNK, and p38. Both LM Pl C-terminal 
domains also mediate the activation o f  the JAK/STAT pathway, although an intermediated region has 
also been shown to bind JAK3 and induce STAT binding activity independently o f  CTAR1 and CTAR2. 
The tran-smembrane domains o f  LM Pl are responsible for the activation o f  the small GTPase Cdc42 
leading to cytoskelatal changes (adapted from Eliopoulos and Young, 2001).
1.9.5.1 LMPl-mediated activation of the NF-kB signalling pathway
N F - kB  signalling has been extensively studied and it has been shown to play a role in 
proliferation, differentiation, apoptosis, oncogenesis and inflammation. The list o f 
potential activators o f N F - kB  is diverse and includes pro-inflammatory stimuli such as
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TNF, cytokines such as CD40 ligand and IL-1, bacterial products such as 
lipopolysaccharide (LPS), as well as stress signals. Additionally, many viruses, 
including, human T-cell leukaemia virus type I (HTLV-1), herpes simplex virus-8 
(HSV-8) and EBV, utilize this pathway to promote survival and transformation of 
infected target cells (Eliopoulos and Young, 2001). The NF-kB pathway provides an 
attractive target to viral pathogens for several reasons. Activation o f NF-kB is a rapid 
event that occurs within minutes after exposure to a relevant stimulus and does not 
require de novo protein synthesis. Additionally, viruses have evolved strategies that 
result in the modulation o f the NF-kB pathway in order to enhance host cell survival 
and evasion o f immune responses. Furthermore, activation o f NF-kB constitutes an 
obvious target because many o f  the NF-KB-responsive genes (growth factors, cytokines, 
proto-oncogenes, and anti-apoptotic proteins) profoundly influence the host cell cycle 
(Hiscott et a l , 2001). In the case o f EBV, LMP1 has appropriated the NF-kB signalling 
pathway into its mechanism o f B cell transformation. Indeed, there is recent evidence to 
suggest that suppression o f  EBV-mediated NF-kB activation compromises the viability 
o f EBV-infected LCLs (Cahir-McFarland et a l ,  2000).
The eukaryotic transcription factor NF-kB was originally identified as a protein that 
bound to a specific DNA sequence within the intronic enhancer o f the Ig kappa light 
chain in mature B- and plasma cells (Sen and Baltimore, 1986). NF-kB has 
subsequently been identified in most cell types, and specific NF-kB binding sites have 
also been identified in promoters and enhancers o f a number o f inducible genes. The 
transcription factor NF-kB consists o f homo- or hetero-dimers composed of different 
subunits. The subunits are all members of the NF-KB/Rel family o f structurally related 
proteins. The Rel proteins share an approximately 300-amino acid amino terminal Rel 
homology domain that contains sequences essential for dimerisation, DNA binding and 
nuclear transport (Hiscott et a l ,  2001). Each dimer combination exhibits differences in 
DNA binding affinity and trans-activation potential (Delfino and Walker, 1999). Five 
different Rel proteins have been identified to date, namely Rel A (p65), RelB, NF-kB 1 
(p50/pl05), NF-kB2 (p52/pl00) and c-Rel. Family members c-Rel, Rel A and RelB 
possess C-terminal trans-activation domains, while p50/pl05 and p52/pl00 function as 
either short DNA binding domains or larger inactive proteins which contain C-terminal 
inhibitory domains (Hiscott et a l ,  2001). Because o f the potential for generating 
diverse homo- and hetero-dimers, these proteins may allow transcriptional specificity by
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forming combinations that can interact specifically with structural variations o f the NF- 
kB DNA binding site.
In its inactive form NF-kB is sequestered in the cytoplasm, bound by members o f the 
IkB family o f inhibitor proteins. The various stimuli that activate NF-kB result in the 
phosphorylation o f IkB by the multi-subunit IkB kinase complex (IKK). IKK contains 
two catalytic subunits, IKKa and IKK|3, and the regulatory subunit IKKy [NF-kB 
essential modulator (NEMO)] (Karin, 1999). Phosphorylation o f IkB by the IKK 
complex, targets the IkB molecules for ubiquitination (the covalent attachment o f 
multiple ubiquitin molecules), whereupon the IkB inhibitor is degraded by the 26S 
proteasome, allowing the release o f NF-kB proteins. The phosphorylation and 
subsequent release o f NF-kB exposes the nuclear localisation signals (NLS) on the NF- 
kB subunits, resulting in translocation o f the molecule to the nucleus. In the nucleus, 
NF-kB binds to promoters bearing kB consensus sequences, leading to activation o f 
transcription. The biochemistry o f NF-kB activation is summarised in Figure 1.14.
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Figure 1.14: The biochem istry o f NF-kB activation. NF-kB is sequestered in the cytoplasm by the 
inhibitory IkB proteins. Stimulation by a diverse array o f  pathogens and other inducers including viruses, 
cytokines and stress-inducing agents leads to the activation o f  signalling cascades that culminate with the 
activation o f  the IKK com plex and phosphorylation o f  the IkB inhibitor. NF-kB D N A  binding subunits 
are released and translocate to the nucleus where they trans-activate NF-KB-responsive genes. Target 
potential genes are selectively regulated by the distinct transcriptional activation potential o f  different NF- 
kB subunit combination (adapted from Hiscott et a l 2001).
38
NF-kB plays a key role in most LMP1-stimulated gene expression (Devergne et al., 
1998; He et al., 2000; Mehl et al., 2001) and this activity is critical for the up-regulation 
o f anti-apoptotic gene products, such as A20 and c-IAPs, cytokines such as IL-6 and IL- 
8, as well as cell surface antigens such as CD40 and CD54 (ICAM1). Moreover, 
inhibition of NF-kB impairs the ability o f LMP1 to promote transformation and 
tumourigenicity in Rat-1 fibroblasts (He et al., 2000). This effect is consistent with the 
observation that the LMP1 domains, which are critical for immortalisation o f EBV- 
infected B-cells, namely CTAR1 and CTAR2 are also responsible for NF-kB signalling 
(Huen et al., 1995; Mitchell and Sugden, 1995). Both CTAR1 and CTAR2 are able to 
independently activate NF-kB (Huen et al., 1995). CTAR2 accounts for the majority 
(70-80 %) o f LMP1-mediated NF-kB activation via its interaction with TRADD. The 
remaining LMPl-mediated NF-kB activation is achieved through CTAR1 via 
interaction with TRAF proteins (Murray and Young, 2001).
Analysis o f nuclear extracts isolated from LMP-1 expressing cells, or from cells 
transfected with LMP1 mutants lacking CTAR1 or CTAR2, have demonstrated the 
presence o f a variety o f NF-kB complexes bound to NF-kB specific sequences. LM Pl- 
mediated NF-kB activation has been extensively studied and shares similarities to the 
pathways activated by clustered TNF receptors or CD40. The interactions o f TRAF2 
and TRAF5 with CTAR1 appear to be critical for NF-kB signalling, as mutations in the 
core o f the TRAF binding motif or over-expression o f dominant negative TRAF2 or 
TRAF5 molecules abrogate CTAR1 mediated NF-kB activation (Eliopoulos and 
Young, 2001). In addition, TRAF1 or TRAF3 may influence these signals indirectly by 
competing or synergising with TRAF2. Therefore, whilst TRAF1 cannot induce NF-kB 
per se, its over-expression significantly augments CTAR1-induced NF-kB activation 
(Devergne et al., 1996).
The ability o f TRAF2 or TRAF5 to recruit NF-kB inducing kinase (NIK) initiates an 
established cascade o f phosphorylation events, which promote phosphorylation of IkB 
proteins, resulting in the activation o f NF-kB. NIK appears to be responsible for these 
LMP1 signals because expression o f a kinase-inactive NIK mutant functions as a 
dominant-negative inhibitor o f CTAR1-mediated activation o f NF-kB in vitro (Sylla et 
al., 1998; Eliopoulos et al., 1999a). Similar experiments using dominant negative 
mutants o f K K a  and IKKJ3 have demonstrated their contribution to CTAR1-emanating 
signals (Sylla et al., 1998) and the ability o f LMP1 to promote phosphorylation and
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degradation o f IkBgi has long been recognised (Herrero et al., 1995). Thus the 
experimental evidence suggests that the CTAR1 domain o f LMP1 activates NF-kB 
through a TRAF2—► NIK—► IKK—» IkB<x pathway (Figure 1.13) (Eliopoulos and 
Young, 2001).
The CTAR2 region o f LMP1 requires TRADD but not RIP for NF-kB activation (Izumi 
et al., 1999). The N-terminus o f TRADD strongly binds to TRAF2 and it is possible 
that the interaction initiates a cascade similar to that engaged by CTAR1. Indeed, 
dominant-negative mutants o f TRAF2, NIK and IKKs inhibit CTAR2-induced NF-kB 
signalling. Thus the available evidence suggests that a TRADD—► TRAF2—► NIK—> 
IKK-» IkB<x pathway is responsible for NF-kB activation by the CTAR2 domain o f  
LMP1 (Eliopoulos and Young, 2001). Taken together, the experimental evidence has 
demonstrated that NF-kB signalling is mediated entirely through the LMP1 carboxy tail 
and may account for most o f the pleiotropic affects o f this key viral protein.
1.9.6 Latent membrane proteins 2A and 2B (LMP2A and LMP2B)
The gene encoding LMP2 yields two distinct proteins: LMP2A and LMP2B. The first 
exons o f LMP2 A and LMP2B are the only unique exons, whereas the remaining eight 
exons are common to both messages (Laux et al., 1989; Sample et al., 1989). As a 
result, the structures o f LMP2A and LMP2B are similar (Figure 1.15); both contain 12 
trans-membrane domains and a 27 amino acid cytoplasmic C-terminus. However, 
LMP2A has a 119 amino acid cytoplasmic N-terminus domain, encoded in exon 1, 
whereas exon 1 is non-coding in LMP2B (Kieff, 1996). Most o f the studies to date 
focus on the LMP2A product, and as such there has been no comprehensive phenotypic 
analysis o f the LMP2B isoform. LMP2A aggregates in patches within the plasma 
membrane o f latently infected B cells (Longnecker and Kieff, 1990). By analogy to 
LMP1, LMP2A probably functions as a constitutively activated receptor via cross- 
linking caused by aggregation o f multiple LMP2A molecules through the association of 
their trans-membrane domains (Gires et al., 1997). Although mRNAs for both LMP2A 
and LMP2B are expressed in immortalized B cells, genetic analyses o f the LMP2 gene 
have shown that neither product is required for transformation o f B cells by EBV 
(Longnecker et al., 1992; Longnecker et al., 1993; Kim and Yates, 1993). Later studies 
with LMP2 A-knockout viruses revealed no discernable defect in their ability to generate
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immortalized cell lines from primary B cells (Konishi et al., 2001). However, LMP2A 
plays an important role in modifying normal B cell development to favour maintenance 
o f EBV latency.
In primary B lymphocytes, cross linking the B cell receptor (BCR) leads to an intricate 
signal cascade including the recruitment and activation o f the Src family o f protein 
tyrosine kinases (PTKs); subsequent activation and recruitment o f other kinases, 
phosphatases or adaptor proteins; the hydrolysis o f phospholipids; mobilisation o f 
intracellular calcium; activation o f protein kinase C; activation o f nuclear transcription 
factors and transcription o f BCR signal specific genes (Freuhling et al., 1998). These 
genes include the EBV immediate early genes, resulting in the induction o f viral lytic 
replication (Miller et al., 1994). EBV-infected B cells are blocked in their ability to 
transduce signals through the BCR and LMP2A has been demonstrated to be 
responsible for this effect (Freuhling et al., 1998).
The LMP2A N-terminal domain contains eight tyrosine residues, two of which form an 
immunoreceptor tyrosine-based activation motif (ITAM) (Freuhling and Longnecker,
1997). This is the same motif that is present on the BCR and is required for signalling 
by the BCR when it binds cognate antigen. Upon phosphorylation, the ITAM present 
on the BCR plays a central role in mediating lymphocyte proliferation and 
differentiation by the recruitment and activation of the Src family o f PTKs, preferably 
with Lyn and Fyn, and the hemopoietic-cell-specific kinase Syk. LMP2A also interacts 
with these PTKs through its phosphorylated ITAM (Figure 1.15) and this association 
appears to negatively regulate PTK activity (Freuhling and Longnecker, 1997). As one 
o f the repercussions o f BCR activation is the induction o f the EBV lytic cycle (Miller et 
al., 1995; Kieff et al., 2001), resulting in the induction o f expression o f EBV genes, 
many o f which are highly immunogenic, LMP2A has an important function in blocking 
BCR-stimulated activation o f the EBV lytic cycle and helping EBV to avoid detection 
by the immune system (Miller et al., 1995). Recent studies also show that LMP2A 
associates with lipid rafts (Dykstra et a l, 2001; Higuchi et a l, 2001), thus LMP2A 
blocks BCR signalling by interfering with raft association o f the BCR (Dykstra et a l,
2001). Expression o f LMP2A in the B cells o f transgenic mice alters normal B cell 
development, allowing BCR-negative B cells to exit the bone marrow and survive in the 
peripheral lymphoid organs (Caldwell et al, 1998). This suggests that LMP2A can 
drive the proliferation and survival o f B cells in the absence o f  signalling through the
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BCR. Taken together, these data support a role for LMP2A in modifying the normal 
programme o f B cell development to favour the maintenance o f EBV latency and to 
prevent inappropriate activation o f the EBV lytic cycle. A modulatory role for LMP2B 
in regulating LMP2A function has been suggested (Scholle et al., 1999).
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Figure 1.15: Structure and function o f LM P2. The structures o f  EB V  LMP2A and LMP2B are 
similar, both have 12 trans-membrane domains and a 27-amino acid cytoplasmic carboxyl terminus. In 
addition, LMP2A has a 119-amino acid cytoplasmic amino-terminal domain that contains eight tyrosine 
residues, two o f  which (Tyr74 and Tyr85) form an immunoreceptor tyrosine-bases activation m otif
(IT AM). The phosphorylated IT AM  recruits members o f  the SRC family o f  protein tyrosine kinases and 
the SYK tyrosine kinase and negatively regulates their activities. A membrane-proximal tyrosine residue 
(T y r ll2 ) binds the LYN tyrosine kinase and mediates the constitutive phosphorylation o f the other 
tyrosine residues in LMP2A. The LMP2A IT AM blocks signalling from the B cell receptor (BCR) by 
sequestering these tyrosine kinases and by blocking the translocation o f  the BCR into lipid rafts. LMP2A  
also recruits NEDD4-like ubiquitin protein ligases through phosphotyrosine (PY) motifs, and these 
promote the degradation o f  LYN and LMP2A by a ubiquitin-dependent mechanism. LMP2A interacts 
with the extracellular signal-regulated kinase 1 (ERK1) mitogen activated protein kinase (MAPK), and 
this results in the phosphorylation o f  two serine residues (S er i5 and Serl02) in LMP2A, and might 
contribute to LMP2A-induced activation o f  JUN (adapted from Young and Rickinson, 2004).
Although LMP2A expression is not essential to EBVs immortalizing properties, 
LMP2A expression seems to mediate signals involved in cellular proliferation and 
survival in mouse transgenic models (Caldwell et al., 1998, Longnecker, 2000). 
Furthermore, the consistent expression o f LMP2A in HD and NPC suggests an 
important function for this protein in oncogenesis but this remains to be shown.
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LMP2A also recruits Nedd4-like ubiquitin protein ligases; this might promote Lyn and 
Syk ubiquitination in a fashion that contributes to a block in B cell signalling (Ikeda et 
al, 2000). Furthermore, recent reports show that LMP2A can transform epithelial cells; 
this effect is mediated, at least in part, by activation o f the phosphoinositide 3-kinase- 
Akt pathway (Scholle et a l , 2000). Because o f the number o f motifs identified in 
LMP2A, a putative role for LMP2A in signal transduction has been proposed 
particularly in light o f the ability o f LMP2A to co-localise with LMP1 in the plasma 
membrane (Longnecker and Kieff, 1990) and enhance LMP1 mediated activation of the 
AP-l/JNK and NF-kB pathways (Dawson et a l, 2001; Kieser et a l, 1997). Recent 
studies found that LMP2A regulates c-Jun protein through extracellular signal-regulated 
kinase (ERK) (Chen et a l, 2002).
1.9.7 Epstein-Barr virus-encoded RNAs 1 and 2 (EBER1 and EBER2)
EBERs 1 and 2 are non-polyadenylated, uncapped, non-coding RNAs o f 167 and 172 
nucleotides respectively (Thompson and Kurzrock, 2004). They are expressed in 
abundance in nearly all EBV-infected cells with the exception o f oral hairy leukoplakia 
lesions from AIDS patients and some hepatocellular carcinomas (Sugawara et al., 
1999). In addition to the latent proteins, EBER1 and EBER2 are expressed in all forms 
o f latency. However, recombinant EBV with EBER genes deleted can transform 
lymphocytes, suggesting that the EBERs are not essential for transformation 
(Swaminathan et a l 1991). The EBERs assemble into stable ribonucleoprotein 
particles with the autoantigen La and ribosomal protein L22, and bind the interferon- 
inducible, double-stranded-RNA-activated protein kinase PKR (Takada and Nanbo,
2001). PKR has a role in mediating the antiviral effects o f the interferons, and it has 
been suggested that EBER-mediated inhibition o f PKR function might be important for 
viral persistence (Nanbo et a l, 2002). Expression o f the EBERs in BL cell lines has 
been found to increase tumourigenicity, promote cell survival and induce interleukin-10 
(EL10) expression (Takada and Nanbo, 2001; Ruf et a l, 2000; Kitiwaga et a l , 2000). 
Furthermore, transfection o f the EBER genes into the EBV-negative Akata cell line 
restored the oncogenic potential that was originally present in the EBV-positive Akata 
cells but was lost in the EBV-negative subclones (Komano et a l , 1999). Such studies 
indicate that EBV genes that were previously shown to be dispensable for 
transformation in B cell systems might make more important contributions to the
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pathogenesis o f some EBV-associated malignancies, and to EBV persistence, than was 
previously appreciated (Young and Rickinson, 2004).
1.9.8 The BamHl A rightward transcripts (BARTs)
The EBV BamHl A rightward transcripts were first described in nasopharyngeal tumour 
tissues where they are the most abundant viral transcripts (Hitt et a l , 1989). BARTs 
were subsequently detected in all EBV latently infected cells (Brooks et a l., 1993; 
Deacon et a l , 1993; Chen et a l , 1999b). These highly spliced transcripts are 
commonly referred to as either BamHl A rightward transcripts (BARTS) or 
complementary-strand transcripts (CSTs) (Karran et a l , 1992; Smith et a l ,  2000). The 
protein products o f these ORFs remain to be conclusively identified, but the products o f 
two of the ORFs, RPMS and RK-BARF0 interact with the Notch pathway when 
expressed exogenously. RPMS functions in a manner that is reminiscent o f 
MINT/SHARP, by binding to CIR in the RBP-Jk/CBF1 repressor complex and 
mediating repression (Zhang et a l ,  2001). RPMS affects the CIR-SKIP interaction in a 
way that prevents EBNA2/NotchlIC from displacing the co-repressor complex. SKIP 
facilitates SHARP function and thus SKIP is not only a key tethering point for 
EBNA2/NotchlIC binding, but also a key target for negative modulation o f their 
activity (Hayward, 2004). The RK-BARF0 protein was found to interact with Notch4 
in a yeast two-hybrid assay (Kusano and Raab-Traub, 2001). RK-BARF0 contains a 
potential signal peptide for ER targeting and interacts with unprocessed Notch4. RK- 
BARF0 appears to potentiate Notch function.
The BARTs are often expressed in circumstances in which the EBNA2 and EBNA3 
proteins are not synthesised, such as epithelial cell infection and in EBV-associated 
malignancies in immuno-competent individuals. It is interesting that these transcripts 
should encode both a positive and a negative Notch regulator and this re-emphasises the 
importance of signal modulation o f the Notch pathway responses. The existence o f 
BARTs also suggests that there may be as yet unappreciated aspects o f EBV biology 
where manipulation o f  Notch signalling occurs (Hayward, 2004). Another transcript 
that is generated from the BamHX A region is BARF1, which encodes a 31 kDa protein 
that was originally identified as an early antigen expressed on induction o f the EBV 
lytic cycle. Recent studies have shown that BARF1 is a secreted protein that is
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expressed as a latent protein in EBV-associated NPC and gastric carcinoma (Decaussin 
et al., 2000; zur Hausen et a l., 2000). BARF1 shares limited homology with the human 
colony stimulating factor 1 receptor (the FMS  oncogene) and displays oncogenic 
activity when it is expressed in rodent fibroblasts and simian primary epithelial cells 
(Sheng eta l., 2001).
1.10 Genes of the viral lytic cycle
The EBV viral lytic cycle is the replicative stage o f the virus life cycle and is essential 
for the production o f infectious pathogens, which can be transmitted by virus shedding 
in the saliva from virus carriers to EBV naive individuals. This cycle involves 
expression of the “lytic programme genes” in an ordered cascade. These genes are 
involved in viral DNA replication and some encode structural glyco-proteins or proteins 
that modify the infected cells in order to permit viral envelopment or egress (IARC 
Monographs, 1997). Like several other herpesviruses, EBV also encodes lytic cycle 
genes that can prevent or delay death o f the host cell, which can result from apoptosis 
triggered by the cell recognizing virus replication as DNA damage (Henderson, et a l., 
1993). Only a small number o f latently infected lymphocytes spontaneously enter the 
replicative cycle, and in these cells the viral DNA is amplified several hundred fold by a 
lytic origin o f replication oriLyt (Hammerschmidt and Sugden 1988).
In vitro, lytic infection is induced mainly using chemicals, such as phorbol esters. 
These chemicals drive the infected cells into the lytic cycle and this effect is probably 
mediated by protein kinase C activation o f jun-fos interaction with AP-1 sites upstream 
o f the immediate early viral genes (Farrell et a l., 1983; Farrell et a l., 1989). Lytic 
replication has been extensively studied in the Akata cell line. Viral replication can be 
induced in this cell line (which carries an LMP2A deleted virus), by cross-linking o f 
surface immunoglobulins (Takada, 1984; Takada and Ono, 1989). Studies carried out 
using the Akata cell line, among others, have permitted the identification of the EBV 
replicative proteins.
The replicative proteins o f the EBV lytic cycle have been classified as early antigens 
(EA), membrane antigens (MA), and viral capsid antigens (VCA) (Figure 1.16). The 
early antigens have been further subdivided into diffuse early antigens (EA-D) and
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restricted early antigens (EA-R), on the basis o f their sensitivity to methanol fixation 
(Kieff, 1996). Following induction o f  the lytic cycle, cells that have become permissive 
to viral replication, undergo cytopathic changes characteristic o f herpesviruses, 
including margination o f nuclear chromatin, synthesis o f viral DNA, assembly o f 
nucleocapsids, envelopment o f the virus by budding through the inner nuclear 
membrane and inhibition o f host macromolecular synthesis (Kieff, 1996). Lytic cycle 
gene expression follows a temporal and sequential order (Farrell, 1992; Takada and 
Ono, 1989). Some viral genes are expressed independently o f new protein synthesis, 
early after induction, and are classified immediate early genes. The early lytic viral 
genes are expressed slightly later and their expression is not affected by inhibition o f 
viral DNA synthesis. Late proteins are formally categorised as late based on a marked 
reduction in expression after inhibition o f viral DNA synthesis (Kieff, 1996).
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Figure 1.16 A schem atic representation o f early and late EB V  gene expression The VCA, the MA  
and the EA are illustrated and their open reading frames are written in bold
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1.10.1 Immediate early genes
After induction o f the lytic cycle in cell lines, such as Akata, in the presence o f protein 
synthesis inhibitors, three leftward mRNAs are transcribed. The BZLF1, BRLF1 and 
BFLF4 encoded proteins are potent trans-activators o f early EBV lytic gene expression 
(Takada and Ono, 1989; Kieff, 1996). BZLF1 also functionally and physically interacts 
with NF-kB (Gutsch et al., 1994), which is an important mediator of LMP1 effects 
during latent infection. BZLF1 can also down-regulate the EBNA Cp promoter possibly 
facilitating the transition from latent to lytic infection (Sinclair et al., 1992). BZLF1 has 
also been shown to inhibit both cellular differentiation and cell cycle progression in 
epithelial cells. The mechanism mediating this effect is not known however activation 
o f cell cycle inhibitors p21 and p27b was not observed (Swenson et al., 1999). BRLF1 
was also shown to bind pRb in vivo shortly after induction of the viral lytic cycle in 
EBV infected Akata cells. This interaction may initiate cell cycle progression and 
facilitate viral DNA synthesis during lytic replication (Zacny et a l., 1998).
1.10.2 Early genes
The early genes are expressed when the lytic cycle is induced in the presence of 
inhibitors o f DNA synthesis. By this criteria at least 30 EBV mRNAs are early gene 
products (Hummel and Kieff, 1982). Two very abundant early proteins have been 
mapped to specific DNA sequences. The BALF2 protein is homologous to a HSV DNA 
binding protein and is important in DNA replication (Hummel and Kieff, 1982; Kieff, 
1996). The BHRF1 protein, which is expressed in moderate abundance, shows partial 
(25 %) sequence homology to the human bcl-2 proto-oncogene. Both BHRF1 and Bcl-2 
have been shown to protect human B lymphocytes from apoptosis (Henderson et al., 
1993). Several o f the early genes are linked to DNA replication. Transfection 
experiments indicate that some o f these genes are activated in the process o f cell 
differentiation in the absence o f other viral gene products, suggesting a possible role for 
cellular factors in regulating the productive cycle at least in certain cell types (Kieff,
1996).
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1.10.3 Late genes
The late genes encode structural glycoproteins or proteins that modify the infected cells 
in order to permit viral envelopment or egress (IARC Monographs, 1997). Among the 
non-glycoproteins, the major nucleocapsid protein is encoded by BCLF1. BNRF1 
encodes the major external non-glycoprotein o f the virion, and BXRF1 is likely to 
encode a basic core protein. The genes encoding the EBV glycoproteins are illustrated 
in bold in Figure 1.16 above. The late BCRF1 gene, which is located in the middle o f 
the EBNA regulatory domain between oriP and Cp, shows 84 % sequence homology to 
the human IL-10 (Vieira et al., 1991). IL-10 was first recognised for its ability to 
inhibit activation and effector function o f monocytes, macrophages and T cells. EBV- 
derived IL-10 is thought to play a role in the establishment o f latent infection by 
suppression o f the host immune system (Helminem et al., 1999; Kurilla et al., 1993; 
Rousset etal., 1992).
1.11 EBV-mediated regulation of cell growth and survival
Cell proliferation and survival are two essential features o f immortalisation. The 
immortalisation o f B cells by EBV requires the co-operative action o f many latent 
genes. EBV genes manipulate the cell survival and proliferation machinery by (i) 
regulating components o f the cell cycle, (ii) influencing pathways that regulate anti- 
apoptotic proteins and (iii) expressing viral homologues to anti-apoptotic proteins. 
While characterisation o f the mechanism o f action o f individual latent genes is essential, 
it is also important to understand how latent genes can co-operate and may have 
overlapping functions for B cell immortalisation. This section attempts to summarize 
the complex interactions o f EBV with the network o f proteins involved in cell 
proliferation and survival.
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1.11.1 EBV regulates components of the cell cycle machinery
1.11.1.1 The cell cycle
The cell cycle (Figure 1.17) is regulated in four distinct phases called G l, S-phase, G2 
and M-phase (Scherr, 1996). The G l phase o f the cell cycle is the longest and occurs 
prior to DNA synthesis, which occurs during S-phase. During M-phase, cell division 
takes place. The progression through the cell cycle is regulated by many different 
proteins, some o f which are illustrated in Figure 1.17. The first biochemical event 
observed, in early G l phase, is the induction o f the D-type cyclins and their partners, 
cyclin dependent kinases (cdks), cdk4 and cdk6. One of either cd4 or cd6 partners a D- 
type cyclin, in the absence o f cyclin dependent kinase inhibitors (CDKIs), to become 
catalytically active. The induction o f D-type cyclins is paralleled by a loss in CDKIs 
(Brennan, 2001). The most important substrate o f the cyclin D/cd4/6 complex is the 
family o f pocket proteins, typified by pRb, the retinoblastoma susceptibility gene 
product (Nevins et a l., 1997). Other members o f the pocket protein family include pi 30 
and p i07. These pocket proteins repress a family o f  transcription factors called E2F, 
and the E2F-pocket protein complexes also act as gene suppressors (Nevins et a l.,
1997). Phosphorylation o f pRb by the cyclin D/cdc4/6 complex results in the release o f 
E2F transcription factors and transcription o f E2F-responsive genes. E2F binding sites 
have been identified in the promoters o f many genes important for cell cycle regulation 
and the promoters o f proteins involved in DNA synthesis. In many systems, the 
induction o f E2F transcriptional activity results in entry into the cell cycle (Johnson et 
al., 1993).
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Figure 1.17. Phases of the cell cycle, (adapted from Brennan, 2001).
The induction of D-type cyclins during early G1 phase is followed by the induction of 
cyclin E during late G1 phase, and the entry into S-phase, whereupon DNA synthesis 
occurs. Cyclin E partners cdk2 and also phosphorylates pocket proteins. Cyclin E/cdk2 
has a wider range o f  substrates than the cyclin D/cd4/6 complex but the importance o f 
these has not yet been characterized (Brennan, 2001).
1.11.1.2 Interactions of EBV proteins with the cell cycle
Cyclin D2 is the first cell cycle protein to be induced following either EBV infection or 
mitogenic stimulation o f B cells (Spender et a l., 1999). It is accompanied by a loss o f 
the CDKI p27kipl. A phosphorylation o f the pocket protein, pRb, is observed 
approximately 6 hours later. All these events parallel those seen during normal B cell 
proliferation, leading to the proposal that EBV exploits normal cell pathways to regulate 
pRb phosphorylation during the cell cycle (Cannell et a l., 1996; Kempkes et a l., 1995b). 
The genes involved in the regulation o f cyclin D2 by EBV have been studied. It has 
been shown that vectors expressing EBNA2 and EBNA-LP are sufficient to activate the 
expression o f cyclin D2 during immortalisation o f resting human B lymphocytes. 
Neither EBNA2 nor EBNA-LP alone induced cyclin D2 (Sinclair et a l., 1994). 
Subsequent studies have further demonstrated the importance o f EBNA2 in cell cycle
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progression, with recent data indicating that EBNA2 has the ability to trans-activate a 
cyclin D2 promoter reporter construct (Spender et al., 2001). However, the evidence to 
date suggests that EBNA2 induction of cyclin D2 is indirect (Spender et al., 2001; 
Kaiser et al., 1999) and the mechanism by which EBNA2 links to cyclin D2 remains to 
be characterised. The c-myc oncogene has been shown to be a direct target o f EBNA2 
(Spender et al., 2001; Kaiser et al., 1999) and c-Myc has also been shown to trans- 
activate the D2 promoter (Bouchard et al., 1999). This was shown to be via an E-box 
located outside the region of the promoter trans-activated by EBNA2, suggesting that c- 
myc is not the cross-link between EBNA2 and cyclin D2. The co-operation o f EBNA2 
with EBNA-LP to induce cyclin D2 has not yet been further investigated. There is one 
report that LMP1 can also regulate D2 (Arvanitakis et al., 1995), suggesting a third 
protein that may play a role in cell cycle induction.
The induction o f  cyclin D2 is paralleled by the loss o f the CDKI p27kipl in response to 
EBV and many other systems (Spender et al., 2001; Slingerland and Pagano, 2000). 
The regulation o f p27kipl in other systems has been investigated, and it has been shown 
to be ubiquitinylated and degraded in response to phosphatidylinositol 3-kinase (PI3K)- 
mediated pathways and is also regulated transcriptionally. The only EBV protein that 
has been shown to play a role in the regulation o f p27kipl is EBNA3C (Parker et al., 
2000), where a cell line expressing EBNA3C in a regulated fashion, showed an inverse 
correlation between EBNA3C induction and the presence o f p27kipl. Since cyclin D2 
and p27kipl together regulate cdk4 and cdk6 activity, the link between EBNA3C and 
p27kipl implicates a fourth EBV protein in the progression through the G1 phase o f the 
cell cycle (Brennan, 2001). Furthermore, both EBNA3C and EBNA-LP have been 
found to interact with pRb (Parker et al., 1996, Szekely et al., 1993), once again 
implicating these latent proteins in the direction o f cell cycle progression.
1.11.1.3 The role of cytokines in EBV-mediated immortalisation
Following B lymphocyte activation, EBV induces the synthesis o f various cytokines. 
While a diverse range o f  cytokines is expressed, for example TNF and IL-1, perhaps the 
most interesting in terms o f cell growth factors, are IL-6 and IL-10. Both o f these 
cytokines play an important role in the growth o f EBV-transformed cells (Haddad et al., 
2001; Kitagawa et al., 2000; Beatty et al., 1997). EBV also encodes a viral homologue
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of IL-10 (from the BCRF1 ORF), albeit expressed in the lytic cycle, which enhances the 
growth transformation o f a B cell infected with EBV (Stuart et al., 1995). IL-6 and IL- 
10 share signalling pathways. The receptor molecules that IL-6 and IL-10 use to 
mediate their activities both activate the JAK family o f tyrosine kinases, and 
downstream signalling cascades including STAT proteins and the PI3K pathway 
(Brennan, 2001). IL-6 is known to be pro-inflammatory, whereas IL-10 is known to be 
anti-inflammatory (Moore et al., 2001). However, IL-10 also acts as a co-factor for B 
cell growth (Moore et a l., 2001), and it has been demonstrated that PI3K is important 
for EL-10-mediated cell growth o f both primary monocytes and a murine mast cell line 
(Crawley et a l., 1996)
Recent reports suggest that EBV uses both common and distinct mechanisms for the 
regulation o f IL-6 and IL-10. Both cytokines have been shown to be regulated by 
LMP1 via NF-kB and the p38 stress activated protein kinase (Eliopoulos et al., 1997; 
Eliopoulos et al., 1999b; Nakagomi et al., 1994; Vockerodt et al., 2001). However, 
new observations have implicated an alternative way in which IL-10 may be regulated 
by the EBERs. Transfection of EBERs into EBV-negative BL cells resulted in the 
induction o f EL-10, while EBER1 and EBER2 was sufficient, the optimal IL-10 
expression was observed when both were introduced (Kitigawa et al., 2000).
1.11.1.4 Signalling molecules that link to the cell cycle
Active signalling pathways are a feature o f many malignant cells. Thus, it is important 
to characterize the potential role o f signalling molecules that are activated by EBV- 
induced cytokines and by EBV genes themselves. The pathways activated by IL-6 and 
IL-10 (for example the JAK family o f tyrosine kinases, PI3K and STATs) have been 
shown to play a role in lymphocyte growth and transformation (Bowman et al., 2000; 
Ihle, 2001; Imada and Leonard, 2000; Brennan et al., 1997), although some o f the data 
is controversial. The pattern o f tyrosine phosphorylation seen in EBV-immortalised B 
cells is distinct form that seen in matched cells that lack expression o f the EBV latent 
genes (Brennan, 2001). This suggests that tyrosine kinases, or phosphatases, have 
altered activity in EBV-immortalised cells, although the identity o f the important 
kinases and their substrates remains unknown.
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The STAT family o f transcription factors are one substrate o f the JAK family o f 
tyrosine kinases. STATs have been shown to be active in EBV-immortalised cells 
(Weber-Nordt et al., 1996) and may play a role in oncogenesis (Bowman et al., 2000). 
It has been reported that LMP1 can activate JAK3 and STAT1 (Gires et al., 1999). 
STAT1 is predominantly growth inhibitory so it is unlikely that it would contribute 
directly to malignancy (Bowman et al., 2000). LMP1 can also activate a STAT reporter 
that is known to bind STAT1, STAT3 and STAT5 (Brennan et al., 2001), but the 
molecular basis o f this is unknown. Over-expression o f STAT3 has been shown to 
contribute to transformation, and STAT5 plays a role in cytokine-induced proliferation, 
so perhaps these are better candidates for STATs involved in EBV-induced proliferation 
(Ihle, 2000). There is also evidence o f functional STAT binding sites in the promoters 
for the LMP1 and EBNA1 genes, demonstrating that another role may be played by this 
family o f transcription factors in EBV biology (Chen et al., 1999a; Chen et al., 2001).
There is some evidence that pathways downstream o f the small G protein Ras are active 
in EBV-immortalised cells and that MAP-ERK can be activated by LMP1 (Roberts and 
Cooper, 1998). However, the MAP-ERK pathway does not appear to be required for 
EBV-induced proliferation, although it is required for normal B cell proliferation 
(Fenton and Sinclair, 1999). PI3K, a lipid kinase that is involved in lymphocyte 
survival (Pogue et al., 2000; Carey and Scott, 2001) and proliferation (Brennan et al., 
1997; Craddock et al., 1999), can be activated by oncogenic Ras (Vanhaesebroeck and 
Alessi, 2000). An active pathway regulated by PI3K in EBV-immortalised cells has 
been identified and inhibition o f PI3K using a chemical inhibitor, inhibits the 
proliferation o f EBV-immortalised cells (Brennan, 2001). Further evidence for the 
importance o f this pathway was provided by a study where LMP2 was found to activate 
a PDK-mediated pathway, Akt (Swart et al., 2000; Scholle et al., 2000). Akt, in 
response to PI3K, has been shown to modulate the forkhead family o f transcription 
factors involved in p27kipl regulation, suggesting a mechanism by which Akt might 
mediate the requirement o f PI3K for cytokine induced proliferation (Dijkers et al., 
2000). Furthermore, PI3K has also been shown to affect D-type cyclin expression in 
EBV-immortalised B cells (Brennan, 2001), suggesting a mechanism for its role in 
EBV-induced lymphocyte growth.
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1.11.2 EBV and cell survival
In addition to proliferation, cell survival is also an important a feature o f malignancy 
and transformation. A central component o f the overall EBV strategy and its role in the 
development o f related malignant disease is the ability o f the viral proteins to suppress 
the cellular apoptotic program (Allday, 1996; Klein, 1994). Apoptosis is a genetically 
controlled pre-programmed form o f cell suicide involving dramatic morphological 
changes including cell shrinkage, nuclear re-organization, plasma membrane blebbing 
and eventual fragmentation o f the cell into membrane bound apoptotic bodies (Allday, 
1996). While the process o f apoptosis is responsible for shaping organs during 
embryogenesis and maintaining tissue homeostasis within the adult organism, it also 
functions as an emergency response to aberrant growth induced by the activation o f 
oncogenes and viral infection. In the case o f virus-infected cells, the induction o f early 
cell death would severely limit virus production and reduce or eliminate spread o f virus 
progeny in the host (Shen and Shenk, 1995). In order to maximize their replicative 
capacity many viruses have evolved mechanisms that suppress the apoptotic programme 
(Shen and Shenk, 1995). EBV utilises such mechanisms to (i) delay cell death during 
the lytic stage o f infection until virion numbers have been sufficiently amplified to 
transmit infection to other individuals via saliva and (ii) to ensure persistence in the host 
memory B cell compartment.
1.11.2.1 EBV up-regulates expression of the anti-apoptotic cellular gene bcl-2
Group I BL cell lines (which display type I latency, thus only express EBNA1, EBERs 
and BARTs) and many EBV-negative BL lines can readily be triggered into apoptosis, 
whereas Group III BL cell lines, which express the complete set o f EBV latent proteins, 
are relatively resistant to a variety apoptotic triggers, including growth factor 
withdrawal, Ca 2" ionophore treatment and over-expression o f the p53 tumour 
suppressor gene (Henderson et a l., 1991; Okan et a l, 1995). EBV-negative BL cells 
converted to the type III latency state by infection with the B95-8 strain o f EBV also 
display elevated thresholds o f resistance to apoptotic stimuli (Gregory et a l., 1991), thus 
implicating EBV latent genes in cell survival.
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In addition to being resistant to apoptotic stimuli, group in  BL cells lines display high 
levels o f the Bcl-2 protein (Henderson et a l., 1991). Bcl-2 is a prototype anti-apoptotic 
protein that interacts with the mitochondrial membrane and inhibits the action o f 
caspases (Adams and Cory, 2001). Transfection of individual EBV latent genes into 
EBV-negative BL cell lines has shown that up-regulation o f Bcl-2 expression correlates 
with the expression o f LMP1 (Liu et a l., 1991; Henderson et a l., 1991; Rowe et al.,
1994) and possibly EBNA2 (Finke et a l., 1992) and EBNA3B (Silins and Sculley,
1995). Several lines o f evidence, however, indicate that in addition to Bcl-2, other 
survival mechanisms play a role protecting type IE BL cells from apoptosis. Firstly, 
over-expression of the Bcl-2 protein in group I cells (well beyond the level o f group III 
cells) is necessary to attain the high levels o f protection observed in group III cells 
(Milner et a l., 1992). Secondly, prolonged culture o f group I lines in vitro has been 
shown to result in enhanced survival in the absence o f Bcl-2 up-regulation (Milner et 
al., 1992). Also, Bcl-2 is not detectable in germinal centre B cells in vivo, the normal 
equivalent o f BL cells, and only appears when the cells reach the follicular mantle 
(Pezzella et al., 1990; Aiello et al., 1992; Akagi et al., 1994). Finally, the induction o f 
Bcl-2 by LMP1 is a delayed response with maximal levels detectable after 2 days o f 
LMP1 induction (Rowe et al., 1994). Subsequent studies have shown that LMP1 can 
also up-regulate other anti-apoptotic proteins, including A20, Mcl-1, cIAPs and Bfl-1 
(Laherty et al., 1992; Wang et al., 1996; Hong et al., 2000; D ’Souza et al., 2000).
1.11.2.2 EBV up-regulates expression of the anti-apoptotic cellular geneA 2 0
A20 is an inducible zinc finger protein that confers resistance to TNFa cytoxicity 
Laherty et al., 1992). The 790 amino acid protein is induced in response to 
inflammatory cytokines and cellular activators in many cell types, including fibroblasts, 
lymphocytes and endothelial cells (Beyaert et al., 2000). Transfection experiments have 
demonstrated that LMP1 induces the expression o f A20 in both lymphocytes and 
epithelial cells, and A20 is constitutively expressed in EBV-immortalised B cells 
(Laherty et al., 1992; Fries et al., 1996; Spender et al., 1999). Studies o f the A20 
promoter have shown that LMP1 transcriptionally activates the A20 gene through cis- 
acting NF-kB binding sites. Furthermore, the electrophoretic mobility shift assay 
(EMSA) confirmed LMP1-inducible binding o f an NF-KB-like factor to the NF-kB 
binding sites within the A20 promoter. A20 has also been identified as functioning in a
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negative feedback loop by inhibiting the activation o f NF-kB from both CTAR1 and 
CTAR2 o f the LMP1 protein (Eliopoulos et a l., 1999b). This effect is mediated by the 
binding o f A20 to TRAF2. This effect is also evident in CD40 signalling which also 
induces expression of A20 in BL cells (Sarma et a l., 1995).
1.11.2.3 EBV up-regulates expression of the anti-apoptotic cellular gene mcl-1
The maximum induction o f Bcl-2 by LMP1 takes about 48-72 hours (Rowe et a l., 
1994). However, induction o f a Bcl-2 homologue, Mcl-1, by LMP1 precedes induction 
of Bcl-2 (Wang et al., 1996). Mcl-1 is an anti-apoptotic protein that has been shown to 
contribute to the longevity o f chronic lymphotrophic leukaemia B cells and its higher 
expression is linked with resistance to chemotherapy (Moshynska et al., 2004). Up- 
regulation of Mcl-1 in response to LMP1 expression is transient, with Mcl-1 levels 
decreasing as Bcl-2 levels increase. These findings support the hypothesis that Mcl-1 
functions as a rapidly inducible, short-term effector o f cell viability. It has also been 
demonstrated that LMP1 blocks the decline in Mcl-1 levels in response to apoptotic 
stimulation by cyclic AMP. This effect o f LMP1 is associated with delayed cell death 
in the EBV-negative cell line BL41. The maintenance o f Mcl-1 expression by LMP1 is 
likely to be a crucial immediate early response that enables cells to survive until such 
time that Bcl-2 is up-regulated (Wang et al., 1996).
1.11.2.4 EBV up-regulates expression of cellular inhibitor of apoptosis protein 2 (c- 
IAP2)
C-IAP2 is a member o f the cellular inhibitor o f apoptosis protein family (c-IAP), which 
has been found to be up-regulated by LMP1 (Hong et al., 2000). C-IAP2 was initially 
identified as a molecule that is recruited to the TNF receptor via TRAF1 and TRAF2 
(Rothe et al., 1995). It has been suggested that C-IAP2 can inhibit apoptosis by 
modulating the TNF-induced activation o f NF-kB (Chu et al., 1997). Other stimuli that 
activate NF-kB, including IL-1, LPS, and CD30 stimulation, have also led to an up- 
regulation in the transcription o f C-IAP2 (Stehlik et al., 1998; Craxton et al., 1998). 
This prompted studies into the regulation o f the C-IAP2 gene, which resulted in the
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finding that expression o f EBV LMP1 trans-activates the C-IAP2 promoter (Hong et al., 
2000).
1.11.2.5 EBV up-regulates expression of the anti-apoptotic cellular gene b fl-l
Recent studies in our laboratory have identified another anti-apoptotic gene, bfl-1 (also 
known as A l), which is up-regulated by LMP1 expression. Expression o f LMP1 in 
EBV-negative BL cell lines coincides with a dramatic increase in bfl-1 mRNA (D'Souza 
et al., 2000). In this study, bfl-1 was shown to protect cells against serum depletion- 
induced apoptosis. Moreover, expression o f LMP1 in EBV-negative cell lines was 
found to trans-activate the bfl-1 promoter (D’Souza et al., 2004). Bfl-1 was originally 
identified from granulocyte macrophage-colony stimulating factor (GM-CSF)-induced 
mouse bone marrow as a novel hemopoietic specific early response gene with sequence 
similarity to Bcl-2 (Lin et al., 1993). Its human homologue was cloned by three 
independent approaches from fetal liver, activated endothelium and myeloid leukaemia 
(Choi et al., 1995; Karsan et al., 1996a; Kenny et al., 1997).
bfl-1 gene expression is generally confined to immune cells and tissues, in a pattern 
similar to that o f NF-kB, and is strongly induced by cytokine simulation o f leukemic, 
endothelial and hemopoietic cells. Constitutively elevated levels o f bfl-1 transcripts are 
seen in mature neutrophils and are selectively induced in long-lived peripheral B cells 
(Tomayko et al., 1998). These observations suggest an important protective role for 
Bfl-1 in the survival and selection o f distinct subsets o f cells in the immune system. 
Consistent with this observation, Bfl-1 suppresses apoptosis induced by the pro- 
inflammatory cytokine TNFa (Karsan et al., 1996b; Zong et al., 1999; Duriez et al.,
2000), tumour suppressor p53 (D’Sa-Eipper et al., 1996), B cell receptor aggregation 
(Kuss et al., 1999; Grumont et al., 1999; Craxton et al., 2000), the pro-apoptotic factors 
Bax and Bad (Zhang et al., 2000; Holmgreen et al., 1999). It has also been found to 
suppress chemotherapy-induced apoptosis (Wang et al., 1999; Cheng et al., 2000; Kim 
et al., 2004). Stimuli inducing Bfl-1 expression share the capacity to activate the 
transcription factor NF-kB, which regulates the bfl-1 gene (Zong et al., 1999; Grumont 
e ta l., 1999; Ltte ta l., 1999; Wangeta l., 1999).
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1.11.2.5.1 Mechanism of action of Bfl-1
Bfl-1 is a member o f the Bcl-2 family o f proteins, which consists o f approximately 20 
homologues o f pro- and anti-apoptotic regulators o f programmed cell death (Kirkin et 
al., 2004). Whether induced by death receptors or other stimuli, apoptosis signalling 
generally involves cytochrome c (Cyt c) release from mitochondria (Li et al., 1997). 
Upon release, Cyt c, together with dATP or ATP, binds to the adapter protein APAF1. 
This molecule then oligomerises and forms the apoptosome complex, which recruits 
and activates caspase 9, resulting in the initiation o f effector caspase activation and the 
execution o f apoptosis (Kirkin et al., 2004). The mode of function o f the individual 
Bcl-2 family members, therefore, is to either preserve or disturb mitochondrial integrity, 
thereby inducing or preventing release o f apoptogenic factors, like Cyt c, from the 
mitochondria. An understanding o f how the Bfl-1 protein functions to inhibit apoptosis 
necessitates examination o f how individual members o f the Bcl-2 family interact with 
each other in order to regulate cell death. Bcl-2 family proteins are defined by inclusion 
o f at least one o f four distinct Bcl-2 homology (BH) domains and the variable presence 
of a putative membrane-spanning region at the C-terminus (Cory and Adams, 2002) 
(Figure 1.18).
Figure 1.18: A schematic representation of Bcl-2 protein domain organisation. The locations of the 
four Bcl-2 homology (BH1 to BH4) domains are indicated, along with the trans-membrane domain (TM) 
and the known alpha-helical regions (al-7) (adapted from Kirkin et al., 2004).
The Bcl-2 family o f proteins can be sub-divided into three groups. The first group 
consists o f the anti-apoptotic Bcl-2 type proteins, which include Bcl-2, Bcl-xL, Bcl-w, 
Bfl-1, Boo/Diva/Bcl-B and Mcl-1 (Kirkin et al., 2004). Members o f this group contain 
three to four BH domains, which are required for their anti-apoptotic function. The BH
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domains mediate interactions between the Bcl-2-like proteins and other members o f the 
Bcl-2 family. The second group o f the Bcl-2 family consists o f the Bax-like pro- 
apoptotic proteins, including Bax, Bak and Bok (Kirkin et a l, 2004). While Bax and 
Bak are widely expressed (Krajewski et a l, 1994; Krajewski et a l., 1996), Bok appears 
to be restricted to the reproductive tissues (Hsu et a l., 1997). The third group o f Bcl-2 
proteins is the pro-apoptotic BH3 domain-only group. This group has many members, 
which differ strikingly in their responsiveness to stimuli and thereby in the pathways 
they regulate (Huang and Strasser, 2000). The BH3 domain-only family members share 
only the short BH3 domain with the other Bcl-2 family members (and with each other).
A model for the mechanism of action o f Bcl-2 family members, prominent until 
recently, predicted that Bcl-2 type proteins autonomously inhibit apoptosis. Hetero- 
dimerisation with pro-apoptotic members would abrogate their protective function and 
thus provoke apoptosis (Huang and Strasser, 2000; Kelekar and Thompson, 1998). 
However, recent findings indicate that death induction is independent o f Bcl-2 type 
proteins, but involves collaboration between Bax-type proteins and BH3 domain-only 
family members. Studies using Bak and Bax knockout mice have provided insight into 
how pro-apoptotic Bcl-2 family members induce cell death. Cells lacking both Bax and 
Bak did not die upon expression of BH3 domain-only proteins, in contrast to cells 
expressing either one o f these molecules. This indicated that BH3 domain-only proteins 
require at least one Bax-type partner to induce cell death (Zong et al., 2001; Wei et a l.,
2001). Both Bax and Bak undergo a conformational change in response to apoptotic 
stimuli (Werner et al., 2002). Moreover, they assemble into homo-multimers in the 
mitochondrial membrane and upon oligomerization, they actively induce Cyt c release 
(Bomer, 2003), possibly by (i) forming a new channel (Schlesinger et a l, 1997); (ii) by 
enlarging an existing permeability transition pore (Tsujimoto and Shimizu, 2000; 
Zamzami and Kroemer, 2001) or (iii) forming supramolecular openings in the outer 
membrane which are different from discrete protein channels (Kuwana et a l, 2002). 
Anti-apoptotic family members like Bcl-2, Bcl-xL, hold Bax and Bak in check, possibly 
forming hetero-dimers, thereby preserving mitochondrial integrity (Bomer, 2003). The 
conformational change and multimerisation o f Bax or Bak is inhibitable by Bcl-2 
(Antonsson et a l, 2001; Mikhailov et a l, 2001) and inducible by the BH3 domain-only 
protein Bid (Wei et a l., 2000; Antonsson et a l, 2001). In healthy cells, BH3-only 
proteins are kept inactive (Cory and Adams, 2002). In response to pro-apoptotic signals, 
they become transcriptionally up-regulated and/or post-translationally modified to gain
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their full apoptotic potential (Kirkin et a l., 2004). The Bid protein is cleaved by caspase 
8 in response to death receptor activation (Li et al., 1998; Luo et al., 1998). Cleavage 
results in exposure o f the Bid BH3 domain, which is normally buried within the full- 
length protein (Chou et al., 1999; McDonnell et al., 1999). The cleaved C-terminus 
complex, truncated Bid (tBid), is then myristoylated and translocated to the 
mitochondria (Zha et al., 2000). Bid seems to form hetero-trimers in the mitochondrial 
membrane, which then may induce mitochondrial Bax or Bak to oligomerise (Wei et 
al., 2000), promoting Cyt c release (Luo et al., 1998; Li et al., 1998).
The novel model emerging from these findings, is that Cyt c release depends on 
interaction between a BH3 domain-only protein and a Bax-type partner, which allows 
the formation o f a Bax-type trans-membrane pore (Werner et al., 2002). Bfl-1 has been 
shown to exert its anti-apoptotic activity by inhibiting the collaboration between the 
BH3 domain-only protein Bid and its pro-apoptotic partners Bax or Bak in the induction 
of Cyt c release (Werner et al., 2002). Bfl-1 does this by binding to the full length Bid 
via the Bid BH3 domain. It does not interfere with the proteolytic activation of Bid, nor 
with its mitochondrial insertion, but remains selectively complexed to tBid in the 
mitochondrial membrane, where it prevents the activity o f a pro-apoptotic complex 
(Werner et al., 2002).
1.11.2.6 EBV lytic proteins encode anti-apoptotic functions.
During the lytic cycle o f virus replication, repressors o f apoptosis can provide a 
selective advantage by protecting from cell death until sufficient virus progeny numbers 
have been reached. Consistent with this model, there are at least two known lytic cycle 
proteins, BHRF1 and BZLF1, which can provide a survival advantage to the EBV- 
infected cells. These lytic gene products can therefore delay apoptosis in order to 
maximize viral production and spread o f virus progeny to other individuals. The 
BHRF1 protein shows partial (25 %) sequence homology to the human bcl-2 proto­
oncogene. Both BHRF1 and Bcl-2 have been shown to protect human B lymphocytes 
from apoptosis (Henderson etal., 1993) and expression o f BHRF1 in epithelial cells has 
been shown to confer enhanced resistance to cisplatin-induced apoptosis and inhibit 
differentiation (Dawson et al., 1995; Dawson et al., 1990). In lymphoid cells, BZLF1 
has been shown to interact with p53 and inhibit its trans-activating function, thereby
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providing a mechanism for preventing p53-mediated apoptosis. However, in epithelial 
cells expression of this EBV protein was shown to result in growth arrest without 
inhibiting the trans-activation function of p53 (Cayrol and Flemington, 1996). EBV 
also encodes a viral homologue of IL-10 albeit expressed in the lytic virus productive 
cycle, which enhances the growth transformation o f B cells infected with EBV (Stuart 
eta l., 1995).
The molecular interactions between EBV proteins and cell survival and proliferation 
machinery are summarised in Figure 1.19. It demonstrates the multiple genes encoded 
by EBV that interact with components o f the cell cycle and the presence o f cytokines 
IL-6 and EL-10. Taken together, these interactions account, at least in part, for the 
ability o f EBV to induce cell proliferation and survival, which is essential for both 
EB V-induced immortalisation o f B cells and establishment o f life-long persistence in 
the memory B cell compartment.
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Figure 1.19: Molecular interactions between EBV proteins and cell survival and proliferation 
machinery. The molecular interactions between EBV proteins and the components of cell survival and 
proliferation are illustrated. The signalling pathways active in lymphoblastoid cell lines, PI3K and 
STATs, and some potential contributions of these pathways are illustrated. An outline of the role of 
LMP1, LMP2A and PI3K to cell survival are also shown (adapted from Brennan, 2001).
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1.12 Objectives of the study
The up-regulation o f anti-apoptotic proteins by EBV plays a central role in the overall 
virus strategy, together with the development of malignancy. It has recently been 
demonstrated in our laboratory that expression o f LMP1 in EBV-negative BL-derived 
cell lines coincides with an increase in bfl-1 mRNA levels, and that expression o f bfl-1 
protected against serum depletion-induced apoptosis (D'Souza et a l., 2000). 
Furthermore, expression o f LMP1 in EBV-negative cell lines was found to trans- 
activate the bfl-1 promoter in an NF-KB-dependent manner (D’Souza et a l., 2004). In a 
related study in our laboratory, it was observed that expression o f EBNA2 as the sole 
EBV protein in an EBV-negative BL-derived cell line (DG75-tTA-EBNA2, Floettmann 
et a l., 1996) also led to an increase in bfl-1 mRNA levels (Pegman et a l., submitted 
December, 2004), demonstrating for the first time that a second EBV protein activates 
transcription o f the bfl-1 gene. EBNA2 expression was subsequently found to trans- 
activate the bfl-1 promoter in EBV-negative BL-derived cell lines, and the ability o f 
EBNA2 to bind RBP-Jk/CBF1 is central for this effect (Pegman et a l., submitted 
December, 2004).
The induction o f bfl-1 by EBV in B cells has implications for the biology of EBV, as 
EBV-mediated up-regulation o f this gene may contribute to the survival o f EBV- 
infected B cells, since cells similar to LCLs are present in the circulation and during 
primary infection by the virus (Qu and Rowe, 1992; Tierney et a l., 1994). Additionally, 
the effect o f bfl-1 may contribute to the development o f EBV-associated B cell 
malignancies, such as post-transplant lymphoproliferative disorders and BL tumours. 
Mechanistic studies o f the contribution o f bfl-1 to cell survival will provide important 
information about both normal B cell development and potential routes to B cell 
malignancy. The main objectives o f the current study were to further investigate the 
molecular basis o f bfl-1 regulation by LMP1 and EBNA2 when expressed individually 
in BL-derived cell lines and when present together in EBV-infected cell lines. In 
summary, the following conclusions may be drawn from the experiments below:
• NF-kB composed o f p65 subunits trans-activates the bfl-1 promoter in the 
EBV-negative BL-derived cell line DG75, and an NF-icB-like binding site at 
position -52 to -43 relative to the transcription start site is essential for this 
effect.
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• EBNA2 trans-activates the bfl-1 promoter in DG75 cells and the DNA 
binding protein RBP-Jk/CBF1 is essential for this effect.
• EBNA2-mediated trans-activation o f bfl-1 in DG75 cells does not lead to the 
activation of NF-kB, and therefore differs from LMP1 -mediated trans­
activation.
• The cellular functional equivalent o f EBNA2, NotchIC, does not trans- 
activate the bfl-1 promoter in DG75 cells, and this is not due to the fact that 
the NotchIC protein has a weaker trans-activation domain than that o f 
EBNA2.
• An EBNA2 mutant, with a trans-activation domain deletion, significantly 
inhibits wild type EBNA2-mediated trans-activation of both the LMP1 and 
bfl-1 promoters in DG75 cells
• Blocking either LMP1- or EBNA2-mediated signalling alone in the EBV- 
infected cell lines Ag876, IB4 or EREB 2.5 does not lead to a decrease in 
bfl-1 promoter activity.
• Blocking both LMP1- and EBNA2-mediated signalling simultaneously in 
the EBV-infected cell lines Ag876, IB4 and EREB 2.5 leads to significant 
inhibition in bfl-1 activity.
• Induction o f EBNA2 in a panel o f estrogen-responsive EBNA2 (EREB) cell 
lines, and the resulting LMP1 expression, leads to a transient increase in the 
level o f bfl-1 mRNA.
• In the absence o f functional EBNA2 and LMP1, bfl-1 mRNA levels 
significantly decrease in the panel o f EREB cell lines.
• LMP1 maintains elevated bfl-1 mRNA levels in the absence o f functional 
EBNA2 in the panel o f EREB cell lines.
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• Induction o f functional EBNA2 alone in the panel o f EREB cell lines leads 
to an increase in the level o f bfl-1 mRNA.
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CHAPTER 2 
Materials & Methods
2.1 BIOLOGICAL MATERIALS
2.1.1 Cell lines
Table 2.1: Cell lines used in the study
Cell Lines EBV Cell Description
Status Classification
Ag876 Type in  BL Type ID BL cell line expressing all of the
EBV latent genes.
DG75 EBV negative Lymphoid B cell line derived from an
BL Israeli Burkitt-like lymphoma case (Ben- 
Bassatetal., 1977).
EREB 2.5 LCL An LCL established by co-infecting B- 
cells with a 28 kb mini-EBV plasmid that 
only expresses estrogen-responsive 
EBNA2, together with the EBV P3HR1 
strain in which it’s own EBNA2 gene is 
deleted. (Kempkes etal., 1995b).
EREB 2.5 
pHEBo
LCL EREB 2.5 cells stably transfected with an 
episomal oriP vector, pHEBo, expressing 
hygromycin phosphotransferase (Zimber- 
Strobl etal., 1996).
EREB 2.5 SV 
LMP clone 2C
LCL EREB 2.5 cell line stably transfected with 
an oriP vector expressing LMP1 from the 
SV40 early promoter/enhancer and 
hygromycin phosphotransferase (Zimber- 
Strobl et a!., 1996).
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EREB 2.5 SV 
LMP clone 
11C
LCL A second EREB 2.5 cell line stably 
transfected with an oriP vector expressing 
LMP1 from the SV40 early 
promoter/enhancer and hygromycin 
phosphotransferase (Zimber-Strobl eta/., 
1996).
EREB 2.5 SV 
LMPMut2
LCL EREB 2.5 cells stably transfected with an 
oriP vector expressing a truncated non­
functional LMP1 and hygromycin 
phosphotransferase (Zimber-Strobl et al.,
1996).
EREB 2.5 Tet 
LMP 3 A
LCL EREB 2.5 cells stably transfected with a 
vector expressing tetracycline-regulatable 
LMP1.
IB4 + LCL An LCL established by infection of 
umbilical cord blood lymphocytes with 
the EBV strain B95.8 (King et al., 1980).
The Ag876, DG75 and IB4 cell lines were obtained from Professor Martin Rowe, 
University o f Wales, Cardiff, Wales. The estrogen-responsive cell lines EREB 2.5 and 
EREB 2.5 derivatives were gifts from Dr. Ursula Zimmer-Strobl, GSF-National Research 
Centre for Environment and Health, Munich, Germany.
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2.1.2 Antibodies used in the study
Table 2.2: Antibodies used in the study
Antibody Name Description Supplier
Goat anti-mouse 
IgG, Alkaline 
Phosphatase (AP) 
Conjugate
Anti­
mouse 
IgG, AP 
conjugate 
(S3721)
An affinity purified goat anti­
mouse antibody that reacts with 
all mouse IgG, and is conjugated 
to alkaline phosphatase.
Promega
Mouse anti-EBNA2 PE2 An affinity purified monoclonal 
antibody that reacts with die 
latent gene product EBNA2.
Professor Martin 
Rowe, University of 
Cardiff, Wales
Mouse anti-LMPl CS1-4 An affinity purified monoclonal 
antibody that reacts with EBV- 
encoded latent gene product 
LMP1.
Professor Martin 
Rowe, University of 
Cardiff, Wales
2.1.3 Bacterial strains 
£<w/f JM109
endk\ , recAl, gyrA96, thi, hsdRM (rk\  mkf), re lA l, supE44, X-, A(lac-proAB), [F', 
traD36,proA + B + , lacl q ZAM15]
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2.1.4 Plasmids
Table 23: Expression and reporter constructs used in the study
Plasmid Source Description
pSG5
pSG5-EBNA2
Lindsey Spender, Ludwig Institute 
for Cancer Research, Imperial 
College School of Medicine, 
London.
pSG5-EBNA2 expresses the wild 
type B95.8 EBNA2 gene which 
has been cloned into pSG5 
(Stratagene).
pSG5-EBNA2-WW323SR Professor Diane Hayward, Johns 
Hopkins School of Medicine, 
Baltimore, Maryland 21231, USA.
This plasmid is identical to pSG5- 
EBNA2 except that EBNA2 has 
had two tryptophan residues 
mutated to serine and arginine 
residues at positions 323 and 324 
respectively. ThuspSG5-EBNA2 
does not bind RBP-Jk/CBF1 (Ling 
et al., 1993).
EBNA2 Mut (447-472) Professor Martin Rowe, 
University of Wales, College of 
Medicine, Cardiff, UK.
Expression vector for an EBNA2 
mutant protein with a trans- 
activation domain deletion (aa 
447-472) in vector pJEF34 (pJEF4 
with a p-globin intron upstream of 
the MCS).
EBNA2 Mut (321-323) Evelyne Manet, INSERM, Saint 
Louis Hospital, Paris, France.
This is an expression vector for 
EBNA2 that contains a deletion 
from aa 321-323 sub-cloned into 
pSG5 (Waltzer etal., 1995).
EBNA2 Mut (437-477) Evelyne Manet, INSERM, Saint 
Louis Hospital, Paris, France.
This is an expression vector for 
EBNA2 that contains a deletion 
from aa 437-477 sub-cloned into 
pSG5 (Waltzer etal., 1995).
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pSG5-HA-mNotchl IC (1751- 
2294)
pSG5~HA-mNotchl IC (1751- 
2294)-E2TANLS
pEFBOSneo 
pEFBOSneo-R218H
pSG5FLAG
pSG5FLAG-RBP
Professor Diane Hayward, Johns 
Hopkins School of Medicine, 
Baltimore, Maryland 21231, USA.
Professor Diane Hayward, Johns 
Hopkins School of Medicine, 
Baltimore, Maryland 21231, USA.
Professor Kenji Tanigaki, 
Department of Medical Chemistry, 
Kyoto University, Kyoto, Japan.
Evelyne Manet, INSERM, Saint 
Louis Hospital, Paris, France.
Evelyne Manet, INSERM, Saint 
Louis Hospital, Paris, France.
Expression vector for mouse 
Notch 1IC (1751-2294) inserted 
after the Gal4 DNA binding 
domain of a modified pSG5 vector 
containing the hemaglutmin (HA) 
epitope at the 5’ translation start 
site (Hsieh eta i, 1996).
A modified pSG5 vector 
containing the HA epitope at the 
5’ translation start site, followed 
by mouse Notch 1IC and then 
sequences containing the EBNA2 
trans-activation domain and 
nuclear localisation signal (Hsieh 
eta i, 1996).
pEFBOSneo-R218H expresses a 
mutant RBP-Jk/CBF1 where an 
arginine residue at position 218 
has been replaced with a histidine 
residue (Chung et al., 1994) 
cloned into the empty vector 
pEFBOSneo (Kato et a i, 1997).
An expression vector for the 
FLAG epitope sub-cloned into 
pSG5 (Stratagene) (Waltzer eta i, 
1995).
An expression vector for the full- 
length human RBP-Jk/CBF1 
cDNA, sub-cloned into the 
pSG5FLAG vector (Waltzer etai., 
1995).
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pSG5FLAG-RBP-VP 16
pSG5-LMPl
pEFCX
pEFCX-kBaDN
pcDNA3.1 HisC 
pCMV-p50
pCM. IN -p65 (pCMV -p65) 
pCMV-CCR c-Rel (pCMV-c-Rel)
pCMV-LacZ
-1374/+81-LUC
Evelyne Manet, INSERM, Saint 
Louis Hospital, Paris, France.
Professor Martin Rowe, 
University of Wales, College of 
Medicine, Cardiff, UK.
Dr. Peter Brodin, Umea 
University, Sweden.
Celine Gelinas, Department of 
Biochemistry, University of 
Medicine and Dentistry of New 
Jersey, Robert Wood Johnson 
Medical School, New Jersey, 
USA.
Clontech
Dr. Brendan D'Souza, Department 
of Biological Chemistry, UCLA 
School of Medicine, California, 
USA.
An expression vector for a fusion 
protein between the transcriptional 
activation domain of VP 16 and 
RBP-Jk/CBFI. (Waltzer et al., 
1995).
pSG5-LMPl expresses wild type 
B95.8 LMP1 which has been 
cloned in front of the SV40 
promoter contained in pSG5 
(Stratagene).
pEFCX-IkB clDN expresses a 
super-repressor mutant form of 
IkBci in which the serine residues 
at positions 32 and 36 have been 
replaced with alanines. pEFCX is 
the empty vector (Liljeholm et al., 
1998).
Expression vectors for the NF-kB 
subunits (p50, p65, pc-Rel) sub­
cloned into pCMV (D’Souza et 
al., 2004).
pCMV-LacZ contains E.coli fi- 
galactosidase gene under the 
control of the CMV promoter- 
enhancer.
-1374/+81 -Luc was generated by 
sub-cloning the bfl-1 promoter 
sequence from a corresponding 
CAT reporter construct (Zong et 
al., 1999) into pGL2-Basic 
(D’Souza et al., 2004).
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-1374/+81 itikB  (-52)
pGa (-129/-34) 
pGa (-129/-34 micB)
-1374/4-81 (mCBFl)
3x enh kB luc
pGa50-7 
PGa981 -6
Dr. Brendan D'Souza, Department 
of Biological Chemistry, UCLA 
School of Medicine, California, 
USA.
Dr. Brendan D’Souza, Department 
of Biological Chemistry, UCLA 
School of Medicine, California, 
USA.
Dr. Pamela Pegman, School of 
Biotechnology, DCU, Dublin, 
Ireland.
Professor Martin Rowe, 
University of Wales College of 
Medicine, Cardiff, U.K.
Dr. Bettina Kempkes, Institute of 
Clinical Molecular Biology and 
Tumour Genetics, GSF, Munich, 
Germany.
-1374/+81 micB (-52) contains a 
mutation at the NF-icB-like 
binding site at position -52 to -43 
(D’Souza et al., 2004).
These reporter constructs contain 
bfl-1 promoter sequences sub­
cloned into the promoterless 
vector pGa50-7 (D’Souza e ta l, 
2004).
A luciferase reporter construct 
where the putative RBP-Jk 
binding site at -243 to -249 on the 
wt bfl-1 promoter has been 
mutated to an Xba I restriction site 
(Pegman et al., submitted 
December, 2004).
This reporter construct contains 3 
kB elements upstream of a 
minimal conalbumin promoter 
linked to the firefly luciferase 
gene (Floettmann and Rowe, 
1997).
The pGa981 -6 reporter construct 
(Minoguchi etal., 1997) was 
generated using a 50 bp 
oligonucleotide harbouring both 
CBF1 binding sites of the EBV 
TP1 promoter, which was then 
ligated as a hexamer into plasmid 
pGa50-7 (Laux etal., 1994a).
pLLO-luc Dr. Gerhard Laux, Institute of 
Clinical Molecular Biology and 
Tumour Genetics, GSF, Munich, 
Germany.
This reporter construct contains 
the LMP1 promoter and an 
upstream regulatory region driving 
expression of the luciferase gene 
(Laux etal., 1994a).
2.1.5 Oligonucleotides
Table 2.4: Oligonucleotides used in the study
Target Primer Sequence Product
Size
Annealing
Temperature
-367/-40
bfl-1
promoter
5 ’ -CGCGGAT CCGGT GT AT ACCT AT G AAT G-3 ’ 
5 ’-CGCGGATCCTGAT ACAT GGAGGCTGGT -3 *
351 bp 60'C
-367/-129
bfl-1
promoter
5 ’ -CGCGGAT CCGGT GT AT ACCT AT GAAT G-3 ’
5 ’ -CGCGGAT CC AAAAT GT G AAAG AGGAAA-3 ’
240 bp 60 °C
-367/-230
bfl-1
promoter
5 ’ -CGCGGAT CCGGT GT AT ACCT AT GAAT G-3 ’ 
5 ’ -CGCGGATCCGAAATT AG AATCCTTGT A-3 ’
151 bp 60 °C
pGa50-7 5 ’ -CTCAAGGATCTTACCGCTGT -3 ’ (ampicillin forward) Variable 
5 ’ -CTTCCAGCGGATAGAATGGC-3 ’ Guciferase reverse)
60 *C
bfl-1 5’-TTCAT ATTTTGTTGCGGAGTTC-3 ’ 
5 ’ -AGC ATTTC AC AG AT CTTT CCT -3 ’
150 bp 55 *C
gapdh 5 ’ -TGCACCACCAACTGCTTA-3 * 
5 ’ -GAT GAT GTT CT GGAGAGC-3 *
168 bp 55 *C
All oligonucleotides were obtained from MWG Biotech.
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2.2 CHEMICAL MATERIALS
BDH
Bromophenol blue (44385), EDTA (280254D), Glycine (444495D), Hydrochloric acid 
(28507BF), Isopropanol (296946H), Magnesium sulphate (29117), Methanol (29192BL), 
Nitrocellulose membrane (436107E), Potassium acetate (295814P), Sodium dihydrogen 
orthophosphate (30716), Sucrose (102745C), Tris base (271195Y).
Boehringer Mannheim
Calf intestinal phosphatase & 10 X dephosphorylation buffer (713023). 
Gibco-BRL/Invitrogen
100 bp DNA ladder (15628-019), Foetal calf serum (10270-106), 1 Kb DNA ladder 
(15615-016), Restriction enzymes, RPMI 1640 (31870-025), Trypan blue (15250-061), 
Trypsin (25090-028).
Labscan
Chloroform (A3505E).
Merck
Calcium chloride (23821000), Glacial acetic acid (100632511), Magnesium chloride 
(1058321000), Potassium Hydroxide (50321000), Sodium carbonate (A654792), di- 
Sodium hydrogen phosphate (1065860500).
National diagnostics
Acrylagel (EC810), Bis-acrylagel (EC820).
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Pierce
Oxoid
Agar (LI 3), PBS tablets (BR14), Tryptone (L42), Yeast extract (L21).
Promega
dNTPs(U1330), Luciferase Assay System (E1501), Magnesium chloride 25mM (A3511), 
M-MLV reverse transcriptase & RT buffer (M l701), 5 X Reporter lysis buffer (E3971), 
RNasin (N2111), Wizard® PCR Preps DNA purification system (A7170).
Qiagen
Qiagen® Plasmid Purification Kit (12143), SYBR Green Kit (204143).
Roche
Taq polymerase & 10 X enzyme buffer (1146173), T4 DNA ligase & 10 X ligation buffer 
(481220), Hygromycin B (843555), Leupeptin (1017128).
Sigma-Aldrich Chemical Co.
3 M sodium acetate, pH5.2 (S7899), Agarose (A5093), Ampicillin (A9518), Aprotinin 
(A4529), APS (215589), BCIP-NBT (B1911), Bovine serum albumin (A9647), Chelating 
resin (C7901), Chlorofirom:isoamyl alcohol (24:1) (C0549), Choleratoxin (C3012), 
Colorburst electrophoresis markers (C4105), Coomassie Brilliant Blue R (B0149), DEAE- 
dextran (D9855), DEPC (D5758), DMEM:F12 Hams (D6421), DMSO (D8779), p-estradiol 
(E8875), Ethidium bromide (E4391), G418 (A1720), Glucose (G7528), Glycerol (G5516), 
Horse serum (C7901), Hydrocortisone (H4001), Hydrogen peroxide (HI 009), Insulin 
(15500), L-glutamine (G7513), Manganese chloride (M3634), MOPS (M3183), ONPG
BCA Protein assay kit (23227).
75
(NI 127), Penicillin/streptomycin (P0781), Phenol:chloroform:isoamyl alcohol (25:24:1) 
(P3803), PMSF (P7626), Ponceau S (P7170), Potassium chloride (P4504), Puromycin 
(P8833), RNase A (R6513), Rubidium chloride (R2252), SDS (L6026), Sodium chloride 
(S3014), Sodium hydroxide (S5881), Tetracycline (T7660), TEMED (T7024), Tri reagent 
(T9424), Tween 20 (P1379), Xylene cyanol FF (33594).
Upstate biotechnology
Epidermal growth factor (01-102).
23 DNA MANIPULATION
23.1 Storage of DNA samples
DNA samples were stored in Tris-EDTA (TE) buffer (pH 8.0) at 4°C. EDTA was used to 
chelate heavy metal ions that are needed for DNase activity while storage at pH 8.0 
minimizes de-amidation. DNA was also stored in sterile distilled H2O (dH20).
23.2 Phenol/chloroform extraction and ethanol precipitation
Phenol/chloroform extraction and ethanol precipitation were carried out to concentrate 
nucleic acid samples or change the buffers in which a sample was dissolved. An equal 
volume of phenol/chloroform/isoamyl alcohol (25:24:1) was added to the DNA solution, 
mixed by vortexing and centrifuged for 10 minutes at 13,000 x g. The upper aqueous phase 
was removed, avoiding any material at the interphase, and placed in a sterile microfuge 
tube. An equal volume of chloroform/isoamyl alcohol (24:1) was added to the aqueous 
phase, vortexed as before, and centrifuged for 5 minutes at 13,000 x g. Again the upper 
aqueous phase was removed to a fresh tube. One-tenth volume of 3 M sodium acetate (pH 
5.2) was added to the solution o f DNA, mixed and followed by 2 volumes of 100 % (v/v) 
ethanol. This mixture was vortexed and incubated at -80°C for 5 minutes. The DNA 
samples were then centrifuged for 30 minutes at 12,000 x g at 4°C, the supernatant was
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removed and pellets were washed with 1 ml 70 % (v/v) ethanol to remove excess salts. The 
tube was centrifuged for 5 minutes at 10,000 x g, the supernatant was removed and pellets 
were air dried for approximately 10 minutes. Pellets were re-suspended in an appropriate 
volume o f sterile TE (pH 8 .0) or dH20.
2.3.3 Restriction digestion of DNA
Restriction digestion of DNA was carried out for identification purposes, plasmid 
linearisation or to cut particular fragments from a plasmid. Restriction enzymes 
specifically bind and cleave double-stranded DNA at specific sites within or adjacent to a 
particular sequence, which is known as the recognition site. All restriction enzymes used 
were supplied with incubation buffers at a concentration of 10 X (working concentration 1 
X). DNA digests were performed by addition of the reagents listed below:
200 ng -1 [ig o f DNA (Final concentration o f <300 ng/pl)
1 fil o f enzyme/^ig o f DNA (10 U).
10 X buffer to a final concentration o f 1 X 
dH20  to the final volume required
The reaction was gently mixed, centrifuged, and then incubated for 2 hours at the optimum 
enzyme temperature (between 37°C and 50°C, usually 37°C).
23 .4  Dephosphorylation of linearised plasmid DNA
To minimize re-circulisation o f linearised DNA required for ligation, treatment with calf 
intestinal phosphatase (CIP) is required. This dimeric glycoprotein prevents re- 
circulisation by removing die 5’ phosphate groups on the linearised DNA molecule.
Digested DNAs (<100 ng/[il) were de-phosporlylated using CIP in a 100 1^ volume (CIP 
was added 1 unit/100 pmoles for cohesive termini). The solution was vortexed, centrifuged 
briefly and incubated for 30 minutes at 37°C. This was followed by an enzyme denaturation
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step achieved by heating to 75 °C for 10 minutes. This DNA was purified by 
phenol/chloroform extraction and ethanol precipitation described in section 2.3.2. The 
purified linearised, CIP-treated DNA was stored at 4°C until required for ligation.
2 J i  Polymerase chain reaction (PCR)
The polymerase chain reaction (PCR) method was used to amplify target sequences of 
DNA for sub-cloning into linearised vectors, or for identification puiposes. PCR involves 
the amplification of specific DNA sequences using DNA primers, which anneal to the DNA 
of interest. The primers are designed so that one anneals to the forward DNA strand and 
the other anneals to the reverse strand thus allowing polymerisation o f both strands by the
enzyme Taq DNA polymerase. This results in exponential amplification of the sequence of
interest. PCR reactions were set up by addition of reagents in the following order:
dH20  37 pi
Template DNA (-500 ng) 1
Forward primer (40 pmole) 2.5 \l\
Reverse primer (40 pmole) 2.5 \i\
1 0 X enzyme buffer (+15mM MgCk) 5 jal 
dNTP mix (each at 5 mM) 2 ul
Taq polymerase (5 U/jil) 1 \i\
All PCR reactions were carried out in a Hybaid thermocycler under the following 
conditions:
First cycle 95°C, 5 minutes
Second cycle 95 °C, 3 minutes
X°C, 2  minutes 
72 °C, 2  minutes
Final cycle 72°C, 15 minutes
> 1 Cycle 
30 Cycles 
1 Cycle
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X = Annealing temperature and was usually calculated by subtracting 5°C from the lowest 
melting temperature (Tm) of a primer pair. Annealing temperatures and primers are listed 
in Table 2.4.
23 .6  Purification of PCR products
PCR products were purified from contaminants (including primer-dimers and amplification 
primers) using the Promega Wizard® PCR Preps DNA Purification System. 100 jil of 
completed PCR reaction was mixed with 100 pi direct purification buffer (provided with 
kit) and vortexed briefly. 1 ml of resin (provided with kit) was then added and the mixture 
was vortexed briefly 3 times over a 1 -minute period. A Wizard® Minicolumn was prepared 
for each PCR product by removing the plunger from a 3 ml disposable syringe and 
attaching a Minicolumn to the syringe barrel. The resin/DNA mix was transferred into the 
barrel, the plunger replaced and the slurry was gently pushed into the Minicolumn. The 
syringe was detached from the Minicolumn and the plunger removed. The syringe barrel 
was reattached to the Minicolumn and 2 ml of 80 % isopropanol was transferred into the 
barrel. The plunger was inserted and the isopropanol was gently pushed through. The 
Minicolumn was detached from the syringe and inserted into a 1.5 ml microfuge tube, and 
centrifuged at 10,000 x g for 2 minutes to dry the resin. After centrifugation, the 
Minicolumn was transferred to a new microfuge tube, 50 \A o f dH20 was applied and left 
for 1 minute. The Minicolumn was then centrifuged for 20 seconds at 10,000 x g to elute 
the DNA fragment. The purified DNA was stored at 4°C until required for further use.
23 .7  Ligation of DNA molecules
Cohesive end ligations o f equimolar amounts of vector and insert DNA (1 pg) were 
generally carried out overnight at 16°C in a commercial ligation buffer (5 mM ATP) with 
10 units o f T4 DNA ligase/ml in a total volume of 10 pi. After ligation, the samples were 
heated at 70°C for 1 0  minutes to inactivate the ligase and stored at -20°C until required for 
transformation.
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2 .3.8 Preparation of competent cells
A modified Rubidium chloride (RbCk) method was employed to prepare competent cells. 
An E.coli strain (JM109) was streaked from a glycerol stock on to a Luria-Bertani (LB) 
agar plate and incubated at 37°C overnight. An isolated colony was then picked using a 
sterile inoculating loop and used to inoculate 5 ml o f LB broth (Appendix). This culture 
was incubated at 37°C in a shaking incubator at 2 0 0  rpm overnight. 2.5 ml of the resulting 
culture was then used to inoculate 250 ml of sterile LB broth supplemented with 20 mM 
MgSC>4 . This 250 ml culture was incubated in a 1 L flask at 37°C until the O.D. o f the 
culture at 640 nm had reached between 0.4 and 0.8 (approximately 4-5 hours). The cells 
were then transferred to two sterile 250 ml centrifuge tubes and pelleted by centrifugation 
at 4,500 x g, 4°C for 5 minutes. The resulting pellets were re-suspended in 0.4 original 
volume ice cold TFB1 (Appendix) (100 ml for 250 ml culture). Cells were kept on ice for 
all subsequent steps and pipettes, tubes and flasks were chilled. The re-suspended cells 
were then incubated on ice at 4°C for 5 minutes followed by centrifugation at 4,500 x g at 
4°C for 5 minutes. Cells were then gently re-suspended in 1/25 of the original volume of 
ice-cold TFB2 (Appendix) (10 ml for a 250 ml culture). Cells were divided into 100 pi 
aliquots and incubated on ice for 1 hour. Prior to storage the aliquoted cells were snap 
frozen in a dry ice/isopropanol bath. JM109 competent cells prepared by this method and 
stored at -80°C are stable for 1 year.
23.9 Transformations
100 pi of competent cells were placed in a pre-chilled microfuge tube containing 5 pi DNA. 
The contents were mixed gently and incubated on ice for 30 minutes, during which time an 
aliquot o f SOC medium (Appendix) was pre-heated at 42°C. After 30 minutes on ice the 
cells were heat-shocked in a water bath at 42°C for 55-65 seconds, followed by incubation 
on ice for a further 2 minutes. 1 ml o f preheated SOC was then added to the cells and 
incubated at 37°C in a shaking incubator for 1 hour 1 0  minutes. The cells were pelleted by 
centrifugation for 3 minutes at 6,000 x g. Following centrifugation, 800 pi of supernatant 
was removed and discarded. The cells were re-suspended in the remaining supernatant and 
plated out, along with controls, on LB plates containing the appropriate antibiotic (usually
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ampicillin at a concentration of 1 0 0  pg/ml) and incubated overnight at 37°C. Transformed 
cells become resistant to die antibiotic, thus only transformed cells will yield colonies. 
These colonies were subsequently used to prepare broth cultures for DNA mini­
preparations.
23.10 Small scale preparation of plasmid DNA (Miniprep)
A single bacterial colony was used to inoculate 5 ml of LB medium (with appropriate 
antibiotic) and incubated overnight at 37°C. An aliquot (1.5 ml) o f this culture was 
transferred to a sterile microfuge tube and centrifuged for 30 seconds at room temperature; 
the remainder was stored at 4°C. The supernatant was removed from the tube, leaving the 
pellet as dry as possible. The pellet was re-suspended thoroughly in 100 pi o f solution I 
(Appendix) by vortexing. 200 pi o f freshly prepared solution II (Appendix) was added, the 
tube contents were mixed by inverting the tube rapidly a number o f times. 150 pi o f ice- 
cold solution HI (Appendix) was added and the tubes were vortexed gently for 10 seconds. 
The lysate was centrifuged for 5 minutes at 12,000 x g, the supernatant was transferred to a 
fresh tube, taking care not to cany over any of the white precipitate. An equal volume of 
phenol/chloroform/isoamyl alcohol (25:24:1) was added, mixed by vortexing and 
centrifuged for 5 minutes at 12,000 x g. The upper aqueous phase was removed to a fresh 
tube, to which 2  volumes of 1 0 0  % (v/v) ethanol were added, the solution was vortexed and 
centrifuged for 5 minutes at 12,000 x g. The supernatant was discarded, the pellet was 
washed with 1 ml 70 % (v/v) ethanol, centrifuged as before and the supernatant was 
removed. The pellet was air-dried, then re-suspended in 50 pi of TE (pH 8.0). 1 pi of 
DNase-free RNase A (20 pg/ml) was also added, and the mixture was vortexed, incubated 
at 37°C for 1 hour and then stored at 4°C. Glycerol stocks o f all bacterial cultures were 
prepared at this stage by the adding 0.5 ml o f a 50 % (v/v) glycerol solution to 0.5 ml of the 
overnight bacterial culture of interest and storing at -80°C.
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2J.11 Qiagen® plasmid DNA purification protocol (Maxiprep)
Plasmid DNA was purified using the QIAGEN® Plasmid Midi Kit from Promega. All 
buffers used are described in the Appendix. A glycerol stock of the bacteria of interest was 
streaked out on LB agar plate (containing the appropriate antibiotic) and incubated 
overnight at 37°C. An isolated colony from this plate was used to inoculate a 5 ml starter 
culture (with the appropriate antibiotic) and incubated in a shaking incubator at 225 rpm 
37°C for 8  hours. 100 pi of the starter culture was used to inoculate 50 ml of LB 
(containing the appropriate antibiotic) in a 250 ml sterile flask and incubated overnight in a 
shaking incubator at 37°C. The O.D. o f the culture must read 1-1.5 at 600 nm. The 
bacteria culture was transferred to a centrifuge tube and centrifuged by spinning at 6 , 0 0 0  x 
g for 15 minutes at 4°C using a JA-20 rotor in a Beckman centrifuge. The supernatant was 
removed and the bacterial pellet was re-suspended completely in 4 ml of Buffer PI 
containing RNase A (100 pg/ml). The bacterial cells were then lysed by addition o f 4 ml 
Buffer P2 and incubation at room temperature for 5 minutes. Following incubation, 4 ml of 
pre-chilled Buffer P3 was added (to precipitate genomic DNA, protein, cell debris and 
SDS), mixed gently by inverting the tube 5-6 times and incubated on ice for 20 minutes. 
The mixture was then centrifuged for 1 hour 30 minutes at 16,000 x g at 4°C and the 
supernatant saved.
The Qiagen-tip 100 was equilibrated by applying 4 ml o f QBT buffer and allowing the 
column to empty by gravity. The column does not dry out at this stage, as the flow of 
buffer will stop when the buffer reaches the upper filter. Following equilibration, the 
supernatant from the previous centrifugation step was applied to the filter and allowed to 
flow through. The QIAGEN-tip was washed with 2 x 10 ml of Buffer QC. DNA was then 
eluted with 5 ml o f Buffer QF. DNA as precipitated by adding 0.7 volumes o f room- 
temperature isopropanol, centrifuged immediately at 13,000 x g for 45 minutes at 4°C and 
the supernatant was carefully removed. The resulting pellet was washed with 70 % (v/v) 
ethanol, allowed to air dry for 5 minutes and re-dissolved in a suitable volume o f TE or 
CIH2O. DNA was then quantified by spectrophotometric analysis.
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23.12 Spectrophotometric analysis of nucleic acids
DNA/RNA concentration was determined by measuring the absorbance at 260 nm, which is 
the wavelength at which nucleic acids absorb maximally (X max). A 50 pg/ml preparation of 
pure DNA has an absorbance o f 1 unit at 260 nm, while 40 pg/ml o f pure RNA also has an 
absorbance reading of 1 at this wavelength. The purity o f an RNA or DNA preparation was 
determined by reading absorbance at 260 nm (the X max for nucleic acids) and at 280 nm 
(the X max for proteins) and obtaining the ratio for these absorbances. Pure DNA and RNA 
have A260/A280 ratios o f 1.8 and 2.0 respectively. Lower ratios indicate the presence of 
protein while higher ratios often indicate residues of organic reagents. Absorbances were 
read on the Shimadzu UV-160A spectrophotometer using a quartz cuvette and nucleic acid 
concentrations were determined according to the following equations:
Concentration of DNA (Mg/pi) = Absorbance (260 nm) x 50 x dilution factor
1000
Concentration of RNA (pg/pl) = Absoibance (260 nm) x 40 x dilution factor
1000
23.13 Agarose gel electrophoresis of DNA
Electrophoresis through agarose gel is the standard method used to separate, identify, and 
purify DNA fragments. The technique is simple, rapid to perform and can be used for the 
isolation of DNA fragments. An appropriate quantity of agarose was added to 100 ml 1 X 
TAE buffer based on the percentage agarose gel required. Increasing the percentage 
agarose (1.8-2 %) in the gel was generally used to improve resolution o f smaller DNA 
fragments while separation of larger DNA molecules was best achieved by using lower 
percentage gels (0.7-0.8 %). The agarose was completely dissolved by boiling and after 
sufficient cooling (~60°C) the gel was cast into the Hybaid horizontal gel electrophoresis 
system. A comb was inserted for formation of the wells. The gel was left to set for at least 
1 hour before filling the chamber with 1 X TAE and removing the comb. Sample buffer,
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containing bromophenol blue as a tracking marker (Appendix), was added to each sample 
before loading up to 20 \i\ per well. DNA sample buffer was also added to 500 ng of a 1 
Kb or 100 bp ladder, which was loaded as a size marker. The gel was run at constant 
voltage (5 V/cm), for 1 to 2 hours. After completion, the gel was stained in ethidium 
bromide (0.5 mg/ml) for 30 minutes, destained in dH20  for 15 minutes and viewed under 
UV illumination.
2.4 CELL CULTURE METHODS
All cell culture techniques were performed in a sterile environment using a Holten laminar 
flow cabinet. Cells were visualized with an Olympus CK2 inverted phase contrast 
microscope.
2.4.1 Culture of cells in suspension
All media compositions and media supplements are given in the Appendix. The cell lines 
DG75, IB4, Ag876, EREB 2.5, and the EREB 2.5 derivatives (pHEBo, SV LMP clone 2C, 
SV LMP clone 11C, SV LMP Mut 2, Tet LMP clone 3 A) were maintained in R PM I1640 
supplemented with 10 % foetal bovine serum (FBS), 2 mM L-glutamine, 100 |ig/ml 
streptomycin and 100 U/ml penicillin (Appendix). Additional supplements were added to 
some culture media as described in section 2.4.2. Cultures were seeded at a density of 2 x 
105 to 5 x 105 cells per ml in 25 cm2 flasks and expanded in 75 cm2 flasks. Cells were sub­
cultured two or three times per week by harvesting into a sterile centrifuge tube and 
pelleting at 1000 x g for 5 minutes at room temperature. The cell pellet was re-suspended 
gently in an appropriate volume o f fresh supplemented media and replaced into the tissue 
culture flask. All cell lines were incubated in a humid 5 % C 0 2 atmosphere at 37°C in a 
Heraeus cell culture incubator.
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2.4.2 Media supplements
Supplements were added to the growth media of certain cell lines to (a) select cells 
containing transfected plasmids or (b) activate function of a gene or (c) induce expression 
of a gene o f interest.
In the case of the estrogen responsive EREB 2.5 cell line and it’s derivatives (pHEBo, SV 
LMP clone 2C, SV LMP clone 11C, SV LMP Mut 2 and Tet LMP clone 3A), the EBNA2 
activation domain is fused to the estrogen receptor binding domain, such that the activity of 
EBNA2 is dependent on the presence of estrogen. These cell lines were maintained in 
supplemented medium containing 1 pM estrogen (P estradiol). To abolish functional 
EBNA2 activity, EREB 2.5 cells were washed 4 times in PBS, with a further 2 washes 24 
hours later. Hygromycin was added to the EREB 2.5 derivatives to select for stably 
transfected cells, at the following concentrations:
pHEBo
SV LMP clone 2C 
SV LMP clonellC  
SV LMP Mut 2 
Tet LMP clone 3 A
150 pg/ml hygromycin 
75 pg/ml hygromycin 
75 pg/ml hygromycin 
75 pg/ml hygromycin 
100 pg/ml hygromycin
The Tet LMP 3A clone has been transfected with a tetracycline-regulatable construct. 
LMP1 expression is off in the presence of 1 pg/ml tetracycline and can be switched on by 
removing tetracycline from the culture medium.
2 .4 3  Cell counts
Cell counts were performed using an improved Neubauer haemocytometer slide. Trypan 
blue exclusion dye was routinely used to determine cell viability. 10 pi o f trypan blue was 
added to 90 pi o f a cell suspension and mixed. A sample o f this mixture was added to the 
counting chamber o f the haemocytometer and cells were visualized by light microscopy. 
Viable cells excluded the dye and remained clear while dead cells stained blue. Cell
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numbers were ascertained by multiplying the average cell count (of 3 individual counts) by 
the dilution factor (usually 1.1) and again by the volume of the haemocytometer chamber (1 
x 104 cells/ml). Thus, cell counts were expressed as the number of cells per ml.
2.4.4 Cell storage and recovery
In order to prepare stocks of suspension cells for long-term storage, 1 x 107 cells in 
exponential phase were pelleted and re-suspended in 750 |il of supplemented RPMI to 
which 150 jxl o f FBS was added, then placed on ice for 10 minutes. DMSO was added to a 
final concentration o f 10 % (v/v), mixed gently and transferred to a sterile ciyotube. The 
cryotubes were slowly lowered into the gas phase of liquid nitrogen and immersed in liquid 
nitrogen in a cryofreezer (Cooper Cryoservices Ltd).
Cells were recovered from liquid nitrogen by thawing rapidly at 37°C and transferring to a 
sterile centrifuge tube containing 5 ml of pre-warmed supplemented media. The cells were 
centrifuged at 1000 x g for 5 minutes, the pellet was re-suspended in 5-10 ml of fresh 
supplemented medium, transferred to a culture flask and incubated at 37°C in 5 % CO2 .
2.4.5 Transient transfections
Transient transfection of cells was performed either by electroporation or the DEAE- 
dextran protocol. In all cases, cells were seeded at a density of 5 x 105 per ml o f medium 
24 hours prior to transfection. After 24 hours in culture, cells were counted again - it was 
essential for cell numbers to have almost doubled before beginning the transfection, thus 
ensuring that cell growth is in logarithmic phase, allowing for optimal DNA uptake during 
transfection. The same quantity of total DNA was used per transfection.
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2.4.5.1 Electroporation of B lymphocytes
Transfection o f IB4, Ag876 and the EREB 2.5 cell line was carried out by electroporation. 
During the electroporation method of transfection, the application of brief high voltage 
electric pulses to the cells leads to the formation of nanometer-sized pores in the plasma 
membrane. DNA is taken directly into the cell cytoplasm either through these pores or as a 
consequence o f redistribution o f membrane components that accompanies the closure o f the 
pores.
Total DNA (10-20 pg per transfection) dissolved in 30 pi TE buffer (pH 8.0) was 
transferred into a sterile electroporation cuvette. 1 x 107 cells were used per transfection. 
Cells were centrifuged at 1,000 x g for 5 minutes and the supernatant discarded. The cells 
were then washed in PBS, centrifuged at 1,000 x g for 5 minutes and the supernatant again 
discarded. For each 1 x 107 cells, 220 pi of fresh medium was used for re-suspension and 
die cells transferred to the DNA-containing electroporation cuvettes. The cell/DNA mix 
was incubated at RT for 5 minutes. Each cell/DNA mix was then pulsed at 250 V with a 
capacitance of 960 pF (using a capacitance extender) and resistence set at infinity in a 
Biorad Gene Pulser. Immediately after electroporation the cuvettes were placed on ice until 
the cell/DNA mix was transferred into 5 ml supplemented medium in a 6 well dish. 
Transfected cells were harvested 48 hours later.
2.4.5.2 DEAE-Dextran-mediated transfection
During this method of transfection, positively-charged DEAE-dextran binds to the 
negatively charged phosphate groups of the DNA, forming aggregates. These complexes, 
when applied to cells, subsequently bind to the negatively charged plasma membrane. It is 
believed that cellular uptake of DNA is mediated by endocytosis, further assisted by 
osmotic shock.
A total o f up to 25 pg of DNA dissolved in dH20  was used per transfection. Total DNA 
was prepared in a sterile microfuge tube and brought to a volume of 600 pi with TBS
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(Appendix). Then, 600 \i\ o f 1 mg/ml DEAE dextran solution made up in TBS was mixed 
with the DNA solution.
1.4 x 107 cells were used for each transfection. On the day of transfection, cells were 
centrifuged at 1,000 x g for 5 minutes and the supernatant was discarded. The cells were 
washed in PBS, centrifuged at 1,000 x g for 5 minutes and the supernatant again discarded. 
The cell pellet was gently re-suspended in the DNA/DEAE-dextran mix. The transfection 
cocktails were incubated at room temperature for 30 minutes with gentle swirling every 5- 
10 minutes to allow homogenization. Transfections were terminated by adding 10 ml 
supplemented medium, and the cells pelleted by centrifugation at 1,000 x g for 5 minutes. 
The cells were then washed in PBS as before and transferred to 25 cm2 cell culture flasks 
containing 10 ml supplemented medium for incubation. Cells were harvested at 48 hours 
post-transfection.
2.4.53 Harvesting cells post-transfection
Cells were pelleted by centrifugation at 1,000 x g for 5 minutes at room temperature. The 
cells were washed once in sterile PBS and centrifuged again at 1,000 x g for 5 minutes. 
The supernatant was discarded, insuring all traces of PBS were removed from the pellet. 
The pellet was re-suspended in 50 pi o f 1 X reporter lysis buffer (diluted with water from a 
5 X stock, Promega) and the cell suspension transferred to a microfuge tube. The tubes 
were vortexed for 10-15 seconds. The lysates were clarified by centrifugation at 13,000 x g 
for 5 minutes and the supernatant saved in a fresh tube. Samples were stored at -80°C.
2.4.5.4 Luciferase assay
During transfections, promoter activity was determined by means o f the luciferase assay. 
Firefly luciferase, a monomeric 61 KDa protein, catalyses luciferin oxidation using ATP- 
M g^ as a co-substrate. Light is produced by converting the chemical energy of luciferin 
oxidation through an electron transition, forming the product molecule oxyluciferin. In the
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conventional assay for luciferase, a flash of light is generated that decays rapidly after the 
enzyme and substrates are combined.
Luciferase assay reagent was prepared by reconstituting luciferase assay substrate with 
luciferase assay buffer (Promega) and stored in aliquots in the dark at -80°C. At the time of 
assay, it was important to allow sufficient time for the luciferase detection reagent to 
equilibrate to room temperature. 20 pi aliquots of cell lysate were dispensed into individual 
wells in a white 96 well plate, along with 20 pi of 1 X lysis buffer to act as a blank. 
Subsequently, 100 pi of detection reagent was added to the lysate to initiate enzyme 
activity, mixed by repetitive pipetting (3 times) and light emission integrated over a period 
of 60 seconds, after lag period o f 10 seconds, was measured on a luminometer (Labsystems 
Luminoskan 391 A). Luciferase activity levels were adjusted for transfection efficiencies, 
estimated using jfr-galactosidase assay.
2.4.5.5 y^-galactosidase assay
When measuring the effect o f promoters or enhancers on gene expression, it is essential to 
include an internal control that will distinguish differences in the level of transcription from 
differences in the efficiency of transfection or in the preparation of extracts. This is best 
achieved by co-transfecting the cells with two plasmids: one that carries the construct under 
investigation, and another that constitutively expresses an activity that can be assayed in a 
separate experiment. An enzyme frequently used for this is E.coli /?-galactosidase. The fi- 
galactosidase assay is a convenient method for assaying /?-galactosidase activity in lysates 
prepared from cells transfected with /?-galactosidase reporter vectors, in this case pCMV- 
LacZ.
The /?-galactosidase assay was performed using a sample from the same lysates used during 
the luciferase activity. Cell extract (30 pi) was added to 3 pi 100 X Mg solution, 66 pi 1 X 
ONPG and 201 pi 0.1 M sodium phosphate (Appendix) and incubated at 37°C for 30 
minutes or until a faint yellow colour developed. This yellow colour development is the 
result o f o-nitrophenyl-P-D-galactopuranoside (ONPG) hydrolysis by /?-galactosidase to
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form 0 -nitrophenyI. A reaction tube was included containing 1 X lysis buffer instead of 
cell lysate in order to obtain a background reading. Reactions were terminated by adding 
500 (jJ 1 M Na2CC>3 . Optical densities were read at 420 nm over a linear range o f 0.2-0.8.
2.5 RNA ANALYSIS
2.5.1 RNase-free environment
Because RNA is easily degraded by ubiquitous RNases, a number o f measures were 
employed to avoid this potential hazard. All glassware and metal spatulas were baked prior 
to use at 80°C for 16 - 24 hours in order to inactivate any RNases. Sterile disposable 
plastic-ware is generally considered RNase-free and therefore, did not require treatment. 
RNases are resistant to autoclaving but can be inactivated by the chemical diethylpyro- 
carbonate (DEPC). DEPC-treatment involves addition of the chemical to solutions at a 
final concentration of 0.1 % (v/v), incubation at room temperature for 18 hours followed by 
autoclaving. Solutions containing amines such as Tris cannot be DEPC-treated, as the 
DEPC is inactivated by these chemicals. Solutions containing amines were prepared using 
DEPC-treated dFhO followed by autoclaving.
Prior to running an RNA gel, the electrophoresis apparatus was treated to remove any 
RNase. The tank, gel tray, comb and lid were washed in detergent and rinsed well in 
DEPC-treated H2O then air dried in 100 % (v/v) ethanol. The tank, gel tray and comb were 
immersed in a 3 % (v/v) solution o f hydrogen peroxide for 15 minutes. The apparatus was 
then rinsed thoroughly in DEPC treated uptfcO and allowed to dry. Because hands are a 
major source o f RNase contamination, gloves were used at all times and changed 
frequently.
2.5.2 RNA extraction from cultured cells
Prior to RNA isolation the cells were examined by phase contrast microscopy to determine 
the condition o f the ceils. A cell count was performed as described in section 2.4.4. RNA
90
was extracted from cultured cells using Tri reagent (Sigma). Cells grown in suspension 
were pelleted at 1,000 x g for 5 minutes, washed once in PBS and the cell pellet lysed by 
repeat pipetting in Tri Reagent. 1 ml o f Tri reagent was used per 1 x 107 cultured cells. 
The lysate was left at room temperature for five minutes after which the procedure may be 
halted by storing samples at -80°C.
Phase separation was achieved by adding 200 pi o f chloroform per 1 ml o f lysate. The 
samples were covered and shaken gently but thoroughly for 15 seconds or until completely 
emulsified. Samples were incubated at room temperature for 15 minutes. The resulting 
mixture was centrifuged at 13,000 x g for 20 minutes at 4°C. During centrifugation the 
mixture separates into a lower red, phenol-chloroform phase, an inteiphase and a colourless 
upper aqueous phase. The aqueous phase, which contains the RNA, was removed to a fresh 
tube and RNA was precipitated by adding 500 pi o f ice-cold isopropanol per ml o f Tri 
reagent used initially. The samples were incubated for 10 minutes on ice, then centrifuged 
at 13,000 x g for 15 minutes at 4°C. The resulting RNA pellet was washed using 1 ml o f 75 
% (v/v) ethanol by inverting the tube 5 times. The pellets were then centrifuged at 13,000 x 
g for 5 minutes at 4°C, and the 75 % (v/v) ethanol was removed. Pellets were air dried and 
dissolved in DEPC treated upH20. The resulting RNA preparation was heated at 60°C and 
mixed gently to ensure a homogeneous solution prior to aliquoting. An aliquot was 
removed for spectrophotometric (section 2.3.12) and gel electrophoretic analysis (section 
2.5.3).
2.5.3 RNA analysis by gel electrophoresis
In order to ascertain the integrity o f RNA, isolated samples were run on 1.5 % (w/v) 
agarose gels. The appropriate amount o f agarose was dissolved in DEPC-treated H2O and 
prepared according to section 2.3.13. The RNA samples (1 pi) were prepared for 
electrophoresis by adding 3 pi of RNA sample buffer and made up to 15 pi in DEPC- 
treated H2O. The samples were heated to 65°C for 10 minutes prior to loading on the gel. 
The gel was run in 1 X TAE as described in section 2.3.13. As ethidium bromide is 
included in the RNA sample buffer the gels did not require further staining and could be 
visualized directly on a UV trans-illuminator. The presence o f two strongly stained bands
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represent the 28 S and the 18 S ribosomal RNAs, which indicated intact RNA. Degradation 
is observed by a smear running down the length of the gel.
2.5.4 Quantification of mRNA by reverse transcription real time PCR
The quantification of mRNA was performed in a two-step procedure. In the first step, 
cDNA was prepared from RNA by reverse transcription with random hexamers serving as 
primers. During the second step, cDNA was amplified by real time PCR. Real-time PCR is 
increasingly being adopted for RNA quantification based on its ability to detect the amount 
of PCR product present at every cycle (i.e. in real time), as opposed to the endpoint 
detection by conventional PCR methods, thus allowing the real-time progress o f the 
reaction, especially its exponential phase, to be viewed. The real-time PCR approach is 
based on the detection and quantification o f a florescent reporter, where the signal increases 
in direct proportion to the amount of PCR product in a reaction. SYBR green was the 
fluorescent reporter employed. SYBR green binds the double stranded PCR product in a 
sequence independent manner and will not bind single stranded DNA (i.e. primers). The 
real-time system was used for comparative gene expression analysis, normalising with 
GAPDH levels.
2.5.4.1 Reverse transcription (RT)
This is the process whereby mRNA is transcribed into cDNA using a reverse transcriptase, 
in this case Moloney Murine Leukemia Virus reverse Transcriptase (M-MLV RT). 
Initially, 2 pi o f random hexamers was added to 2 pg RNA and the volume brought up to 
10 pi with DEPC H2O. The mixture was heated to 70°C for 5 minutes, to destabilize 
secondary mRNA structures, and then placed on ice. Then, the reagents listed below were 
added in the following order:
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Reverse Transriptase buffer (5 X) 
dNTP mix (20 mM)
MgCl2 (25 mM)
BSA (4 pg/pl)
RNasin ribonuclease inhibitor 
M-MLV reverse transcriptase (200 U/pl) 
DEPC H20
8 pi 
lpl 
4 ul 
lp l
1 Ml
2 pi
13 pi
The reactions were placed in a Hybaid thermocycler at 37°C for 1 hour and 95°C for 2 
minutes followed by storage at 4°C.
2.5.4.2 Real time PCR
cDNA generated by reverse transcription was quantified by real time PCR using the 
QuantiTect® SYBR® Green PCR kit (Qiagen). The kit provided a SYBR® Green master 
mix that contained Taq polymerase and dNTPs. Real time PCR reactions were set up as 
follows:
cDNA 2 pi
SYBR Green 12.5 pi
Nuclease Free H20  8.5 pi
Forward primer 1 pi
Reverse primer 1 pi
Samples were quantified using the Rotor Gene™ 3000 multiplex system (Corbett 
Research) under the following thermo-cycling conditions:
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First cycle (denature) 95°C for 15 minutes 1 cycle
Second cycle (cycling)
Third cvcle (hold) 
Final cycle (melt)
95°C for 20 seconds 
55°C for 30 seconds 
72°C for 20 seconds
60°C for 1 minute
50 cycles
} 1 cycle
50-99°C rising by 1°C each step, waiting for 15 
seconds on first step, then 5 seconds for each step 
afterwards.
2.6 PROTEIN ANALYSIS
2.6.1 Preparation of cellular protein
Proteins were isolated from suspension cells for analysis by SDS-polyaciylamide gel 
electrophoresis (SDS-PAGE) and by western blotting. Prior to isolation, cells were washed 
in PBS. Cells were pelleted at 1,000 x g for 5 minutes and the supernatant removed. 10 ml 
of ice-cold PBS was added, the cells were centrifuged again at 1,000 x g and all of the 
supernatant removed. The cell pellet was re-suspended in ice-cold suspension buffer 
(Appendix) using 200 jxl of suspension buffer for every 1 x 107 cells and the cell suspension 
transferred to a microfuge tube. An equal volume o f 2 X SDS gel loading buffer 
(Appendix) was immediately added to the cell suspension, after which the sample becomes 
extremely viscous. The sample was then placed in a boiling water bath for 10 minutes and 
then subjected to sonication for 1 minute on full power to shear the DNA. The lysate was 
clarified by centrifugation at 12,000 x g for 10 minutes at room temperature. The 
supernatant was aliquoted and stored at -20°C until required for analysis.
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2.6.2 Estimation of protein concentration
In order to standardize the amount o f protein used in SDS-PAGE, the concentration of 
protein in the cell extracts was determined using the BCA (bicinchoninic acid) protein 
assay kit. In this assay, C u^ reacts with the protein under alkaline conditions to give Cu+, 
which in turn reacts with BCA to give a coloured product. Two separate reagents were 
supplied in the commercially available kit (Pierce Chemicals): an alkaline bicarbonate 
solution (reagent A) and a copper sulphate solution (reagent B). Working solution was 
prepared by mixing 1 part reagent B with 50 parts reagent A. 200 pi of working solution 
was added to 10 pi of protein standard or unknown protein sample in wells o f a microtitre 
plate. The plate was incubated at 37°C for 30 minutes in the dark. The absorbance o f each 
well was read at 560 nm using a microtitre plate reader (Rosys Anthos 2010). Protein 
concentrations were determined from a bovine serum albumin (BSA) standard curve in the 
0-2 mg/ml range. Standards were prepared as indicated in Table 2.5.
Table 2.5: Préparation of BSA standard solutions for BCA assay
Concentration of 
Standard (pg/ml)
Volume of 2 mg/ml 
BSA Stock Solution
(MO
Volume of dH20
(M)
Total Volume 
0*1)
2000 100 0 100
1800 90 10 100
1600 80 20 100
1400 70 30 100
1200 60 40 100
1000 50 50 100
800 40 60 100
600 30 70 100
400 20 80 100
200 10 90 100
0 0 100 100
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2.6.3 SDS-polyacrylamide gel electrophoresis of proteins
During polyacrylamide gel electrophoresis (PAGE), proteins are driven through a gel 
composed of polyacrylamide that is cross-linked to form a molecular sieve, by an applied 
current. PAGE is usually carried out in the presence of die negatively charged detergent 
sodium dodecylsulphate (SDS), which binds in large numbers to all types o f protein 
molecules. The electrostatic repulsion between the bound SDS molecules causes the 
proteins to unfold into a similar rod-like shape, thus eliminating differences in shape as a 
factor in separation. As the amount of SDS bound is proportional to the molecular weight 
of the polypeptide and is sequence independent, SDS-polypeptide complexes migrate 
through polyacrylamide gels in accordance with the size of the polypeptide.
2.63.1 Preparation of SDS-polyacrylamide gels
SDS-PAGE was performed using 10 % polyacrlyamide gels. The 10 % resolving gels and 
5 % stacking gels were prepared as follows:
Resolving Gel Stacking Gel
10 ml 10 % (ml) 2.5 ml 5 % (m
acrylagel 3.33 acrylagel 0.42
bis-acrylagel 1.35 bis-acrylagel 0.168
1.5 M Tris (pH 8.8) 2.5 1 M Tris (pH 6.8) 0.312
dH20 2.61 dH20 1.5475
10 % (v/v) SDS 0.10 10%  (v/v) SDS 0.025
10 % (v/v) APS 0.10 10%  (v/v) APS 0.025
TEMED 0.01 TEMED 0.0025
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rAn ATTO protein gel electrophoresis system was used in this study. Glass plates were 
washed with detergent, rinsed first with tap water, then with dFkO and finally wiped in one 
direction with tissue soaked in 100 (v/v) ethanol. The gasket was placed around the ridged 
plate, the plates were assembled and secured with clamps. The depth of the resolving gel 
was marked on the outer plate. The resolving gel was then poured to within 2 cm of the top 
of the larger plate and overlaid with 100 % (v/v) ethanol. When set, the ethanol was 
removed and the stacking gel was poured. A clean comb that had been wiped in 100 % 
ethanol was inserted and the gel was allowed to polymerise for at least 45 minutes. The 
electrophoresis tank was filled with 1 X Tris-glycine running buffer to a level of about 5 cm 
deep. After polymerisation, the gaskets and clamps were removed and the pre-poured gels 
were lowered into the buffer at an angle to exclude air bubbles from the gel buffer 
interface. The tank was completely filled with 1 X running buffer and the comb removed 
from the gel. Un-polymerised gel was removed by gently rinsing the wells with 1 X 
running buffer and the wells were then straightened using a loading tip. The gel plates 
were fixed firmly in place with the pressure platens. The chamber formed by the inner 
plates (notched plate facing inwards) was filled with 1 X running Buffer, the samples were 
loaded and the electrodes attached. The gels were electrophoresed at a constant current of 
30 mA per gel until the blue dye front had reached the bottom of the gel. When complete, 
the plates were removed, separated and the gel was either placed in transfer buffer prior to 
western blotting or stained in Coomassie blue. Staining took place for 30 minutes, 
agitating constantly. The gel was then placed in destain (see Appendix) with constant 
agitation, until all background staining was removed. The destain was changed 4 or 5 times 
at 30 minute intervals, until all background stain was removed from the gel.
2.6.4 Western blotting
During western blotting, electrophoretically separated proteins are transferred from the 
polyacrylamide gel to a solid support, usually a nitrocellulose membrane, and probed with 
antibodies that react specifically with antigenic epitopes displayed by the target protein 
attached to the solid support. The bound antibody is detected by a secondary 
immunological reagent, in this case a secondary antibody conjugated to the alkaline 
phosphatase enzyme.
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2.6.4.1 Transfer of protein to nitrocellulose filters
Following gel electrophoresis, gels were equilibrated in transfer buffer (Appendix) for at 
least 30 minutes. Equilibration facilitates the removal o f electrophoresis salts and 
detergents. If the salts are not removed, they increase the conductivity o f the transfer and 
the amount of heat generated during transfer. Also, low percentage gels (<12 %) shrink in 
methanol-containing buffers. Equilibration allows the gel to adjust to its final size prior to 
electrophoretic transfer. Nitrocellulose membrane was cut to the dimensions o f the gel, 
along with 6 pieces o f 3 MM filter paper that were required for the gel/membrane sandwich 
(Figure 2.1). Protein transfer was carried out on the Bio-Rad Trans-Blot® SD semi-diy 
electrophoretic transfer cell. A pre-soaked sheet o f filter paper was placed onto the 
platinum anode. A pipette was rolled over the surface of the filter paper to exclude all air 
bubbles. This step was repeated with two more sheets of filter paper. Then, the pre-wetted 
blotting membrane was placed on top o f the filter paper and all bubbles rolled out. The 
equilibrated gel was carefully placed on top of the nitrocellulose membrane, aligning the 
gel on the centre of the membrane. Any air bubbles were again rolled out. 3 more sheets 
of pre-wetted filter were placed on top of the gel, with care being taken to remove air 
bubbles. The cathode was placed on top of the stack and the safety cover replaced on the 
transfer unit. Gels were transferred for 30 minutes at 17 V.
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Figure 2.1: Semi-diy transfer o f  protein from polyacrylamide gel to nitrocellulose membrane.
2.6.4.2 Staining of proteins immobilized on nitrocellulose filters
Ponceau S staining was employed to determine whether uniform transfer of proteins to the 
nitrocellulose membrane had taken place. Transferred protein can be detected as red bands 
on a white background. This staining technique is reversible to allow further 
immunological analysis. Ponceau S is a negative stain, which binds to positively charged 
amino acid groups of the protein. It also binds non-covalently to non-polar regions in the 
protein. Following electrophoretic transfer, the nitrocellulose membrane was immersed in 
20 ml Ponceau S solution (0.1 % Ponceau S (w/v), 5 % acetic acid (w/v), Sigma) and 
stained for 5 minutes with constant agitation. After proteins were visualised, the membrane 
was washed in several changes o f dIfeO until all the stain had been washed away. The 
membrane is then used for immunological probing.
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2.6.4.3 Immunological probing
Following Ponceau S staining, the membrane was incubated in blocking buffer (Appendix) 
for 2 hours at room temperature followed by incubation with the appropriate primary 
antibody (diluted in blocking buffer, see Table 2.6) at 4°C overnight. Sodium azide was 
added to each antibody solution to a final concentration o f 0.02 % (w/v) as a preservative 
thus permitting reuse of the antibody.
Table 2.6: Incubation Conditions for Antibodies Used in Western Blotting
Primary Name Dilution Secondary Antibody Dilution
Antibody In Blocking In Blocking
Buffer Buffer
Anti-EBNA2 PE2 1/1000 AP-Conjugated Anti Mouse IgG 1/5000
Anti -LMP1 CS1-4 1/1000 AP-Conjugated Anti Mouse IgG 1/5000
After overnight incubation, the membrane was washed three times in TBS-T (0.1 % (v/v) 
Tween-20 in TBS) for 15 minutes. The filter was then incubated with the appropriate 
secondary antibody for 1 hour 30 minutes at room temperature, followed by three 15- 
minute washes in TBS-T. All o f the above incubations were carried out with constant 
agitation. Membranes were then placed in a clean container and covered with 5-Bromo-4- 
chloro-3-indolyl phosphate/Nitro Blue Tetrazolium (BCEP/NBT, Sigma), which is used for 
the colourimetric detection of alkaline phosphatase-labeled molecules. This substrate 
system, when incubated with alkaline phosphatase, produces an insoluble NBT diformazan 
product that is easily observable with its purple colour. Therefore, proteins bound by 
antibody conjugated to alkaline phosphatase stain purple. The BCIP/NBT container was 
placed in the dark at room temperature without shaking for 30 minutes or longer if required. 
The membranes were then rinsed in distilled water to stop the reaction, photographed and 
then wrapped in cling film and stored in the dark.
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CHAPTER 3
Regulation of the Anti-Apoptotic Cellular bfl-1 
Gene in the EBV-Negative Burkitt’s Lymphoma- 
Derived Cell Line DG75
3.1 INTRODUCTION
This chapter set out to investigate the regulation o f the cellular bfl-1 gene in the EBV- 
negative Burkitt’s lymphoma (BL)-derived cell line DG75. Indeed, most non-EBV 
infected continuous B lymphocyte cell lines are derived from sporadically occurring 
EBV-negative BL and many can be infected with EBV in vitro (Calender et a l, 1990). 
The growth o f BL cells in vitro is attributed to deregulated c-myc expression resulting 
from a specific translocation, in which c-myc is juxtaposed to a heavy or light-chain Ig 
locus (Dallas-Favara et a l., 1983), and to less characterised changes on chromosome 1 
(Berger and Bemheim, 1985). Since BL cell lines exhibit phenotypic features 
reminiscent o f germinal centre B cells (MacLennan et a l., 1988), the EBV-negative 
DG75 cell line provided a suitable system for determining the contribution o f individual 
EBV genes to the regulation bfl-1 in the context of the B lymphocyte. The EBV genes 
under investigation in the study included LMP1 and EBNA2, both o f which are key 
effectors o f EBV-mediated transformation.
3.2 RESULTS
3.2.1 NF-kB plays a role in LMPl-mediated activation of the bfl-1 promoter
A key role for the transcription factor NF-kB in the regulation o f the anti-apoptotic 
cellular gene bfl-1 was established when it was shown that treatment o f a variety o f  cell 
lines with the chemical agent phorbol-12-myristate 13-acetate (PMA), a well-known 
activator o f NF-kB, up-regulated bfl-1 mRNA levels in BL cell lines (Moreb and 
Schweber, 1997). A study carried out in our laboratory demonstrated that EBV latent 
membrane protein 1 (LMP1) trans-activated the bfl-1 promoter in EBV-negative BL- 
derived cell lines by a mechanism that is dependent upon NF-kB (D5 Souza et al. 2004). 
A previously identified NF-kB binding site at position -833 to -823 relative to the 
transcription initiation site o f the bfl-1 promoter was shown to be essential for activation 
by the NF-kB sub-unit c-Rel in HeLa cells (Zong et a l., 1999). However, experiments 
performed in our laboratory demonstrated that elimination o f this binding site by site 
directed mutagenesis did not affect the level o f  LM Pl-mediated promoter activity in 
EBV-negative BL-derived cell lines (D’Souza et al. 2004). Subsequently it was found 
that a 210 bp bfl-1 promoter fragment (-129/+81-Luc, Figure 3.1 A) containing a
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deletion from the 5’ end o f the full-length bfl-1 promoter (-1374/+81-Luc, Figure 3.1 A) 
mediated NF-icB-dependent trans-activation by both LMP1 and PMA. Using 
Transcription Element Search Software, an NF-KB-like binding site at position -52 to 
-43 (Figure 3.1 A) was identified in the region 5’ to the transcription initiation site. 
When base substitutions were introduced into the core o f this binding motif, complete 
loss o f trans-activation by LMP1 was observed, thus demonstrating a direct role for the 
NF-KB-like binding site at position -52 to -43 in LMP1-mediated activation o f the bfl-1 
promoter (D’Souza et al. 2004).
The subunit composition o f NF-kB can greatly influence not only its ability to bind a 
particular DNA sequence motif, but also the extent o f promoter activation (Perkins et al. 
1992). To directly investigate the ability o f Rel family members to drive transcription 
from the bfl-1 promoter, transient co-transfections were performed using DG75 cells 
with vectors that express individual NF-kB subunit proteins and bfl-1 promoter reporter 
constructs (Figure 3.1 A). It can be seen that the -129/+81-Luc reporter was trans­
activated approximately 2.5-fold when co-transfected with the p65 expression vector 
(Figure 3. IB) and that trans-activation was completely abolished upon mutation o f the 
NF-KB-like binding motif at position -52/-43 [Figure 3. IB, -129/+81 (micB-52)]. The 
fact that p65 trans-activated this 210 bp bfl-1 promoter fragment, which does not 
contain the -833 to -823 site, indicates that this previously identified NF-kB binding 
motif is not essential for p65-associated activation o f the promoter in this cell context. 
Co-transfection with either a p50 or c-Rel expression vector failed to significantly trans- 
activate the -129/+81-Luc construct (Figure 3 .IB). It can also be seen that there was a 
lack o f any synergistic when either p65/p50 or p65/c-Rel expression vector 
combinations were co-transfected the same reporter construct (Figure 3. IB).
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Figure 3.1: The NF-icB-like binding site at -52 to -43 is essential for conferring p65-responsiveness 
on the A/7-2 promoter reporter construct -129/+81-Luc. (A) Schematic representation of the bjl-1 
promoter-reporter constructs. The upper panel shows a 1.4 Kb DNA sequence from the 5’ regulatory 
region of the bfl-1 gene (from -1374 to +81 relative to the transcription initiation site). The position of a 
previously identified NF-kB binding site at position -833 to -823 (Zong et al., 1999) is indicated by the 
green box and the NF-icB-like binding site at -52 to -43 is indicated by the yellow box. -129/+81-Luc 
contains a deletion from the 5’ end of the bfl-1 promoter sequence (co-ordinates of the 5’ end are to the 
left of each construct). Base substitutions were introduced into the core of the NF-icB-like binding motif 
at position -52 to -43 (marked with a red X) by site directed mutagenesis to generate the construct - 
129/+81 micB (-52) (Figure 1A, lower panel). They all share a 3’ end terminus 81 bp downstream from 
the transcription initiation site (designated by the bent arrow) at which point they are joined to the 
luciferase gene (LUC). (B) DG75 cells were transfected with 2 \ig of vector expressing various NF-kB 
subunits and 2 \ig of reporter construct indicated underneath the graph. Cells were harvested at 48 hours 
post-transfection and analysed for luciferase activities, which were then normalised for transfection 
efficiency (based on /?-galactosidase activity measured from co-transfected pCMV-LacZ reporter, which 
was included in all transfections). Normalised luciferase values were expressed as activation (w-fold) 
relative to the corresponding value obtained for each reporter construct when co-transfected with the 
empty vector (pcDNA3.1HisC), which was arbitrarily assigned a value of 1.0. Error bars indicate 
standard deviations of mean values from three independent experiments. This was the case for all 
subsequent transfection experiments. (* p < 0.05).
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In order to determine whether this region o f the A/7-7 promoter could confer p65- 
responsiveness on a heterologous promoter, the -129/-34 portion o f the sequence was 
sub-cloned upstream o f the minimal |3-globin promoter in the luciferase reporter 
construct pGa50-7 (D’Souza et a l., 2004, Figure 3.2A). Transient co-transfections o f 
these reporter constructs were carried out with DG75 cells, and the results o f the 
experiment are shown in Figure 3.2B. It can be seen that the pGa(-129/-34) reporter 
was trans-activated approximately 3.0 fold (over pGa50-7) when co-transfected with 
p65 expression vector and that trans-activation was again completely abolished upon 
mutation o f the NF-icB-like binding motif at position -52 to -43 (Figure 3.2B, pGa(- 
129/-34) micB). The effect o f p65 was mediated by the -129/-34 sequence o f the bfl-1 
promoter since p65 expression did not affect the corresponding minimal promoter 
vector, pGa50-7. Co-transfection with either a p50 or c-Rel expression vector failed to 
significantly trans-activate the pGa(-129/-34) construct (Figure 3.2B). Once again it can 
be seen that there was a lack o f any synergistic when either p65/p50 or p65/c-Rel 
expression vector combinations were co-transfected the same reporter construct. It may 
be concluded that the -129/-34 region o f the bfl-1 promoter functions as a p65- 
dependent transcriptional enhancer and that the NF-icB-like binding site at position -52 
to -43 is essential for this effect.
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Figure 3.2: The NF-icB-like binding site at -52 to -43 is essential for conferring p65-responsiveness 
on a heterologous minimal promoter. (A) Schematic representation of luciferase reporter constructs 
generated after sub-cloning the -129/-34 portions of the bfl-1 promoter upstream of the /?-globin minimal 
promoter (green box with bent arrow) in pGa50-7. The name of each reporter construct includes the 
relevant 5’ and 3’ ends of the bfl-1 sequence. The mutation introduced at the NF-xB-like site is indicated 
with a red X. (B) DG75 cells were transfected with 2 fig of vector expressing various NF-kB subunits 
along with 2 \ig of luciferase reporter construct. Cells were harvested at 48 hours post-transfection and 
assayed for luciferase activity. Normalised luciferase values were expressed as activation (/7-fold) 
relative to the corresponding value obtained for each reporter construct when co-transfected with the 
empty vector (pcDNA3. lHisC). (* p < 0.05).
Taken together these experiments showed that p65 directly trans-activates the bfl-1 
promoter and that the NF-icB-like binding site at -52/-43 was essential both for this 
effect, and also for conferring p65-responsiveness on a heterologous minimal promoter 
in DG75 cells.
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3.2.2 EBNA2-mediated activation of the bfl-1 promoter is inhibited by co­
expression of a dominant-negative mutant form of the Notch signalling pathway 
protein RBP-Jk/CBF1
It has already been observed in our laboratory that LMP1 up-regulates expression o f the 
anti-apoptotic cellular gene bfl-1 (D’ Souza et a l., 2004). In a related study, elevated bfl- 
1 mRNA levels were observed in an LMP1-negative derivative o f the cell line MUTU- 
III (a group Hi/latency III BL-derived cell line) (Gregory et al., 1990) relative to its 
isogenic group I/latency I counterpart MUTU-I (Pegman et a l., submitted December 
2004). This prompted us to investigate if  other EBV latent proteins were able to 
modulate the expression o f bfl-1. As EBNA2 is a transcription factor and a key effector 
of phenotypic change, its contribution towards regulating the expression o f bcl-2 family 
members, including bfl-1, was firstly assessed by ribonuclease protection assay (RPA) 
using a tightly regulatable tetracycline-based system to express EBNA2 in the EBV- 
negative BL cell line DG75 (DG75-tTA-EBNA2) (Floettman et a l., 1996). In this 
experiment, the steady state level o f bfl-1 mRNA increased significantly in response to 
EBNA2 induction (Figure 3.3), demonstrating for the first time that a second EBV 
protein, EBNA2, when expressed at physiological levels, activated transcription o f the 
bfl-1 gene (Pegman et al., submitted December 2004).
Transient transfections o f the EBV-negative BL-derived cell lines DG75, BL41 and 
BJAB showed that co-transfection o f the bfl-1 promoter reporter construct -1374/+81- 
Luc (D’Souza et al., 2004) with EBNA2 expression vector led to an increase in 
luciferase activity at 48 hours post-transfection (Pegman et al., submitted December 
2004). It is known that EBNA2 does not bind to DNA directly, but is tethered to 
responsive promoters by a ubiquitously expressed and highly conserved cellular DNA 
binding repressor protein RBP-Jk/CBF1 (Henkel et al., 1994; Grossmann et al., 1994; 
Waltzer et al., 1994; Zimber-Strobl et al., 1994). This protein was characterised and 
cloned by virtue o f its ability to bind the recombination signal o f the murine 
imunoglobulin k  joining region (Matsunami et al., 1989). In the absence o f EBNA2, 
RBP-Jk/CBF1 acts as a transcriptional repressor by recruiting a histone deacetylase 
(HDAC) co-repressor complex to the promoter (Zimber-Strobl and Strobl, 2001). 
EBNA2 has the ability to bind the transcriptional repression domain o f RBP-Jk/CBF1, 
thereby relieving repression by replacing the co-repressor complex with its trans­
activation domain. When transfections were carried out replacing EBNA2 with an
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EBNA2 mutant that cannot bind RBP-Jk/CBF1 (EBNA2-WW323SR), a major decrease 
in the trans-activation o f the bfl-1 promoter in DG75 cells was observed (Pegman et al., 
submitted December 2004). These results indicated that EBNA2 directly trans-activates 
the bfl-1 promoter in EBV-negative BL-derived cell lines and that the ability o f EBNA2 
to bind RBP-Jk/CBF1 is central for this effect.
DG75-tT A-EBNA2
0 24 48
EBNA2 #  ----------
0 24 48
GAPDH
B
Figure 3.3: Induction of EBNA2 as the sole EBV protein leads to an increase in bfl-1 mRNA levels 
in the EBV-Negative BL CeU Line DG75-tTA-EBNA2. EBNA2 expression was induced over a 72- 
hour time-course in the DG754TA-EBNA2 cell line, by the removal of tetracycline from cell culture 
medium. Total protein and RNA were prepared simultaneously from cells harvested at the indicated 
time-points post-EBNA2 induction (A) Western blotting was performed to detect EBNA2 in protein 
samples isolated during the 72-hour time-course. Protein isolated from the X50-7 (LCL) cell line was 
used as a positive control for EBNA2. (B) mRNA levels from the apoptosis-related genes bclx-L, bclx-S, 
bfl-1, bik, bak, box, bcl-2, and mcl-1 were analysed by RPA. Unprotected 32P labelled antisense 
riboprobes (5000 cpm per lane) were loaded alongside RPA-processed samples and are shown linked to 
their smaller RNase-protected fragments, which correspond to the level of mRNA in the sample. 
Exposure to film was for 24 hours, (adapted from Pegman et al., submitted December 2004).
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In a control experiment to further investigate the role o f RBP-Jk/CBF1 in EBNA2- 
responsiveness, co-transfections using DG75 cells were carried out with increasing 
amounts o f an EBNA2 expression vector (pSG5-EBNA2) and the RBP-Jk/CBFI- 
regulated luciferase reporter construct pGa981-6, which contains a 50 bp 
oligonucleotide harbouring both RBP-Jk/CBF1 binding sites o f the EBV TP 1 promoter 
sub-cloned as a hexamer into the plasmid pGa50-7 (Minoguchi et al., 1997). EBNA2 
trans-activated the RBP-Jk/CBF1-regulated reporter construct in a dose-dependent 
manner (Figure 3.4), with maximum trans-activation o f approximately 4,500-fold 
observed upon co-transfection with 11 \ig o f the effector plasmid pSG5-EBNA2.
Figure 3.4: EBNA2 trans-activates the RBP-JK/CBFl-regulated luciferase reporter construct 
pGa981-6. DG75 cells were co-transfected with increasing amounts of pSG5-EBNA2 together with 2 \ig 
of the luciferase reporter construct pGa981-6. Cells were harvested at 48 hours post-transfection. 
Luciferase values were normalised as described earlier and expressed as activation (w-fold) relative to the 
corresponding value obtained for co-transfection with the empty vector (pSG5) and pGa981-6.
Based on the evidence that EBNA2 trans-activated the RBP-Jk/CBF1-regulated 
promoter pGa981-6, it may be deduced that RBP-Jk/CBF1 is present and functional in 
the EBV-negative BL-derived DG75 cell line.
The role o f RBP-Jk/CBF1 in mediating EBNA2-mediated responsiveness was further 
investigated using an expression vector for a non-DNA binding mutant o f RBP- 
Jk/CBF1 (pEFBOSneo-R218H, Chung et a l., 1994). To investigate if pEFBOSneo-
[ ■ PGa9B1-6l
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R218H could inhibit trans-activation o f the luciferase reporter construct pGa981-6 by 
EBNA2, co-transfections were performed in DG75 cells with increasing amounts o f 
pEFBOSneo-R218H and constant quantity o f the expression vector for EBNA2. It can 
be seen from this experiment that expression o f the mutant RBP-Jk/CBF1 
(pEFBOSneo-R218H) efficiently inhibited EBNA2-mediated trans-activation o f 
pGa981-6 (Figure 3.5). This effect was dose-dependent, with maximum inhibition o f 
approximately 70 % when 12 pg o f pEFBOSneo-R218H was used. pEFBOSneo- 
R218H or the corresponding empty vector (pEFBOSneo) did not significantly alter the 
basal levels o f promoter activity. It was also observed that pEFBOSneo did not affect 
EBNA2-mediated trans-activation o f the luciferase reporter construct pGa981-6.
Inhibition of EBNA2-Mediated Trans-Activation by an RBP-Jk/CBF1 Mutant
Figure 3.5: An RBP-Jk/CBFI mutant inhibits EBNA2-mediated trans-activation of the luciferase 
reporter construct pGa981-6. DG75 cells were co-transfected with a constant amount of pSG5-EBNA2 
(3 ng) and increasing amounts of the RBP-Jk/CBFI mutant (pEFBOSneo-R218H), along with 2 pg of the 
luciferase reporter construct pGa981-6. Cells were harvested at 48 hours post-transfection and 
normalised luciferase values were expressed as activation (w-fold) relative to the corresponding value 
obtained for co-transfection with the empty vector (pSG5) and the reporter. In a control transfection 
experiment, pSG5-EBNA2 was co-transfected with the empty vector for the RBP-Jk/CBFI mutant, 
pEFBOSneo.
These results showed that expression o f the RBP-Jk/CBFI mutant, pEFBOSneo- 
R218H, effectively inhibits EBNA2-mediated responsiveness o f the luciferase reporter 
construct pGa981-6 in DG75 cells.
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As mentioned earlier, it has been found in our laboratory by transient transfections o f 
the EBV-negative BL-derived cell lines DG75, BL41 and BJAB, that co-transfection o f 
the bfl-1 promoter reporter construct -1374/+81-Luc with EBNA2 expression vector led 
to an increase in luciferase activity at 48 hours post-transfection. Because EBNA2 
trans-activated the RBP-Jk/CBF1-regulated promoter pGa981-6 in DG75 cells and this 
activity was effectively inhibited by the RBP-Jk/CBF1 mutant, tests were then 
performed to determine whether EBNA2-mediated trans-activation o f the bfl-1 
promoter construct -1374/+81 could also be inhibited by expression o f the mutant RBP- 
Jk/CBF1. Firstly, transient co-transfections were carried out with DG75 cell using 
various amounts o f the expression vector for EBNA2 (pSG5-EBNA2) together with the 
full-length bfl-1 promoter reporter construct -1374/+81-Luc (Figure 3.6). EBNA2 was 
shown to trans-activate the bfl-1 promoter reporter construct in a dose-dependent 
manner with maximum trans-activation using 11 fig o f effector plasmid.
Trans-Activation of the  bfl-1 Prom oter by EBNA2
12.000 
10.000 '
Figure 3.6: EBNA2 trans-activates the blf-1 promoter reporter construct -1374/+81-Luc. DG75 
cells were co-transfected with increasing amounts of pSG5-EBNA2 along with 2 fig of the bfl-1 promoter 
reporter construct -1374/+81-Luc. Cells were harvested at 48 hours post-transfection and normalised 
luciferase values were expressed as activation (/7-fold) relative to the corresponding value obtained for 
transfection with the empty vector (pSG5).
To determine whether the expression vector for the RBP-Jk/CBF1 mutant could be used 
as a tool to inhibit this EBNA2-mediated bfl-1 promoter activation, co-transfections 
were performed as before using DG75 cells with the inclusion o f various amounts of
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pEFBOSneo-R218H. It can be seen from this experiment that co-expression o f the 
mutant efficiently inhibited EBNA2-associated bfl-1 promoter trans-activation in this 
cell context in a dose-dependent manner, to a maximum o f 70 % when 12 jig o f 
pEFBOSneo-R218H was used (Figure 3.7). It was noted that inhibition was to a similar 
degree as for the control reporter construct pGa981-6 (Figure 3.5). Expression o f  
pEFBOSneo-R218H or the corresponding empty vector (pEFBOSneo) did not 
significantly alter the basal levels o f bfl-1 promoter activity. It was also observed that 
pEFBOSneo did not affect EBNA2-mediated trans-activation o f the promoter.
Inhibition of EBNA2-Mediated Trans-Activation by an  RBP-Jk/CBF1 Mutant
Figure 3.7: The RBP-Jk/CBF1 mutant blocks EBNA-2-mediated trans-activation of the bfl-1 
promoter reporter construct, -1374/+Sl-Luc. Co-transfections with DG75 cells were carried out using 
a constant amount of pSG5-EBNA2 (7 pg) and an increasing amount of the RBP-Jic/CBFl mutant 
(pEFBOSneo-R218H), along with 2 pg of the bfl-1 promoter reporter construct -1374/+81-Luc. Cells 
were harvested at 48 hours post-transfection and normalised luciferase values were expressed as 
activation (/7-fold) relative to the corresponding value obtained for co-transfection with the empty vector 
(pSG5) and the reporter. During control transfections, pSG5-EBNA2 was co-transfected with the empty 
vector for the RBP-Jk/CBFI mutant, pEFBOSneo.
These results showed that co-expression o f the RBP-Jk/CBFI mutant effectively 
blocked EBNA2-mediated responsiveness on the bfl-1 promoter reporter construct 
-1374/+81-Luc in the EBV-negative BL-derived cell line DG75.
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3.2.3 EBNA2-mediated trans-activation of the bfl-1 promoter does not lead to the 
activation of NF-kB
It has well been established that bfl-1 is an NF-kB responsive gene (Moreb and 
Schweber, 1997, Zong et a l., 1999; Grumont et al., 1999; Lee et a l., 1999; Wang et a l., 
1999; D ’Souza et a l., 2004) and there is an increasing body o f evidence showing cell- 
context specific antagonistic or synergistic connections between NF-kB and 
CBFl/Notch signal transduction pathways (Guan et a l., 1996; Bash et a l., 1999; Wang 
et a l., 2001). Furthermore, it has recently been shown that basal expression of IicBa, 
and as a consequence NF-kB activity, is under CBFl/Notch control (Oakley et a l.,
2003). It was therefore important to monitor the level o f activated NF-kB in DG75 cells 
when either EBNA2 or the RBP-Jk/CBF1 mutant was expressed. To this end, co­
transfections were carried out using a known NF-KB-dependent reporter construct, 3 x 
enh kB luc (Floettmann and Rowe, 1997), which contains 3 NF-kB binding sites 
upstream o f a minimal conalbumin promoter, linked to the luciferase gene. It can be 
seen from Figure 3.8 that there is a high basal level o f activated NF-kB present in this 
cell context. As expected, the NF-KB-responsive promoter was activated by a further 
2.7-fold upon co-transfection with the LMP1 expression vector (pSG5-LMPl). It was 
observed that the basal level o f activated NF-kB did not change significantly in 
response to co-transfection with expression vectors encoding EBNA2 or during co­
transfections with EBNA2 in the presence o f various amounts o f the RBP-Jk/CBF1 
mutant (pEFBOSneo-R218H). However, some increase in the basal level o f activated 
NF-kB was found upon co-transfection with pEFBOSneo-R218H and the reporter 
construct in the absence o f EBNA2. Co-transfections with the expression vector for 
EBNA2 and the empty expression vector for the RBP-Jk/CBF1 mutant (pEFBOSneo) 
did not significantly affect the levels o f activated NF-kB.
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Figure 3.8: Activated NF-kB levels are not dramatically affected by expression of EBNA2 or the 
RBP-Jk/CBF1 mutant DG75 cells were co-transfected with the expression vector for LMP1 (2 fig 
pSG5-LMPl), EBNA2 (7 fig of pSG5-EBNA2) or EBNA2 along with various quantities of pEFBOSneo- 
R218H together with 2 fig of the NF-icB-responsive reporter construct 3 x enh kB luc. Cells were 
harvested 48 hours post-transfection and normalised luciferase values were expressed as activation in­
fold) relative to the value obtained during transfection with the empty vector (pSG5) in the absence of any 
reporter construct (empty).
It was next tested if inhibition o f NF-kB activation would affect EBNA2-mediated 
trans-activation of the bfl-1 promoter. To this end, co-transfections were carried out 
using an expression vector for a mutant form o f IkBcx (pEFCX-IkBglDN), in which 
serine residues at positions 32 and 36 have been replaced with alanines (Liljeholm et 
al., 1998). As a result, IkBgi can no longer be phosphorylated and subsequently 
proteolysed. Therefore, this mutant effectively retains NF-kB in the cytoplasm, thus 
blocking its function as a regulator o f transcription by preventing NF-kB translocation 
to the nucleus. In a preliminary control experiment to demonstrate the functionality o f 
the IkBgi mutant, co-transfections were performed using the NF-xB-responsive reporter 
construct (3 x enh kB luc) together with increasing amounts o f the super-repressor 
pEFCX-lKBaDN. In the presence o f the IkBgi super-repressor, a dramatic decrease in 
luciferase activity was observed (Figure 3 .9A). This decrease in activated NF-kB levels 
was observed upon co-transfection when just 1 fig o f pEFCX-lKBaDN was used, with a 
decrease o f approximately 75 %. When larger quantities o f the expression vector for 
the IkBcx mutant were used in transfection experiments, luciferase activity decreased 
even further. In order to investigate if the IkBgi mutant could inhibit EBNA2-mediated
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trans-activation o f the bfl-1 promoter, co-transfections were performed using various 
amounts o f the mutant, along with the bfl-1 promoter reporter construct -1374/+81-Luc. 
Over-expression o f the I k B ol super-repressor only resulted in a marginal decrease (< 10  
%) in luciferase activity, even when up to 12 fig o f expression vector was used (Figure
3.9B).
O ver-E xpression of an  hcBot S u p er-R e p resso r B locks N F-k B  A c t iv a t io n
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Figure 3.9: Over-expression of an IicBa super-repressor inhibits NF-kB activation but does not 
affect EBNA2-mediated trans-activation of the bfl-1 promoter. (A) Co-transfections were performed 
using 2 \ig of the activated NF-KB-responsive reporter construct 3 x enh kB luc, together with increasing 
quantities of the expression vector for the IicBa super-repressor (pEFCX-IicBaDN). (B) Co-transfections 
were performed using a constant amount of pSG5-EBNA2 (7jig), various amounts of the IkBci super­
repressor and 2 fig of the bfl-1 promoter reporter construct -1374/+81-Luc. Transfected cells were 
harvested at 48 hours post-transfection and normalised luciferase values were expressed as activation in­
fold) relative to the corresponding value obtained upon co-transfection with the empty vector.
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These results suggested that the activation o f NF-kB does not play a role in EBNA2- 
mediated trans-activation o f the bfl-1 promoter in DG75 cells, based on evidence that 
EBNA2-mediated bfl-1 promoter activity is not associated with an increase in the level 
of activated NF-kB and over-expression of an IkBo, mutant does not affect EBNA2- 
mediated trans-activation o f the bfl-1 promoter in DG75 cells.
3.2.4 EBNA2-meditated trans-activation of the LMP1 promoter is inhibited by co­
expression of a dominant-negative mutant form of the Notch signalling pathway 
protein RBP-Jk/CBFI.
Regulation o f expression o f the LMP1 gene has been well studied and it has previously 
been shown that the LMP1 promoter is EBNA2-responsive (Abbot et a l., 1990; 
Fahraeuseta l., 1990; Wang e ia l., 1990; Zimber-Strobl eta l., 1991; Lauxe ta l., 1994a). 
This responsiveness is demonstrated in Figure 3.10, which shows the results o f co- 
transfections performed using increasing quantities o f the expression vector for EBNA2 
(pSG5-EBNA2) and the IM P1 promoter reporter construct (pLLO-luc). It was 
observed that EBNA2 trans-activated the promoter in a dose-dependent fashion, 
reaching a peak when 7 fig o f expression vector were used. Using this quantity a 22- 
fold trans-activation was achieved. When higher quantities o f expression vector were 
used this maximum activation decreased somewhat.
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Figure 3.10: EBNA2 trans-activates the LMP1 promoter reporter construct pLLO-luc. Transient 
transfections were performed using DG75 cells with various quantities of the expression vector for 
EBNA2 (pSG5-EBNA2) and 2 fig of the IM P I promoter reporter construct pLLO-luc. Cells were 
harvested at 48 hours post-transfection and normalised luciferase values were expressed as activation {n- 
fold) relative to the corresponding value obtained upon co-tranfection with the empty vector (pSG5).
To investigate the role o f RBP-Jk/CBF1 in mediating EBNA2-responsiveness on the 
LMP1 promoter, co-transfections were performed using DG75 cells with the inclusion 
of various amounts o f pEFBOSneo-R218H along with the LMP1 promoter reporter 
construct pLLO-luc. It can be seen from this experiment that expression of the mutant 
efficiently inhibited EBNA2-associated IM P  I  promoter trans-activation in a dose- 
dependent manner, with almost complete inhibition when 12 fig o f pEFBOSneo-R218H 
was used (Figure 3.11). It was noted that inhibition EBNA2-mediated activation o f the 
LMP1 promoter by the RBP-Jk/CBF1 mutant was to a greater degree than that o f the 
bfl-1 promoter (Figure 3 .7). In the case o f the bfl-1 promoter, it is possible that the 
remaining residual bfl-1 promoter activity may be due to the high basal level o f 
activated NF-kB present in DG75 cells. Co-transfection with pEFBOSneo-R218H or 
the corresponding empty vector (pEFBOSneo) did not significantly alter the basal levels 
o f LMP1 promoter activity. It was also observed that pEFBOSneo did not affect 
EBNA2-mediated trans-activation o f the LMP1 promoter.
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Inh ib ition o f EBNA2-Mediated T rans-A ctiva tion  by an RBP-Jk/CBF1 Mutant
Figure 3.11: The RBP-Jk/CBF1 mutant blocks EBNA-2-mediated trans-activation of the LMP1 
promoter reporter construct, pLLO-luc. DG75 cells were co-transfected with a constant amount of 
pSG5-EBNA2 (7 fig) and various amounts of the RBP-Jk/CBFI mutant (pEFBOSneo-R218H), along 
with 2 fig of the LMP1 promoter reporter construct pLLO-luc. Cells were harvested at 48 hours post­
transfection and normalised luciferase values were expressed as activation (w-fold) relative to the 
corresponding value obtained for co-transfection with the empty vector (pSG5) and the reporter. During 
control transfections, pSG5-EBNA2 was co-transfected with the empty vector for the RBP-Jk/CBFI 
mutant, pEFBOSneo.
These results showed that EBNA2 trans-activated the IM P  I  promoter in DG75 cells, 
and that RBP-Jk/CBFI is essential for this effect. Based on the evidence that the RBP- 
Jk/CBFI mutant significantly inhibits EBNA2-mediated trans-activation o f the LMP1 
promoter, in addition to the control reporter constructs pGa981-6 and the bfl-1 
promoter, it may be considered a useful tool for blocking EBNA2 mediated activity.
3.2.5 The cellular functional equivalent of EBNA2, NotchllC, does not trans- 
activate the bfl-1  promoter
Although no cellular homologue o f the EBNA2 protein has been identified, the 
intracellular domain o f the Notch receptor (NotchIC) is considered to be a cellular 
equivalent from a mechanistic and functional point o f view (Hsieh et a l., 1996). There 
is no obvious sequence homology between EBNA2 and NotchIC, however both 
proteins interact with RBP-Jk/CBFI to modulate gene expression. Both EBNA2 and
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NotchIC interact with similar regions o f RBP-Jk/CBF1 and displace repressor proteins 
by their trans-activation domains (Zimber-Strobl and Strobl, 2001). The set o f 
promoters, which is regulated by EBNA2 and NotchIC is overlapping but not identical 
(reviewed in Chapter 1). In order to understand to what extent EBNA2 is a functional 
equivalent o f NotchIC, it would prove interesting to identify further target genes for 
NotchIC and EBNA2 in B cells. This study set out to investigate if the bfl-1 gene is a 
target o f NotchIC.
In a preliminary experiment to demonstrate NotchlC-mediated promoter activation via 
RBP-Jk/CBF1, transient transfections using DG75 cells with increasing amounts o f a 
mouse NotchllC  expression vector (pSG5-HA-mNotchlIC (1751-2294), Hsieh et a l, 
1996) and the luciferase reporter construct pGa981-6 were performed. N otchllC  used in 
these experiments consists o f amino acids 1751-2294 o f the Notch receptor (Figure 
3.15). This region encompasses the sequences between the trans-membrane domain and 
the PEST motif at the C-terminus, and includes 6 tandem cdclO/ankyrin repeats and 2 
putative nuclear localisation sequences (NLS). Similarly to EBNA2, it can be seen that 
mNotchllC trans-activated pGa981-6 in a dose-dependent manner (Figure 3.12). It was 
noted that the maximum trans-activation for EBNA2 (approximately 4,500-fold using 
11 fig o f effector plasmid, Figure 3.4) was greater than the maximum trans-activation 
for mNotchllC (approximately 2,300-fold using 11 jig o f effector plasmid). This 
observation o f greater trans-activation efficiency for EBNA2 when compared with 
mNotchllC is in keeping with the findings o f others (Hsieh et a l., 1996).
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Figure 3.12: mNotchllC trans-activate the luciferase reporter construct pGa981-6. DG75 cells were 
co-transfected with increasing amounts pSG5-HA-mNotchlIC (1751-2294) and 2 fig of the luciferase 
reporter construct pGa981-6. Cells were harvested at 48 hours post-transfection. Luciferase values were 
normalised as described earlier and expressed as activation (/7-fold) relative to the corresponding value 
obtained for co-transfection with the empty vector (pSG5) and pGa981-6.
The role o f RBP-Jk/CBF1 in mediating mNotchllC-mediated responsiveness was 
further investigated using the expression vector for the non-DNA binding RBP- 
Jk/CBF1 mutant (pEFBOSneo-R218H). To investigate if pEFBOSneo-R218H could 
inhibit trans-activation o f the luciferase reporter construct pGa981-6 by Notch 1IC, co­
transfections were performed in DG75 cells with increasing amounts o f pEFBOSneo- 
R218H and constant quantity o f mNotchllC. It can be seen from this experiment that 
expression o f the mutant RBP-Jk/CBF1 (pEFBOSneo-R218H) efficiently inhibited 
mNotchllC-mediated trans-activation o f pGa981-6 (Figure 3.13). This effect was 
dose-dependent, with maximum inhibition o f approximately 66%, when 12 pg o f 
pEFBOSneo-R218H was used. pEFBOSneo-R218H or the corresponding empty vector 
(pEFBOSneo) did not significantly alter the basal levels o f promoter activity. It was 
also observed that pEFBOSneo did not affect mNotchllC-mediated trans-activation o f 
the luciferase reporter construct pGa981-6.
1 2 0
Inh ib ition o f m N o tch l 1C-Mediated T rans-A ctiva tion  by an RBP-Jk/CBF1 Mutant
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Figure 3.13: An RBP-Jk/CBF1 mutant inhibits mNotchlIC-mediated trans-activation of the 
luciferase reporter construct pGa981-6. DG75 cells were co-transfected with a constant amount of 
mNotchllC (5 \ig) and increasing amounts of the RBP-Jk/CBFI mutant (pEFBOSneo-R218H), along 
with 2 fig of the luciferase reporter construct pGa981-6. Cells were harvested at 48 hours post­
transfection and normalised luciferase values were expressed as activation («-fold) relative to the 
corresponding value obtained for co-transfection with the empty vector (pSG5) and the reporter. In a 
control experiment, mNotchlIC was co-transfected with the empty vector for the RBP-Jk/CBFI mutant, 
pEFBOSneo.
These results demonstrated Notch 1 IC-mediated activation via RBP-Jk/CBFI and 
showed that expression o f the RBP-Jk/CBFI mutant, pEFBOSneo-R218H, effectively 
blocks mNotchlC-mediated responsiveness on the luciferase reporter construct pGa981- 
6 in DG75 cells.
It was demonstrated in Section 3.2.2 that EBNA2 trans-activated the bfl-1 promoter in 
DG75 cells. Because both EBNA2 and mNotchl IC trans-activated the RBP-Jk/CBFI 
regulated promoter pGa981-6 in DG75 cells, and this activation was effectively 
inhibited by an RBP-Jk/CBFI mutant, it would prove interesting to determine whether 
mNotchllC could trans-activate the bfl-1 promoter in this cell context. To this end, 
transient co-transfections were carried out with DG75 cell using various amounts o f the 
expression vector for mNotchllC [pSG5-HA-mNotchlIC (1751-2294)] together with 
the bfl-1 promoter reporter construct -1374/+81-Luc (Figure 3.14), and the resulting 
data compared with that obtained in the EBNA2 co-transfections. EBNA2 was seen to 
trans-activate the bfl-1 promoter reporter construct in a dose-dependent manner.
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However, the A/7-7 reporter construct was not found to be mNotchllC-responsive, even 
when up to 11 fig o f effector plasmid was used during co-transfections.
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Figure 3.14: Unlike EBNA2, mNotchllC does not trans-activate the blf-1 promoter reporter 
construct -1374/+81-Luc* DG75 cells were co-transfected with increasing amounts of pSG5-EBNA2 
(grey) or mNotchllC (black) along with 2 fig of the bfl-1 promoter reporter construct -1374/+81-Luc. 
Cells were harvested at 48 hours post-transfection and normalised luciferase values were expressed as 
activation (/7-fold) relative to the corresponding value obtained for transfection with the empty vector 
(pSG5).
This set o f data indicated that, like EBNA2, mNotchllC trans-activates the RBP- 
Jk/CBF1-regulated control promoter pGa981-6 and that RBP-Jk/CBF1 is essential to 
this effect. However, unlike EBNA2, mNotchllC does not trans-activate the bfl-1 
promoter reporter construct -1374/+81-Luc in DG75 cells.
3.2.6 Failure of NotchllC to trans-activate the bfl-1 promoter is not due to a weak 
trans-activation domain.
It has been reported that the NotchIC trans-activation domain is weaker that that o f 
EBNA2 (Hsieh et a l., 1996). Further experiments in the EBV-negative BL-derived cell 
line DG75 were conducted to determine whether the inability o f mNotchllC to trans- 
activate the bfl-1 promoter was due to differences in the strength o f  the NotchIC trans­
activation domain (TAD) relative to that o f EBNA2. For this purpose, co-tranfections
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were carried out using a vector expressing a chimeric protein in which the 
transcriptional activation domain and nuclear localisation sequence o f the EBNA2 
protein (E2TANLS) were fused to the carboxy terminus o f mNotchllC 
(mNotchlIC:E2TANLS, Hsieh et a l 1996). The E2TANLS domain lies outside the 
RBP-Jk/CBF1 interaction domain o f EBNA2, which is located between amino acids 
252 and 425. Therefore, the chimeric protein mNotchlIC:E2TANLS binds RBP- 
Jk/CBF1 via mNotchllC and contains the additional TAD and NLS o f EBNA2. 
Schematic representations o f EBNA2, NotchllC  and Notch 1IC:E2TANLS are shown in 
Figure 3.15.
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Figure 3.15: Schematic representation of EBNA2, mNotchllC and mNotchlIC:E2TANLS. The
upper panel shows the structure of the EBNA2 protein. EBNA2 consists of a negatively charged region 
at the amino-terminus, which is likely to play a role in homo-dimerization (Dim), a polyproline region 
(Pro) consisting of 10-40 consecutive prolines depending on the virus strain, a diversity region, a domain 
responsible for interaction with RBP-Jk/CBFl (RBP-Jk), an arginine-glycine rich stretch (ArgGly) and a 
negatively charged region carboxy terminus, which harbors a trans-activation domain (TAD) and nuclear 
localization signal (NLS). The middle panel is a schematic representation of mNotchllC from amino 
acids 1751 to 2294. This region encompasses the sequences between the trans-membrane domain and the 
PEST motif at the C-terminus, and includes the RAM domain, 6 ankyrin repeats and 3 putative nuclear 
localisation sequences (NLS). The structure of mNotchlIC:E2TANLS is shown in the lower panel. This 
is a fusion protein in which the NLS and TA of the EBNA2 protein (amino acids 400 to 487) are fused to 
the carboxy terminus of mNotchllC.
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Co-transfections using the expression vector for mNotchlIC:E2TANLS (pSG5-HA- 
m NotchllC (1751-2294):E2TANLS) and the luciferase reporter construct pGa981-6 are 
shown in Figure 3.16. Similarly to co-transfections using EBNA2 (Figure 3.4) and 
mNotchllC (Figure 3.12) together with pGa981-6, it was found that 
mNotchlIC:E2TANLS trans-activated pGa981-6 in a dose-dependent manner. A 
maximum trans-activation o f approximately 9,000-fold was observed when 11 fig o f 
expression vector was used. It was noted that the maximum trans-activation for 
mNotchlIC:E2TANLS was greater than the maximum trans-activation for both EBNA2 
(approximately 4,500-fold using 11 fig of effector plasmid) and mNotchllC 
(appromimately 2,300-fold using 11 fig o f effector plasmid). This observation is in 
keeping with the findings o f others (Hsieh et al., 1996).
Trans-Activation of pGa981-6 by mNotchllC:E2TANLS
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Figure 3.16: A fusion protein between mNotchllC and the trans-activation domain and nuclear 
localisation sequence of EBNA2 trans-activates the luciferase reporter construct pGa981-6. Co­
transfections were performed using DG75 cells with increasing amounts of an expression vector for a 
fusion protein between mNotchllC and the trans-activation domain and nuclear localisation sequence of 
EBNA2 (mNotchlIC:E2TANLS) together with 2 ng of the luciferase reporter construct pGa981-6. Cells 
were harvested at 48 hours post-transfection and normalised luciferase values were expressed as 
activation (n-fold) relative to the corresponding value obtained for transfection with the empty vector 
(pSG5).
Once it was established that mNotchlIC:E2TANLS could trans-activate the control 
RBP-Jk/CBF1-regulated promoter pGa981-6, further experiments were conducted in 
order to determine whether the bfl-1 promoter reporter construct -1374/+81-Luc was
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responsive to this fusion protein. It was observed during earlier co-transfections that 4 
jig o f EBNA2 expression vector (from Figure 3.4), 11 fig o f mNotchllC (from Figure 
3.12) and 2 fig o f mNotchlIC:E2TANLS (Figure 3.16) trans-activated the control 
reporter construct pGa981-6 to a similar degree (approximately 2,300-fold). It was 
therefore reasoned that these quantities o f expression vector should be used in an 
attempt to directly compare the ability o f EBNA2, mNotchllC and 
mNotchlIC:E2TANLS to trans-activate the bfl-1 promoter. Firstly, co-transfections 
were performed in DG75 cells using these quantities o f effector plasmid along with 
pGa981-6 and the resulting data is displayed in Figure 3.17A. These quantities o f 
expression vector for EBNA2, mNotchllC and mNotchlIC:E2TANLS were seen to 
result in a comparable rate o f trans-activation. Subsequently, these quantities were used 
for co-transfections using the bfl-1 promoter reporter construct -1374/+81-Luc (Figure 
3.17B). As expected, EBNA2 trans-activated the bfl-1 promoter. By contrast, neither 
mNotchllC or mNotchlIC:E2TANLS were seen to trans-activate the bfl-1 promoter.
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Figure 3.17: Trans-activation of the lueiferase reporter constructs pGa981-6 and -1374/+81-Luc by 
EBNA2, mNotchllC and mNotchlIC:E2TANLS. Transient co-transfections were performed using 
DG75 cells with expression vectors for EBNA2 (pSG5-EBNA2, 4 fig), mNotchllC (pSG5-HA- 
mNotchllC (1751-2294), 11 fig) and mNotchlIC:E2TANLS (pSG5-HA-mNotchlIC (1751-
2294):E2TANLS, 2 fig) together with 2 fig of the RBP-Jk/CBF1-regulated lueiferase reporter construct 
pGa981-6 (A) or 2 fig of the bfl-1 promoter reporter construct -1374/+81-Luc (B). Cells were harvested 
at 48 hours post-transfection and normalised lueiferase values were expressed as activation (/7-fold) over 
the corresponding value obtained upon co-transfection with the empty vector (pSG5).
It was demonstrated in Section 3.2.4 that EBNA2 trans-activated the LM Pl promoter 
and that this activation was effectively inhibited by expression o f an RBP-Jk/CBF1 
mutant. To compare EBNA2 activity with that o f mNotchllC and
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mNotchlIC:E2TANLS with regard to the LMP1 promoter, co-transfections were 
performed using DG75 cells and expression vectors for EBNA2, mNotchllC and 
mNotchlIC:E2TANLS along with the LMP1 promoter reporter construct pLLO-luc 
Figure 3.18). It was found, as before that EBNA2 trans-activated the LMPJ promoter 
approximately 22-fold. The LMPJ promoter construct not found to be responsive to 
mNotchllC. This observation is in keeping with others (Zimber-Strobl and Strobl, 
2001). It can also be seen from Figure 3.18 that mNotchlIC:E2TANLS did not trans­
a c t vate the LMP1 promoter reporter construct pLLO-luc in DG75 cells.
EBNA2, but not mNotchllC or mNotch1IC:E2TANLS. Trans-Activates the  LMP1
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Figure 3.18: EBNA2, but not mNotchllC or mNotch 1IC:E2TANLS, trans-activates the LMP1 
promoter. DG75 cells were co-transfected with expression vectors for EBNA2 (pSG5-EBNA2, 4 fig), 
mNotchllC (pSG5-HA-mNotch 1IC (1751-2294), U  fig) and mNotchlIC:E2TANLS (pSG5-HA- 
mNotchllC (1751-2294):E2TANLS, 2 fig) together with 2 fig of the IMP1 promoter reporter construct 
pLLO-luc. Cells were harvested at 48 hours post-transfection and normalised luciferase values were 
expressed as activation (//-fold) over the corresponding value obtained upon co-transfection with the 
empty vector (pSG5).
This data demonstrated that even when the transcriptional activation domain and 
nuclear localisation sequence from EBNA2 were fused to the mNotchllC protein, it was 
not sufficient to activate the either the bfl-1 promoter or the IM P  I  promoter in the 
EBV-negative BL-derived cell line DG75. Therefore, failure o f mNotchllC to trans- 
activate these promoters is not merely due to a weaker trans-activation domain than that 
o f EBNA2. It is possible that binding o f additional proteins (e.g. members o f the Spi
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family), as well as RBP-Jk/CBF1, to EBNA2 is required for EBNA2-mediated promoter 
activation.
3.2.7 A strong trans-activation domain alone is not sufficient for trans-activation of 
the bfl-1 promoter
To further evaluate the role o f trans-activation domains in bfl-1 promoter activation, co­
transfections were performed using a construct containing the acidic activation domain 
o f the herpes simplex virus VP 16 transcriptional activator. Because RBP-Jk/CBF1 is a 
transcriptional repressor that tethers a repression complex to the promoter, it was tested 
whether providing RBP-Jk/CBF1 with a trans-activation domain would be sufficient to 
counter-balance repression. For this purpose, the sequence coding for the acidic 
activation domain o f the herpes simplex virus VP 16 transcriptional activator was fused 
to the C-terminus o f the RBP3 coding sequence (RBP3 being one o f the known RBP- 
Jk/CBF1 isoforms, Brou etal. 1994). This protein, called RBP-VP16 (Figure 3.19) has 
been shown by EMSA to bind to DNA as efficiently as RBP3 (Waltzer et al., 1995).
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Figure 3.19: Schematic representation of the proteins used during co-transfections. The upper panel 
represents the RBP3 protein from amino acids 1 to 486. RBP3 is one of the known RBP-Jic/CBFl 
isofroms. The middle panel represents a fusion protein between the herpes simplex virus VP 16 trans­
activation domain and RBP3. The EBNA2 protein is illustrated in the lower panel.
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Firstly, it was evaluated if this fusion protein could activate transcription o f the 
luciferase reporter construct pGa981-6 in DG75 cells. Upon co-transfection o f the 
expression vector for the RBP3 protein alone with the reporter construct, a level o f 
luciferase activity similar to that obtained upon co-transfection with the empty vector 
(pSG5FLAG) was observed (Figure 3.20A). This result was in keeping with a role in 
promoter repression for RBP3. However, when the RBP3 protein was fused to the 
VP 16 trans-activation domain, a significant increase in luciferase activity was detected 
(approximately 1,700-fold (Figure 3.20A). This result shows that RBP-Jk/CBF1 
provided with an activation domain functions as an transcriptional activator, indicating 
that the VP 16 activation domain added in cis to RBP-Jk/CBFl counter-balanced RBP- 
Jk/CBF1-mediated repression. The expression vector for EBNA2 was also co­
transfected with the RBP-Jk/CBF1-regulated reporter construct to act as a positive 
control for luciferase activity.
In order to determine whether the bfl-1 promoter was responsive to the RBP3-VP16 
fusion protein, transfections were also performed using the expression vector for the 
fusion protein together with the bfl-1 promoter reporter construct -1374/+81-Luc. The 
promoter was not found to be RBP3-VP16 responsive (Figure 3.20B).
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Figure 3.20: An RBP-VP16 fusion protein trans-activates the RBP-jK/CBFl-regulated reporter 
construct pGa981-6, but not the bfl-1 promoter. DG75 cells were transiently co-transfected with 2 fig 
of either the luciferase reporter contruct pGa981-6 (A) or the bfl-1 promoter reporter construct -1374/+81- 
Luc (B) together with 7 fig of the expression vectors indicated underneath the graphs. Cells were 
harvested at 48 hours post-transfection and normalised luciferase values were expressed as activation in­
fold) relative to the corresponding value obtained upon co-transfection with the empty vector 
(pSG5FLAG) along with the reporter construct
These results suggested that providing RBP-Jk/CBF1 with a strong trans-activation 
domain without concomitant masking of the RBP-Jk/CBF1 repression domain, is 
sufficient to counter-balance RBP-Jk/CBF l-mediated repression of the pGa981-6
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reporter construct. However, recruitment o f a strong trans-activation domain alone is 
not sufficient for trans-activation o f the bfl-1 promoter in the EBV-negative BL-derived 
cell line DG75. It is possible that EBNA2 trans-activates transcription of the bfl-1 
promoter by (i) providing an activation domain, (ii) interfering with the function o f a 
co-repressor recruited by RBP-Jk/CBFl and (iii) binding to co-activator proteins.
3.2.8 bfl-1 promoter sequence analysis
It has previously been shown in our laboratory using bfl-1 promoter deletion reporter 
constructs, that the sequence from position -367 to -129 is essential in mediating 
EBNA2-responsiveness on the bfl-1 promoter (Pegman et a l., submitted December 
2004). Analysis o f this region o f the promoter using transcription element search 
software and the Alibaba transcription factor prediction database revealed a consensus 
binding sequence for RBP-Jk/CBF1 in the reverse orientation at position -243 to -249 
relative to the transcription start site. This sequence has been found in all EBNA2 
responsive promoters characterised to date (Tun et a l., 1994). Further analysis revealed 
additional 5’-GGAA-3’ tracts, the core sequence motif known to be central in DNA 
binding o f the Ets family o f transcription factors (Karim, 1990; Gutman and Wasylyk, 
1991). This was identified in four places between -367 and -129 on the promoter. The 
locations o f these possible transcription factor binding sites are shown in Figure 3.23. 
The contribution o f these sites in facilitating EBNA2-mediated trans-activation o f the 
bfl-1 promoter was then investigated using site directed mutagenesis to knock out the 
relevant transcription factor binding sites, and thus assess their potential contribution to 
EBNA2-responsiveness on the promoter. Mutation of any o f the transcription factor 
binding sites resulted in a dramatic reduction in EBNA2-mediated activation o f the bfl-1 
promoter (Pegman et a l., submitted December 2004).
To determine whether sequences from the bfl-1 promoter could confer EBNA2- 
responsiveness on a heterologous minimal promoter, portions o f the -367 to -40 region 
o f the sequence were sub-cloned upstream o f the minimal /?-globin promoter in the 
luciferase reporter construct pGa50-7. The sub-cloning strategy is summarised in 
Figure 3 .21. Firstly 3 different regions o f the bfl-1 promoter were amplified using the 
construct -1374/+81-Luc as template DNA. This construct contains the longest 
available bfl-1 promoter sequence from position -1374 to +81 sub-cloned upstream o f
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the luciferase gene in promoterless vector pGL2-Basic (D ’Souza et al., 2004). This 
DNA was characterised by restriction digestion prior to PCR and the digested fragments 
are shown in Figure 3.22.
Figure 3.21: Generation of luciferase reporter constructs by sub-cloning portions of the bfl-1 
promoter into pGa50-7. Flow diagram detailing the steps involved in generating the pGa50-7 luciferase 
reporter constructs. Briefly, portions of the bfl-1 promoter were amplified by PCR, digested with BamUl 
and sub-cloned into the BamHl site upstream of the p-globin minimal promoter in the pGa50-7 vector. 
Competent E.coli JM109 cells were transformed with the recombinant plasmid and a number of 
independently transformed colonies were selected for growth of small-scale cultures. Plasmid DNA 
isolated from each culture was then analysed by digestion with restriction enzymes and PCR. Large-scale 
DNA preparations of the recombinant plasmids were performed using the Qiagen® Midi Kit and the 
pGa50-7 luciferase reporter constructs were used in co-transfections with DG75 cells.
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Figure 3.22: Restriction analysis of -1374/+81-Luc. (A) Schematic circular map of -1374/+81-Luc. 
Indicated on the map are the BamHl and EcoRl sites targeted during restriction digestion. (B) The 6,866 
bp -1374/+81-Luc plasmid was characterised prior to PCR by restriction digestion using BamHl and 
EcoRl. A 1 Kb DNA ladder (Invitrogen) is shown in lane 1. Undigested DNA can be seen in lane 2. 
DNA linearised by restriction digestion with BamHl resulted in a fragment at 6,886 bp as expected (lane 
3). Restriction digestion with EccRl yields two fragments of 4,781 bp and 2,085 bp (lane 4). 
Electrophoresis was carried out at 100 V for 1 hour using a 1 % agarose-IX TAE gel.
bfl-1 promoter sequences were amplified by PCR with a forward oligonucleotide primer 
from the -367 region of the bfl-1 promoter and one o f three reverse primers from 
various regions on the promoter (-40, -129 and -230). The locations o f these primers 
relative to the full-length bfl-1 promoter are indicated in Figure 3.23. All primers 
included a BamHl restriction site (GGATCC) and a digestion clamp (CGC) at its 5’ end. 
Details o f primer sequences are shown in Table 3.1.
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Figure 3.23: Schematic representation of the bfl-1 promoter. The full-length bfl-1 promoter from 
position -1374 to +81 relative to the transcription start site is illustrated. The locations of the putative 
RBP-Jk/CBF1 (red), Ets (orange) and PU.l (yellow) transcription factor binding sites are indicated. The 
positions of the primers used during PCR are also shown.
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Table 3.1: Primers used for PCR amplification o f  bfl-1 promoter sequences
Target Oligonucleotide Primer Sequence Product Size
-367/-40 bfl-1 (Forward) 5 ’ -CGCGG ATCCGGTGT AT ACCT AT G AAT G-3 ’ 
promoter
(Reverse) 5’-CGCGGATCCTGATACATGGAGGCTGGT-3’
-367/-129 bfl-1 (Forward) 5-CGCGGATCCGGTGTATACCTATGAATG-3 ’
promoter 240 bp
(Reverse) 5’-CGCGGATCCAAAATGTGAAAGAGGAAA-3’
-367/-230 bfl-1 (Forward) 5’-CGCGG ATCCGGTGT AT ACCT ATGAATG-3’ 151 bp
promoter
(Reverse) 5 * -CGCGGATCCGAAATTAGAATCCTTGTA-3 *
Following PCR, the products were analysed by agarose gel electrophoresis to check for 
migration o f fragments at the expected size (Figure 3.24). The PCR products were 
subsequently purified using the Promega Wizard® DNA purification system, digested 
with Bam\R and purified again by phenol.chloroform extraction followed by ethanol 
precipitation. The individual digested, purified PCR products were then sub-cloned into 
the BamYR site o f pGa50-7.
134
<.----- 2,072 bp
1 2  3 4
■*----- 600 bp
«----- 500 bp
■*  400 bp
■*----- 300 bp
<«----- 200 bp
«----- 100 bp
Figure 3.24: Agarose gel electrophoresis of PCR products. PCR products amplified from the 
expression vector for the full-length bfl-1 promoter sequence (-1374/+81-Luc) were analysed by agarose 
gel electrophoresis on a 2 % agarose-1 X TAE gel and electrophoresis was carried out at 100 V for 1 hour 
in 1 X TAE. Amplification of the -367 to -40 region of the promoter resulted in a band at 351 bp (lane 1), 
amplification of the -367 to -129 region resulted in a band at 240 bp (lane 2) and amplification of the -367 
to -230 region of the sequence resulted in a band at 151 bp (lane 3). A 100 bp DNA ladder (Invitrogen) is 
shown in lane 4.
A circlar map o f pGa50-7 is shown in Figure 3.25A. The plasmid was firstly 
characterised by restriction digestion (Figure 3.25B). Prior to ligation, the plasmid was 
linearised by digestion with BamHl, followed by dephosphorylation using calf intestinal 
phosphatase (CIP) to prevent recircularisation o f the linearised DNA. The linearised, 
CIP-treated DNA was then purified by phenonl: chloroform extraction followed by 
ethanol precipitation. Ligations o f vector and insert DNA were carried out overnight at 
16°C.
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Figure 3.25: Restriction analysis of pGa50-7. (A) A schematic circular map of the pGa50-7 vector. 
The BamHl site (into which insert DNA was sub-cloned) can be seen at position 245 on the plasmid. (B) 
The 5,180 bp pGa50-7 plasmid was characterised by restriction digestion Digested samples were 
analysed by agarose gel electrophoresis on a 1 % agarose-1 X TAE gel and electorphoresis was carried 
out at 100 V for 1 hour in 1 X TAE. Uncut plasmid DNA is shown in lane 1. The plasmid was linearised 
by digestion with BamHl yielding a band at 5,180 bp (lane 2). Digestion with EcoRl resulted in two 
fragments at 3,208 bp and 1,972 bp as expected. A 1 Kb DNA ladder (Invitrogen) is shown in lane 4.
Following the ligation reaction, competent E.coli JM109 cells were transformed with 
the recombinant plasmid DNA. Single colonies were used to inoculate cultures from 
which DNA mini-preparations were generated. Restriction analysis was performed on 
the DNA to detect the presence o f  insert DNA. Because both PCR product and the 
pGa50-7 plasmid were digested with the BamHl restriction endonuclease, it was 
possible for the insert DNA to ligate into the vector in either the forward or reverse 
orientation. To determine whether insert DNA had ligated in the forward orientation, a 
PCR based strategy was employed using the -367 forward primer and a reverse primer 
from the luciferase region o f the pGa50-7 vector (Table 2.3). A PCR product would 
only be generated if the insert DNA had ligated in the forward orientation. To confirm 
correct insertion, further PCR was carried out using the individual reverse primers (i.e. 
-40 Rev, -129 Rev and -230 Rev) and a forward primer from the ampicillin resistance 
region o f the pGa50-7 vector. Once it was established that the bfl-1 sequences had 
ligated into pGa50-7 in the forward orientation, DNA maxi-preparations were carried 
out using the Qiagen® Midi Kit and restriction analysis o f the resulting DNA is shown 
in Figure 3.26.
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Figure 3.26: Restriction analysis of recombinant plasmid DNA. Bacterial colonies transformed with 
recombinant plasmid were analysed by digestion with restriction enzymes followed by agarose gel 
electrophoresis using a 1.2 % agarose-lX TAE gel. A 1 Kb DNA ladder (Invitrogen) is shown in lane 1. 
Undigested pGa50-7 DNA can be seen in lane 2. pGa50-7 digested with EcoRI and ff/nDIII yielded 
three fragments at 2,443 bp, 1,992 bp and 745 bp as expected. The pGa (-367/-230) plasmid created by 
ligating the 139 bp digested PCR product from -1374/+81-Luc into pGa50-7 is shown undigested in lane 
4. When this construct was digested with EcoRI and HinDYll, three fragments at 2,433 bp, 1,992 bp (as 
for the empty vector) and at 884 bp were found (lane 5). This increase in fragment size from 745 bp to 
884 bp indicates the presence of insert DNA. The pGa (-367/-129) plasmid created by ligating the 228 bp 
digested PCR product from -1374/+81-Luc into pGa50-7 is shown undigested in lane 6. Digestion of this 
construct with EcoRI and HinDIU yielded fragments at 2,433, 1,992 bp and 973 bp. The pGa (-367/-40) 
construct created by ligating the digested 339 bp PCR product from -1374/+81-Luc into pGa50-7 is 
shown undigested in lane 8. Digestion of this construct with the same restriction endonucleases yielded 
fragments at 2,433 bp, 1,992 bp and 1,084 bp. A 100 bp DNA ladder (Invitrogen) is shown in lane 10.
Transient co-transfections o f the pGa50-7 luciferase reporter constructs (Figure 3 .27 A) 
and the expression vector for EBNA2 (pSG5-EBNA2) were performed using DG75 
cells (Figure 3.27B). As expected EBNA2 expression trans-activated the full-length bfl-  
1 promoter (approximately 11-fold). However, none o f the pGa50-7 luciferase reporter 
constructs were found to be EBNA2-responsive.
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Figure 3,27: The recombinant luciferase reporter constructs are not EBNA2-responsive. (A) 
Schematic representation of the recombinant luciferase reporter constructs generated after sub-cloning 
portions of the bfl-1 promoter upstream of the p-globin minimal promoter (green box with bent arrow) in 
pGa50-7. The name of each reporter construct includes the relevant 5’ and 3’ ends of the bfl-1 sequence. 
The upper panel shows the full-length bfl-1 promoter. Putative RBP-Jk/CBFI (red), Ets (orange) and 
PU.l transcription factor binding sites are indicated. The constructs pGa (-367/-40), pGa (-367/-129), 
pGa (-367/-230) and pGa50-7 are also shown. (B) DG75 cells were co-transfected with 7 pg of either 
pSG5 or pSG5-EBNA2 along with 2 fig of reporter construct indicated to the left of the graph. Cells were 
harvested at 48 hours post-transfection and normalised luciferase values were expressed as activation in­
fold) relative to the corresponding value obtained upon co-transfection with the empty vector (pSG5).
These results indicated that the -367 to -40 region o f  the bfl-1 promoter does not 
function as an EBNA2-dependent transcriptional enhancer in the EBV-negative BL- 
derived cell line DG75.
3.2.9 Identification of an EBNA2 mutant demonstrating dominant-negative 
activity
This study set out to investigate the ability o f a set o f established EBNA2 mutants to 
impair wild type EBNA2-mediated promoter activation, with a view to identifying an 
EBNA2 mutant that demonstrated dominant-negative activity. The application o f such 
an inhibitor molecule would prove useful in further investigating the function o f 
EBNA2, especially in EBV-infected cells, and would possibly have useful therapeutic 
applications. The first mutant investigated (EBNA2-WW323SR, Figure3.28A) was 
identical to wild type EBV B95.8 EBNA2 except that two tryptophan residues at 
positions 323 and 324 were mutated to serine and arginine respectively (Ling e t a l.,
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1993). Therefore this form o f EBNA2 is unable to bind RBP-Jk/CBF1. The ability o f 
EBNA2-WW323SR to activate the RBP-Jk/CBF1-regulated control promoter pGa981-6 
was tested. It was demonstrated that wild type EBNA2 trans-activated this promoter 
efficiently (approximately 2,700-fold when 5 jig o f expression vector was used, Figure 
3.28B). However, upon co-transfection o f 7 fig o f EBNA2-WW323SR with the 
luciferase reporter construct, no activation was observed. Since EBNA2-WW323SR 
did not trans-activate pGa981-6, it was postulated that it might be able to inhibit wild 
type EBNA2 function. To test this hypothesis co-transfections were performed using a 
constant amount o f expression vector for wild type EBNA2 (pSG5-EBNA2) and 
various amounts o f EBNA2-WW323SR along with the pGa981-6. EBNA2-WW323SR 
was not seen to inhibit wild type EBNA2-mediated activation o f this reporter construct 
(Figure 3.28B).
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Figure 3.28: The EBNA2 mutant EBNA2-WW323SR does not inhibit EBNA2-mediated trans­
activation of the luciferase reporter construct pGa981-6. (A) A schematic representation of the 
EBNA2 mutant EBNA2-WW323SR, which is identical to wild type EBNA2 except that two tyrptophan 
residues at positions 323 and 324 have been replaced with serine and arginine respectively (indicated by 
an black rectangle). Therefore, this mutant form of EBNA2 is unable to bind RBP-Jk/CBF1. (B) DG75 
cells were co-transfected with a constant quantity of EBNA2 (5 ng) and/or various quantities of the 
expression vector for EBNA2-WW323SR together with 2 ng of the luciferase reporter construct pGa981- 
6. Cells were harvested at 48 hours post-transfection and normalised luciferase values were expressed as 
activation (n-fold) relative to the value obtained upon co-transfection with the empty vector (pSG5).
A second EBNA2 mutant was investigated for its ability to inhibit wild type EBNA2 
function. This mutant (EBNA2 Mut (321-323), Figure 3.29 A) contains deletions o f the 
two tryptophan residues at position 322 and 323 (Waltzer et a l., 1995). As this deletion 
is located in the RBP-Jk/CBF1 interaction domain, this mutant form of EBNA2 is 
unable to bind RBP-Jk/CBF1. The ability o f EBNA2 Mut (321-323) to activate the
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RBP-Jk/CBF1-regulated control promoter pGa981-6 was tested. It was found that wild 
type EBNA2 trans-activated this promoter efficiently (approximately 2,000-fold when 5 
jig o f expression vector was used, Figure 3.29B). However, upon co-transfection using 
7 [ig o f EBNA2 Mut (321-323) with the pGa981-6, no activation was observed. Even 
though EBNA2 Mut (321-323) was unable to trans-activate the luciferase reporter 
construct, it was not seen to inhibit wild type EBNA2 activation o f this promoter, even 
when up to 7 fig o f the mutant was used in co-transfections (Figure 3.29B).
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Figure 3.29: The EBNA2 mutant EBNA2 Mut (321-323) does not inhibit EBNA2-mediated trans­
activation of the luciferase reporter construct pGa981-6. (A) A schematic representation of EBNA2 
Mut (321-323), which is identical to wild type EBNA2 except that it contains an in-frame deletion from 
amino acids 321-323 (indicated by the orange rectangle) and therefore, cannot bind to RBP-Jk/CBF1. (B) 
DG75 cells were co-transfected with a constant quantity of EBNA2 (5 ng) and/or various quantities 
EBNA2 Mut (321-323) together with 2 ng of the luciferase reporter construct pGa981-6. Cells were 
harvested at 48 hours post-transfection and normalised luciferase values were expressed as activation in­
fold) relative to the value obtained upon co-transfection with the empty vector (pSG5).
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A third EBNA2 mutant was investigated for dominant-negative activity over wild type 
EBNA2. This mutant (EBNA2 Mut (447-472), Figure 3.30A) is identical to wild type 
EBNA2 except that it bears a trans-activation domain deletion from amino acids 447- 
472. When this mutant was co-transfected with the luciferase reporter construct 
pGa981-6 in DG75 cells, no activation was observed (Figure 3.30B). This contrasted 
with the result obtained when wild type EBNA2 was co-transfected with the reporter 
construct, where approximately 2,300-fold trans-activation was seen. When increasing 
amounts o f EBNA2 Mut (447-472) were co-transfected with a constant quantity o f wild 
type EBNA2 along with the reporter construct, a dose-dependent inhibition was 
observed. A maximum inhibition o f approximately 66 % resulted when 12 ng o f the 
mutant were co-transfected along with EBNA2.
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Figure 3.30: The EBNA2 mutant EBNA2 Mut (447-472) inhibits EBNA2-mediated trans-activation 
of the luciferase reporter construct pGa981-6. (A) A schematic representation of EBNA2 Mut (447- 
472), which is identical to wild type EBNA2 except that it contains a trans-activation domain deletion 
from amino acids 447 to 472 (indicated by orange rectangle). (B) Co-transfections were performed using 
DG75 cells with a constant quantity of EBNA2 (5 pg) and/or various quantities EBNA2 Mut (447-472) 
together with 2 \ig of the luciferase reporter construct pGa981-6. Cells were harvested at 48 hours post­
tran sfec tion  an d  normalised luciferase values were exp ressed  as ac tiv a tio n  (/7-fold) re la tive  to  the value 
obtained upon co-transfection with the empty vector (pSG5).
The final EBNA2 mutant investigated for dominant-negative activity also contained a 
deletion in the trans-activation domain (EBNA2 Mut (437-477), Figure 3.31 A). In the 
case o f EBNA2 Mut (437-477), an in-frame deletion is present from amino acids 437 to 
477 (Waltzer et al., 1995). This mutant was unable to trans-activate the reporter 
construct (Figure 3.3IB). This contrasted with the result obtained when wild type 
EBNA2 was co-transfected with the reporter construct, where approximately 2,250-fold 
trans-activation was observed. When increasing amounts o f EBNA2 Mut (437-477) 
were co-transfected with a constant quantity o f wild type EBNA2 along with the
1 4 3
EBNA2 Mut 447-472
Pro
diversity
Dim
reporter construct, a dose-dependent inhibition was observed. A maximum inhibition o f 
approximately 90 % resulted when 12 [ig o f the mutant were co-transfected along with 
EBNA2. O f all the EBNA2 mutants tested, EBNA2 Mut (437-477) was the most 
efficient dominant inhibitor o f wild type EBNA2-mediated activation o f the RBP- 
Jk/CBF1-regulated control promoter pGa981-6 in DG75 cells.
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Figure 3.31: The EBNA2 mutant EBNA2 Mut (437-477) inhibits EBNA2-mediated trans-activation 
of the luciferase reporter construct pGa981-6. (A) A schematic representation of EBNA2 Mut (447- 
472), which is identical to wild type EBNA2 except that it contains an in-frame deletion in the trans­
activation domain from amino acids 437 to 477. (B) Co-transfections were performed using DG75 cells 
with a constant quantity of EBNA2 (5 jig) and/or various quantities EBNA2 Mut (437-477) together with 
2 fig of the luciferase reporter construct pGa981-6. Cells were harvested at 48 hours post-transfection and 
normalised luciferase values were expressed as activation (/7-fold) relative to the value obtained upon co­
transfection with the empty vector (pSG5).
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To strengthen the observation that EBNA2 Mut (437-477) was an effective inhibitor o f 
wild type EBNA2 activity, its ability to inhibit EBNA2-mediated trans-activation o f 
both the cellular bfl-1 promoter and the viral LMP1 promoter was investigated. To this 
end, co-transfections were conducted using equal quantities o f the expression vectors 
for EBNA2 and EBNA2 Mut (437-477) together with the bfl-1 promoter reporter 
construct -1374/+81-Luc (Figure 3.32A) or the LMP1 promoter reporter construct 
pLLO-luc (Figure 3.32B). It was observed that EBNA2 Mut (437-477) dramatically 
inhibited EBNA2-mediated trans-activation o f both the bfl-1 and IMP1 promoters when 
co-expressed with wild type EBNA2.
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Figure 3.32: The EBNA2 mutant EBNA2 Mut (437-477) inhibits EBNA2-mediated trans-activation
of the bfl-1 promoter and the LMP1 promoter. Co-transfections were performed using DG75 cells with 
equal amounts (7 ng) of EBNA2 and EBNA2 Mut (437-477) together with 2 \ig of either the bfl-1 
promoter reporter construct -1374/+81-Luc (A) or the LMP1 promoter reporter construct pLLO-luc (B). 
Cells were harvested at 48 hours post-transfection and normalised luciferase values were expressed as 
activation («-fold) relative to the value obtained upon co-transfection with the empty vector (pSG5).
Taken together, this set o f data demonstrated that an EBNA2 mutant with a deletion in 
the trans-activation domain [(EBNA2 Mut (437-477)], efficiently impaired EBNA2- 
mediated activation o f the luciferase reporter construct pGa981-6, the bfl-1 promoter 
and the LMP1 promoter in the EBV-negative BL-derived cell line DG75. This mutant
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form o f EBNA2 would prove a useful tool in elucidating the role o f EBNA2 in bfl-1 
regulation in EBV-infected cells.
3.3 DISCUSSION
It has already been shown in our laboratory that expression o f LMP1 in EBV-negative 
BL-derived cell lines coincides with a dramatic increase in the level o f bfl-1 mRNA 
(D’Souza et a l, 2000), and that LMP1 trans-activates the bfl-1 promoter in this cell 
context (D’Souza et al., 2004). Additionally, an important role for the transcription 
factor NF-kB was implied in the LMP1-mediated regulation o f the bfl-1 promoter in this 
study. Firstly, co-expression o f a super-repressor IkBolDN mutant inhibited LMP1- 
mediated trans-activation o f the bfl-1 promoter. Secondly, treatment with PMA, a well- 
known activator o f NF-kB in many cell types, stimulated bfl-1 promoter activity 
(D’Souza et a l., 2004). The implication o f a role for NF-kB is in keeping with other 
studies, where increases in bfl-1 mRNA levels have been demonstrated in response to 
agents such as LPS, TNFa or etoposide, all o f which are known to lead to activation o f 
NF-kB (Hu et a l., 1998; Wang et a l., 1999; Zong et a l., 1999). In addition, mitogen 
stimulation o f primary B cells was shown to induce expression o f mouse Al (the 
murine bfl-1 homologue) in a c-Rel-dependent fashion (Grumont et a l., 1999). 
Elsewhere, ectopic expression o f the NF-kB subunits c-Rel and p65 (but not p50) was 
also shown to independently up-regulate bfl-1 mRNA levels in the epithelial cell line 
HeLa (Zong et a l., 1999). In the same study, it was shown that c-Rel trans-activated the 
bfl-1 promoter through its interaction with a consensus NF-kB binding site at position 
-833 to -823 relative to the transcription start site o f the bfl-1 gene. However, 
experiments performed in our laboratory demonstrated that removal o f this binding site 
did not affect the level o f LMP1-mediated bfl-1 promoter activity in EBV-negative BL- 
derived cell lines (D’Souza et al., 2004). Subsequently it was found that a 210 bp bfl-1 
promoter fragment (-129 to +81) mediated NF-KB-dependent trans-activation by both 
LMP1 and PMA in this cell context. Furthermore, it was demonstrated that an NF-kB- 
like binding site at position -52 to -43 relative to the transcription start site o f the bfl-1 
gene, is essential for LMP1-mediated trans-activation o f the bfl-1 promoter (D’Souza et 
a l, 2004).
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Regulation o f NF-icB-dependent transcription displays several levels o f complexity. A 
number o f NF-kB sites have been found in association with various cellular and viral 
genes. Although these sites are recognised by NF-kB, they exhibit considerable DNA 
sequence variation (Perkins et al., 1992). In addition, the sub-unit composition o f NF- 
kB can greatly influence the ability o f this transcription factor to bind a particular DNA 
sequence and the extent o f promoter activation (Perkins et a l., 1992). Specific 
combinations o f Rel proteins can therefore distinguish between variant NF-kB sites. In 
the current study, it was demonstrated that homo-dimers o f p65 directly trans-activated 
the 210 bp bfl-1 promoter fragment (-129 to +81 relative to the transcription start site) 
and that the NF-icB-like binding site at -52 to -43 was essential both for this effect, and 
for conferring p65-responsiveness on a heterologous minimal promoter. Classic NF-kB 
(p65/p50) binds the sequence 5’-GGGRNNYYCC-3’, whereas the p65/c-Rel dimer 
binds to the sequence 5’-HGGARNYYCC-3’ [H indicates A, C or T; R is purine (A or 
G); and Y is pyrimdine (T or C)] (Baldwin, 1996). The NF-kB site at position -52 to 
-43 on the bfl-1 promoter differs from the p65/p50 and p65/c-Rel consensus binding 
sites at nucleotide positions 3 and 2 respectively. NF-icB-like sites that diverge from the 
consensus sequence have been identified in the promoters o f several apoptosis-related 
genes, such as bcl-xL, c-IA P l, C-1AP2 and mouse A l, as well as cytokine genes such as 
IL-8 , and the functionality o f these sites in the promoter activation has been 
demonstrated in several o f these cases (Chen et a l., 1999a; Grumont et a l., 1999; Hong 
et a l., 2000; Okamoto et al., 1994). Significantly, the -52 to -43 site on the bfl-1 
promoter is 100 % complimentary to a CD28-responsive kB site in the IL-2 promoter 
(Civil et al., 1996; Civil et al., 1999; Verweij et al., 1991) and both c-Rel and p65 have 
been shown to play roles in mediating this process (Ghosh et al., 1993).
The previously identified NF-kB binding site at position -833 to -823 relative to the 
transcription start site o f the bfl-1 gene is regulated by c-Rel in the HeLa epithelial cell 
line (Zong et al., 1999). It has already been shown in our laboratory that, in the context 
o f EBV-negative BL-derived cells, that removal o f this -833 to -823 site by deletion or 
mutation did not affect LMP1-associated activation o f the bfl-1 promoter (D’ Souza et 
al., 2004). In the current study, p65 trans-activated a 210 bp bfl-1 promoter fragment (- 
129 to + 81) that did not contain the -833 to -823 site, indicating that this previously 
identified NF-kB binding site is not essential for p65-mediated trans-activation o f the 
bfl-1 promoter in DG75 cells. Although LMP1 activates different subsets o f NF-kB 
subunit proteins in a cell-type dependent manner (Chien and Hammarskjöld, 2000;
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Herrero et al., 1995; Paine et al., 1995), c-Rel is known to be LMP1-responsive in the 
context o f the B cell, including in DG75 cells (Chien and Hammarskjöld, 2000; 
Liljeholm et al., 1998). Because the -833 to -823 site was not essential for mediating 
trans-activation o f the bfl-1 promoter by p65, and the fact that c-Rel failed to activate 
luciferase expression via the -52 to -43 site, this may indicate that p65, and not c-Rel, is 
the predominant subunit involved in regulating the bfl-1 promoter in EBV-negative BL 
cells in response to LMP1. The failure o f LMP1 to trans-activate via the -833 to -823 
site might therefore be due to its low affinity for p65. It is also possible, however, that 
access to this site may be obstructed in EBV-negative BL cells by lymphocyte-specific 
nuclear proteins binding in its vicinity.
It has also recently been demonstrated in our laboratory that induction o f EBNA2 in the 
cell line DG75-tTA-EBNA2 (Floettmann et al., 1996) coincides with an increase in the 
level o f bfl-1 mRNA (Pegman et al., submitted December, 2004), indicating for the first 
time that a second EBV protein modulates expression o f the bfl-1 gene in a system 
where LMP1 is not present. Furthermore, EBNA2 trans-activates the bfl-1 promoter in 
EBV-negative BL-derived cell lines. The DNA binding protein RBP-Jk/CBF1 was 
found to be essential for this effect, as over-expression o f an EBNA2 mutant (EBNA2- 
WW323SR), that cannot bind RBP-Jk/CBF1, did not lead to trans-activation o f the bfl-1 
promoter (Pegman et al., submitted December, 2004). The observation that RBP- 
Jk/CBF1 is required for EBNA2-mediated trans-activation was strengthened in the 
current study, when it was shown that co-expression o f an RBP-Jk/CBF1 replacement 
mutant (pEFBOSneo-R218H, Chung et al., 1994), that is unable to bind DNA, inhibited 
EBNA2-responsiveness o f the bfl-1 promoter. The RBP-Jk/CBF1 mutant could 
compete with endogenous wild type RBP-Jk/CBF1 for binding to EBNA2. This mutant 
has been shown by EMSA to reduce the DNA binding activity o f RBP-Jk/CBF1 to 2 % 
(Chung et al., 1994) and block both EBNA2- and NotchlC-mediated trans-activation o f 
the HES1 promoter in COS7 cells (Kato et al., 1997; Sakai et al., 1998). In addition, 
co-expression o f the non DNA-binding RBP-Jk/CBF1 mutant blocked EBNA2- 
mediated transcriptional activation o f the LMP1 promoter in the current study, 
demonstrating that RBP-Jk/CBF1 is also essential for EBNA2-mediated activation o f 
this viral promoter. The observation that RBP-Jk/CBF1 is required for LMP1 promoter 
activity is in keeping with the findings o f  others, who have demonstrated that mutation 
of the RBP-Jk/CBF1 binding site in the IM P1 promoter dramatically decreases 
EBNA2-responsiveness (Laux et al., 1994b; Johannsen et al., 1995).
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Because bfl-1 is a known NF-KB-responsive gene, and recent evidence has 
demonstrated cell-context specific interplay between the NF-kB and Notch signalling 
pathways (Guan et a l, 1996; Bash et a l, 1999; Wang et a l, 2001 Oakley et a l, 2003), 
it was therefore necessary to monitor the level o f activated NF-kB in DG75 cells when 
EBNA2 was expressed. EBNA2 was not seen to affect the level o f activated NF-kB in 
the context o f the EBV-negative BL-derived cell line DG75. Furthermore, over­
expression o f an IkBcx super-repressor did not affect the ability o f EBNA2 to trans- 
activate the bfl-1 gene. By contrast, it was shown in the current study that LMP1 
expression resulted in the activation o f the NF-kB transcription factor, and it has already 
been shown in our laboratory that over-expression o f the IkBo, super-repressor inhibits 
LMP1-mediated trans-activation o f bfl-1 (D5 Souza et a l, 2004). These findings suggest 
that, unlike LMP1, EBNA2-mediated trans-activation o f the bfl-1 promoter does not 
lead to the activation o f NF-kB.
Because both EBNA2 and NotchIC trans-activate genes by interacting with the DNA 
binding transcription factor RBP-Jk/CBF1, they are often regarded as functional 
homologues. Although there is no obvious sequence homology between these two 
proteins, they interact with similar regions o f RBP-Jk/CBF1 and replace repressor 
proteins with their trans-activation domains. Moreover, there are parallels between 
EBNA2 and NotchIC in the ways in which transcriptional activation through RBP- 
Jk/CBF1 is modified. Both EBNA2 and NotchIC interact with co-activating proteins to 
modulate gene expression. These co-activating proteins include members o f the HAT 
family o f proteins (Zimber-Strobl and Strobl, 2001), which play a role in chromatin 
opening and initiation o f transcription. Gene regulation by both proteins is regulated, in 
part, by loss o f RBP-Jk/CBFI binding as a result o f antagonistic proteins that prevent 
either EBNA2 or NotchIC binding to RBP-Jk/CBFI (Zimber-Strobl and Strobl, 2001). 
Since both EBNA2 and NotchIC share common mechanisms for regulating target gene 
expression, it is not surprising that they also overlap in the genes that they regulate. 
Both proteins have been found to modulate the same RBP-Jk/CBFI-regulated genes. 
Common gene targets include the EBV LMP2A (Strobl et a l, 2000) and the cellular 
genes BATF (Johansen et a l, 2003), CD21 (Strobl et a l, 2000), Hesl (Sakai et a l, 
1998; Kuroda et a l, 1999) and the Ig enhancer (Strobl et a l, 2000; Morimura et a l, 
2001). However, although the set o f promoters, which is regulated by EBNA2 and 
NotchIC is overlapping, it is not identical. Only EBNA2, but not NotchIC, can induce 
LMP1, CD23 and c-Myc expression (Strobl et a l, 2000). The results presented here
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also demonstrate that the IM P1 promoter is not NotchlC-responsive, and extend the list 
o f genes that are responsive to EBNA2, but not to NotchIC, to include the anti-apoptotic 
cellular gene bfl-1.
Although the NotchIC trans-activation domain is considered weaker than that o f 
EBNA2 (Hsieh et a l., 1996), this was not found to be the reason for the inability o f 
NotchIC to trans-activate the bfl-1 promoter. Even when the trans-activation domain 
and nuclear localisation sequence o f EBNA2 were fused to the NotchIC protein, it was 
not sufficient to drive transcription from the bfl-1 promoter in the EBV-negative BL- 
derived cell line DG75. It was shown that the presence o f a strong trans-activation 
alone is not sufficient for transcriptional activation o f the bfl-1 gene. Because RBP- 
Jk/CBF1 is a transcriptional repressor that tethers a co-repressor complex to promoters 
with cognate Jk binding sites, it was tested whether providing RBP-Jk/CBF1 with the 
strong VP 16 trans-activation domain would be sufficient to counter-balance repression. 
This system mimics the recruitment o f an activation domain by RBP-Jk/CBF1 without 
concomitant masking o f the RBP-Jk repression domain. Although this fusion protein 
was seen to trans-activate the control promoter, it did not trans-activate the bfl-1 
promoter, in contrast to EBNA2. These observations suggest that the mechanism by 
which EBNA2 trans-activates the bfl-1 promoter involves more than simply providing a 
trans-activation domain. It is likely that EBNA2 mediates trans-activation o f bfl-1 by 
interfering with the function o f a co-repressor in addition to the recruitment o f a trans­
activation domain. This mechanism o f EBNA2-mediated promoter activation is in 
keeping with the findings o f others (Hsieh et a l., 1995; Waltzer et a l., 1995). Another 
possible reason for the inability o f the RBP3-VP16 fusion protein to trans-activate the 
bfl-1 promoter, could be that the RBP-Jk/CBF1 isoform (RBP3) present in the fusion 
protein does not bind to the RBP-Jk/CBF1 binding site in the bfl-1 promoter with high 
affinity. Although the RBP-Jk/CBF1 consensus binding motif is present in the bfl-1 
promoter, it has been reported that nucleotides on both sides o f the core sequence may 
contribute to maximal DNA binding (Chung et a l., 1994).
Because NotchIC is also thought to mediate promoter trans-activation by interfering 
with RBP-Jk/CBF1-mediated repression and providing a trans-activation (Hayward,
2004), and yet still cannot trans-activate the bfl-1 promoter, it is likely that other 
proteins play a role in EBNA2-mediated activation this promoter. Additional factors 
have been demonstrated to play a role in EBNA2-mediated trans-activation o f other
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EBNA2-responsive promoters that are not NotchlC-responsive. For example, although 
the RBP-Jk/CBF1 binding site is essential for EBNA2-responsiveness on the LMP1 
promoter, it is not sufficient for trans-activation. Other binding sites have been 
identified in the EBNA2 responsive element (ERE) of the LMP1 promoter. One such 
binding site was identified as Spi-1, also known as PU .l, a member o f the Ets family o f 
transcription factors, which plays a pivotal role in regulating transcription from the 
LMP1 promoter (Johannsen et a l, 1995; Laux et a l, 1994b). It has also been shown 
that a POU domain protein is involved in the EBNA2-mediated trans-activation of 
LMP1 (Sjoblom et a l., 1995). Another protein DP 103, the dead box protein, which is 
complexed to the survival neuron protein SMN, also binds to EBNA2 and these can 
cooperatively trans-activate the LMP1 promoter (Voss et a l., 2001). Interestingly, 
transcription element search software has revealed four possible Ets binding sites, 
aswell as a possible RBP-Jk/CBF1 binding site, on the bfl-1 promoter and mutation o f 
any o f these sites results in a dramatic decrease in EBNA2-mediated transcriptional 
activation o f the bfl-1 gene (Pegman et a l, submitted December, 2004). It is likely that 
EBNA2 acts as an adaptor molecule that has the potential to recruit a large number o f 
interacting proteins in order to modulate gene expression. One explanation as to why 
NotchIC does not trans-activate the bfl-1 promoter, therefore, may be that it is unable to 
interact with some o f these proteins.
It has previously been shown in our laboratory using bfl-1 promoter reporter constructs 
with 5’ deletions, that the sequence from position -367 to -129 (which harbours the 
putative RBP-Jk/CBF1 and four Ets binding sites) is essential for mediating EBNA2- 
responsiveness on the bfl-1 promoter (Pegman et a l, submitted December 2004). In 
order to define the limits o f an EBNA2-responsive enhancer on the bfl-1 promoter, 
portions o f the sequence (between -367 and -40) were sub-cloned upstream o f the 
minimal /?-globin promoter in the luciferase reporter construct pGa50-7. However, 
none o f the bfl-1 promoter sequences, even those containing the putative RBP-Jk/CBF1 
binding site and four putative Ets binding sites, were found to confer EBNA2- 
responsiveness on the reporter construct. It is possible that other elements downstream 
of the region o f the promoter tested (between -40 and +81) are required for EBNA2- 
mediated activity. Another possibility for the inactivity o f the reporter constructs 
generated, is that the interaction between the transcription factors/co-activating proteins 
bound to the bfl-1 promoter sequences, and basal promoter associated proteins on the 
minimal promoter used in the study, did not cooperate for efficient enhancement of
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transcription initiation. Further experiments would need to be carried out in order to 
determine whether other minimal promoters, such as the conalbumin or HSV thymidine 
kinase minimal promoters, would yield more successful results regarding EBNA2- 
mediated activity.
Another aim o f study set out to identify an EBNA2 mutant that exhibited dominant- 
negative activity. The identification o f such an inhibitoiy molecule would provide a 
useful tool for investigation o f EBNA2 function in EBV-infected cells. In total, four 
EBNA2 mutants were tested in their ability to block wild type EBNA2 function. Two 
of these mutants, namely EBNA2-WW323SR and EBNA2 Mut (321-323), contained 
replacements/deletions in the region where EBNA2 interacts with RBP-Jk/CBFI. The 
other two EBNA2 mutants, EBNA2 Mut (447-472) and EBNA2 Mut (437-477) 
contained deletions within the trans-activation domain o f the EBNA2 protein. Only the 
EBNA2 mutants with trans-activation domain deletions were found to inhibit EBNA2- 
mediated promoter activation.
An explanation for this may be provided by studies that suggest the EBNA2 amino- 
terminus is involved in self-association, and that self association may be important for 
transcriptional activation, and as a result cell growth transformation (Harada et a l, 
2001). First, purified recombinant EBNA2 is 440 kDa, and EBNA2 from EBV-infected 
cells sediments in sucrose gradients at 13S and 34S, indicative o f complexes that are 
much larger than monomeric EBNA2 (Grasser et a l, 1991; Tsui and Schubach, 1994). 
Second, EBNA2 residues 122 to 344 can interact with residues 1 to 428 in yeast two 
hybrid assays (Tsui and Schubach, 1994). Third, EBNA2 interacts with several sites in 
all EBNA2-responsive promoters and mediates transcriptional activation by recruiting 
multiple factors through its acid trans-activation domain. For example, the LMP1 
promoter has two RBP-Jk/CBFI binding sites, but also requires EBNA2 interaction 
with PU .l, while the Cp promoter has one RBP-Jk/CBFI site and also requires CBF2 
(Jin and Speck, 1992; Johannsen et al., 1995; Laux et al., 1994b). Thus, there appears 
to be a requirement for several EBNA2 molecules to be in close proximity to enable 
interactions among transcription factors that are necessary for appropriate promoter 
regulation. The transcriptional effects o f EBNA2 are mediated by the acidic trans­
activation domain o f the EBNA2 protein. This region o f EBNA2 is responsible for 
interaction with factors o f the basal transcription machinery, and includes TFIIH, TATA 
box binding protein (TBP), associated binding factor TAF40, TFIIB, and the co­
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activator plOO that interacts with TFIIE (Tong et al., 1995a; Tong et a l., 1995b; Tong et 
a l., 1995c). The trans-activation domain also interacts with the histone 
acetyltransferases (HATs) p300/CBP and PCAF (Wang et a l., 2000), in order to 
facilitate chromatin opening.
Upon co-transfection with wild type EBNA2 and any o f the EBNA2 mutants, it is likely 
that the EBNA2 molecules (wild type or mutant) self-associate. It is possible that 
EBNA2 complexes containing EBNA2 mutants with RBP-Jk/CBFl binding site 
deletions could still bind DNA via an RBP-Jk/CBF1 binding site on a wild type EBNA2 
molecule. Because all o f the EBNA2 molecules in such a complex contain intact trans­
activation domains, the EBNA2 complex could still have the ability to mediate 
transcriptional activation. However, in complexes where there are mutant EBNA2 
molecules with trans-activation domain deletions, the complex may be unable to recruit 
all the co-activating molecules required for EBNA2-mediated promoter activation.
It was observed that one o f the EBNA2 mutants with a trans-activation domain deletion, 
of amino acids 437 to 477 was more efficient at inhibiting wild type EBNA2-mediated 
trans-activation than the other trans-activation domain deletion mutant tested [EBNA2 
Mut (447-471)]. In addition EBNA2 Mut (437-477) was shown to significantly 
decrease EBNA2-mediated trans-activation o f  (i) the control promoter, (ii) the viral 
LMP1 promoter and (iii) the cellular bfl-1 promoter. The EBNA2 trans-activation 
domain has been mapped to amino acids 425 to 462 on the EBNA2 protein (Kieff, 
1996). It is possible that EBNA2 Mut (437-477) was a more effective inhibitor due to 
the fact that a greater proportion o f the protein was deleted in this particular mutant.
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CHAPTER 4
Regulation of the Anti-Apoptotic Cellular bfl-1 
Gene in EBV-Infected Cell Lines
4.1 INTRODUCTION
The regulation o f the anti-apoptotic cellular bfl-1 gene has been studied extensively in 
our laboratory using the EBV-negative Burkitt lymphoma-derived cell line DG75. It 
has been demonstrated that EBV latent membrane protein 1 (LMP1) trans-activated the 
bfl-1 promoter in this cell context by a mechanism that is dependent upon the 
transcription factor NF-kB (D’ Souza et al. 2004). It was shown in the previous chapter 
that NF-kB homo-dimers composed o f p65 subunits directly trans-activated the bfl-1 
promoter and that the NF-KB-like binding site at -52 to -43 was essential for this effect, 
thus highlighting the role o f NF-kB pathway signalling components in LMP1 -mediated 
bfl-1 promoter activation. In a related study in our laboratory, an increase in bfl-1 
mRNA levels was observed upon EBNA2 induction using a tightly regulatable 
tetracycline-based system to express EBNA2 in the EBV-negative BL cell line DG75 
(DG75-tTA-EBNA2) (Floettman et a l., 1996), demonstrating the ability o f EBNA2 to 
activate transcription o f the bfl-1 gene independently o f LMP1 (Pegman et a l., 
submitted December 2004). It is known that EBNA2 does not bind to DNA directly, but 
is tethered to responsive promoters by the DNA binding repressor protein RBP- 
Jk/CBF1 (Henkel et al., 1994; Grossmann et a l., 1994; Waltzer et al., 1994; Zimber- 
Strobl et al., 1994). This protein, which is a component o f the Notch signalling 
pathway, was shown in the previous chapter to be essential for EBNA2-mediated 
activation o f the bfl-1 promoter in EBV-negative DG75 cells.
The regulation o f the bfl-1 gene in the EBV-negative BL-derived cell line DG75 
investigated up to this point was determined by transfection o f either the LMP1 or 
EBNA2 gene into DG75 cells. Because EBV-negative BL cells are immortalised by a 
mechanism not requiring expression o f LMP1 or EBNA2, it is difficult to assess the 
contribution o f these genes to cell survival o f EBV-infected primary B cells. To 
overcome this obstacle, experiments were performed using EBV-infected cell lines, 
where both EBNA2 and LMP1 are expressed, and transcription o f the LMP1 gene is 
induced by EBNA2 (Abbot et a l, 1990; Fahraeus et al., 1990; Laux et a l, 1994a; Wang 
et a l, 1990). Because both EBNA2 and LMP1 are present in these cell lines, and these 
EBV proteins regulate bfl-1 expression through two different cellular signalling 
pathways, experiments were performed to elucidate the roles o f EBNA2 and LMP1 in 
the regulation o f the bfl-1 gene in EBV-infected cells. The regulation o f the bfl-1 
promoter in the cell lines Ag876 and IB4 was investigated. Ag876 is a latency type III
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BL cell line, in which all EBV latent genes including LMP1 and EBNA2 are expressed. 
The IB4 cell line is an EBV-transformed lymphoblastoid cell line (LCL) generated by 
infection o f normal human umbilical cord blood lymphocytes with the EBV B95.8 
strain (King et al., 1980).
4.2 RESULTS 
4.2.1 LMPl-mediated bfl-1 promoter activation in the cell lines Ag876 and IB4
Firstly the role o f LMP1 in the trans-activation o f the bfl-1 promoter in Ag876 and IB4 
cells was investigated. In a preliminary experiment, co-transfections were performed 
using the NF-kB responsive reporter construct (3 x enh kB luc). When this reporter 
construct was transfected into either Ag876 cells (Figure 4.1 A) or IB4 cells (Figure 
4. IB), a high level o f luciferase activity was observed, relative to the level obtained 
upon transfection with the empty vector. This value was set at 100 %. A high level o f  
activated NF-kB was expected as LMP1, which is present in both these cell lines, is 
known to trigger signalling pathways that result in the activation o f NF-kB (Huen et al., 
1995). The NF-KB-responsive reporter construct was also co-transfected into Ag876 
and EB4 cells along with the expression vector for a mutant form o f IkBoi (pEFCX- 
IkBoDN), in which the serine residues at positions 32 and 36 have been replaced with 
alanines (Liljeholm et a l., 1998). When various quantities o f  this mutant form o f IkBoi 
were co-transfected along with the NF-KB-responsive reporter construct 3 x enh kB luc, 
a dramatic decrease in luciferase activity was observed in both Ag876 cells (Figure
4.1 A) and IB4 cells (Figure 4. IB). This decrease in activated NF-kB levels was 
observed upon co-transfection with just 1 jig o f pEFCX-lKBaDN, with a decrease in 
luciferase activity o f approximately 80 % in Ag876 cells and approximately 70 % in 
IB4 cells. When larger quantities o f the expression vector for the IkBgi mutant were 
used in transfection experiments, luciferase activity was almost completely abolished in 
both cell lines.
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Expression of IkBolDN Leads to a Decrease in Activated NF-kB Levels 
in Ag876 Cells
Expression of ItcBaDN Leads to a Decrease in Activated NF-kB Levels
in IB4 Cells
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Figure 4.1: Over-expression of a dominant negative form of IicBa leads to a decrease in activated 
NF-kB levels in the Ag876 and IB4 cell lines. Co-transfections were carried out in Ag876 cells (A) and 
IB4 cells (B) using various amounts of pEFCX-IicBaDN and 2 ng of the NF-icB-responsive luciferase 
reporter construct 3 x enh kB luc. Cells were harvested at 48 hours post-transfection and normalised 
luciferase values were expressed as % activation relative to the corresponding value obtained upon co- 
transfection with the reporter and the empty vector (pEFCX). Luciferase activity obtained upon co­
transfection with the reporter construct along with the empty vector was arbitrarily assigned a value of 
100 %.
These results indicated that there is a high level o f activated NF-kB in the EBV-infected 
cell lines Ag876 and EB4, most likely as a result o f LMP1 signalling. Over-expression
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o f a dominant negative IicBa mutant effectively decreases this level o f activated NF-kB 
in these cell contexts.
Once it was established that the dominant negative IicBa mutant effectively blocked 
activation o f NF-kB in Ag876 and IB4 cells, co-transfections were performed to 
investigate if this mutant could block bfl-1 promoter activation in these EBV-infected 
cell lines. To this end, various amounts o f the expression vector for the IicBa mutant 
were co-transfected into Ag876 cells (Figure 4.2A) and IB4 cells (Figure 4.2B) along 
with the bfl-1 promoter reporter -1374/+81-Luc. In the absence of the mutant, 
transfection o f the bfl-1 promoter reporter construct (-1374/+81-Luc) into both cell lines 
resulted in a high level o f luciferase activity relative to that obtained upon transfection 
with the empty vector (pGL2-Basic). This value was set at 100 %. A high level o f 
luciferase activity was expected, as the bfl-1 promoter is responsive to both LMP1 and 
EBNA2, which are present in both Ag876 and IB4 cells. When the bfl-1 promoter was 
co-transfected with the expression vector for the IicBa mutant, only a marginal decrease 
in promoter activity (<20 %) was observed in either Ag876 or IB4 cells.
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The Effect of IkBolDN on bfl-1  Promoter Activity in Ag876 Cells
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Figure 4.2: Over-expression of a dominant negative form of ItcBa does not dramatically affect bfl-1 
promoter activity in EBV-infected cell lines Ag876 and LB4. Co-transfections were carried out with 
Ag876 cells (A) and IB4 cells (B) using various amounts of pEFCX-IicBaDN and 2 \ig of the bfl-1 
promoter reporter construct -1374/+81-Luc. Cells were harvested at 48 hours post-transfection and 
normalised luciferase values were expressed as % activation relative to the corresponding value obtained 
upon co-transfection with the bfl-1 reporter construct and the empty expression vector for IkBoDN 
(pEFCX). Luciferase activity obtained upon co-transfection with the reporter construct along with the 
empty vector was arbitrarily assigned a value of 100 %.
This data showed that although the mutant from o f I k B ol effectively blocks activation o f 
the NF-icB-responsive reporter construct 3 x enh k B  luc, it does not affect bfl-1 
promoter activity in the EBV-infected cell lines Ag876 and IB4. It is possible that 
although LMP1-mediated activation o f the bfl-1 promoter is inhibited by expression o f
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the IidBa mutant, EBNA2 is maintaining the level o f bfl-1 promoter activity by 
signalling independently through the CBF 1/Notch pathway.
4.2.2 EBNA2-mediated bfl-1 promoter activation in the cell lines Ag876 and EB4
4.2.2.1 The effect of the RBP-Jk/CBF1 mutant on bfl-1 promoter activity in the cell 
lines Ag876 and IB4
It was shown in Chapter 3, using the EBV-negative cell line DG75, that an RBP- 
Jk/CBF1 mutant effectively blocked EBNA2-mediated responsiveness on three 
different promoters: an RBP-Jk/CBF1-regulated control promoter (pGa981-6), the bfl-1 
promoter (-1374/+81-Luc) and the LMP1 promoter (pLLO-luc). To determine whether 
this mutant could also inhibit bfl-1 promoter activation in EBV-infected cells, co­
transfections were performed using an expression vector for this mutant (pEFBOSneo- 
R218H) along with pGa981-6. When this reporter construct was transfected into either 
Ag876 cells (Figure 4.3A) or IB4 cells (Figure 4.3B) in the absence o f the RBP- 
Jk/CBF1 mutant, a high level o f  luciferase activity was observed, most likely due to the 
fact that this construct is responsive to EBNA2, which is present in both Ag876 and IB4 
cells. Expression o f the RBP-Jk/CBF1 mutant inhibited trans-activation o f  pGa981-6 in 
both Ag876 cells (Figure 4.3 A) and IB4 cells (Figure 4.3B). The inhibitory effect was 
found to be dose-dependent with maximum inhibition o f approximately 70 % in both 
cell lines when 12 pg o f pEFBOSneo-R218H was used during co-transfection 
experiments. It was noted that inhibition was to the same degree as that observed 
during similar co-transfection experiments performed in the EBV-negative cell line 
DG75 (Figure 3.5).
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Figure 4.3: Over-expression of the RBP-Jk/CBFI mutant inhibits activation of the luciferase 
reporter construct pGa981-6 in EBV-infected cell lines. Co-transfections were carried out using 
Ag876 cells (A) and IB4 cells (B) with various amounts of pEFBOSneo-R218H and 2 \ig of the RBP- 
Jk/CBFI responsive control promoter pGa981-6. Cells were harvested at 48 hours post-transfection and 
normalised luciferase values were expressed as % activation relative to the corresponding value obtained 
upon co-transfection with the reporter construct and the empty expression vector for the RBP- 
Jk/CBFI mutant (pEFBOSneo). Luciferase activity obtained upon co-transfection with the reporter 
construct and the empty vector was arbitrarily assigned a value of 100 %.
These data showed that expression o f the RBP-Jk/CBFI mutant, pEFBOSneo-R218H, 
effectively inhibits trans-activation o f the luciferase reporter construct pGa981-6 in both 
Ag876 and IB4 cells.
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To determine whether expression o f the RBP-Jk/CBF1 mutant could affect the levels o f 
bfl-1 promoter activity in the EBV-infected cells, transient co-transfections were 
performed using various amounts o f the expression vector for the RBP-Jk/CBF1 mutant 
along with the bfl-1 promoter reporter construct -1374/+81-Luc. When the bfl-1 
promoter reporter construct was transfected into the cells in the absence o f the RBP- 
Jk/CBF1 mutant, high levels o f promoter activity were observed in both Ag876 cells 
(Figure 4.4A) and IB4 cells (Figure 4.4B). Upon co-transfection o f  the RBP-Jk/CBF1 
mutant along with the bfl-1 promoter, a small decrease in bfl-1 promoter activity was 
observed (30 % in Ag876 cells, Figure 4.4A and 10 % in IB4 cells, Figure 4.4B). This 
effect on bfl-1 promoter activity was not as potent as the effect observed in transfection 
experiments using the RBP-Jk/CBF1 regulated control promoter pGa981-6, where 
inhibition o f approximately 70 % was demonstrated. It was also noted that inhibition of 
EBNA2-mediated activation o f the bfl-1 promoter in the EBV-negative BL-derived cell 
line DG75 by the RBP-Jk/CBFI mutant was far more effective (approximately 75 %, 
Figure 3.7).
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Figure 4.4: Over-expression of an RBP-Jk/CBF1 mutant does not dramatically affect bfl-1 
promoter activity in EBV-infected cell lines. Co-transfections were performed in Ag876 cells (A) and 
IB4 cells (B) using various amounts of pEFBOSneo-R218H and 2 \ig of the bfl-1 promter reporter 
construct -1374/+81-Luc. Cells were harvested at 48 hours post-transfection and normalised luciferase 
values were expressed as % activation relative to the corresponding value obtained upon co-transfection 
with the bfl-1 promoter reporter construct and the empty expression vector for the RBP-Jk/CBF1 mutant 
(pEFBOSneo). Luciferase activity obtained upon co-transfection with the reporter construct and the 
empty vector was arbitrarily assigned a value of 100 %.
This data shows that although over-expression o f the RBP-Jk/CBF1 mutant inhibits 
trans-activation o f the control luciferase reporter construct pGa981-6 in Ag876 and IB4 
cells, it does not significantly affect bfl-1 promoter activity.
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It was demonstrated in Chapter 3 that over-expression o f the RBP-Jk/CBF1 mutant 
inhibited EBNA2-mediated activation o f the IM P1 promoter in the EBV-negative BL- 
derived cell line DG75 (Figure 3.10). If EBNA2-mediated activation o f the LMP1 
promoter was inhibited by the RBPJk/CBFI mutant in EBV-infected cells, it is likely 
that there would be a decrease in NF-kB activity as a result. In order to test this 
hypothesis, co-transfections were carried using various amounts o f the expression 
vector for the RBP-Jk/CBF1 mutant along with the NF-icB-responsive reporter construct 
3 x enh kB luc. Over-expression o f the mutant did indeed affect the level o f NF-kB- 
responsive promoter activity in both Ag876 cells (Figure 4.5A) and IB4 cells (Figure 
4.5B). A maximum inhibition in luciferase activity o f approximately 40 % was 
observed in both cell lines. Because this decrease in NF-kB activity was observed, it is 
difficult to conclude whether RBP-Jk/CBF1 mutant-mediated partial inhibition o f bfl-1 
promoter activity observed in the Ag876 cells (Figure 4.4A) was due to (i) inhibition o f 
EBNA2-mediated activation o f the bfl-1 promoter by over-expression o f the RBP­
Jk/CBFI mutant, (ii) inhibition o f EBNA2-mediated trans-activation o f the IM P  I  
promoter due to over-expression o f the RBP-Jk/CBF1 mutant, and as a result lower 
levels o f LMP1 in the cells, resulting in a decrease in bfl-1 promoter activity or (iii) a 
combination o f these two factors. Although over-expression o f the RBP-Jk/CBF1 
mutant affected NF-kB levels in IB4 cells (Figure 4.5B), no decrease in bfl-1 promoter 
activity was observed (Figure 4.4A).
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Figure 4.5: The effect of the RBP-Jk/CBF1 mutant on activated NF-kB levels in EBV-infected cell 
lines. Co-transfections were performed using Ag876 cells (A) and IB4 cells (B) with various amounts of 
pEFBOSneo-R218H and 2 \ig of the NF-icB-responsive luciferase reporter construct 3 x enh kB luc. 
Cells were harvested at 48 hours post-transfection and normalised luciferase values were expressed as % 
activation relative to the corresponding value obtained upon co-transfection with the reporter construct 
and the empty expression vector for the RBP-Jk/CBF 1 mutant (pEFBOSneo). Luciferase activity 
obtained upon co-transfection with the reporter construct and the empty vector was arbitrarily assigned a 
value of 100 %.
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4.2.2.2 The effect of the EBNA2 mutant on bfl-1 promoter activity in the cell lines 
Ag876 and IB4
In a second attempt to block EBNA2-mediated trans-activation o f the bfl-1 promoter in 
EBV-positive cell lines, co-transfections were carried out using an EBNA2 mutant with 
a deletion in its trans-activation domain. This mutant was shown to dramatically inhibit 
EBNA2-mediated trans-activation o f the control reporter construct pGa981-6 (Figure 
3.3IB), the viral IM P1 promoter (Figure 3.32B) and the cellular bfl-1 promoter in the 
EBV-negative cell line DG75 (Figure 3.32A) in the previous chapter. In a preliminary 
experiment, transfections were carried out using the RBP-Jk/CBF1 -responsive control 
promoter pGa981-6. As before, high levels o f promoter activity were observed when 
this reporter construct was transfected into Ag876 cells (Figure 4.6A) and IB4 cells 
(Figure 4.6B). However, upon co-transfection o f this reporter construct with different 
quantities o f the expression vector for the EBNA2 mutant, a decrease in promoter 
activity was observed. This decrease was dose-dependent with maximum inhibition 
observed when 12 fig o f EBNA2 Mut (437-477) expression vector was used. Co­
transfections using this quantity o f EBNA2 mutant resulted in 90 % inhibition in 
luciferase activity in experiments using Ag876 cells (Figure 4.6A). A similar degree o f 
inhibition was observed during co-transfection experiments using EBNA2 Mut (437- 
477) in the EBV-negative cell line DG75 (Figure 3.3IB). A maximum inhibition of 
approximately 70 % was noted when IB4 cells were used (Figure 4.6B).
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Figure 4.6: Over-expression of an EBNA2 mutant inhibits activation of pGa981-6 in EBV-positive 
cell lines. Co-transfections were performed using Ag876 cells (A) and IB4 cells (B) using various 
amounts of and expression vector for EBNA2 Mut (437-477) and 2 jxg of the luciferase reporter construct 
pGa981-6. Cells were harvested at 48 hours post-transfection and normalised luciferase values were 
expressed as % activation relative to the corresponding value obtained upon co-transfection with the 
reporter and the empty expression vector for the EBNA2 mutant (pSG5). Luciferase activity obtained 
upon co-transfection with the reporter and the empty vector was arbitrarily assigned a value of 100 %.
These results indicated that the EBNA2 mutant (with a deletion in its trans-activation 
domain) effectively inhibited EBNA2-mediated trans-activation o f the control luciferase 
reporter construct pGa981-6 in Ag876 and IB4 cells.
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In order to determine whether EBNA2 Mut (437-477) could inhibit EBNA2-mediated 
activation o f the bfl-1 promoter, co-transfections were carried out using either Ag876 
cells (Figure 4.7A) or IB4 cells (Figure 4.7B) and the expression vector for the EBNA2 
mutant, along with the bfl-1 promoter reporter construct -1374/+81-Luc. As expected a 
high level o f bfl-1 promoter activity was observed upon transfection o f the reporter into 
both cell lines. When increasing quantities o f the expression vector for EBNA2 Mut 
(437-477) were co-transfected along with the bfl-1 promoter, a small decrease in 
promoter activity was observed. Promoter activity was inhibited by approximately 10 
% in experiments using Ag876 cells (Figure 4.7A) and approximately 30 % in 
experiments using EB4 cells (Figure 4.7B). This degree o f inhibition is not as great as 
that observed during transfections using the control luciferase reporter construct 
pGa981-6 (Figure 4.6, 90 % inhibition in Ag876 cells and 70 % in IB4 cells) or in EBV- 
negative cell line DG75 (Figure 3.32A, 90 % inhibition)
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Figure 4.7: Over-expression of an EBNA2 mutant does not dramatically affect EBNA2-mediated 
activation of the bfl-1 promoter in EBV-positive cell lines. Co-tiansfections were carried out with 
Ag876 cells (A) and IB4 cells (B) using various amounts of EBNA2 Mut (437-477) and 2 fig of the bfl-1 
promoter reporter construct -1374/+81-Luc. Cells were harvested at 48 hours post-transfection and 
normalised luciferase values were expressed as % activation relative to the corresponding value obtained 
upon co-transfection with the reporter construct and the empty expression vector for the EBNA2 mutant 
(pSG5). Luciferase activity obtained upon co-transfection with the reporter and the empty vector was 
arbitrarily assigned a value of 100 %.
This data shows that although over-expression o f EBNA2 Mut (437-477) inhibits trans­
activation o f the control luciferase reporter construct pGa981 -6, it does not inhibit b fl-l 
promoter activity as efficiently.
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It was demonstrated in Chapter 3 that over-expression o f  EBNA2 Mut (437-477) 
inhibited EBNA2-mediated activation o f the LMP1 promoter in the EBV-negative BL- 
derived cell line DG75 (Figure 3.32B). If EBNA2-mediated activation o f the LMP1 
promoter was inhibited by over-expression o f the EBNA2 mutant in EBV-infected cells, 
it is likely that there would be a decrease in NF-kB activity as a result. In order to 
investigate this, co-transfections were carried using various amounts o f the expression 
vector for EBNA2 Mut (437-477) along with the NF-icB-responsive reporter construct 3 
x enh kB luc. Over-expression o f the mutant was found to affect the level o f NF-kB- 
responsive promoter activity in both Ag876 cells (Figure 4.8A) and IB4 cells (Figure 
4.8B). A maximum inhibition in luciferase activity o f approximately 20 % was 
observed in Ag876 cells and 40 % in IB4 cells. Similarly to the experiments using the 
RBP-Jk/CBF1 mutant, it is difficult to conclude whether EBNA2 Mut (437-477)- 
mediated inhibition o f  bfl-1 promoter activity observed in the 1B4 cells (Figure 4.7B) 
was due to (i) inhibition of EBNA2-mediated activation of the bfl-1 promoter by over­
expression o f the EBNA2 mutant, (ii) inhibition o f EBNA2-mediated trans-activation o f 
the IMP1 promoter by over-expression o f the EBNA2 mutant, and as a result lower 
levels o f LMP1 in the cells, resulting in a decrease in bfl-1 promoter activity or (iii) a 
combination o f these two factors. Over-expression o f the EBNA2 mutant affected NF- 
kB levels in Ag876 cells (Figure 4.8A) to a lesser extent than in the IB4 cells. This 
correlates with the decrease in bfl-1 promoter activity observed in Figure 4.7.
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Figure 4.8: The effect of the EBNA2 mutant on activated NF-kB levels in EBV-infected cell lines.
Co-transfections were performed using Ag876 cells (A) and IB4 cells (B) using various amounts of the 
expression vector for the EBNA2 mutant and 2 fig of the NF-kB-responsive luciferase reporter construct 
3 x enh kB luc. Cells were harvested at 48 hours post-transfection and normalised luciferase values were 
expressed as % activation relative to the corresponding value obtained upon co-transfection with the 
reporter construct and the empty expression vector for the EBNA2 mutant (pSG5). Luciferase activity 
obtained upon co-transfection with the reporter construct and the empty vector was arbitrarily assigned a 
value of 100 %.
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4.2.3 Co-expression of the RBP-Jk/CBFI and IicBa mutants in the cell lines Ag876 
and 1B4 inhibits bfl-1 promoter activation
It has already been demonstrated that over-expression of either the RBP-Jk/CBFI 
mutant or the IkBgi mutant alone (Figure 4.4 and Figure 4.2 respectively) does not lead 
to a potent inhibition in bfl-1 promoter activity using the cell lines Ag876 and IB4. 
These results are summarised in Figure 4.9. Consequently, transient co-transfections 
were performed to investigate whether co-expression of these two mutants at the same 
time would affect the level of bfl-1 promoter activity. Co-transfection with 12 ¿ig of the 
expression vector for the RBP-Jk/CBFI mutant (pEFBOSneo-R218H) together with 12 
|ig of the the vector expressing the IkBoi mutant (pEFCX-lKBaDN) resulted in 
approximately 50 % inhibition in the level of bfl-1 promoter activity in Ag876 cells 
(Figure 4.9A) and approximately 40 % inhibition in EB4 cells (Figure 4.9B).
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Figure 4.9: Co-expression of the RBP-Jk/CBF1 and IicBa mutants affects bfl-1 promoter activity in 
the cell lines Ag876 and IB4. Co-transfections were performed using Ag876 cells (A) and IB4 cells (B) 
using 12 fig of the expression vector indicated underneath the graph along with 2 fig of the bfl-1 promoter 
reporter construct -1374/+81-Luc. Cells were harvested at 48 hours post-transfection and normalised 
luciferase values were expressed as % activation relative to the corresponding value obtained upon co­
transfection with the empty expression vector. Luciferase activity obtained upon co-transfection with the 
empty vector was arbitrarily assigned a value of 100 %.
These results demonstrated that blocking both EBNA2- and LMP1-mediated activation 
of the bfl-1 promoter by co-expression of the RBP-Jk/CBFI and IicBa mutants 
simultaneously resulted in stronger inhibition in bfl-1 promoter activity than expression 
of either of these mutants alone.
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4.2.4 Co-expression of the EBNA2 and Iidta mutants in the cell lines Ag876 and 
1B4 inhibits bfl-1 promoter activation
It was demonstrated in Section 4 2 2 that over-expression of the EBNA2 mutant with a 
trans-activation domain deletion does not inhibit bfl-1 promoter activity as efficiently as 
the control reporter construct in Ag876 and IB4 cells (Figure 4 7) In order to 
investigate whether co-expression o f this mutant along with the IicBa mutant would 
have a greater inhibitory effect on the level of bfl-1 promoter trans-activation, transient 
co-transfections were performed using the expression vector for the EBNA2 mutant 
(EBNA2 Mut (437-477) together with the vector expressing the IicBa mutant (pEFCX- 
IkBoDN) Co-expression of the two mutants at the same time resulted in approximately 
60 % inhibition in the level o f bfl-1 promoter activity in Ag876 cells (Figure 4 10A) and 
40 % inhibition in IB4 cells (Figure 4 10B) The levels of inhibition were similar to 
those obtained upon co-transfection with the RBP-Jk/CBF1 and IicBa mutants (Figure 
4 9)
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Figure 4.10: Co-expression of the EBNA2 and IicBa mutants affects bfl-1 promoter activity in EBV- 
infected cell lines Ag876 and IB4. Co-transfections were performed using Ag876 cells (A) and IB4 cells 
(B) using 12 fig of the expression vector indicated underneath the graph and 2 fig of the bfl-I promoter 
reporter construct -1374/+81-Luc. Cells were harvested at 48 hours post-transfection and normalised 
luciferase values were expressed as % activation relative to the corresponding value obtained upon co­
transfection with the empty expression vector. Luciferase activity obtained upon co-transfection with the 
empty vector was arbitrarily assigned a value of 100 %.
These results demonstrated for a second time that inhibition of both EBNA2- and 
LMP1-mediated trans-activation of the bfl-1 promoter, in this case by co-expression of  
the EBNA2 and IicBa mutants simultaneously, resulted in a significant decrease in the 
level of bfl-1 promoter activity in Ag876 and IB4 cells.
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4.2.5 The effect of an IkBoDN on promoter activity in the cell lines Ag876 and 1B4
In order to further investigate inhibition of bfl-1 promoter activity by blocking both 
EBNA2- and LMPl-mediated activation simultaneously, experiments were performed 
using a bfl-1 promoter construct containing a mutation in the putative RBP-Jk/CBF1 
binding site at position -343 to -249 relative to the transcription start site (-1374/+81 
(mCBFl), Pegman et a l , submitted December 2004) and the expression vector for the 
IicBa mutant In a preliminary control experiment, the NFicB-responsive reporter 
construct 3 x enh kB luc was transfected into Ag876 cells (Figure 4 11 A) or IB4 cells 
(Figure 4 1 IB), resulting in a high level of luciferase activity This finding was not 
surprising as LMP1 is known to trigger signalling pathways that result m the activation 
of NF-kB Upon co-transfection of the NF-icB-responsive reporter along with the 
expression vector for the IicBa mutant (pEFCX-IicBaDN), a significant decrease in 
luciferase activity (approximately 95 %) was observed This finding was similar to that 
observed m experiments using the EBV-negative BL-denved cell line DG75 (Figure 
3 9A) When the IicBa mutant was co-transfected along with the bfl-1 promoter reporter 
construct -1374/+81-Luc, only a small decrease in luciferase activity was detected in 
experiments earned out using both cell lines Ag876 and IB4 cells were also transfected 
with the bfl-1 promoter construct containing a mutation in the putative RBP-Jk/CBF1 
binding site at position -343 to -249 relative to the transcription start site [-1374/+81 
(mCBFl)] This mutation was not found to significantly inhibit bfl-1 promoter activity 
in either cell line However, upon co-transfection of the IicBa mutant together with the 
promoter bearing the mutation m the putative RBP-Jk/CBF1 binding site, a 45 % 
decrease m luciferase activity was observed in Ag876 cells and a 50 % decrease was 
observed in IB4 cells
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Figure 4 11 The effect of expression of the IkB<x mutant on promoter activity in Ag876 and IB4 
cells. Co-transfections were performed using Ag876 cells (A) and IB4 cells (B) using 12 ng of either 
pEFCX or pEFCX-IicBaDN and 2 i^g of the reporter construct indicated underneath the graph Cells were 
harvested at 48 hours post-transfection and normalised luciferase values were expressed as % activation 
relative to the corresponding value obtained upon co-transfection with the empty vector Luciferase 
activity obtained upon co-transfection with the empty vector was arbitrarily assigned a value of 100 %
These results indicated that blocking LMP1-mediated bfl-1 promoter activity by over- 
expression o f the IkB<x mutant as well as blocking EBNA2-mediated bfl-1 promoter 
activity by mutating the putative RBP-Jic/CBFl binding site on the promoter, results in 
inhibition in bfl-1 promoter trans-activation in the cell lines Ag876 and IB4
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4.2.6 The effect of RBP-Jk/CBF1 mutant on promoter activity in the cell lines 
Ag876 and IB4
The effect of the RBP-Jk/CBF1 mutant on the activity of the bfl-1 promoter construct 
containing a mutation in the NF-icB-like binding site at position -52 to -43 relative to the 
transcription start site was also investigated using Ag876 and IB4 cells Initially, the 
RBP-Jk/CBF1-regulated reporter construct (pGa981-6) was transfected into Ag876 cells 
(Figure 4 12A) or IB4 cells (Figure 4 12B) A high level of luciferase activity was 
observed This was an expected finding as the reporter construct is known to be 
responsive to EBNA2, which is present in both these cell lines When pGa981-6 was 
co-transfected along with the expression vector for the RBP-Jk/CBFI mutant 
(pEFBOSneo-R218H), a 70 % decrease in luciferase activity was detected m Ag876 
cells and a 60 % decrease was detected in IB4 cells This finding was similar to that 
observed in experiments performed using the EBV-negative BL-denved cell line DG75 
(Figure 3 5) When the bfl-1 promoter reporter construct -1374/+81-Luc was co­
transfected along with the RBP-Jk/CBFI mutant, no decrease in luciferase activity was 
observed in either of the EBV-infected cell lines Ag876 and IB4 cells were also 
transfected with the bfl-1 promoter construct containing a mutation in the NF-icB-like 
binding site at position -52 to -43 relative to the transcription start site (-1374/+81 micB 
(-52), D’Souza et a l , 2004) This mutation was not found to inhibit bfl-1 promoter 
activity in either o f the cell lines However, upon co-transfection with the RBP- 
Jk/CBFI mutant together with the promoter containing the NF-icB-like binding site 
mutation, a decrease of approximately 50 % in luciferase activity was observed in both 
cell lines
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Figure 4 12 The effect of expression of the RBP-nJk/CBFI mutant on promoter activity in the cell 
lines Ag876 and IB4 Co-transfections were performed using Ag876 cells (A) and IB4 cells (B) using 12 
of either pEFBOSneo or pEFBOSneo-R218H together with 2 jig of the reporter construct indicated 
underneath the graph. Cells were harvested at 48 hours post-transfection and normalised luciferase values 
were expressed as % activation relative to the corresponding value obtained upon co-transfection with the 
empty expression vector (pEFBOSneo) Luciferase activity obtained upon co-transfection with the empty 
vector was arbitrarily assigned a value of 100 %
These results indicated that blocking LMPl-mediated bfl-1 promoter activity by 
mutating the NF-xB-hke binding site at position -52 to -43 relative to the transcription 
start site on the bfl-1 promoter as well as blocking EBNA2-mediated bfl-1 promoter
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4.2.7 The effect of the EBNA2 mutant with a trans-activation domain deletion on 
promoter activity in the cell lines Ag876 and 1B4
The effect of the EBNA2 mutant on the activity o f the bfl-1 promoter construct 
containing a mutation in the NF-icB-like binding site at position -52 to -43 relative to the 
transcription start site was also investigated using Ag876 and IB4 cells Initially, the 
RBP-Jk/CBF1-regulated reporter construct (pGa981-6) was transfected into either 
Ag876 or IB4 cells As before, a high level o f luciferase activity was observed m both 
Ag876 cells (Figure 4 13A) and IB4 cells (Figure 4 13B) When pGa981-6 was co­
transfected along with the expression vector for the EBNA2 mutant (EBNA2 Mut (437- 
477), a dramatic decrease (approximately 80 %) in luciferase activity was detected in 
both cell lines This finding was similar to that observed in experiments using the EBV- 
negative BL-denved cell line DG75 (Figure 3 3 IB) Upon co-transfection of the 
EBNA2 mutant together with the wild-type bfl-1 promoter reporter construct (- 
1374/+81-Luc) a 10 % decrease in luciferase activity was observed in Ag876 cells 
(Figure 4 13A) and a 20 % decrease was observed in IB4 cells (Figure 4 13B) The two 
EBV-infected cell lines were also transfected with the bfl-1 promoter construct 
containing a mutation m the NF-icB-like binding site at position -52 to -43 relative to the 
transcription start site [-1374/+81 micB (-52)] This mutation was not found to inhibit 
the level o f promoter activity in either cell line However, upon co-transfection with the 
EBNA2 mutant together with the promoter bearing the NF-icB-like binding site 
mutation, a 40 % decrease m luciferase activity was observed in Ag876 cells and a 50 % 
decrease in IB4 cells
activity by over-expression of the RBP-Jk/CBF1 mutant, results in inhibition in bfl-1
promoter trans-activation in both Ag876 and IB4 cells
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The Effect of EBNA2 Mut (437-477) on Promoter Activity in Ag876 Cells
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Figure 4.13: The effect of expression of the EBNA2 mutant on promoter activity in the cell lines 
Ag876 and IB4. Co-transfections were performed with Ag876 cells (A) and IB4 cells (B) using 12 ng of 
either pSG5 or EBNA2 Mut (437-477) together with 2 \ig of the reporter construct indicated underneath 
the graph. Cells were harvested at 48 hours post-transfection and normalised luciferase values were 
expressed as % activation relative to the corresponding value obtained upon co-transfection with the 
empty expression vector (pSG5). Luciferase activity obtained upon co-transfection with the empty vector 
was arbitrarily assigned a value of 100 %.
These results indicated that blocking LMP1-mediated bfl-1 promoter activity by 
mutating the NF-KB-like binding site at position -52 to -43 relative to the transcription 
start site on the bfl-1 promoter, as well as blocking EBNA2-mediated bfl-1 promoter
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4.3 DISCUSSION
Modulation o f the expression o f bfl-1 has been studied extensively in our laboratory 
using the EBV-negative Burkitt’s lymphoma-derived cell line DG75 It has been 
demonstrated that two EBV latent proteins, LMP1 and EBNA2, usurp the NF-kB and 
Notch signalling pathways respectively, to affect transcription of the anti-apoptotic bfl-1 
gene in this cell context It is widely accepted that the oncogenic EBV protein LMP1 
induces survival signals through the up-regulation of anti-apoptotic proteins, such as 
A20, Bcl-2, Mcl-1 and cIAPs (Henderson et a l , 1991, Fries et a l , 1996, Wang et a l , 
1996, Laherty et a l , 1992, Hong et a l , 2000) The ability of EBNA2 to up-regulate bfl- 
1 implies that EBNA2 may also contribute to cell survival, as well as to the proliferative 
response that occurs upon EBV infection It is not yet clear whether the anti-apoptotic 
effect of EBNA2 is to simply complement that of LMP1, and/or to provide initial 
protection from apoptosis before LMP1 is expressed The contribution of EBNA2 to the 
trans-activation of the bfl-1 gene in EBV-infected cells was investigated here Because 
both EBNA2 and LMP1 are expressed in EBV-infected cell lines, and EBNA2 is 
responsible for inducing expression of LMP1 (Abbot et a l , 1990, Fahraeus et a l , 1990, 
Laux et a l , 1994a, Wang et a l , 1990), experiments were performed to uncouple the 
roles of EBNA2 and LMP1 in the trans-activation of the bfl-1 promoter in the EBV- 
positive type HI (latency HI) BL cell line Ag876 and the LCL IB4, both of which are 
typical of EBV-infected cells that express all the latent gene products
It has already been demonstrated using DG75 cells that over-expression of an IicBa 
super-repressor dramatically inhibits LMP1-mediated trans-activation of the bfl-1 
promoter (D’Souza et a l , 2004) However, this was not found to be the case in the 
EBV-infected cell lines Ag876 and IB4 Although co-expression of the IicBa super­
repressor was seen to significantly decrease the level of activated NF-kB in these cell 
lines, bfl-1 promoter activity was not dramatically affected m this cell context, where 
inhibition o f less than 20 % was observed It is possible that the level of bfl-1 promoter 
activity is maintained by some other factor, EBNA2 being a likely candidate, as the bfl-
activity by over-expression of the EBNA2 mutant, results in inhibition in bfl-1 promoter
trans-activation in the cell lines Ag876 and IB4
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1 promoter was found to be responsive to this protein in EBV-negative BL-denved 
cells, and EBNA2 is present in both the EBV-infected cell lines Ag876 and EB4
The observation that expression of an IkBo, super-repressor did not have a dramatic 
effect on the level o f bfl-1 promoter activity is in discordance with the findings of 
another study, in which tetracyclme-mducible expression of an IkB<x mutant (with a 
deletion from amino acids 1 to 36) in the LCLIB4 resulted in a 50 % decrease m bfl-1 
mRNA, as determined by Northern blot analysis 2 days post induction (Cahir- 
McFarland et a l , 2000) Although this mutant form of IicBa differs from the one used 
in the current study, in which senne residues at positions 32 and 36 have been replaced 
with alanines (Liljeholm et a l , 1998), both mutants can no longer be phosphorylated 
and subsequently ubiquitinated, resulting m the detainment of the NF-kB transcription 
factor in the cytoplasm (Brockman et a l , 1995) Furthermore, both mutants have been 
shown to inhibit NF-kB activation (Figures 3 9A and 4 1, Cahir-McFahrland et a l , 
2000) Thus, the discrepancies between the two studies may lie in the fact that two 
different approaches were taken to momtor activity of the bfl-1 gene Results provided 
from the current study reflect the rate of transcription initiation from the bfl-1 promoter, 
as determined by transfection o f bfl-1 promoter reporter constructs followed by 
luciferase assay On the other hand, bfl-1 mRNA levels were monitored in the study 
carried out Cahir-McFahrland et al (2000) It has been demonstrated that although the 
transcription rates and mRNA abundance of most genes change with the same direction, 
they usually have different ranges m variation (Shu and Hong-Hui, 2004) bfl-1 has 
been classified as an immediate-early response gene (Karsan et a l , 1996a, Lin et a l , 
1996, Moreb and Schweber, 1997), many of which are thought to be regulated at the 
level of mRNA. It has previously been shown m our laboratory that induction of LMP1 
expression m the cell line DG75-tTA-LMPl (Floettmann et a l , 1996) results in a 
significant increase in the stability of bfl-1 mRNA (D’ Souza et a l , 2000) Expression 
of an IicBa super-repressor/mutant inhibits LMP1-mediated signalling, and as a result, 
could possibly reduce the ability o f LMP1 to increase bfl-1 mRNA stability This could 
explain the 50 % decrease in bfl-1 mRNA observed by Northern blot analysis following 
induction of the IxBa mutant (Cahir-McFahrland et a l , 2000), but would not affect the 
level o f transcription initiated from the bfl-1 promoter, observed during the current 
study
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EBNA2-mediated trans-activation o f the control reporter construct pGa981-6, the viral 
LMPl promoter and the cellular bfl-1 promoter was seen to be significantly inhibited in 
DG75 cells, upon co-expression of an RBP-Jk/CBF1 mutant or an EBNA2 mutant with 
a deletion in the trans-activation domain [EBNA2 Mut (437-477)] By contrast, 
expression o f either of these mutants was not found to affect the level o f bfl-1 promoter 
activity as efficiently in the EBV-mfected cell lines Ag876 or IB4 Although both 
mutants were found to inhibit EBNA2-mediated trans-activation o f the control reporter 
pGa981-6 in the EBV-infected cells, the maximum inhibition observed, by either of 
these mutants, was 30 % It has been established that the LMP1 promoter is EBNA2- 
responsive (Abbot et a l , 1990, Fahraeus et a l , 1990, Laux et a l , 1994a, Wang et a l , 
1990), and it was demonstrated m Chapter 3 that both the dominant-negative RBP- 
Jk/CBFI mutant and EBNA2 Mut (437-477) blocked EBNA2-mediated trans-activation 
of the LMP1 promoter in DG75 cells If EBNA2-mediated activation o f LMP1 
expression were to be inhibited by these mutants m the context of the EBV-mfected cell 
lines, it is likely that there would be a decrease in the level of activated NF-kB as a 
result This would, however, be indirect and take longer to take effect, unlike when 
IkBoDN is expressed and can sequester NF-kB subunits directly m the cytoplasm Both 
the RBP-Jic/CBFl and EBNA2 mutants were indeed seen to affect the level of NF-kB 
activity, albeit to a small degree The degree of inhibition in activated NF-kB levels 
generally mirrored that observed during RBP-Jk/CBF1- or EBNA2-mutant-mediated 
inhibition of bfl-1 promoter activity Therefore, it is difficult to conclude whether the 
slight inhibition in bfl-1 promoter activity as a result of co-expression with the RBP- 
Jk/CBFI or EBNA2 mutants, is due to (1) inhibition of EBNA2-mediated activation of 
bfl-1, (11) inhibition of EBNA2-mediated trans-activation o f the LMP1 promoter, and as 
a result lower levels of LMPl in the cells, leading to a decrease in bfl-1 promoter 
activity or (111) a combination of these two factors
Because blocking either LMPl by over-expression of an iKBa super-repressor, or 
blocking EBNA2 by over-expression of either an RBP-Jk/CBF1 mutant or an EBNA2 
Mut (437-477), did not result in a significant decrease m bfl-1 promoter activity, it was 
subsequently tested whether blocking both LMPl- and EBNA2-mediated trans- 
activation simultaneously would affect the level o f bfl-1 promoter activity in the EBV- 
mfected cell lines Ag876 and IB4 To this end, co-transfections were earned out using 
the IkB<x super-repressor together with either the RBP-Jk/CBF1 mutant or EBNA2 Mut 
(437-477) Co-expression of the IicBa super-repressor with either the RBP-Jk/CBF1 or
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EBNA2 mutant resulted in between 40 % to 60 % inhibition in bfl-1 promoter activity 
in both cell lines, suggesting that blocking both LMP1- and EBNA2-mediated 
activation significantly affects the level of bfl-1 promoter activity This implies that 
both these EBV latent proteins play a role in maintaining the level of bfl-1 promoter 
activity m the context of the EB V-mfected B lymphocyte
In a second attempt to block both LMP1- and EBNA2-mediated trans-act 1 vat ion of the 
bfl-1 promoter, co-transfections were earned out using either the RBP-Jk/CBF1 or 
EBNA2 mutant along with a bfl-1 promoter reporter construct containing a mutation in 
the NF-icB-like binding site at position -52 to -43 relative to the transcnption start site of 
the bfl-1 gene The mutation in this NF-xB-hke binding site has been found to almost 
completely abolish LMP1-responsiveness on the bfl-1 promoter in the EBV-negative 
BL-denved cell line DG75 (D’Souza et a l , 2004) By contrast, tranfection o f this bfl-1 
promoter reporter construct containing the -52 to -43 deletion was not found to affect 
the level of bfl-1 promoter activity in Ag876 or IB4 cells, strengthening the observation 
that blocking LMP1-mediated signalling does no affect the level of bfl-1 promoter 
activity in Ag876 or IB4 cells However, by blocking LMP1-mediated bfl-1 promoter 
activity by mutating the NF-icB-like binding site, and blocking EBNA2-mediated 
promoter activity by co-expression with either the RBP-Jk/CBFI or EBNA2 mutants, 
the level of promoter activity was reduced by approximately 50 % The level of  
inhibition was similar to that observed after blocking both LMP1 and EBNA2 signalling 
by co-expression of the IicBa super-repressor along with the RBP-Jk/CBFI or EBNA2 
mutants The observation that blocking both LMP1- and EBNA2-mediated trans- 
activation o f the bfl-1 promoter at the same time results in approximately 50 % decrease 
in promoter activity was reinforced dunng transfection expenments using the IicBa 
super-repressor and a bfl-1 promoter reporter construct containing a mutation in putative 
RBP-Jk/CBFI binding site at position -343 to -249 relative to the transcnption start site 
of the bfl-1 gene Mutation of this putative RBP-Jk/CBFI binding site has been shown 
to significantly inhibit EBNA2-mediated trans-activation of the bfl-1 promoter in DG75 
cells (Pegman et a l , submitted December, 2004) It was observed m the current study 
that the presence o f this mutation did not affect the level o f bfl-1 promoter activity in 
the EBV-infected cell lines Ag876 and IB4 However, upon co-transfection of the 
RBP-Jk/CBFI mutated promoter reporter construct together with the IicBa super- 
repressor, an approximate 50 % decrease in bfl-1 promoter activity was observed This 
novel finding implies a role for the putative RBP-Jk/CBFI binding site m the trans-
<
186
activation of the bfl-1 promoter in the context of EBV-infected cell Although blocking 
both EBNA2- and LMP1-mediated trans-activation results in a significant decrease in 
bfl-1 promoter activity, inhibition was not found to be as efficient as that observed by 
blocking either pathway m the EBV-negative B cell line DG75 It is possible that the 
bfl-1 promoter is responsive to other, as yet unidentified, factors present in these cell 
contexts
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Chapter 5
Regulation of the Anti-Apoptotic Cellular bfl-1 
Gene in Conditional Lymphoblastoid Cell Lines
5.1 INTRODUCTION
The EBV-mfected cell lines (Ag876 and IB4) used up to this point express LMP1 and 
EBNA2 simultaneously, and LMP1 expression is induced by EBNA2 In order to 
uncouple the roles o f LMP1 and EBNA2 in the regulation of the bfl-1 gene, a series of  
cell lines were used in which EBNA2 could be expressed conditionally Fusion of a 
given protein with the hormone-binding domain of a steroid receptor can render its 
function dependent on the presence of hormone (Picard et a l , 1988, Ellers et a l , 1989) 
Kempkes et al (1995b) exploited this approach to develop a conditional system m 
which the function of EBNA2 could be switched on and off Firstly, they generated a 
chimenc protein, m which the N-terminus of EBNA2 was fused with the hormone- 
binding domain of the estrogen receptor Conditional function of this construct in the 
presence or absence of hormone was verified by testing the trans-activation o f the IMP  
genes, which are known target genes for transcriptional activation by EBNA2 (Abbot et 
a l , 1990, Fahraeus et a l , 1990, Wang et a l , 1990, Zimber-Strobl et a l , 1991, Laux et 
a l , 1994a) Both the trans-activation o f these genes by estrogen responsive (ER)- 
EBNA2 and interaction between the chimenc EBNA2 and RBP-Jk/CBF1, were found 
to be dependent on the presence of estrogen (Kempkes et a l , 1995a)
Kempkes et al (1995b) subsequently cloned the gene encoding the conditional EBNA2 
into a mim-EBV vector carrying all the c/s-acting elements, which are essential for 
propagation of the plasmid m all phases o f the EB V life cycle The mim-EBV plasmid 
(Figure 5 1A) cames the ongin o f replication (onP), which is required for the 
maintenance of the EBV plasmid m target cells, the lytic ongin of replication (onLyt), 
which allows high copy number amplification upon induction of the lytic cycle, and the 
terminal repeats (TR), which permit packaging of the mim-EBV into vinons The non­
transforming P3HR1 strain of EBV (Figure 5 IB), in which the EBNA2 open reading 
frame has been deleted served as a helper virus for amplification and packaging of these 
mini-EBV plasmids P3HR1 cells were transfected with the mim-EBV plasmid 
expressing the chimenc EBNA2 and simultaneously induced for lytic cycle replication 
(Kempkes et a l , 1995b) Supematents of transfected cells containing the mim-EBV 
plasmid, together with the P3HR1 helper virus, were harvested and used to co-infect 
pnmary B-cells, which were cultivated m the presence o f estrogen (Kempkes et a l , 
1995b) The resulting LCL, designated EREB 2 5, contained mim-EBV plasmid 
expressing the chimenc EBNA2 protein as an autonomously replicating plasmid, plus
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the P3HR1 viral genome, thus complementing the EBNA2 deletion o f the P3HR1 virus 
(Kempkes et a l., 1995b). Therefore, in the presence o f estrogen, functional EBNA2 
trans-activates the P3HR1 viral promoters o f the three latent membrane proteins 
(LMP1, LMP2A and LMP2B) and the Cp promoter, which regulates the expression of 
the EBV nuclear antigens. In the absence o f estrogen EBNA2 is non-functional and is 
unable to trans-activate P3HR1 virus genes. Therefore LMP1 expression is dependent 
on the presence o f functional EBNA2 (i.e. the presence of estrogen in the culture 
medium).
A B
Figure 5.1: Strategy for expression of conditional EBNA2 mutants in EREB 2.5 cells. (A) Mini-EBV 
plasmids are composed of c/s-acting elements, which are essential for the propagation of these plasmids 
in all phases of the EBV life cycle. They carry the oriP necessary for the maintenance of the EBV 
plasmids in target cells, the oriLyt, which allows high copy number amplification upon induction of lytic 
replication of the virus, and the TRs, which allow packaging of the mini-EBV plasmids into virions. The 
hormone-binding domain of the estrogen receptor (white boxes) is fused to the N-terminus of the wild 
type EBNA2 ORF (black boxes) yielding ER-EBNA2. The EBNA2 expression cassettes are flanked by 
EBNA2 sequences, the BamHl restriction fragments C, W, Y, and H of the EBV genome, which represent 
in part the genomic organisation of the EBV DNA and encompass the deletion present in the non­
transforming P3HR1 EBV strain (AP3HR1 open bar in B). EBNA2 and ER-EBNA2 can be transcribed 
from two alternative promoters situated in the C or W fragments. (B) The EBV map shows the position 
of EBNAs and LMPs transcribed and the location of their promoters relative to the BamYtt restriction 
map of EBV strain B95.8 (adapted from Kempkes et al., 1995b).
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5.2 RESULTS
To uncouple the roles o f EBNA2 and LMP1 with regard to the regulation o f  bfl-1 
mRNA levels in the context o f an EBV-infected cell, experiments using a panel o f  
EREB 2.5 cell derivatives were performed. Zimber-Strobl et al. (1996) established a 
system in which LMP1 is expressed constitutively from a stably transfected vector in 
EREB 2.5 cells. This group cloned the LMP1 gene, expressed from the SV40 early 
promoter/enhancer, onto an episomal oriP vector encoding the gene for hygromycin 
phosphotransferase (Sugden et a l 1985). This construct, termed p581, was then 
introduced into EREB 2.5 cells, resulting in the establishment o f two stably transfected 
cell lines, namely EREB 2.5 SV LMP clone 2C and EREB 2.5 SV LMP clone 11C 
(Zimber-Strobl et a l., 1996). As negative controls, a p581-based plasmid with a 
truncated non-functional LMP1 gene or the parental oriP vector (pHEBo) were 
introduced into EREB 2.5 cells, generating the cell lines EREB 2.5 SV LMP Mut 2 and 
EREB 2.5 pHEBo. These EREB 2.5 stable transfectants allow dissection o f the role o f 
LMP1 in the regulation o f the bfl-1 gene in the absence o f EBNA2. The LMP1 and 
EBNA2 expression profile o f these cells lines grown in the presence or absence o f 
estrogen is summarised in Table 5.1.
5.2.1 Regulation of bfl-1 mRNA levels in EREB 2.5 stable transfectants
Table 5.1: EBNA2 & LMP1 expression profile o f EREB 2.5 cell stable transfectants
Cell line + Estrogen - Estrogen
pHEBo EBNA2&LMP1 no EBNA2, no LMP1
SV LMP clone 2C EBNA2 & LMP1 no EBNA2, plasmid LMP1
SV LMP clone 11C EBNA2 & LMP1 no EBNA2, plasmid LMP1
SV LMP Mut 2 EBNA2&LMP1 no EBNA2, LMP1 mutant
In order to monitor bfl-1 mRNA levels in the presence o f EBNA2 and/or LMP1 a series 
o f time courses were performed with the various EREB 2.5 cell line derivatives, 
cultivated in the presence or absence o f estrogen. All cell lines were washed four times 
in PBS, followed by another two washes 24 hours later. At this point each cell line was
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divided, with one half seeded into medium supplemented with 1 jiM estrogen and the 
other half seeded into medium without estrogen Protein and RNA extracts were 
prepared at various time points over a 96-hour penod The level of EBNA2 and LMP1 
protein expressed during the time-course was analysed by western blot, and bfl-l 
mRNA levels were assayed by reverse transcription followed by real-time PCR
5.2.1.1 Regulation of bfl-l mRNA levels in EREB 2.5 pHEBo cells
Western blot analysis on samples isolated dunng the time course using EREB 2 5 
pHEBo cells is shown in Figure 5 2A EREB 2 5 pHEBo cells grown in the presence of  
estrogen expressed chimeric EBNA2 with an apparent molecular weight of 120 kDa (in 
contrast to 86 kDa, which is the molecular weight of wild type EBNA2) An increase in 
EBNA2 expression was observed over time This result is compatible with a functional 
role for EBNA2 in positive regulation of its own promoter (Sung e t a l , 1991, Rooney et 
a l , 1992) It was noted that LMP1 expression also increased over time, indicating that 
the LMP1 gene is under strict control o f functional EBNA2 In the absence of estrogen, 
only non-functional EBNA2 was detected and LMP1 levels were seen to deteriorate 
over time, reinforcing the idea that functional EBNA2 regulates LMP1 expression 
Removal o f estrogen also affected the electrophoretic mobility of the ER-EBNA2 fusion 
protein Chimeric EBNA2 was seen to migrate more rapidly and homogeneously in the 
absence of hormone, indicating that switching ER-EBNA2 function on and off is 
associated with post-translational modification or profound changes in the tertiary 
structure of ER-EBNA2 Furthermore, the amount of ER-EBNA2 fusion protein 
appeared to decrease in the absence o f hormone, indicating once again that functional 
EBNA2 positively regulates its own promoter
Initially RNA isolated dunng all the time-courses performed was analysed by agarose 
gel electrophoresis Analysis o f the RNA extracted from EREB 2 5 pHEBo cells is 
shown in Figure 5 2B The presence of two strongly stained bands represent the 28 S 
and 18 S nbosomal RNAs, which indicated intact RNA
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Figure 5.2: Protein and RNA analysis on samples isolated during the time-coursc using EREB 2.5 
pHEBo cells. EREB 2.5 pHEBo cells were washed 4 times in PBS, followed by another 2 washes 24 
hours later. Cells were re-seeded into medium with or without estrogen (est) and/or cyclohexamide (chx). 
Protein and RNA were isolated at various time-points over a 96-hour period. Protein samples were 
analysed for EBNA2 or LMP1 expression (A). Isolated RNA stained with ethidium bromide was 
analysed by agarose gel electrophoresis (B). The presence of two strongly stained bands represent the 28 
S and 18 S ribosomal RNAs, which indicated intact RNA.
Once it was established that the RNA was of good integrity, reverse transcription (RT) 
reactions were carried out to generate cDNA, which was subsequently used in a real-
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time PCR assay to determine the level o f bfl-1 mRNA present. mRNA levels o f the 
house keeping gene gapdh were also monitored, and the resulting data obtained was 
used to normalise data acquired for bfl-1. Following real-time PCR assays, PCR 
products were analysed by agarose gel electrophoresis to determine whether the PCR 
products migrated at the expected size. The real-time PCR products generated from 
samples acquired during the time-course using EREB 2.5 pHEBo cells cultivated in the 
presence o f estrogen are shown in Figure 5.3. The PCR products for bfl-1 and gapdh 
migrated at the expected band sizes o f 150 bp and 168 bp respectively, and only one 
PCR product was found in each reaction, indicating the specificity o f the PCR assay.
Figure 5.3: PCR products amplified from cDNA generated from the RNA isolated from EREB 2.5 
pHEBo cells. cDNA was generated from RNA isolated from EREB 2.5 pHEBo cells by reverse 
transcription PCR. The cDNA was then used as template for real time PCR to quantitate the amount of 
bfl-1 and gapdh present. Figure 2 shows real-time PCR products amplified from cDNA generated from 
EREB 2.5 pHEBo cells grown in the presence of estrogen over a time-course (0 - 96 hours). PCR 
products for bfl-1 and gapdh migrated at the expected band sizes of 150 bp and 168 bp respectively.
Figure 5.4 shows the differences in bfl-1 mRNA levels over time in the EREB 2.5 
pHEBo cells. A dramatic increase in bfl-1 levels (approximately 4-fold) was observed 6 
hours following the addition o f estrogen to the culture medium. Both functional 
EBNA2 and LMP1 were expressed at high levels at this time point (Figure 5.2 A). The 
amount o f bfl-1 decreased gradually over time, with the level o f bfl-1 mRNA at 96 
hours similar to that observed at time 0. bfl-1 mRNA levels were seen to decrease 
significantly over time in EREB 2.5 pHEBo cells grown in the absence of estrogen. 
This correlated with a decrease in the expression o f functional EBNA2 and LMP1.
194
These results indicated that turning on functional EBNA2, and therefore LMP1, by 
addition of estrogen, led to a transient increase in the level of bfl-1 mRNA in the LCL 
EREB 2 5 pHEBo
In order to determine whether up-regulation of bfl-1 mRNA was a direct effect of 
functional EBNA2, EREB 2 5 pHEBo cells were cultivated in medium containing 
50 pg/ml cyclohexamide (chx), which is a well-known protein synthesis inhibitor It 
should be noted that some chimenc EBNA2 is already present in the cells and estrogen 
simply activates its function, thus the expression of existing ER-EBNA2 is not inhibited 
by cyclohexamide However, because EBNA2 positively regulates it’s own promoter, a 
lot more functional EBNA2 is expressed in the absence o f cyclohexamide Translation 
of genes trans-activated by functional EBNA2 (i e IM P  and Cp genes) is significantly 
inhibited by the presence of cyclohexamide m the culture medium
Cells cultivated in the presence of cyclohexamide were harvested after 6 hours in order 
to prepare protein and RNA extracts The level of bfl-1 mRNA prepared from cells 
grown in the presence of both estrogen and cyclohexamide for 6 hours was compared 
with that of cells grown m estrogen only for the same period of time It was observed 
that the level o f bfl-l mRNA in cells cultivated in the presence of estrogen and 
cyclohexamide was 1 5 fold lower than that of cells grown m estrogen only after 6 
hours in culture (Figure 5 4) This was not due to instability o f the bfl-1 mRNA, as 
there was no difference between the levels of bfl-1 observed in cells grown m the 
absence of estrogen and cells grown in the absence of estrogen plus cyclohexamide after 
6 hours One possible reason for the decrease in the level o f bfl-1 mRNA in cells grown 
in the presence of both estrogen and cyclohexamide may lie in the fact that less EBNA2 
is expressed in the presence of cyclohexamide (Figure 5 2A) As cyclohexamide is a 
protein synthesis inhibitor, it would inhibit EBNA2 expression resulting from functional 
EBNA2 positively regulating it’s own promoter There was also a notable decrease in 
the level o f LMP1 expression in cells grown in cyclohexamide, relative to cells grown 
in the absence of cyclohexamide harvested at the same time-point (Figure 5 2A), 
suggesting that LMP1 plays a possible role in up-regulating bfl-1 Furthermore, the fact 
that bfl-1 levels in the presence o f estrogen and cyclohexamide is greater than the level 
of bfl-1 at time 0 implies a direct role for EBNA2 m the up-regulation o f bfl-1
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Quantitation of bfl-1 in EREB 2.5 pHEBo Cells
0 6 12 24 % 6 (♦chx)
Tim* (Hours)
Figure 5.4: bfl-1 mRNA quantitation in EREB 2.5 pHEBo cells. EREB 2.5 pHEBo ceils were washed 
4 times with PBS, followed by another 2 washes 24 hours later. Cells were re-seeded into medium with 
or without estrogen, and in some cases in the presence of cyclohexamide (chx). RNA was isolated at 
intervals over a period of time (0 - 96 hours) and quantitated by reverse transcription followed by real­
time PCR. The level of bfl-1 mRNA was assayed in triplicate and normalised by gapdh level. Fold 
differences were calculated relative to bfl-1 levels at time zero.
These data indicated that turning on functional EBNA2, and as a result LMP1, leads to a 
transient increase in the level o f  bfl-1 m RNA in EREB 2.5 pHEBo cells. Inhibition o f  
protein synthesis, including that o f  LMP1 causes a decrease in the level o f  bfl-1 m RNA  
relative to cells in which protein synthesis has not been blocked. In cells where LMP1 
translation is inhibited, however, an increase in the level o f  bfl-1 is observed after 6 
hours, implying a direct role for EBNA2 in the up-regulation o f  bfl-1 in this cell 
context.
5.2.1.2 Regulation of bfl-1 mRNA levels in EREB 2.5 SV LMP clone 11C cells
Protein expression and bfl-1 m RNA levels observed during the time-course performed 
using EREB 2.5 SV LMP clone 11C cells is shown in Figure 5.5. Western blot analysis 
for EBNA2 and LMP1 may be seen in Figure 5.5A. Similarly to EREB 2.5 pHEBo 
cells grown in the presence o f  estrogen, an increase in chimeric EBNA 2 expression was 
observed over the 96-hour time-course. When estrogen was withdrawn from the culture
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medium, only non-functional EBNA2 was detected. As for EREB 2.5 pHEBo cells, it 
was observed that ER-EBNA2 migrated more rapidly and homogenously in the absence 
o f hormone. In contrast to the EREB 2.5 pHEBo cell line, cells transfected with the 
p581 vector expressing the wild type LMP1 gene expressed from the SV40 
promoter/enhancer, revealed a level o f  LMP1 that was not down-regulated after 
estrogen withdrawal. The LMP1 levels were comparable or even slightly higher than in 
EREB 2.5 pHEBo cells in the presence o f estrogen, which is not unexpected because in 
the transfectants there is probably expression o f LMP1 both from the resident viral 
genome and from the introduced vector.
Figure 5.5B shows the differences in bfl-1 mRNA levels over time in the EREB 2.5 SV 
LMP clone 11C cells. A dramatic increase in bfl-1 levels was observed 6 hours after 
addition o f estrogen to the culture medium. A further increase in the level o f bfl-1 
mRNA was observed at the 12-hour time point. Both functional EBNA2 and LMP1 
were expressed at high levels at these time points (Figure 5.5A). The amount o f bfl-1 
decreased gradually over time, with the level o f bfl-1 mRNA at 96 hours slightly higher 
than that observed at time 0. In the absence o f estrogen, the level o f  bfl-1 mRNA was 
maintained at a level higher than that recorded at time 0, with a 2.5-fold increase in the 
level o f bfl-1 after 96 hours in culture. In the absence o f estrogen only non-functional 
chimeric EBNA2 was expressed, but LMP1 was expressed from the p581 vector (Figure 
5.5A). The observation that bfl-1 levels are maintained in the absence o f estrogen 
contrasts with the levels o f bfl-1 mRNA recorded using the EREB 2.5 pHEBo cell line, 
which has been transfected with the empty exression vector for LMP1. When these 
cells were grown in the absence o f estrogen, the level o f bfl-1 mRNA decreased over 
time (Figure 5.4). These results demonstrate that LMP1 is capable o f maintaining 
elevated bfl-1 mRNA levels in the absence o f functional EBNA2 in the LCL EREB 2.5 
SV LMP clone 11C.
EREB 2.5 SV LMP clone 11C cells cultivated in cyclohexamide were again used to 
determine whether up-regulation o f bfl-1 mRNA was a direct effect o f functional 
EBNA2. The level o f bfl-1 mRNA prepared from cells grown in the presence o f both 
estrogen and cyclohexamide for 6 hours was compared with that o f cells grown in 
estrogen only for the same period o f time. It was observed that the level o f bfl-1 mRNA 
in cells cultivated in the presence o f estrogen and cyclohexamide was lower than that o f 
cells grown in estrogen only after 6 hours in culture (Figure 5.5B). No difference in the
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level o f bfl-l was observed between cells grown in the absence of estrogen at 6 hours 
and cells grown in the absence of estrogen and cyclohexamide, indicating that bfl-l 
mRNA remains stable for this period o f time The level o f LMP1 expression was seen 
to decrease in cells grown m cyclohexamide, relative to cells grown in the absence of 
cyclohexamide harvested at the same time-point (Figure 5 5 A), suggesting that LMP1 
plays a possible role in up-regulating bfl-l in this cell context The level of bfl-l mRNA 
at time 0 was lower than that of cells grown in the presence of estrogen and 
cyclohexamide Although the level of LMP1 was observed to decrease in the presence 
of the translation inhibitor, some LMP1 was still detectable As a result, it is difficult to 
conclude whether EBNA2 plays a direct role in bfl-l up-regulation in this case
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Figure 5.5: Protein expression and bfl-1 quantitation in EREB 2.5 SV LMP clone 11C cells. EREB
2.5 SV LMP clone 11C cells were washed 4 times in PBS, followed by another 2 washes 24 hours later. 
Cells were re-seeded into medium with or without estrogen. Protein and RNA were isolated at various 
time-points over a 96-hour period. Protein samples were analysed for EBNA2 or LMP1 expression (A). 
The amount of bfl-1 mRNA present in the cells at individual time-points over the 96-hour period was 
quantitated by reverse transcription followed by real time PCR. bfl-1 levels were assayed in triplicate and 
normalised by gapdh levels (B). Fold differences were calculated relative to bfl-1 levels at time zero.
Taken together, these results indicated once again that turning on functional EBNA2, 
and as a result LMP1, leads to a transient increase in bfl-1 mRNA in the cell line EREB
2.5 SV LMP clone 11C. Inhibition o f protein translation, resulting in a lower level o f 
LMP1 expression, causes a decrease in the level o f bfl-1 mRNA relative to cells in
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which protein translation has not been blocked Importantly, it was also observed that 
LMP1 is capable of maintaining elevated A/7-7 mRNA levels in the absence o f  
functional EBNA2 in this cell context
5.2.1.3 Regulation of bfl-1 mRNA levels m EREB 2.5 SV LMP clone 2C cells
i
The data obtained from the time-course earned out using EREB 2 5 SV LMP clone 2C 
cells is shown in Figure 5 6 Western blot analysis for EBNA2 and LMP1 may be seen 
in Figure 5 6A As was the case for the other EREB 2 5 transfectants, chimenc EBNA2 
and LMP1 expression increased over time m cells grown in the presence of estrogen, 
strengthening the observation that turning on functional EBNA2 positively regulates it’s 
own expression, as well as that of LMP1 When estrogen was withdrawn from the 
culture medium, only non-functional EBNA2 was detected LMP1 levels were seen to 
detenorate by 12 hours post-withdrawal of estrogen from the culture medium This 
result was unexpected, as this cell line (similarly to EREB 2 5 SV LMP clone 11C) has 
been transfected with the p581 vector that expresses wild type LMP1 from the SV40 
promoter/enhancer and should, therefore, express LMP1 from the plasmid, independent 
of EBNA2 It is possible that this cell line has lost the LMP1 expression vector
Figure 5 6B shows the differences in bfl-1 mRNA levels over time in the EREB 2 5 SV 
LMP clone 2C cell line An increase in bfl-1 levels was observed 6 hours after addition 
of estrogen to the culture medium, which was increased further after 12 hours The 
increase in bfl-1 mRNA coincided with an increase in the expression o f functional 
EBNA2 and LMDP1 (Figure 5 6A) The amount of bfl-1 decreased gradually over time, 
with the level o f bfl-1 mRNA at 96 hours slightly lower than that observed at time 0 
bfl-1 mRNA levels were seen to decrease over time in cells grown in the absence of 
estrogen This correlated with a decrease in the expression of functional EBNA2 and 
LMP1 These results indicated for the second time that turning on functional EBNA2, 
and therefore LMP1, up-regulates the level o f bfl-1 mRNA in an LCL
In order to determine whether up-regulation of bfl-1 mRNA was a direct effect of 
functional EBNA2, EREB 2 5 SV LMP clone 2C cells were cultivated m medium 
containing cyclohexamide The level of bfl-1 mRNA prepared from cells grown in the 
presence o f both estrogen and cyclohexamide for 6 hours was compared with that of
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cells grown in estrogen only for the same period of time It was observed that the level 
of bfl-1 mRNA in cells cultivated in the presence of estrogen and cyclohexamide was 
slightly lower than that of cells grown in estrogen only after 6 hours m culture (Figure 
5 6B) The level o f LMP1 expression also decreased significantly m cells grown in 
cyclohexamide, relative to cells grown in the absence o f cyclohexamide harvested at the 
same time-point (Figure 5 6A) It is possible that the decrease in the level of bfl-1 
mRNA is due to mhibiton of LMP1 expression by cyclohexamide, implying a role for 
LMP1 m up-regulation of bfl-1 The fact that level of bfl-1 mRNA in the presence of 
estrogen and cyclohexamide is greater than at time 0 indicates a direct role for EBNA2 
in the up-regulation of bfl-1
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Figure 5.6: Protein expression and bfl-1 quantitation in EREB 2.5 SV LMP clone 2C cells. EREB 
2.5 SV LMP clone 2C cells were washed 4 times in PBS, followed by another 2 washes 24 hours later. 
Cells were re-seeded into medium with or without estrogen. Protein and RNA extracts were prepared at 
various time-points over a 96-hour period. Protein samples were analysed for the expression of EBNA2 
or LMP1 (A). The amount of bfl-1 mRNA present in the EREB 2.5 SV LMP clone 2C cells at individual 
time-points over the 96-hour period was quantitated by reverse transcription followed by real time PCR. 
bfl-1 levels were assayed in triplicate and normalised by gapdh levels (B). Fold differences were 
calculated relative to bfl-1 levels at time zero.
These results indicated that turning on functional EBNA2, and as a result LMP1, results 
in a transient increase in bfl-1 mRNA in EREB 2.5 SV LMP clone 2C cells. Inhibition 
of protein translation causes a decrease in the level o f  bfl-1 mRNA relative to cells in
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which protein translation has not been blocked In cells where protein translation has 
been inhibited, however, an increase m the level of bfl-1 is observed after 6 hours, 
implying a direct role for EBNA2 m the up-regulation of bfl-1 m this cell context
5.2.1.4 Regulation of bfl-1 mRNA levels m EREB 2.5 SV LMP Mut 2 cells
The data obtained from the time-course earned out using the EREB 2 5 SV LMP Mut 2 
cell line is shown m Figure 5 7 Expression of both ER-EBNA2 and LMP1 was seen to 
increase over the 96-hour time-course when the cells were grown in the presence of  
estrogen (Figure 5 7A) In the absence o f estrogen only non-functional EBNA2 was 
detected In contrast with the EREB 2 5 SV LMP clone 11C cells, LMP1 levels were 
seen to detenorate over time in the EREB 2 5 SV LMP Mut 2 cells grown without 
estrogen These cells have been transfected with a vector expressing a non-functional 
truncated LMP1, which is undetectable with the LMP1 antibody (CS1-4)
Figure 5 7B shows the differences in bfl-1 mRNA levels over time in the EREB 2 5 SV 
LMP Mut 2 cells An increase in bfl-1 levels was observed 6 hours after addition of 
estrogen to the culture medium, which was increased further after 12 hours The 
increase in bfl-1 mRNA coincided with an increase in the expression of functional 
EBNA2 and LMP1 (Figure 5 7A) The amount of bfl-1 decreased gradually over time, 
with the level of bfl-1 mRNA at 96 hours slightly higher than that observed at time 0 
bfl-1 mRNA levels were seen to decrease over time in cells grown in the absence of  
estrogen This correlated with a decrease in the expression of functional EBNA2 and 
LMP1 Only non-functional truncated LMP1 is expressed from the SV40 promoter 
enhancer
EREB 2 5 SV LMP Mut 2 cells were cultivated in cyclohexamide to determine whether 
up-regulation o f bfl-1 mRNA was a direct effect of functional EBNA2 The level of bfl- 
1 mRNA prepared from cells grown m the presence of both estrogen and 
cyclohexamide for 6 hours was compared with that of cells grown in estrogen only for 
the same penod o f time It was observed that the level o f bfl-1 mRNA in cells 
cultivated m the presence o f estrogen and cyclohexamde was slightly higher than that of 
cells grown in estrogen only after 6 hours in culture (Figure 5 7B) Western blot 
analysis of cells grown in cyclohexamide and estrogen revealed a decrease in LMP1
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expression after 6 hours (Figure 5.7A). These results indicate a direct role for EBNA2 
in the up-regulation o f bfl-1.
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Figure 5.7: Protein expression and bfl-1 quantitation in EREB 2.5 SV LMP Mut2 cells. EREB 2.5 
SV LMP Mut2 cells were washed 4 times in PBS, followed by another 2 washes 24 hours later. Cells 
were re-seeded into medium with or without estrogen. Protein and RNA were isolated at various time- 
points over a 96-hour period. Protein samples were analysed for EBNA2 or LMP1 expression (A). The 
amount of bfl-1 mRNA present in the EREB 2.5 SV LMP Mut2 cells at individual time-points over the 
96-hour period was quantitated by reverse transcription followed by real time PCR. bfl-1 levels were 
assayed in triplicate and normalised by gapdh levels (B). Fold differences were calculated relative to bfl- 
1 levels at time zero.
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These data indicated once again that turning on functional EBNA2, and therefore 
LMP1, leads to a transient up-regulation in the level bfl-1 mRNA in EREB 2.5 SV LMP 
Mut 2 cells. Inhibition o f protein translation, including that o f LMP 1 causes a decrease 
in the level o f bfl-1 mRNA relative to cells in which protein translation has not been 
blocked. In cells where LMP1 translation has been inhibited, however, an increase in 
the level o f bfl-1 is observed after 6 hours, implying a direct role for EBNA2 in the up- 
regulation o f bfl-1. In contrast to EREB 2.5 SV LMP clone 11C cells, the non­
functional truncated LMP1 is unable to maintain the level o f bfl-1 mRNA in the absence 
o f functional EBNA2.
5.2.1.5 Regulation of bfl-1 mRNA levels in EREB 2.5 Tet LMP clone 3A cells
An additional cell line, in which LMP1 expression could be inducibly regulated, was 
generated by Zimber-Strobl et al., namely EREB 2.5 Tet LMP clone 3 A (unpublished). 
This cell was established by transfection o f EREB 2.5 cells with a tetracycline 
regulatable LMP1 construct. LMP1 expression is off in the presence o f 1 jig/ml 
tetracyline, and can be switched on by removal o f tetracycline from the culture medium. 
This cell line allows further dissection o f the role o f  LMP1 in the regulation bfl-1 
mRNA levels, in the absence o f EBNA2. The LMP1 and EBNA2 expression profile o f 
this cell line, grown in the presence and absence o f estrogen and/or tetracycline is 
summarised in Table 5.2.
Table 5.2: EBNA2 and LMP1 expression profile o f EREB 2.5 Tet LMP clone 3 A 
Cell line + Estrogen - Estrogen
+ Tetracycline - Tetracycline + Tetracycline - Tetracycline
Tet LMP EBNA2 & LMP1 EBNA2 & LMP1 no EBNA2 no EBNA2,
clone 3A no LMP1 plasmid LMP1
Protein expression and bfl-1 mRNA levels observed during the time-course performed 
using EREB 2.5 Tet LMP clone 3 A cells grown in the presence o f tetracycline is shown 
in Figure 5.8. LMP1 expression from the transfected expression vector is off in the 
presence o f tetracycline. Western blot analysis for EBNA2 and LMP1 is shown in 
Figure 5.8A. As for the other EREB 2.5 cell derivatives, chimeric EBNA2 and LMP1
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expression increased over time in cells grown in the presence of estrogen In the 
absence of estrogen only non-functional ER-EBNA2 was detected, and as a result no 
LMP1 was expressed from the viral genome (Figure 5 8A) Because tetracycline was 
present in the medium no LMP1 was expressed from the transfected plasmid either
Figure 5 8B shows the differences in bfl-l mRNA levels over time in the EREB 2 5 Tet 
LMP clone 3 A cells grown in the presence of tetracycline A dramatic increase in bfl-l 
levels was observed 6 hours after addition of estrogen to the culture medium A further 
increase in the level o f bfl-1 mRNA was observed at the 12-hour time point Both 
functional EBNA2 and LMP1 were expressed at high levels at these time points (Figure 
5 8A) The amount o f bfl-1 decreased gradually over time, with the level of bfl-1 
mRNA at 96 hours still higher than that observed at time 0 In the absence of estrogen, 
the level of bfl-1 mRNA decreased over time
EREB 2 5 Tet LMP clone 3A cells cultivated in cyclohexamide were used to determine 
whether up-regulation o f bfl-1 mRNA was a direct effect of functional EBNA2 The 
level of bfl-1 mRNA prepared from cells grown in the presence of both estrogen and 
cyclohexamide for 6 hours was compared with that of cells grown m estrogen only for 
the same period o f time It was observed that the level of bfl-1 mRNA in cells 
cultivated in the presence o f estrogen and cyclohexamide was lower than that of cells 
grown in estrogen only after 6 hours in culture (Figure 5 8B) One possible reason for 
this decrease could be due to the fact that less EBNA2 is expressed m the presence of 
cyclohexamide, which would block EBNA2 expression resulting from EBNA2 
positively regulating it’s own promoter The level of LMP 1 expression also decreased 
significantly m cells grown in cyclohexamide (Figure 5 8A), relative to cells grown in 
the absence of cyclohexamide harvested at the same time-pomt, suggesting that LMP1 
plays a possible role m up-regulating bfl-1 The level o f bfl-1 mRNA at time 0 was 
lower than that of cells grown in the presence of estrogen and cyclohexamide, implying 
a direct role for EBNA2 m the up-regulation of bfl-1
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Figure 5 8 Protein expression and bfl-1 quantitation in EREB 2.5 Tet LMP clone 3A cells grown in 
the presence of tetracycline. EREB 2 5 Tet LMP clone 3 A cells were washed 4 tunes in PBS, followed 
by another 2 washes 24 hours later Cells were re-seeded into medium containing 1 jig/ml tetracycline, 
with or without estrogen Protein and RNA extracts were prepared at various tune-points over a 96-hour 
period Protein samples were analysed for EBNA2 or LMP1 expression (A) The amount of bfl-1 mRNA 
present m the EREB 2 5 Tet LMP clone 3A cells at individual time-points over the 96-hour penod was 
quantitated by reverse transcnption followed by real tune PCR. bfl-1 levels were assayed in triplicate and 
normalised by gapdh levels (B) Fold differences were calculated relative to bfl-1 levels at time zero
Protein expression and bfl-1 mRNA levels observed during the time-course performed 
using EREB 2 5 Tet LMP clone 3A cells cultivated in the absence o f tetracycline is
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shown in Figure 5 9 LMP1 expression from the transfected plasmid is turned on in the 
absence o f tetracycline Western blot analysis for EBNA2 and LMP1 is shown in 
Figure 5 9A Similarly to western blot analysis performed using protein extracts from 
the other EREB 2 5 cell derivatives, chimeric EBNA2 and LMP1 expression increased 
over time in cells grown in the presence of estrogen In the absence of estrogen only 
non-functional ER-EBNA2 was detected In contrast to EREB 2 5 Tet LMP clone 3 A 
cells grown in the presence of tetracycline, LMP1 expression was not down regulated 
upon withdrawal o f estrogen from the culture medium
Figure 5 9B shows the differences in bfl-1 mRNA levels over time in the EREB 2 5 Tet 
LMP clone 3 A cells cultivated in the absence o f tetracycline A significant increase m 
bfl-1 levels was observed 6 hours after addition of estrogen to the culture medium A 
further increase in the level of bfl-1 mRNA was observed at the 12-hour time point 
Both functional EBNA2 and LMP1 were expressed at high levels at these time points 
(Figure 5 9 A) The amount of bfl-1 decreased gradually over time, with the level of bfl- 
1 mRNA at 96 hours slightly higher than that observed at time 0 In the absence of 
estrogen, the level o f bfl-1 mRNA was maintained at a level greater than or equal to that 
recorded at time 0, with a 3 7-fold increase in the level o f bfl-1 after 96 hours in culture 
In the absence of estrogen only non-functional chimeric EBNA2 was expressed, but 
LMP1 was expressed from the tetracycline-regulatable vector (Figure 5 9A) The 
observation that bfl-1 levels are maintained in the absence o f estrogen contrasts with the 
levels o f bfl-1 mRNA recorded using the EREB 2 5 Tet LMP clone 3 A cells, m which 
LMP1 expression has been switched off by the presence of tetracycline When these 
cells were grown m the absence o f estrogen, the level o f bfl-1 mRNA decreased over 
time (Figure 5 9B) These results demonstrate that LMP1 is capable of maintaining 
elevated bfl-1 mRNA levels in the absence of functional EBNA2 in the LCL EREB 2 5 
Tet LMP clone 3A
Cyclohexamide was included m some cultures of EREB 2 5 Tet LMP clone 3 A cells, to 
inhibit protein translation As before, the level of bfl-1 mRNA prepared from cells 
grown m the presence of both estrogen and cyclohexamide for 6 hours was compared 
with that of cells grown m estrogen only for the same period of time It was observed 
that the level of bfl-1 mRNA in cells cultivated in the presence of estrogen and 
cyclohexamide was slightly higher than that of cells grown in estrogen only after 6 
hours in culture (Figure 5 9B) Although the level of LMP1 expression decreased
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slightly in cells grown in cyclohexamide, relative to cells grown in the absence o f  
cyclohexamide harvested at the same time-point, a strong band for LMP1 was observed 
following treatment with cyclohexamide (Figure 5 9A), indicating that protein 
expression was not significantly inhibited in this case As a result it cannot be 
concluded whether the up-regulation in the level of bfl-1 mRNA is a direct result of 
functional EBNA2 The level o f bfl-1 observed between cells grown in the absence of  
estrogen was higher than that of cells grown in the absence of estrogen plus 
cyclohexamide
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Figure 5.9: Protein expression and bfl-1 quantitation in EREB 2.5 Tet LMP clone 3A cells grown in 
the absence of tetracycline. EREB 2.5 Tet LMP clone 3A cells were washed 4 times in PBS, followed 
by another 2 washes 24 hours later. Cells were re-seeded into medium supplemented with or without 
estrogen. Protein and RNA extracts were prepared at various time-points over a 96-hour period. Protein 
samples were analysed for EBNA2 or LMP1 expression (A). The amount of bfl-1 mRNA present in the 
EREB 2.5 Tet LMP clone 3A cells at individual time-points over the 96-hour period was quantitated by 
reverse transcription followed by real time PCR. bfl-1 levels were assayed in triplicate and normalised by 
gapdh levels (B). Fold differences were calculated relative to bfl-1 levels at time zero.
Taken together, these results indicated as before that turning on functional EBNA2, and 
as a result LMP1, up-regulates the expression o f bfl-1 mRNA in the cell line EREB 2.5 
Tet LMP clone 3A. It was also observed that LMP1 is capable o f maintaining bfl-1
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mRNA levels in the absence o f functional EBNA2 in this cell context. This result is in 
keeping with results from the time-course carried out using EREB 2.5 SV LMP clone 
11C cells.
5.2.2 The regulation of the bfl-1 promoter in EREB 2.5 cells
Having established that both EBNA2 and LMP1 are both likely to play a role in the up- 
regulation in the level o f bfl-1 mRNA in derivatives o f the EREB 2.5 cell line, 
experiments were conducted to investigate their role in the regulation o f the bfl-1 
promoter in the parental cell line EREB 2.5. EREB 2.5 is an LCL, in which all the EBV 
latent proteins are expressed during cell culture in the presence o f estrogen. Transient 
transfections were performed to investigate the effect o f the expression vectors for (i) 
the IkBgl super-repressor (pEFCX-IicBaDN), (ii) the RBP-Jk/CBF1 mutant 
(pERBOSneo-R218H) and (iii) the EBNA2 mutant [EBNA2 Mut (437-477)] on bfl-1 
promoter activity in this cell context. Because EREB 2.5 is an LCL, it was expected 
that co-transfections using the I k B o , RBP-Jk/CBF1 and EBNA2 mutants, would yield 
similar results to those obtained in Chapter 4 using the IB4 LCL.
5.2.2.1 The effect of the IkBci mutant on promoter activity in EREB 2.5 cells
In a preliminary control experiment, the NFicB-responsive reporter construct 3 x enh kB 
luc was transfected into EREB 2.5 cells, resulting in a high level o f luciferase activity 
(Figure 5.10). This finding was not surprising as LMP1, which is present in EREB 2.5 
cells grown in the presence o f estrogen, is known to trigger signalling pathways that 
result in the activation o f  NF-kB. Upon co-transfection o f the NF-icB-responsive 
reporter along with the expression vector for the IkBol mutant (pEFCX-lKBaDN), a 
significant decrease in luciferase activity (approximately 98%) was observed. This 
finding was similar to that observed in similar experiments using the EBV-negative BL- 
derived cell line DG75 and the EBV-infected cell lines Ag876 and IB4. When the IicBa 
mutant was co-transfected along with the bfl-1 promoter reporter construct -1374/+81- 
Luc, only a small decrease (approximately 10 %) in luciferase activity was detected. 
EREB 2.5 cells were also transfected with the bfl-1 promoter construct containing a 
mutation in the putative RBP-Jk/CBF1 binding site at position -343 to -249 relative to
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the transcription start site [-1374/+81 (mCBFl)]. This mutation was not found to 
inhibit bfl-1 promoter activity in EREB 2.5 cells. However, upon co-transfection with 
the IkB gi mutant together with the promoter bearing mutation in the putative RBP- 
Jk/CBF1 binding site, a 50 % decrease in luciferase activity was observed.
Figure 5.10: The effect of a dominant negative form of IicBa on promoter activity in EREB 2.5 cells.
EREB 2.5 cells grown in the presence of estrogen were transiently co-tranfected with either 12 fig of the 
expression vector IkBoDN or 12 \ig of the empty vector (pEFCX) together with 2 fig of the reporter 
construct indicated underneath the graph. Cells were harvested at 48 hours post-transfection and 
normalised luciferase values were expressed as % activation relative to the corresponding value upon co- 
tranfection with the empty vector and the reporter construct.
These results indicated that blocking LMP1-mediated bfl-1 promoter activity by over­
expression o f the iKBa mutant as well as blocking EBNA2-mediated bfl-1 promoter 
activity by mutating the putative RBP-Jk/CBF1 binding site on the promoter, results in 
significant inhibition in the level o f  bfl-1 promoter trans-activation in EREB 2.5 cells.
5.2.2.2 The effect of the RBP-Jk/CBFI mutant on promoter activity in EREB 2.5 
cells
The effect o f the RBP-Jk/CBFI mutant (pEFBOSneo-R218H) on the activity o f various 
promoters in EREB 2.5 cells was investigated. Initially, the RBP-Jk/CBFI-regulated
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reporter construct (pGa981-6) was transfected into EREB 2.5 cells. A high level o f 
luciferase activity was observed (Figure 5.11). This was expected as the reporter 
construct is known to be responsive to EBNA2, which is present in this cell context. 
When pGa981-6 was co-transfected along with the expression vector for the RBP- 
Jk/CBF1 mutant (pEFBOSneo-R218H), a dramatic decrease (approximately 80 %) in 
luciferase activity was detected. This finding was similar to that observed in 
experiments using the EBV-negative BL-derived cell line DG75 and the EBV-infected 
cell lines Ag876 and IB4. The effect o f the RBP-Jk/CBF1 mutant on bfl-1 promoter 
activity was not as potent. When the bfl-1 promoter reporter construct -1374/+81-Luc 
was co-transfected along with the RBP-Jk/CBF1 mutant, a decrease in luciferase 
activity o f only 20 %  was observed. EREB 2.5 cells were also transfected with the bfl-1 
promoter construct containing a mutation in the NF-KB-like binding site at position -52 
to -43 relative to the transcription start site [-1374/+81 micB (-52)]. This mutation was 
not found to inhibit bfl-1 promoter activity in EREB 2.5 cells. However, upon co­
transfection with the RBP-Jk/CBF1 mutant together with the promoter containing the 
NF-KB-like binding site mutation, a 65 % decrease in luciferase activity was observed.
Figure 5.11: The effect of an RBP-Jk/CBF1 mutant on promoter activity in EREB 2.5 cells. EREB 
2.5 cells cultivated in estrogen were transiently co-tranfected with either 12 fig of the expression vector 
the RBP-Jk/CBFI mutant (pEFBOSneo-R218H) or 12 fig of the empty vector (pEFBOSneo) together 
with 2 fig of the reporter construct indicated underneath the graph. Cells were harvested at 48 hours post­
transfection and normalised luciferase values were expressed as % activation relative to the corresponding 
value upon co-tranfection with the empty vector and the reporter construct.
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These data showed that blocking EBNA2-mediated bfl-1 promoter activity by over­
expression o f  the RBP-Jk/CBF1 mutant as well as blocking LMP1-mediated bfl-1 
promoter activity by mutating the NF-icB-like binding site at -52 to -43 on the promoter, 
results in inhibition in bfl-1 promoter -activity in the cell line EREB 2.5.
5.2.2.3 The effect of the EBNA2 mutant with a trans-activation domain deletion on 
promoter activity in EREB 2.5 cells
The effect o f the EBNA2 mutant, with a trans-activation domain deletion, on the 
activity o f various promoters in EREB 2.5 cells was also investigated. Initially, the 
RBP-Jk/CBF1-regulated reporter construct (pGa981-6) was transfected into EREB 2.5 
cells. As before, a high level o f luciferase activity was observed (Figure 5.12). When 
pGa981-6 was co-transfected along with the expression vector for the EBNA2 mutant 
(EBNA2 Mut (437-477), a dramatic decrease (approximately 80 %) in luciferase 
activity was detected. This finding was reminiscent o f observations in similar 
experiments using the EBV-negative BL-derived cell line DG75 and the EBV-infected 
cell lines Ag876 and IB4. EREB 2.5 cells were also transfected with the bfl-1 promoter 
construct containing a mutation in the NF-icB-like binding site at position -52 to -43 
relative to the transcription start site [-1374/+81 micB (-52)]. This mutation was not 
found to inhibit bfl-1 promoter activity in EREB 2.5 cells. However, upon co- 
transfection with the EBNA2 mutant together with the promoter bearing the NF-KB-like 
binding site mutation, a 65 % decrease in luciferase activity was observed.
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Figure 5.12: The effect of an EBNA2 mutant on promoter activity in EREB 2.5 ceils. EREB 2.5 cells 
cultivated in the presence of estrogen were transiently co-tranfected with either 12 pg of the expression 
vector an EBNA2 mutant with a deletion in its trans-activation domain (EBNA2 Mut (437-477) or 12 \ig 
of the empty vector (pSG5) together with 2 \ig of the reporter construct indicated underneath the graph. 
Cells were harvested at 48 hours post-transfection and normalised luciferase values were expressed as % 
activation relative to the corresponding value upon co-tranfection with the empty vector and the reporter 
construct.
These results indicated that blocking EBNA2-mediated bfl-1 promoter activity, inthis 
case by over-expression o f the EBNA2 mutant, as well as blocking LMP1-mediated bfl- 
1 promoter activity by mutating the NF-icB-like binding site at position -52 to -43 on the 
promoter, results in inhibition in the level o f bfl-1 promoter trans-activation in EREB
2.5 cells.
5.2.2.4 Co-expression of the RBP-Jk/CBF1 and IicBa mutants inhibits bfl-1 
promoter activation
It has already been demonstrated that over-expression o f either the IicBa super-repressor 
or the RBP-Jk/CBF1 mutant does not lead to a potent inhibition in bfl-1 promoter 
activity using EREB 2.5 cells (Figure 5.10 and Figure 5.11). These results are 
summarised in Figure 5.13. Consequently, transient co-transfections were performed to 
investigate whether co-expression o f these two mutants at the same time would affect 
the level o f bfl-1 promoter activation. Co-transfection with the expression vector for the
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RBP-Jk/CBF1 mutant (pEFBOSneo-R218H) together with the vector expressing the 
IkBol mutant (pEFCX-IicBaDN) resulted in approximately 80 %  inhibition in the level 
o f bfl-1 promoter activity in EREB 2.5 cells (Figure 5.13).
Co-Expression of kB a and the RBP-Jk/CBF1 Mutants Affects bfl-1 
Promoter Activity
Figure 5.13: Co-expression of the IicBa and RBP-Jk/CBFI mutants affects bfl-1 promoter activity 
in EREB 2.5 cells. Transient transfections were performed in EREB 2.5 cells grown in estsrogen with 2 
\ig of the bfl-1 promoter reporter construct -1374/+81-Luc along with 12 fig of the expression vector 
indicated underneath the graph. Cells were harvested at 48 hours post-transfection and normalised 
luciferase values were expressed as % activation relative to the corresponding value obtained upon 
transfection of the reporter construct and the empty vector.
These results demonstrated that inhibition o f both EBNA2- and LMP1 -mediated trans­
activation o f the bfl-1 promoter by co-expression o f the RBP-Jk/CBFI and IicBa 
mutants simultaneously resulted in stronger inhibition in bfl-1 promoter activity than 
expression o f either o f these mutants alone. Blocking both LMP1- and EBNA2- 
mediated signalling was required to significantly decrease bfl-1 promoter activity in 
EREB 2.5 cells.
5.2.2.5 Co-expression of the EBNA2 and IicBa mutants inhibits bfl-l promoter 
activity
It has previously been demonstrated in this study, that over-expression o f  the EBNA2 
mutant with a deletion in its trans-activation domain does not inhibit in bfl-1 promoter
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activity using EREB 2.5 cells (Figure 5.12). To determine whether co-expression o f 
this mutant along with the IkBcx super-repressor would affect bfl-1 promoter trans­
activation, transient co-transfections were performed using the expression vector for the 
EBNA2 mutant [EBNA2 Mut (437-477)] together with the vector expressing the IkB<x 
super-repressor (pEFCX-IicBaDN). Co-expression o f the two mutants at the same time 
resulted in approximately 80 % inhibition in the level o f bfl-1 promoter activity in 
EREB 2.5 cells (Figure 5.14).
Co-Expression of the teBa and EBNA2 Mutants Affects bfl-1 
Promoter Activity
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Figure 5.14: Co-expression of the IkBol and RBP-Jk/CBF1 mutants affects bfl-1 promoter activity 
in EREB 2.5 cells. Transient transfections were performed in EREB 2.5 cells cultivated in the presence 
of estrogen using 2 \ig of the bfl-l promoter reporter construct -1374/+81-Luc along with 12 pg of the 
expression vector indicated underneath the graph. Cells were harvested at 48 hours post-transfection and 
normalised luciferase values were expressed as % activation relative to the corresponding value obtained 
upon transfection of the reporter construct and the empty vector
These results demonstrated that inhibition o f both EBNA2- and LMP1-mediated trans­
activation o f the bfl-1 promoter by co-expression o f the EBNA2 and IkB ol mutants 
simultaneously resulted in stronger inhibition in bfl-1 promoter activity than expression 
o f either o f these mutants alone.
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5.3 DISCUSSION
The regulation o f bfl-1 activity in the EBV-infected cell lines Ag876 and EB4 was 
investigated in Chapter 4. Because these EBV-infected cell lines express EBNA2 and 
LMP1 simultaneously, with trans-activation o f the LMP1 gene under the strict control 
of EBNA2 (Abbot et al., 1990; Fahraeus et a l., 1990; Laux et a l., 1994a; Wang et al., 
1990), it is difficult to assess the contribution o f each o f these individual EBV latent 
proteins to the modulation o f bfl-1 expression. To overcome this obstacle, experiments 
were carried out using a panel o f cell lines, based a cell system established by Kempkes 
et al. (1995b), in which primary B cells have been co-infected with a mini-EBV plasmid 
that expresses estrogen-responsive EBNA2 (ER-EBNA2), together with the EBV strain 
P3HR1, which is a non-immortalising viral strain that is deleted for it’s own EBNA2 
(Figure 5.1). As a result the function o f EBNA2 in the resulting cell line, EREB 2.5, 
may be switched on and off by addition or removal o f estrogen from the culture 
medium. Therefore, in the presence of estrogen, functional EBNA2 trans-activates the 
P3HR1 viral promoters, including that o f LMP1. Thus, addition o f estrogen, and the 
subsequent induction o f functional EBNA2, results in EBV-infected cells with a 
phenotype similar to those found in healthy individuals upon primary infection with the 
virus, or EBV-infected cells found in immuno-suppressed patients.
Experiments performed in the current study involved a panel o f derivatives o f the 
parental EREB 2.5 cell line, which had been stably transfected with additional 
expression vectors (Zimber-Strobl et al., 1996). This panel o f cell lines allowed (i) 
investigation into the effects o f the induction o f functional EBNA2 (and as a result 
LMP1) on bfl-1 mRNA levels in EBV-infected cells and (ii) dissection o f the 
contribution o f the LMP1 protein, in the absence o f EBNA2, to maintenance o f bfl-1 
activity in this cell context. Five cell lines were used in total. Two o f these cell lines, 
namely EREB 2.5 SV LMP clone 2C and EREB 2.5 SV LMP clone 11C, describe 
EREB 2.5 cells, which have been stably transfected with a vector expressing LMP1 
from the SV40 early promoter/enhancer (Zimber-Strobl et al., 1996). An additional 
LMP 1-inducible cell line, (EREB 2.5 Tet LMP 3A), which has been transfected with a 
tetracycline regulatable LMP1 expression vector, was also used in the study (Zimber- 
Strobl et al., unpublished). EREB 2.5 cells transfected with a plasmid expressing a 
truncated non-functional LMP1 gene (EREB 2.5 SV LMP Mut 2) or the empty vector 
(EREB 2.5 pHEBo) served as negative controls.
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These experiments demonstrated that turning on functional EBNA2 (by addition o f 
estrogen) leads to an increase in EBNA2 expression over time (Figure 5.2A). This 
observation is compatible with a functional role for EBNA2 in the positive regulation o f 
its own promoter (Sung et al., 1991; Rooney et al., 1992). LMP1 expression coincided 
with an increase in EBNA2 expression in all the cell lines tested, indicating that the 
LMP1 gene is under the strict control o f EBNA2. Expression o f functional EBNA2, 
and the resulting induction o f LMP1, led to a transient increase in the level o f bfl-1 
mRNA at 6 hours post-addition o f estrogen, as quantitated by reverse transcription real 
time PCR. Removal o f estrogen from the culture medium, and therefore “switching 
o ff’ functional EBNA2 resulted in a decrease in both functional EBNA2 and LMP1 
levels, as determined by Western blot analysis, reinforcing the idea that EBNA2 
regulates it’s own expression, as well as that o f LMP1. In the absence o f estrogen, the 
ER-EBNA2 protein was observed to migrate more rapidly and homogenously, 
suggesting that switching on EBNA2 function is associated with a post-translational 
modification or profound changes in the tertiary structure o f ER-EBNA2, possible due 
to phosphorylation (Grasser et a l., 1991). Switching off functional EBNA2 also 
coincided with a decrease in the level o f bfl-1 mRNA.
As both EBNA2 and LMP1 were expressed rapidly following activation o f functional 
EBNA2, it is difficult to assess which protein was responsible for the up-regulation in 
bfl-1 mRNA levels in the EREB 2.5 cell lines. To address the question o f whether 
LMP1 maintains bfl-1 mRNA levels in the absence o f EBNA2, EREB 2.5 cells stably 
transfected with LMP1 expression vectors were used. In experiments performed using 
the negative control cell lines transfected with either the empty vector (EREB 2.5 
pHEBo) or the truncated non-functional LMP1 mutant (EREB 2.5 SV LMP Mut 2), 
LMP1 expression was significantly down-regulated after removal o f hormone, 
indicating that the LMP1 gene is under strict control o f EBNA2 in these cell lines. It 
was also observed that bfl-1 mRNA levels deteriorated significantly in the absence o f 
functional EBNA2 and LMP1. In contrast, experiments using cells transfected with the 
LMP1 expression vector (EREB 2.5 SV LMP clone 11C) or cells in which LMP1 was 
induced from the tetracycline regulatable vector (EREB 2.5 Tet LMP clone 3A), 
revealed LMP1 levels that were not down-regulated following estrogen withdrawal. 
These results clearly demonstrate that LMP1 expression from either the SV40 promoter 
or the tetracycline inducible vector maintains elevated bfl-1 mRNA levels, 
independently o f functional EBNA2. However, in the case o f the cell line EREB 2.5
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SV LMP clone 2C, LMP1 levels were seen to decrease following removal o f estrogen 
from the culture medium. This suggests that this particular clone was unstable, and had 
possibly lost the expression vector for LMP1.
Because EBNA2 trans-activates the LMP1 promoter, it is believed that the primary role 
for EBNA2 is to maintain LMP1 levels in EBV-infected ceils. In order to determine 
whether functional EBNA2 plays a direct role in the up-regulation o f bfl-1 mRNA 
levels, the various stably transfected EREB 2.5 derivatives were cultivated in medium 
containing cyclohexamide, which is a known inhibitor o f protein synthesis.
It should be noted that chimeric ER-EBNA2 is already present in the EREB 2.5 
derivatives, thus the expression o f functional EBNA2 is not subject to inhibition by 
cyclohexamide. However, because EBNA2 positively regulates it’s own promoter, a lot 
more functional EBNA2 is expressed in the absence o f cyclohexamide. Translation o f 
genes trans-activated by functional EBNA2 (i.e. genes from the LMP and Cp 
promoters), is inhibited by the presence o f cyclohexamide in the culture medium. 
During experiments where translation o f EBNA2-responsive genes (including LMP1), 
expressed from the viral genome was inhibited by cyclohexamide, an increase in bfl-1 
mRNA was observed 6 hours post-induction o f functional EBNA2 in all o f the cell lines 
tested, implying a possible direct role for EBNA2 in the regulation o f bfl-1 in the 
context o f an LCL. In the majority o f cases, Western blot analysis revealed that LMP1 
expression was almost completely abolished following 6 hours culture in the presence 
o f cyclohexamide. It was noted however, in experiments using two o f the cell lines 
(EREB 2.5 SV LMP clone 11C and EREB 2.5 Tet LMP 3A grown in the absence o f 
tetracycline) that although LMP1 expression decreased somewhat in cells cultured in 
the presence of cyclohexamide for 6 hours, LMP1 was still detectable by Western blot 
analysis, so it was difficult to conclude whether EBNA2 and/or LMP1 was responsible 
for the increase in bfl-1 mRNA levels in these cases. For more effective inhibition o f 
translation a combination o f protein synthesis inhibitors may have proved more 
effective, for example a mixture o f cyclohexamide and anisomycin has been 
demonstrated to be effective in other studies (Spender et al., 2001).
It was observed that the level o f bfl-1 mRNA prepared from cells grown in the presence 
o f both estrogen and cyclohexamide (where only functional EBNA2 is expressed) was 
generally lower than the level o f mRNA in cells grown in estrogen only (where
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functional EBNA2 at pre-existing levels and all its responsive genes are expressed). 
The decrease in mRNA levels was not due to mRNA instability, as no difference in bfl- 
1 mRNA levels was observed between cells grown in the absence of estrogen and cells 
grown in the absence o f estrogen plus cyclohexamide. One possible reason for the 
decrease in bfl-1 mRNA levels observed when cyclohexamide is present, could be that 
less EBNA2 is expressed in the presence o f cyclohexamide, as the protein synthesis 
inhibitor would result in a decrease in EBNA2 expression that would result from 
EBNA2 positively regulating its own promoter. It is also possible that an additional 
factor plays a role in the maintenance o f bfl-1 levels in this cell context. LMP1 is a 
likely candidate for such an additional factor, as western blot analysis revealed it was 
down-regulated in the presence o f cyclohexamide. Furthermore, LMP1 expression 
from the plasmid in the absence o f functional EBNA2 was demonstrated to be sufficient 
for maintaining elevated bfl-1 mRNA levels independently o f functional EBNA2, 
indicating a key role for LMP1 in the regulation o f bfl-1 in EREB cell lines. It must be 
taken into consideration that cyclohexamide would inhibit translation o f other EBNA2- 
responsive viral and cellular genes expressed from the P3HR1 viral genome present in 
the EREB 2.5 stable transfectants and the effects o f inhibition o f these genes on bfl-1 
regulation have not been analysed in this study.
Having established that both EBNA2 and LMP1 are both likely to play a role in the up- 
regulation o f bfl-1 mRNA in derivatives o f the EREB 2.5 cell line, experiments were 
conducted to investigate the role o f these two EBV latent proteins in the regulation o f 
the bfl-1 promoter in the parental cell line EREB 2.5. Transient transfections were 
performed to investigate the effects o f the IicBa super-repressor, the RBP-Jk/CBFI 
mutant and the EBNA2 mutant on bfl-1 promoter activity in this cell context. Since 
EREB 2.5 cells grown in the presence o f estrogen is in fact an LCL, it was expected that 
co-transfections using the IicBa, RBP-Jk/CBFI and EBNA2 mutants, would yield 
similar results to those obtained in using the IB4 LCL in Chapter 4.
As was the case for experiments carried out using IB4 cells, blocking both EBNA2-and 
LMP1-mediated signalling was required in order to significantly decrease bfl-1 
promoter activity in EREB 2.5 cells. This was demonstrated using bfl-1 promoter 
reporter constructs containing mutations in either the NF-icB-like binding site at position 
-52 to -43, or the putative RBP-Jk/CBFI binding site at -343 to -249 relative to the 
transcription start site on the bfl-1 promoter. Firstly, co-transfections using either the
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RBP-Jk/CBF1 or EBNA2 mutant along with a bfl-1 promoter reporter construct 
containing a mutation in the NF-icB-like binding site were performed. This mutation in 
this NF-KB-like binding site has been found to almost completely abolish LMP1- 
responsiveness on the bfl-1 promoter in the EBV-negative BL-derived cell line DG75 
(D’Souza et al., 2004). However, the mutation was not found to affect the level o f bfl-1 
promoter in EREB 2.5 cells. On the other hand, by mutating the NF-KB-like binding 
site, and blocking EBNA2-mediated promoter activity by co-expression with either the 
RBP-Jk/CBFI or EBNA2 mutants, the level o f promoter activity was reduced by up to 
70 %. The observation that blocking both LMP1- and EBNA2-mediated trans- 
activation o f the bfl-1 promoter simultaneously, results in a significant decrease in 
promoter activity, was reinforced during transfection experiments using the IicBa super­
repressor and the bfl-1 promoter reporter construct containing a mutation in putative 
RBP-Jk/CBFI binding site. Mutation o f this putative binding site has been shown to 
significantly inhibit EBNA2-mediated trans-activation o f the bfl-1 promoter in EBV- 
negative BL-derived cell lines (Pegman et a l., submitted December, 2004). It was 
observed in the current study that the presence o f this mutation did not affect the level 
o f bfl-1 promoter activity in EREB 2.5 cells. However, upon co-transfection o f the 
RBP-Jk/CBFI mutated promoter reporter construct together with the IicBa super- 
repressor, an approximate 50 % decrease in bfl-1 promoter activity was observed. 
These results imply a role for the putative RBP-Jk/CBFI binding site in the trans­
activation o f the bfl-l promoter in the context of the EREB 2.5 cell line and are in 
keeping with results obtained during similar experiments carried out in the IB4 LCL, 
and the type III BL cell line Ag876.
To further investigate the effect o f blocking both LMP1- and EBNA2-mediated 
signalling, co-transfections were carried out using the IicBa super-repressor together 
with either the RBP-Jk/CBFI mutant or the EBNA2 mutant with the deletion in the 
trans-activation domain. Co-expression o f the IkBcx super-repressor with either the 
RBP-Jk/CBFI or EBNA2 mutant resulted in up to 80 % inhibition in bfl-1 promoter 
activity in both cell lines, further strengthening the observation that blocking both 
LMP1- and EBNA2-mediated activation significantly affects the level o f bfl-1 promoter 
activity. This implies that pathways leading to NF-kB activation and CBF1 work 
simultaneously and in a mutually redundant fashion to maintain the level o f bfl-1 
promoter activity in EBV-infected cell lines with a type III latency programme and that
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EBNA2 and LM Pl are the key EBV latent proteins that drive the expression of this 
cellular gene in the cell line EREB 2.5, in addition to the cell lines Ag876 and IB4.
223
Chapter 6 
General Discussion
6.1 General discussion
A central component o f the overall EBV strategy and its role in the development of 
related malignant disease is the ability o f the viral proteins to suppress the cellular 
apoptotic program (Allday, 1996; Klein, 1994). One well-documented mechanism by 
which EBV can protect against apoptosis is through the LMP1-mediated up-regulation 
o f anti-apoptotic proteins, including Bcl-2, A20, Mcl-1 and C-IAP2 (Henderson et a l., 
1991; Fries et a l ,  1996; Wang et a l ,  1996; Laherty et a l ,  1992; Hong et a l ,  2000), thus 
raising the apoptotic threshold o f the infected cell and also providing protection against 
a wide range o f apoptosis-inducing stimuli. It has previously been shown in our 
laboratory that elevated mRNA levels o f the anti-apoptotic bfl-1 gene are a feature of 
EBV-infected B lymphocytes exhibiting type III latency, and that expression o f either 
LMP1 or EBNA2 as the sole EBV protein in an EBV-negative BL cell line coincides 
with a dramatic increase in bfl-1 mRNA levels (D ’Souza et a l ,  2000; Pegman et a l ,  
submitted December, 2004). In addition, Bfl-1 protects against serum depletion- 
induced apoptosis when expressed in the same cell context (D’Souza et a l, 2000), and 
both LMP1 and EBNA2 stimulate bfl-1 promoter activity in EBV-negative BL-derived 
cell lines by a mechanism that involves components o f the NF-kB and Notch signalling 
pathways respectively (D’Souza et a l ,  2004; Pegman et a l ,  submitted December, 
2004).
Here it was shown that NF-kB composed o f p65 subunits trans-activated the bfl-1 
promoter in the EBV-negative BL-derived cell line DG75, and that an NF-KB-like 
binding site at position -52 to -43 relative to the transcription start site was essential for 
this effect. The crucial role for the DNA-binding protein RBP-Jk/CBF1 in EBNA2- 
mediated trans-activation o f bfl-1 was demonstrated, as an RBP-Jk/CBF1 mutant 
(pEFBOSneo-R218H) blocked trans-activation o f bfl-1 by EBNA2. In contrast to that 
of LMP1, EBNA2-mediated trans-activation o f  bfl-1 was not associated with an 
increase in the level o f activated NF-kB. The cellular functional equivalent o f EBNA2, 
NotchIC, did not trans-activate the bfl-1 promoter in DG75 cells, and this was not due to 
the fact that the NotchIC protein has a weaker trans-activation domain than that o f 
EBNA2. An EBNA2 mutant, with a trans-activation domain deletion [EBNA2 Mut 
(437-477)], significantly inhibited wild type EBNA2-mediated trans-activation o f both 
the LMP1 and bfl-1 promoters in DG75 cells. The signalling pathways that link EBV 
to the up-regulation o f Bfl-1 are summarised in Figure 6.1. The inhibition o f both
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EBNA2- and LMP1-mediated activity by the mutant constructs used in the study is also 
indicated.
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Figure 6.1: Signalling pathways that link EBV to the up-regulation of Bfl-1. It was demonstrated in 
the current study that EBNA2 trans-activates the bfl-1 promoter in an RBP-Jic/CBFl-dependent manner. 
Co-expression of an RBP-Jk/CBFI mutant (pERBOSneo-R218H) that cannot bind DNA was found to 
inhibit this activity. In addition an EBNA2 mutant with a trans-activation domain deletion [EBNA2 Mut 
437-477)] was also found to block EBNA2-mediated trans-activation of bfl-1. Over-expression of an 
IkBci super-repressor mutant (pEFCX-IicBaDN) was used to block LMP1-mediated activation of the bfl-1 
promoter. Other EBV proteins that are known to modulate EBNA2 and LMP1 activity are also indicated.
A role for both LMP1 and EBNA2 was demonstrated in the context o f the EBV- 
infected B lymphocyte. While blocking either LMP1- or EBNA2-mediated signalling 
alone did not lead to a decrease in bfl-1 promoter activity, blocking signalling from both 
these proteins simultaneously led to significant inhibition in bfl-1 activity. A panel o f 
cell lines (EREB 2.5 and it’s derivatives), in which functional EBNA2 could be 
expressed conditionally, allowed dissection o f the individual roles o f  EBNA2 and 
LMP1 with regard to bfl-1 regulation. Induction o f EBNA2, and the resulting LMP1 
expression, led to a transient increase in the level o f bfl-1 mRNA. In the absence o f
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functional EBNA2 and LMP1, bfl-1 mRNA levels were seen to significantly decrease in 
the panel o f EREB cell lines. LMP1 maintained elevated bfl-1 mRNA levels in the 
absence o f functional EBNA2. Induction o f functional EBNA2 alone in the panel o f 
EREB cell lines led to an increase in the level o f bfl-1 mRNA. These data indicate that 
both LMP1 and EBNA2 play a role in the regulation o f the bfl-1 gene. The up- 
regulation o f bfl-1 by these two EB V latent proteins may be a key event in the rescue o f 
EBV-infected B cells from apoptosis and an important route by which EBV gains 
access to the memory B cell pool and contributes to oncogenesis.
In healthy EBV-carriers, all o f the EBV latent proteins, including EBNA2 and LMP1 
have been found in naive IgD+ tonsillar B cells (Joseph et a l., 2000). These latently 
infected naive B cells are present in the tonsil only when viral replication has been 
detected, suggesting that they represent newly infected cells (Joseph et al., 2000). 
EBNA2 induction, by addition o f estrogen to the culture medium o f EREB cell lines, 
represents an established regulatable model for the growth transformation o f resting B 
cells by EBV. Induction o f  functional EBNA2, and the resulting LMP1 expression, was 
demonstrated to lead to a transient increase in the level o f bfl-1 mRNA after 6 hours in 
all o f the EREB cell lines tested. The maximum induction o f the anti-apoptotic bcl-2 by 
LMP1 peaks at 48-72 hours (Rowe et al., 1994). In contrast to bcl-2, the induction o f 
bfl-1 mRNA appears to be an immediate and direct effect o f EBV infection, as is the 
case with A20  (Laherty et a l ,  1992). These findings support the hypothesis that bfl-1 
possibly functions as a rapidly inducible, short-term effector o f cell viability. Elevated 
levels o f several anti-apoptotic proteins would increase the range o f apoptotic stimuli 
against which the host cell can protect itself The anti-apoptotic effects o f Bfl-1 have 
been demonstrated, and it has been shown to suppress apoptosis induced by serum 
depletion (D’Souza et al., 2000), the pro-inflammatory cytokine TNFa (Karsan et al., 
1996b; Zong et al., 1999; Duriez et al., 2000), tumour suppressor p53 (D’Sa-Eipper et 
al., 1996), B cell receptor aggregation (Kuss eta l., 1999; Grumont eta l., 1999; Craxton 
et al., 2000), the pro-apoptotic factors Bax and Bad (Zhang et al., 2000; Holmgreen et 
al., 1999). It has also been found to suppress chemotherapy-induced apoptosis (Wang 
et al., 1999; Cheng et al., 2000; Kim et al., 2004). The up-regulation o f  bfl-1 by LMP1 
and/or EBNA2 during primary EBV infection is likely to be a crucial immediate early 
response that enables cells to survive, or in any case, survive until such time that Bcl-2 
is up-regulated.
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In lymphoid follicles, the bfl-1 transcript has been detected in the germinal centres 
(Jung-Ha et al., 1998), which are the sites where an activated naive B cell, which is 
responding to foreign antigen during an immune response, undergoes the transition into 
a long-lived memory B cell (Liu and Arpin, 1997; MacLennan et a l., 1988). CD40 
activation is necessary for rescuing germinal centre B cells from spontaneous apoptosis, 
and long-lived B cells are distinguished by elevated expression of bfl-1 (Tomakayo et 
al., 1998). In this regard, Bfl-1 might be viewed as a key determinant o f cell fate for 
immature peripheral B cells. The strong induction o f bfl-1 by pro-inflammatory 
cytokines in endothelial, leukemic, and hemopoietic cells is in keeping with a role for 
protecting them from apoptotic extinction (Choi et a l., 1995; Karsan et a l., 1996a; 
Karsan et al., 1996b; Lin et al., 1996; Moreb and Scheweber, 1997). Consistent with a 
role for NF-kB in this process is the reduction in constitutive bfl-1 mRNA levels in B 
cell lines derived from c-Rel"' mice (Grumont et al., 1999). The ability o f LMP1 to 
mimic the cellular growth and cell survival signals, that normally result from the 
binding o f CD40 ligand, by up-regulating the expression o f anti-apoptotic members of 
the Bcl-2 family o f proteins, including bfl-1, is very significant from the standpoint of 
the mechanism o f persistence o f EBV in the memory B cell in the peripheral blood. In  
vivo, EBV-positive tonsillar memory B cells express a restricted pattern o f latent gene 
expression, where only EBNA1, LMP1 and LMP2A are expressed (Babcock and 
Thorley-Lawson, 2000). The actions o f LMP1 and LMP2A, provide surrogate T-cell 
help and B-cell receptor signals, in a ligand-independent manner, that memory B cells 
require for long-term survival (Caldwell et al., 1998). Since BL cells, such as DG75, 
exhibit phenotypic features reminiscent of germinal centre B cells (MacLennan et al., 
1988), the NF-icB-dependent activation o f bfl-1 by LMP1 may be a key event in the 
rescue o f EBV-infected B cells from apoptosis and an important route by which EBV 
gains access to the memory B cell pool, in order to establish a life-long infection in the 
host.
Experiments carried out using the panel o f EREB cell lines, demonstrated that LMP1 
maintains elevated bfl-1 mRNA levels in the absence o f functional EBNA2. This 
finding implies a role for LMP1 in the up-regulation o f bfl-1 in cells that do not express 
EBNA2. Indeed LMP1 has been detected in the absence o f EBNA2 in the majority o f 
EBV-associated tumours such as NPC, HD and T- and NK-cell lymphomas. Although 
EBNA2 is the major viral trans-activator of LMP1 expression, recent studies have 
implicated the EBV BART RK-BARFO in the activation o f  LMP1 expression (indicated
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in Figure 6.1). It has been demonstrated using yeast two-hybrid screening, co- 
immunoprecipitation and confocal microscopy that RK-BARFO interacts with the 
Notch4 ligand binding domain, inducing translocation of a portion o f the full-length, 
un-processed Notch4 to the nucleus by using the Notch4 NLS (Kusano et a l,  2001). In 
EBV-infected, EBNA2-negative cells, RK-BARFO induced expression o f LMP1 and 
this induction was found to be dependent on the RK-B ARF0/Notch4 interaction domain 
(Kusano et a l., 2001). Furthermore, functional binding sites for members o f the ST AT 
family o f transcription factors have been identified in the promoter for LMP1 gene, 
which was found to be responsive to JAK/STAT signalling in reporter assays (Chen et 
a l , 2001). The activation o f LMP1 expression by RK-BARFO or JAK/STAT signalling 
may be responsible for the expression o f LMP1 in EBV-associated tumours, in which 
EBNA2 is not expressed. The question remains, however, as to whether LMP1 is the 
only EBV latent protein that maintains bfl-1 in these EBNA2-negative tumours.
The trans-activation o f bfl-1 by EBNA2 demonstrates for the first time that EBNA2 
directly targets the transcriptional regulation o f an anti-apoptotic protein. The 
identification o f an anti-apoptotic function for EBNA2 implies that, in addition to 
LMP1, EBNA2 contributes to cell survival, as well as to the proliferative response that 
occurs during initial EBV infection. A protective role for EBNA2 may both 
complement the LMP1-induced survival signals, and provide initial protection before 
LMP1 is expressed during primary EBV infection o f B cells. During experiments 
carried out using the EREB cell lines, LMP1 expression was detected at one hour post­
induction o f functional EBNA2. As a result, it was difficult to assess which protein was 
responsible for the initial up-regulation in the level o f bfl-1 mRNA. The majority o f 
EBV-associated tumours do not express EBNA2, presumably because the EBNA2 and 
co-ordinately expressed EBNA3 latency proteins are highly immunogenic. However, 
EBNA2 is expressed in EBV-associated tumours arising in immuno-compromised 
patients, for example in post-transplant lymphoproliferative disease (PTLD) and in 
primary central nervous system lymphomas in AIDS patients (Auperin et a l , 1994; Cen 
et a l , 1993; Delecluse et a l , 1995), and the anti-apoptotic effect o f EBNA2 may be a 
factor in the development o f these malignancies. Furthermore, there is increasing 
evidence to suggest an anti-apoptotic role for EBNA2 independently o f LMP1. EBNA2 
has been detected in LMP1-negative smooth muscle tumours in PTLD patients (Lee et 
a l , 1995), providing a possible mechanism for bfl-1 up-regulation in the absence o f 
LMP1. Additionally, EBNA2 interacts with Nur77, an orphan member o f the nuclear
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hormone receptor super-family, to protect against Nur77-mediated apoptosis (Lee et a l., 
2002). As LMP1 cannot protect against Nur77-mediated apoptosis, EBNA2 has the 
ability to protect B cells against specific apoptotic agents, against which LMP1 is not 
effective (Lee et a l ,  2004). Since a tumourigenic cell phenotype is associated not only 
with increased proliferation, but also with increased resistance to apoptosis, EBNA2 
may provide such resistance by both blocking the effects o f stimuli that elicit Nur77- 
mediated apoptosis and simultaneously up-regulating expression of the bfl-1 gene.
The crucial role o f the DNA binding protein RBP-Jk/CBF1 in EBNA2-mediated trans­
activation was demonstrated during the study, when it was shown that over-expression 
o f a non-DNA binding RBP-Jk/CBF1 mutant dramatically inhibited EBNA2-mediated 
trans-activation o f the bfl-1 and LMP1 promoters (Figure 6.1). RBP-Jk/CBF1 also 
plays an important role in the Notch signalling pathway, which regulates cell fate 
decisions in many different organisms. It is o f interest that EBNA2 interacts with 
components o f a cellular signalling pathway to modulate gene expression. Expression 
o f EBNA2 is restricted to naive IgD+ B cells in secondary lymphoid tissue in healthy 
EBV-positive individuals (Joseph et al., 2000; Babcock and Thorley-Lawson, 2000). 
IgD+ B cells are concentrated in the marginal zone o f germinal centres. Studies using 
transgenic mice that are conditionally deficient for RBP-Jk/CBF1 in B cells show a 
selective loss o f marginal zone B cells, implicating Notch signalling in the development 
o f this cell type (Tanigaki et al., 2002). Reinforcing this observation, transfer o f MINT- 
deficient splenic B cells into recipient mice led to preferential differentiation into 
marginal zone B cells (Kuroda et al., 2003). MINT/SHARP, which interacts with RBP- 
Jk/CBF1 and antagonizes Notch activity, is highly expressed in mouse follicular B cells 
and has low expression in marginal zone B cells. It has been postulated that marginal 
zone B cells express high levels o f Notch2 (Witt et al., 2003) and furthermore, 
conditional deletion o f  Notch2 in mice resulted in a deficiency in marginal zone B cells 
(Saito et a l ,  2003). The fact that EBNA2 is selectively expressed in the same 
compartment o f the germinal centre where Notch2 expression is essential for B cell 
development suggests that EBV is using EBNA2 as a virally controlled, constitutive 
Notch substitute (Hayward, 2004).
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A P P E N D IX
SO LUTIO NS FOR DNA M ANIPULATIO N
STORAGE OF DNA 
0.5 M EDTA (pH 8.0)
186.1g EDTA
800 ml dH20
The pH was adjusted to 8.0 by addition of NaOH pellets and the volume adjusted to 1 L 
with dH20. The solution was sterilised by autoclaving and stored at RT.
TE buffer (pH 8.0)
10 mM Tris-Cl (pH 8.0)
1 mM EDTA (pH 8.0)
BACTERIAL GROWTH MEDIA 
Ampicillin stock solution
A stock solution of ampicillin was made up to a concentration of 100 mg/ml of dH20. 
The stock solution was filter sterilised and stored at -20°C.
LB broth
5 g tryptone
2.5 g yeast extract
5g NaCl
The volume was adjusted to 500 ml, followed by autoclaving for 15 minutes at 15 lb/sq. 
and storage at 4°C.
a
LB broth with ampicillin
Ampicillin was added to autoclaved LB broth to a final concentration of 100 [tg/ml and 
stored at 4°C.
The volume was adjusted to 500 ml with dH20, followed by autoclaving and agar plates 
were stored at 4°C.
LB agar with ampicillin
Ampicillin was added to autoclaved LB agar to a final concentration of 100 jig/ml (after 
cooling the LB agar to ~50°C). Plates were stored at 4°C.
SOB medium
10 g tryptone
2.5 g yeast extract
0.025 g NaCl
5 ml KC1 (250 mM)
The pH was adjusted to 7.0 with 5 M NaOH.
The volume was adjusted to 500 ml with dt^O and the medium autoclaved.
2.5 ml of 2 M MgCh was added after cooling the broth to 5°C and the medium was 
stored at 4°C.
LB agar
5g  
2.5 g 
5 g 
7-5 g
tryptone 
yeast extract 
NaCl
agar
b
SOC medium
98 ml SOB medium
2 ml 1 M glucose (filter sterilised)
Stored at 4°C.
SOLUTIONS FOR PREPARATION OF COMPETENT CELLS 
TFB1
30 mM potassium acetate
10 mM CaCl2
50 mM MnCl2
100 mM RbCl
15% glycerol
The pH was adjusted to 5.8 with 1 M acetic acid, and the solution filter sterilised and 
stored at RT.
TFB2
100 mM MOPS (pH 6.5)
75 mM CaCl2
10 mM RbCl
15 % glycerol
The pH was adjusted to 6.5 with 1 M KOH, and the solution filter sterilised and stored 
atRT.
c
S O L U T I O N S  F O R  M I N I P R E P A R A T I O N S  O F  P N A
Solution I
50 mM glucose
25 mM Tris-Cl (pH 8.0)
10 mM EDTA (pH 8.0)
Stored at RT
Solution II (prepared on day of use)
0.2 M NaOH
1 % (w/v) SDS
Solution m  (3 M potassium acetate)
29.6 g potassium acetate
50 ml dH20
11.5 ml glacial acetic acid
Adjust volume to 100 ml with dH20.
The resulting solution is 3 M with respect to potassium and 5 M with respect to acetate. 
Stored at RT.
DNase-free RNase
RNase A (1 mg/ml) in upH20.
Heated to 100°C for 30 minutes.
Cooled slowly and stored at -20°C.
d
25 ml glycerol
25 ml dH20
The solution was autoclaved and stored at RT.
SOLUTIONS FOR MAXIPREPARATIONS OF DNA (OIAGEN^ BUFFERS!
Buffer PI (Re-suspension buffer)
50 mM Tris-Cl (pH 8.0)
10 mM EDTA (pH8 .0)
100 ng/ml RNase A
Stored at 4°C following addition of RNase A.
Buffer P2 (Lysis buffer)
200 mM NaOH
1 % (w/v) SDS
Stored at RT.
Buffer P3 (Neutralization buffer)
3 M potassium acetate (pH 5.5)
Stored at RT.
5 0  %  ( v / v )  G l y c e r o l
e
Buffer QBT (Equilibration buffer)
750 mM NaCl
50 mM MOPS (pH 7.0)
15 %  (v/v) isopropanol
0.15 % (v/v) Triton-X100
Stored at RT.
Buffer QC (Wash buffer)
1 M NaCl
50 mM MOPS (pH 7.0)
15 % (v/v) isopropanol
Stored at RT.
Buffer QF (Elution buffer)
1.25 M NaCl
50 mM Tris-Cl (pH 8.5)
15% isopropanol
Stored at RT.
SOLTUIONS FOR AGAROSE GEL ELECTROPHORESIS
50 X TAE (Tris-acetate/EDTA electrophoresis buffer)
242 g Tris base
57.1 ml glacial acetic acid
100 ml 0.5 M EDTA (pH 8.0)
The volume was adjusted to 1 L with dH20  and the buffer was stored at RT.
f
1 X  T A E  ( W o r k i n g  s o l u t i o n )
20 ml 50 X TAE
980 ml dH20
Stored at RT.
Agarose gel loading dye
40 % (w/v) sucrose
0.25 % (w/v) bromophenol blue
Stored at RT.
Ethidium bromide
10 mg ethidium bromide
1 ml dH20
The solution was stored in the dark at RT.
SOLUTIONS FOR CELL CULTURE
MEDIA & SUPPLEMENTS 
Supplemented RPMI1640 (200 ml)
176 ml RPMI 1640
20 ml foetal bovine serum (decomplemented at 50°C for 30 minutes)
2 ml 200 mM L-glutamine
2 ml penicillin/streptomycin (10 mg/ml)
g
E s t r o g e n  ( ß - E s t r a d i o l )
A 20 mM solution was prepared in 100 % ethanol and stored at -20°C.
Tetracycline
A 5 mg/ml stock was prepared in 100 % ethanol and stored at -20°C.
Phosphate buffered saline (PBS)
5 tablets were dissolved in 500 ml dH20  to give a 1 X working concentration of PBS, 
and the solution was sterilised by autoclaving.
SOLUTIONS FOR DEAE-DEXTRAN TRANSFECTIONS PROTOCOL
Tris buffered saline (TBS)
25 mM Tris-Cl (pH 7.4)
137 mM NaCl
5 mM KCL
0.7 mM CaCl2
0.5 mM MgCl2
0.6 mM Na2HP04
To make 200 ml TBS:
5 ml 1 M Tris-Cl (pH 7.4)
5.48 ml 5 M NaCl
0.5 ml 2MKC1
1.4 ml 100 mM CaCl2
0.1 ml 1 M MgCh
0.2 ml 0.6 M Na2HP04
187.32 ml upH20
TBS was prepared from autoclaved stocks, aliquoted and filter sterilised before use.
h
DEAE dextran
DEAE dextran was prepared at a concentration of 1 mg/ml in TBS on the day of use and 
filter sterilised.
ff-GALACTOSIDASE ASSAY
100 X Mg solution
0.1 M MgCl2
4.5 M 2-mercaptoethanol
Stored at -20 °C.
0.1 M sodium phosphate buffer
41 ml 0.2 M Na2HP04.2H20
9 ml 0,2 M NaH2P04.2H20
50 ml dH20
1 X ONPG substrate
ONPG was prepared at a concentration of 4 mg/ml in 0.1 M sodium phosphate buffer 
(pH 7.5) and stored at -20°C.
SOLUTIONS FOR RNA ANALYSIS 
DEPC-treated H20
1 ml DEPC
1000 ml dH20
The mixture was left in a fume cupboard overnight, followed by autoclaving.
R N A  l o a d i n g  b u f f e r
50% glycerol
1 mM EDTA (pH 8.0)
0.25 % bromophenol blue
0.25 % xylene cyanol FF
1 ng/ul ethidium bromide
I
SO LUTIO NS FOR PRO TEIN AN ALYSIS
SOLUTIONS FOR PROTEIN ISOLATION
Suspension buffer
0.1 M 
0.01 M 
0.001 M 
1 i^g/ml 
1 ng/ml 
100 jig/ml
Stored at 4°C
Leupeptin
A stock solution of leupeptin was made to a concentration 2 mg/ml in dH20  and stored
at -20°C.
Aprotinin
0.1 M stock solution of aprotinin was made up in dH20  and stored at -20°C.
NaCl
Tris-Cl (pH 7.6) 
EDTA (pH 8.0) 
leupeptin 
aprotinin 
PMSF
j
PMSF
A stock solution of PMSF was made up inj isopropanol and stored at -20°C in the dark. 
2 X SDS loading buffer
100 mM Tris-Cl (pH 7.6)
4 % (w/v) SDS
20 % (w/v) glycerol
10 % (v/v) 2-mercaptoethanol
0.2 % bromophenol blue
Stored at RT.
SOLUTIONS FOR SDS PAGE/WESTERN BLOTTING
5 X Tris-glycine running buffer
15.1 g Tris base
95.4 g glycine(pH 8.3)
50 ml 10% (w/v) SDS
Made up to 1 L with dH20  and stored at RT.
1 X Tris-glycine running buffer
200 ml 5 X Tris-glycine running buffer
800 ml dH20
Destain
450 ml methanol
450 ml dH20
100 ml glacial acetic acid
Store at RT.
k
C o o m a s s i e  b l u e  s t a i n
0.25 g Coomassie Brilliant Blue R250
100 ml destain
Store at RT.
Transfer buffer
750 ml dH20
2.9 g glycine
5.8 g Tris base
3.7 ml 10 % (w/v) SDS
200 ml methanol
Adjusted volume to 1 L with dH20  and stored at 4°C.
IX Tris buffered saline (TBS)
6.1 g Tris base
8.8 g NaCl
800 ml dH20
The pH was adjusted to 7.5 with HCl and the volume adjusted to 1 L. Stored at RT. 
TBS-T
1 L 1 X TBS
1 ml Tween 20
Stored at RT.
1
B l o c k i n g  B u f f e r
5 g non fat dry milk powder
100 ml TBS-T
Stored at 4°C.
m
